Methods for vaccine identification and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the herpesvirus family

ABSTRACT

The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a herpesvirus genome, in particular an HSV-1 genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an antigen to produce an immune response may be employed in vaccination or antibody preparation technique.

[0001] This application claims the benefit of U.S. Provisional Application Serial No. 60/412,956 Entitled “METHODS AND COMPOSITIONS FOR VACCINATION COMPRISING NUCLEIC ACID AND/OR POLYPEPTIDE SEQUENCES OF THE HERPESVIRUS FAMILY” filed Sep. 23, 2002.

[0002] The government owns rights in the present invention pursuant to DARPA Grant number MDA9729710013.

BACKGROUND OF THE INVENTION

[0003] A. Field of the Invention

[0004] The present invention relates generally to the fields of vaccinology, immunology, virology, functional genomics, and molecular biology. More particularly, the invention relates to methods for screening and obtaining vaccines generated from the administration of gene expression libraries derived from a herpesvirus genome. In particular embodiments, it concerns methods and compositions for the vaccination of a subject against herpesvirus infections and diseases, wherein vaccination of the subject may be via compositions that contain single or multiple polypeptides or polynucleotides or variants thereof derived from part or all of the genes or similar sequences validated as protective or immunogenic by the described methods.

[0005] B. Description of Related Art

[0006] Purely on empirical grounds, Edward Jenner first demonstrated protective vaccination against an infectious disease in the 1790s. After observing that milkmaids did not contract smallpox, he intentionally infected a boy with cowpox then subsequently found him immune to smallpox infection. Since then, vaccines against measles, polio, anthrax, rabies, typhoid fever, cholera, and plague, and many other infectious agents have been developed. The methods of developing new vaccines vary and differ for each virus, bacterium, or other pathogen target; however, they have traditionally consisted of whole pathogens in an attenuated or killed form, as did Jenner's vaccine. Both social and economic considerations make vaccination the optimal method for protecting animals and humans against infectious diseases. However, vaccines are not available for many of the most serious human infectious diseases, including Malaria, tuberculosis, HIV, respiratory syncytial virus (RSV), Streptococcus pneumoniae, rotavirus, Shigella and other pathogens. There is a need to develop effective vaccines, yet for many pathogens vaccines are not readily produced. For example, the antigenic drift of influenza virus requires that new vaccines be constantly developed annually. Research efforts continue to try to identify effective vaccines for rabies (Xiang, et al, 1994), herpes (Rouse, 1995); tuberculosis (Lowrie, et al, 1994); HIV (Coney, et al, 1994) as well as many other diseases or pathogens.

[0007] Most currently available vaccines are composed of live/attenuated or killed pathogens (Ada, 1991). These whole-pathogen inocula elicit a broad immune response in the host. The strength of this approach is that no antigen identification is required, because all the components of the pathogen are presented to the immune system. However, this straightforward approach carries an inherent problem. Pathogenicity of the live/attenuated strain or its reversion to virulence is possible. At best, components of the pathogen that are not needed for the protective immune response are carried as baggage; alternatively some components may compromise protective immunity. In some instances, protective antigens maybe lost or denatured during the process of inactivation of the pathogen. Pointedly, pathogens become pathogenic by evolving or acquiring factors to defend themselves against or avoid a host immune system. In particular, many HSV genes are involved in immune evasion and pathogenesis, especially those that have been shown to be dispensable in vitro. In whole organism vaccines, whether live/attenuated or killed, the repertoire of antigens and their expression levels are controlled by the pathogen. Consequently, the host immune system is often not directed to the most protective antigen determinants. Another consideration is that when all the potential protective antigens of a pathogen are presented to the host, there are opportunities for the non-protective ones to cause deleterious side effects such as autoimmunity, toxicity, or interference with the response to the protective antigens.

[0008] Alternatives to the use of whole-pathogen vaccines include the use of a single immunodominant component or a small group of components for stimulation of a protective immune response in the host. Some component vaccines, such as tetanus toxoid, consist of an enriched, but not highly purified pathogen component. Others, consist of recombinant components, such as the hepatitis B vaccine. They have provided improved immunogenicity and safety, reduced side-reactivities, and easier quality control relative to whole organism vaccines. However, the antigens conferring the best protection are not always known, so the choice has often fallen to educated guessing or technical convenience, followed by further study. For example, subunits have been chosen as vaccine candidates on the basis that they correspond to components of the pathogen that i) generate high levels of antibodies, ii) are expressed on the pathogen surface or are secreted, iii) carry consensus major histocompatibitilty (MHC) binding sites, or iv) are abundant and easy to purify. Unfortunately these candidates must be unsystematically tested by trial and error, because broad-based functional screens for vaccine candidates are impractical using protein, peptide, or live vector delivery methods. This defines a more basic and unsolved problem of identifying the particular gene or genes of the pathogen that will express an immunogen capable of priming the immune system for rapid and protective response to pathogen challenge.

[0009] Certain non-viral pathogens and some viruses have very large genomes; for example, protozoa genomes contain up to about 10⁸ nucleotides, thus posing an expensive and time-consuming analytical challenge to identify or isolate effective immunogenic antigens. Evaluating the immune potential of the millions of possible determinants from even one pathogen, antigen by antigen, is a significant hurdle for new vaccine development.

[0010] In particular, new protective antigens need to be discovered against Herpesviridae, a family of viral pathogens. Herpesvirus (HSV) infections are increasingly common worldwide, with HSV types 1 and 2 (HSV-1, HSV-2) inflicting the greatest disease burden (Stanberry et al., 1997). Over the past 20 years the U.S. population has suffered a steep rise in HSV infections (Whitley and Miller, 2001; and Farrell et al., 1994) and the vast majority of the world population is infected with at least one member of the human Herpesvirus family (Kleymann et al., 2002). The viruses cause a variety of similar illnesses that are determined by the transmission route, infection site, dose, and host immune status (Whitley et al., 1998). A defining characteristic of HSVs is their acute phase infection, followed by life-long infection of neuronal cells. The Greek translation of their namesake is “creeping”, which describes their persistence and latency (Whitley and Roizman, 2001). Most adults harbor HSV-1 in their peripheral nervous systems in a latent state. Viral reactivation in the sensory ganglia is induced by stress and causes recurrent symptoms, lesions and viral shedding. HSV-1 is most often associated with orofacial infections, encephalitis and infections of the eye, which can cause blindness from resultant corneal scarring. HSV-2 is usually associated with genital infections, however primary genital herpes resulting from HSV-1 has become increasingly common (Whitley and Miller, 2001). Antiviral drugs including acylovir are the mainstays of current herpes therapy (Leung and Sacks, 2000). These treatments suppress episodic symptoms but are only effective with continuous administration, which is both demanding and encourages the emergence of resistant strains. Poignantly, the availability of these drugs has not prevented genital herpes from becoming the third most prevalent sexually transmitted disease in the world (Whitley, and Miller, 2001), and ocular herpes from becoming the second leading cause of blindness in industrialized countries. Rampant infection in the general population combined with severe disease in young and immune compromised hosts has stimulated efforts to develop a herpes vaccine (Bernstein and Stanberry, 1999).

[0011] While the ultimate goal of an HSV vaccine would be long-lasting protection from viral infection, the suppression of disease symptoms would also provide significant health benefits. One of the current goals for either a prophylactic or therapeutic vaccine is to reduce clinical episodes and viral shedding from primary and latent infections. Three categories of prophylactic vaccines have been tested in clinical trials with disappointing results i) whole virus, ii) protein subunit and iii) gene-based subunit vaccines (Stanberry et al., 2000). In the 1970s a number of killed virus vaccines were explored, none of which were efficacious. More recently an attenuated HSV was found to be poorly immunogenic. A replication incompetent virus is being used in clinical trials, but the clinical use of a replication incompetent virus raises safety concerns. Subunit vaccines based on two recombinant glycoproteins have been clinically evaluated in combination with different adjuvant formulations. One developed by Chiron contains truncated forms of both gD₂ and gB₂ of HSV-2, purified from transfected CHO cells and formulated in the adjuvant MF59. Another developed by Glaxo-Smithkline (GSK) contains a truncated gD₂ formulated with adjuvants alum and 3-O-deacylated monophosphoryl lipid A (MPL). Both vaccines were immunogenic and well tolerated in phase I/II trials. However in phase III analyses, the Chiron vaccine showed no overall efficacy against HSV-2 seroconversion and work was discontinued. The GSK vaccine showed significant efficacy (73-74%) in HSV-1, HSV-2 seranegative women volunteers but no efficacy in men. Also, a genetic vaccine using gD₂ was placed in a phase I trial, and the immunogenicity data are currently being analyzed.

[0012] While even limited vaccine efficacy would beneficially impact HSV sufferers, these trials are testing only a small number of vaccine possibilities. This is because the vaccine discovery has not been systematic. Pursuance of a whole-virus vaccine assumes that presentation of the pathogen itself to the immune system will generate optimal immunity. Indeed the breadth and duration of immune responses to whole pathogen vaccines historically have been better than subunit vaccines. However, pathogenicity of the vaccine strain must be considered. Subunit vaccines, to date, have been selected for vaccine testing based on their assumed importance in disease pathogenesis and immunogenicity during infection. These approaches have identified one candidate against HSV with limited efficacy in some but no efficacy in other formulations. Thus, new and improved methodologies for herpesvirus vaccine discovery are needed to protect against herpes diseases.

SUMMARY OF THE INVENTION

[0013] In certain embodiments of the invention two methods were employed to systematically screen the coding sequences of HSV-1 for protective antigens. Random ELI (RELI), as previously demonstrated, provided novel candidates. However, the development of microbial genomics, high-throughput oligonucleotide synthesis, and the invention of linear expression elements (LEEs) enable the screening power of ELI to be increased in terms of breadth and speed. Various embodiments of the invention use a novel directed ELI (DELI) method and idnetify various novel candidates from the HSV-1 genome. Using the sequence of a pathogen's genome, primers can be designed to amplify genes by polymerase chain reaction (PCR) or other nucleic acid amplification techniques. Inexpensive oligonucleotide synthesis in microtiter-formats makes production of primer-sets for entire genomes of pathogen practical. The construction of each PCR-amplified ORF into an expression vector for genetic immunization is required to perform ELI. To avoid several hundred anticipated cloning steps and the associated artifacts, the inventors developed linear expression elements. (U.S. Pat. No. 6,410,241, incorporated herein by reference). In the LEE protocol, PCR-amplified ORFs are covalently or non-covalently linked to advantageous promoter and terminator elements then directly delivered into animals for expression by genetic immunization. This alternative to cloning dramatically streamlines the process of obtaining expression vectors. Genes of many different lengths from many sources have been PCR-amplified and efficiently linked to different expression elements using a variety of methods. Quantitation of LEE and plasmid-borne gene expression in vivo has shown that activity levels are nearly identical. Immune responses and protection-assay readouts that are generated by genetic antigens delivered as LEEs and plasmids are indistinguishable.

[0014] These technologies have been combined to design new ELI screening methods that significantly increase the sensitivity while decreasing the time, expense, and variability of the process. Because each library member is sequence-defined, the components of each sub-library pool can be designed, complete genomic coverage is ensured, and constructs are positioned for proper expression. This circumvents a statistically invoked requirement for library clone redundancy and for carrying unexpressed DNA baggage. Construction of sequence-directed fragments (directed amplification) decreases library sizes, mouse numbers, sibbing rounds, and mistakes. Each defined gene of a pathogen can now be generated to create an ordered array representing the full coding capacity of the pathogen in microtiter plates. The gene arrays are expressed without E. coli-based plasmid propagation, thereby saving time and resources, and avoiding cloning-associated pitfalls.

[0015] The present invention overcomes various difficulties and problems associated with immunization against viruses of the Herpesvirus family. Various embodiments of the invention include compositions comprising herpesvirus polypeptides and polynucleotides, which encode such polypeptides, that may be used as antigens for immunization of a subject. The present invention may also include vaccines comprising antigens derived from other viruses of the Herpesvirus family, as well as methods of vaccination using such vaccines. Vaccine compositions and methods may be broadly applicable for immunization against a variety of herpesvirus infections and the diseases and disorders associated with such infections. An antigen, as used herein, is a substance that induces an immune response in a subject. In particular, compositions and methods may include polypeptides and/or nucleic acids that encode polypeptides obtained by functionally screening the genome of a virus or viruses of the Herpesvirus family, e.g., HSV-1, HSV-2, varicella zoster virus (VZV), bovine herpes virus (BHV), equine herpes virus (EHV), cytomegalovirus (CMV), Cercopithecine herpes virus (CHV or monkey B virus), or Epstein-Barr virus (EBV).

[0016] Certain embodiments of the invention include isolated polynucleotides derived from members of the Herpesvirus family. In some embodiments, polynucleotides may be isolated from viruses of the Alphaherpesvirus sub-family, in particular HSV-1, HSV-2, or other members of the simplexvirus genus. Polynucleotides may include but are not limited to nucleotide sequences comprising the sequences as set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 and/or SEQ ID NO:115; or a complement, a fragment, or a closely related sequence thereof. In additional embodiments, the invention may relate to such polynucleotides comprising a region having a sequence comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100, 125, 150, 200, or more contiguous nucleotides in common with at least one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69 SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 and/or SEQ ID NO:115; a complement, or fragment thereof, as well as any intervening lengths or ranges of nucleotides. In some specific embodiments, the invention relates to, but is not limited, to polynucleotides comprising full length, fragments of, variants of, or closely related sequences of specific nucleic acids encoding UL1 (SEQ ID NO:7); UL17 (SEQ ID NO:39); UL28 (SEQ ID NO:63); or US3 (SEQ ID NO:105). Even more specific embodiments are related to the specific fragments, further fragments, variants, or closely related sequences of the nucleic acids of: UL1 set forth in SEQ ID NO:5; UL17 set forth in SEQ ID NO:37; UL28 set forth in SEQ ID NO:59; and US3 set forth in SEQ ID NO:103.

[0017] A herpesvirus polynucleotide may be isolated from genomic DNA or a genomic DNA expression library but it need not be. For example, the polynucleotide may also be a sequence from one species that is determined to be protective based on the protective ability of a homologous sequence in another species. For example, the polynucleotide could be a sequence selected from a Varicellovirus genus of the same Alphaherpesvirus sub-family (Alphaherpesvirnae) or a different sub-family such as the Betaherpesvirus (Betaherpesvirnae) sub-family, or Gammaherpesvirus (Gammaherpesvirinae) sub-family that was determined to be protective after analysis of the respective genomic sequence(s) for homologs of HSV-1 that had previously been shown to be protective in an animal or human subject. As discussed below, the polynucleotides need not be of natural origin, or to encode an antigen that is precisely a naturally occurring herpesvirus antigen.

[0018] In many embodiments, a polynucleotide encoding a herpesvirus polypeptide may be comprised in a nucleic acid vector, which may be used in certain embodiments for immunizing a subject against a herpesvirus (e.g., genetic immunization). In various embodiments a genetic immunization vector may express at least one polypeptide encoded by a herpesvirus polynucleotide. In other embodiments, the genetic immunization vector may express a fusion protein comprising a herpesvirus polypeptide. A polypeptide expressed by a genetic immunization vector may include a fusion protein comprising a herpesvirus polypeptide, wherein the fusion protein may comprise a heterologous antigenic peptide, a signal sequence, an immunostimulatory peptide, an oligomerization peptide, an enzyme, a marker protein, a toxin, or the like. A genetic immunization vector may also, but need not, comprise a polynucleotide encoding a herpesvirus/mouse ubiquitin fusion protein.

[0019] A genetic immunization vector, in certain embodiments, will comprise a promoter operable in eukaryotic cells, for example, but not limited to a CMV promoter. Such promoters are well known to those of skill in the art. In some embodiments, the polynucleotide is comprised in a viral or plasmid expression vectors. A variety of expression systems are well known. Expression systems include, but are not limited to linear or circular expression elements (LEE or CEE), expression plasmids, adenovirus, adeno-associated virus, retrovirus and herpes-simplex virus, PVAX1™ (Invitrogen); pCI neo, pCI, and pSI (Promega); Adeno-X™ Expression System and Retro-X™ System (Clontech) and other commercially available expression systems. The genetic immunization vectors may be administered as naked DNA or incorporated into viral, non-viral, cell-mediated, pathogen mediated or by other known nucleic acid delivery vehicles or vaccination methodologies.

[0020] In other embodiments, a polynucleotide may encode one or more antigens that may or may not be the same sequence. A plurality of antigens may be encoded in a single molecule in any order and/or a plurality of antigens may be encoded on separate polynucleotides. A plurality of antigens may be administered together in a single formulation, at different times in separate formulations, or together in separate formulations. An expression vector for genetic immunization may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polynucleotides or fragments thereof encoding at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more antigens derived from one or more virus of the Herpesvirus family, and may include other antigens or immunomodulators from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more other pathogens as well.

[0021] Various embodiments of the invention may include viral polypeptides, including variants or mimetics thereof, and compositions comprising viral polypeptides, variants or mimetics thereof. Viral polypeptides, in particular herpesvirus polypeptides, include, but are not limited to amino acid sequences set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116; fragments, variants, or mimetics thereof, or closely related sequences. In additional embodiments, the invention may relate to polypeptides comprising a region having an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100, 125, 150, 200, or more contiguous amino acids, as well as any intervening lengths or ranges of amino acids, in common with at least one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, or SEQ ID NO:72; a complement, or fragment thereof. In some specific embodiments, the invention relates to, but is not limited, polypeptides comprising full length, fragments of, variants of, mimetics of, or closely related sequences of the amino acid sequences of UL1 (SEQ ID NO:8); UL17 (SEQ ID NO:40); UL28 (SEQ ID NO:64); or US3 (SEQ ID NO:106). Even more specific embodiments are related to the specific fragments, further fragments, variants, mimetics, or closely related sequences of: UL1 set forth in SEQ ID NO:6; UL17 set forth in SEQ ID NO:38; UL28 set forth in SEQ ID NO:60; and US3 set forth in SEQ ID NO:104.

[0022] Additional embodiments of the invention also relate to methods of producing such polypeptides using known methods, such as recombinant methods.

[0023] Polypeptides of the invention may be synthetic, recombinant or purified polypeptides. Polypeptides of the invention may have a plurality of antigens represented in a single molecule. The antigens need not be the same antigen and need not be in any particular order. It is anticipated that polynucleotides, polypeptides and antigens within the scope of this invention may be synthetic and/or engineered to mimic, or improve upon, naturally occurring polynucleotides or polypeptides and still be useful in the invention. Those of ordinary skill will be able, in view of the specifications, to obtain any number of such compounds.

[0024] Various embodiments of the invention include vaccine compositions. A vaccine composition may comprise (a) a pharmaceutically acceptable carrier; and (b) at least one viral antigen or nucleic acid encoding a viral antigen. In certain embodiments of the invention the vaccine may be against viruses of the Herpesvirus family. In other embodiments, a vaccine may be directed towards a member of the Alphaherpesvirus sub-family and in particular HSV-1, HSV-2, or VZV. In some embodiments, an HSV antigen has a sequence as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116; fragments, variants, or mimetics thereof, or closely related sequences. In other specific embodiments, the vaccine compostion comprises a nucleic acid encoding such an HSV antigen, including but not limited to nucleotide sequences comprising the sequences as set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 and/or SEQ ID NO:115; or a complement, a fragment, or a closely related sequence thereof. In some specific embodiments, the invention relates to, but is not limited, to vaccine compositions comprising full length, fragments of, variants of, mimetics of, or closely related sequences of the nucleic acid and amino acid sequences of UL1 (SEQ ID NO:7 and SEQ ID NO:8); UL17 (SEQ ID NO:39 and SEQ ID NO:40); UL28 (SEQ ID NO:63 and SEQ ID NO:64); or US3 (SEQ ID NO:105 and SEQ ID NO:106). Even more specific embodiments are related to the specific fragments, further fragments, variants, mimetics, or closely related sequences of: UL1 set forth in SEQ ID NO:5 and SEQ ID NO:6; UL17 set forth in SEQ ID NO:37 and SEQ ID NO:38; UL28 set forth in SEQ ID NO:59 and SEQ ID NO:60; and US3 set forth in SEQ ID NO:103 and SEQ ID NO:104.

[0025] In certain embodiments of the invention a vaccine may comprise: (a) a pharmaceutically acceptable carrier, and (b) at least one polypeptide and/or polynucleotide encoding a polypeptide having a herpesvirus sequence, including a fragment, variant or mimetic thereof. Herpesvirus polypeptides and/or polynucleotides include, but are not limited to HSV polypeptides or polynucleotides; fragments thereof, or closely related sequences. In some embodiments a herpesvirus polypeptide or polynucleotide may be an HSV-1 sequence.

[0026] The vaccines of the invention may comprise multiple polynucleotide sequences and/or multiple polypeptide sequences. In some embodiments, the vaccine will comprise at least a first polynucleotide encoding a polypeptide or a polypeptide having a herpesvirus sequence. Other embodiments, include at least a second, third, fourth, and so on, polynucleotide or polypeptide, wherein a first polynucleotide or polypeptide and a second or subsequent polynucleotide or polypeptide have different sequences. In more specific embodiments, the first polynucleotide may have a sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 and/or SEQ ID NO:115; a complement, or fragment thereof and/or encode a polypeptide sequence as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116; fragments, variants, or mimetics thereof, or closely related sequences. In other embodiments antigenic fragments may be presented in a multi-epitope format, wherein two or more antigenic fragments are engineered into a single molecule.

[0027] In various embodiments, the invention relates to methods of isolating herpesvirus (e.g., HSV-1, HSV-2, VZV, BHV, EHV, CMV, or CHV) antigens and nucleic acids encoding such, as well as methods of using such isolated antigens for producing an immune response in a subject. Antigens of the invention may be used in vaccination of a subject against a herpesvirus infection or herpes disease.

[0028] Embodiments of the invention may include methods of immunizing an animal comprising providing to the animal at least one herpesvirus antigen or antigenic fragment thereof, in an amount effective to induce an immune response. A herpesvirus antigen can be derived from HSV-1, HSV-2, or any other Herpesvirus species. As discussed above, and described in detail below, the herpesvirus antigens useful in the invention need not be native antigens. Rather, these antigens may have sequences that have been modified in any number of ways known to those of skill in the art, so long as they result in or aid in an antigenic or immune response.

[0029] In various embodiments of the invention, an animal or a subject is a mammal. In some cases a mammal may be a mouse, horse, cow, pig, dog, or human. Alternatively, a subject may be selected from chickens, turtles, lizards, fish and other animals susceptible to herpesvirus infection. In preferred embodiments, an animal or subject is a human.

[0030] Alternatively, these methods may be practiced in order to induce an immune response against a Herpesvirus species other than the simplexvirus genus, HSV, for example, but not limited to, cytomegalovirus (CMV), and/or Varicella Zoster Virus/human herpesvirus 3 (VZV).

[0031] In other aspects of the invention, methods of screening at least one test polypeptide or test polynucleotide encoding a polypeptide for an ability to produce an immune response comprising (i) obtaining at least one test polypeptide or test polynucleotide by (a) modifying the amino acid sequence of a known antigenic polypeptide or polynucleotide sequence of a polynucleotide encoding a known antigenic polypeptide; (b) obtaining a homolog of a known antigenic sequence of a polynucleotide encoding such a homolog, or (c) obtaining a homolog of a known antigenic sequence or a polynucleotide encoding such a homolog and modifying the amino acid sequence of the homolog or the polynucleotide sequence of the polynucleotide encoding such a homolog; and (ii) testing the test polypeptide or test polynucleotide under appropriate conditions to determine whether the test polypeptide is antigenic or the test polynucleotide encodes an antigenic polypeptide are contemplated. The test polypeptide may comprise a modified amino acid sequence or a homolog of a least one polypeptide as described herein or a fragment thereof. The test polypeptide may comprise an amino acid sequence of at least one of amino acid sequences described above or a fragment thereof, which sequence has been modified.

[0032] In certain embodiments, the method may comprise obtaining a test polynucleotide. The test polynucleotide may comprise a polynucleotide encoding a modified amino acid sequence of or a homolog of at least one polypeptide having a sequence as described herein or a fragment thereof. Embodiments may include obtaining the test polynucleotide comprising modifying the polynucleotide sequence of at least one of the nucleic acid sequences described herein or a fragment thereof.

[0033] In various embodiments, methods may further comprise identifying at least one test polypeptide as being antigenic or at least one test polynucleotide as encoding an antigenic polypeptide. The identified antigenic polypeptide or the polynucleotide encoding an antigenic polypeptide may be comprised in a pharmaceutical composition. The identified antigenic polypeptide or polynucleotide encoding an antigenic polypeptide may be used to vaccinate a subject. In particular embodiments, the subject is vaccinated against a herpesvirus. In a preferred embodiment, the herpesvirus is HSV-1. In other embodiments the subject is vaccinated against a non-herpesvirus disease.

[0034] In yet another aspect of the invention, methods of preparing a vaccine comprising obtaining an antigenic polypeptide or a polynucleotide encoding an antigenic polypeptide as determined to be antigenic by any of methods described herein, and placing the polypeptide or polynucleotide in a vaccine composition is contemplated.

[0035] Also contemplated are methods of vaccinating a subject comprising preparing a vaccine of composition of the invention and vaccinating a subject with the vaccine. In certain embodiments methods of treating a subject infected with a pathogen comprising administering a vaccine composition comprising at least one herpesvirus antigen or fragment thereof, or at least one polynucleotide encoding a herpesvirus antigen or a fragment thereof is contemplated. The vaccine composition may include, but is not limited to a genetic vaccine, a polypeptide vaccine, a cell-mediated vaccine, an attenuated pathogen vaccine, a live-vector vaccine, an edible vaccine, a killed pathogen vaccine, a purified sub-unit vaccine, a conjugate vaccine, a virus-like particle vaccine, or a humanized antibody vaccine. In particular embodiments, the vaccine composition comprises a polynucleotide encoding at least one herpesvirus antigen or fragment thereof as described herein. In various embodiments, the vaccine composition comprises at least one herpesvirus antigen or fragment thereof as described above.

[0036] Certain embodiments include methods of raising a therapeutic immune response against reactivation disease comprising administering a vaccine composition comprising at least one herpesvirus antigen or fragment thereof, as described above, or at least one polynucleotide encoding a herpesvirus antigen or a fragment thereof, also as described above.

[0037] In still a further aspect of the invention includes methods of passive immunization comprising administering at least one antigen binding agent reactive to one or more herpesvirus antigen to a subject. The herpesvirus antigen may comprise an amino acid sequence of at least one polypeptide, peptide or variant thereof as described herein. An antigen binding agent may include, but is not limited to an antibody, an anticalin or an aptamer.

[0038] In certain embodiments, methods for vaccination include administering a priming dose of a herpesvirus vaccine composition. The priming dose may be followed by a boost dose. In various embodiments, the vaccine composition is administered at least once, twice, three times or more. Vaccination methods may include (a) administering at least one nucleic acid and/or polypeptide or peptide vaccine composition and then (b) administering at least one polypeptide and/or nucleic acid vaccine composition.

[0039] Certain aspects of the invention may include methods of detecting Herpesvirus and/or antibodies to a herpesvirus comprising: (a) admixing an antibody that is reactive against an antigen having an amino acid sequence as set forth above with a sample; and (b) assaying the sample for antigen-antibody binding.

[0040] In further aspects, regardless of the source of nucleic acid encoding an antigen, the method of directed ELI (DELI) may be used. Exemplary methods of screening at least one, two, three, four, five, six, seven, ten, twenty, fifty, one hundred five hundred, thousands and hundreds of thousands of open reading frames, including all intergers therebetween, to determine whether it encodes a polypeptide with an ability to generate an immune response in an animal may comprise preparing in vitro at least one linear or circular expression element comprising an open reading frame linked to a promoter by amplification or synthesis of a known or predicted open reading frame; introducing the at least one linear or circular expression element into a cell within an animal with or without intervening cloning or bacterial propagation; and assaying to determine whether an immune response is generated in the animal by expression of a polypeptide encoded by the open reading frame in the expression element. In certain embodiments, the open reading frame can be produced in vivo and then non-covalently linked to the promoter in vitro. In various embodiments, the linear or circular expression element may further comprise a terminator linked to the open reading frame. The open reading frame may be derived from a pathogen RNA, DNA, and/or genomic nucleotide sequence. The pathogen can be a virus, bacterium, fungus, alga, protozoan, arthropod, nematode, platyhelminthe, or plant. In certain embodiments, the preparing of the expression element may comprise non-covalently or covalently linking the promoter and/or terminator to the open reading frame. The preparation of the expression element may comprise using polymerase chain reaction, or other nucleic acid amplification technique, and/or nucleic acid synthesis methods known in the art. In various embodiments, preparing the expression element can comprise chemical synthesis of the open reading frame. The method can further comprise identifying and/or isolating an antibody produced by the animal and directed against the polypeptide encoded by the open reading frame. In certain emdoiments, the linear or circular expression element may be injected into the animal. In various embodiments, the animal is protected from the challenge with the pathogen. The method can comprise identifying one or more antigens conferring protection to the animal.

[0041] In certain embodiments of the invention, the methods comprise generating chimeric DNAs for LEE/CEE production and include, but are not limited to generating complementary, single-stranded overhangs for non-covalent linkage, which can be subsequently turned into covalent attachments, if desired. Non-limiting examples of methods for linking or attachment of nucleic acid elements include dU/UDG, rU/Rnase, T4 polymerase/dNTP exclusion, dspacer, d block, ribostoper and annealing linear DNAs of different lengths. Methods for generating linkages with covalent attachments include, but are not limited to PCR and gene assembly techniques.

[0042] As used herein in the specification, “a” or “an” may mean one or more. As used herein, when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more.

[0043] As used herein, “plurality” means more than one. In certain specific aspects, a plurality may mean 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or more, and any integer derivable therein, and any range derivable therein.

[0044] As used herein, “any integer derivable therein” means an integer between the numbers described in the specification, and “any range derivable therein” means any range selected from such numbers or integers.

[0045] As used herein, a “fragment” refers to a sequence having or having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, or more, or any range between any of the points or any other integer between any of thes points, contiguous residues of the polypeptide sequences set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70 SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, but less than the full-length of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116; or nucleotides of the recited SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113, and/or SEQ ID NO:115, but less than the full-length of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 and/or SEQ ID NO:115. It is contemplated that the definition of “fragment” can be applied to amino acid and nucleic acid fragments.

[0046] As used herein, an “antigenic fragment” refers to a fragment, as defined above, that can elicit an immune response in an animal.

[0047] Reference to a sequence in an organism, such as a “herpesvirus sequence” refers to a segment of contiguous residues that is unique to that organism(s) or that constitutes a fragment (or full-length region(s)) found in that organism(s) (either amino acid or nucleic acid).

BRIEF DESCRIPTION OF THE DRAWINGS

[0048] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0049]FIG. 1. RELI round 1 challenge assay results by symptoms readout. Herpes disease severity was scored for groups of mice immunized with one of the 12 tPA-fused sublibraries (T1 through T12) or one of the 12 UB fused sublibraries (U1 through U12). Day 7 post-infection is presented since this is the day before control animals began to die. All animals were visually inspected for a variety of disease parameters. Values were assigned for the disease symptom, with increasing numbers indicting a worse disease. Edema, abdominal swelling, scabbing and scar formation were scored as 3, blisters and swollen lymph nodes as 5, lesions and erythemia as 6, ulcers and gut poresis were scored as 7, hypothermia as 8, paralysis and neural infections as 10 and death or euthanasia as 20. The values were further modified depending on whether the effect was very mild (+2), mild (+3), moderate (+5), severe (+7) or very severe (+9). The mouse groups scored as positive are displayed as black bars. Vector=plasmid without an HSV insert. Error bars represent standard errors of the mean.

[0050]FIG. 2. RELI round 1 challenge assay results by lethality readout. Protection from death was evaluated by determining survival rates for groups of mice immunized with one of the 12 tPA-fused sublibraries (T1 through T12) or one of the 12 UB fused sublibraries (U1 through U12). The percentage of animals remaining alive on days 7 through 9 post-exposure are plotted. Negative control animals began to die on day 7, no further deaths were observed from day 9 through the end of the monitoring period (day 14). The mouse groups scored as positive are marked with astericks. Vector=plasmid without an HSV insert; NI=non-immunized.

[0051]FIG. 3 An illustration of the three-dimensional grid built virtually to array the individual components of the HSV-1 library. The planar dimensions of the grid were used to define multiplexed pools. These pools were used as genetic inocula for ELI testing.

[0052]FIGS. 4A and 4B. Lethality results from challenge-protection assays in a second round of RELI, from the (FIG. 4A) tPA and (FIG. 4B) UB fusion libraries. The library components comprising the positively scoring pools from the round 1 study were re-arrayed into new pools defined by the X, Y, and Z planes of a cube. These were assayed by genetic immunization alongside control inocula, which are displayed as gray bars. Vector=plasmid without insert; NI=no inoculum. The round 1 sublibraries selected for reduction were retested. RD1#1, RD1#3, and RD1#8 from the tPA screen and RD1#6 (Rd+) and RD1#11 (Rd+) from the UB screen. The mouse groups scored as positive are marked with astericks.

[0053]FIGS. 5A and 5B. Protection analyses of single plasmid clones reduced from the two HSV1 libraries. Sequencing of the library clones inferred from the matrix analyses of the round 2 data identified ORFs for testing in round 3. These were assayed by genetic immunization alongside control inocula, which are displayed as gray bars. pCMVigD=plasmid expressing the previously described HSV antigen, Irrel=a non-HSV library inoculum, NI=non-immunized. The UB library-derived clones were administered at a 200-fold diluted DNA-dose relative to that used for the tPA-derived clones. (FIG. 5A) For the round 3 testing from the tPA library, the percentage of mice alive on representative days 9, 12, 13, and 14 is presented. (FIG. 5B) For the round 3 testing from the UB library, days 8, 9, and 14 are plotted. Inocula scored as positive are marked with astericks.

[0054]FIGS. 6A and 6B. Comparative testing of the ORFs inferred from both the tPA and UB grids. Library clones were tested in parallel, at equivalent doses. (FIG. 6A) The survival rates of mice immunized with each candidate on representative days 8, 9, 10, 11, and 14. (FIG. 6B) The average survival scores for each of these inoculated groups of mice plotted. These calculated values integrate survival during the period from 8 to 14 days post-challenge.

[0055]FIG. 7A-7C. Survival rates from a directed-ELI study. Groups of mice were immunized with HSV-1 ORFs that had been pooled for three-dimensional matrix analyses. Each data set represents the (FIG. 7A) X, (FIG. 7B) Y, or (FIG. 7C) Z axis. Error bars represent standard errors of the mean.

[0056]FIG. 8A-8C. Average survival scores from a directed-ELI study. The same data presented above as percent survival on individual days was used to derive a single score representing extended survival during the monitoring period. Once the non-immunized began to die, the day-numbers that each mouse survived were summed. The sum for each animal per group was averaged to determine a group survival score. As in FIG. 1, each data set represents the (FIG. 8A) X, (FIG. 8B) Y, or (FIG. 8C) Z axes. Positively scored groups are shaded black. Positive and negative control groups are gray-shaded.

[0057]FIGS. 9A and 9B. Initial testing of individual ORFs inferred from the triangulation analysis of the DELI grid. Both the ORFs tested and their derivative genes are given. Protection is presented as (FIG. 9A) rates of extended survival on several representative days and as (FIG. 9B) survival scores, calculated from days 8 through 14 post-exposure. Groups displaying non-overlapping error bars with the non-immunized are shown in black. Positive and negative control groups are gray-shaded.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0058] The present invention overcomes the current limitations of herpesvirus vaccines by providing isolated nucleic acids and/or polypeptides from one or more members of the Herpesvirus family (Herpesviridae) that are typically protective. Certain embodiments include isolated nucleic acids and/or polypeptides from Herpes Simplex Virus type 1 and type 2 (HSV-1 and HSV-2, respectively) or other herpesviruses (i.e., , VZV, BHV, EBV, CMV, CHV, or EHV). Compositions comprising isolated nucleic acids and polypeptides of a herpesvirus, as well as methods of using such compositions, may provide prophylactic or therapeutic immunization against members of the Herpesvirus family. By introduction of one or more of the compositions of the present invention, a subject may be induced to produce antibodies against one or more viruses of the Herpesvirus family, specifically the Alphaherpesvirus sub-family (Alphaherpesvirinae), which includes the closely related viruses HSV-1 and HSV-2. In other embodiments of the invention, binding agents such as antibodies, anticalins, and the like may be used in passive immunization or in other therapeutic modalities.

[0059] Widespread human infection by members of the Herpesvirus family represents a particular challenge for vaccinology. For example, herpesvirus infections in humans may lead to mononucleosis, blindness, encephalitis, cancer or other disease conditions. Thus, an effective treatment for herpesvirus infections in humans and other vertebrate animals is of clinical importance. In the present invention, the expression library immunization (ELI) process used both without, and also in combination with, LEEs may be utilized to identify vaccine candidates against herpesvirus infections and associated diseases. Clinically, some of the goals of treatment for or immunization against herpesviruses may include reducing the severity of disease associated with primary infection; reducing the frequency of reactivation of latent virus; limiting the severity of reactivated disease; and restricting the transmission of virus associated with either primary or reactivated infection(s).

[0060] A comprehensive, unbiased approach to antigen selection for a subunit vaccine is enabled by combining genetic immunization (Tang et al., 1992) with the invention of expression library immunization (ELI) (Barry et al., 1995). ELI is an empirical method, as was Jenner's, to identify protective vaccines. However, unlike Jenner's it is based on a subunit rather than whole pathogen endproduct. Using ELI, the entire genome of a pathogen can be searched for protective antigens. Pathogen DNA is fragmented and cloned into a mammalian expression vector to generate a library corresponding to all of the genetic material of the organism. In 1995 the utility of ELI was demonstrated in the protection of mice against Mycoplasma (M.) pulmonis challenge by prior vaccination with a pathogen library. The complete library is partitioned into sub-libraries that are used to separately immunize groups of test animals. Sub-library inocula that protect animals from disease following challenge are scored as positive. Presumably one or more plasmids within a positive sub-library are responsible for the protective response. To identify the constituent antigen-expressing plasmid(s) that holds protective capacity, the sub-libraries can be further subdivided and tested. Plasmid DNA is prepared from the pools and used to inoculate more test animals, which are assayed for protection. Other researchers have subsequently reported the successful application of ELI against other bacterial and parasitic pathogens. Brayton et. al. used a Rickettsia (Cowdria ruminantium) expression library to screen for protective sub-library pools in a murine model of Heartwater disease. Four out of ten groups of mice inoculated with different sub-libraries and challenged with an optimal level of bacteria showed reduced levels of infection (Brayton et al., 1998). In another study, a partial expression library was made from cDNA of the parasitic helminth Taenia crassiceps and used to immunize mice against cysticerosis disease. Though the inoculum only represented a portion of the genome, a two-fold reduction in parasitemia was observed (Manoutcharian et al., 1998). Alberti et. al. found that an expression library made from the genome of Trypanosoma cruzi (a protozoa that causes Chagas' disease) stimulated specific immune responses in mice (Alberti et al., 1998). A library made from the genomic DNA of Leishmania major (a protozoan that causes leismaniasis) was able to marginally reduce parasite load in challenged mice (Piedrafita et al., 1999). Test mice inoculated with further sub-divisions of this library displayed greater levels of protection than the original. This indicates that the protective clone(s) was being enriched through two rounds of reduction in the complexity of the plasmid inocula. In a recent study, random genomic DNA fragments from Mycoplasma hyopneumoniae were cloned into an expression vector, screened for open-reading frames, and then used to immunize pigs. These libraries were shown to protect this natural pathogen host from infection (Moore et al., 2001). In addition, Smooker et al. (2000) have studied ELI in the context of immunization of rodents against Malaria.

[0061] The ELI studies presented to date have shown that mixed antigen libraries can protect against disease, and in some cases the complexities of the original mixtures have been reduced. ELI as originally presented, with random-fragment plasmid-clones (RELI) is capable of providing effective vaccine candidates. However, we have also dramatically improved ELI so as to yield many more vaccine candidates and with much less time and technical difficulty. The availability of sequenced pathogen genomes enables sequence-directed primers to be designed and ORFs to be amplified by PCR. Since each library member is defined, complete genomic coverage is ensured and constructs can be placed in position for proper expression. This eliminates a statistically invoked redundancy that was necessary, and consequently directed-ELI (DELI) reduces the library sizes and number of sibbing rounds. The technical challenge for practicing directed-ELI was constructing enough individual library clones to represent all ORFs of the genome. To avoid the formidable task of thousands of cloning steps linear expression elements (LEEs) were developed. In an LEE protocol, PCR-amplified ORFs can be linked to a desired promoter and a terminator, and then directly delivered into animals for gene expression.

[0062] The present invention provides compositions and methods for the immunization of vertebrate animals, including humans, against herpesvirus infections. Compositions of the invention may comprise isolated nucleic acids encoding herpesvirus polypeptide(s); herpesvirus polypeptides, including complements, fragments, mimetics or closely related sequences, as antigenic components; and/or binding or affinity agents that bind antigens derived from herpesvirus members. Identification of the nucleic acids and polypeptides of the invention is typically carried out by adapting ELI and LEE methodology to screen a herpesvirus genome(s) (e.g., an HSV-1 genome) for vaccine candidates. The compositions and methods of the invention may be useful for vaccination against herpesvirus infections (e.g., HSV-1 and HSV-2 infections).

[0063] In various embodiments, a vaccine composition directed against a member of the Herpesvirus family may be provided. The vaccine according to the present invention may comprise a herpesvirus nucleic acid(s) and/or polypeptide(s). In particular embodiments, the herpesvirus is a HSV virus, preferably HSV-1 or HSV-2. The vaccine compositions of the invention may confer protective or therapeutic resistance to a subject against HSV and/or other herpesvirus infections.

[0064] In still other embodiments, the invention may provide screening methods that include constructing an expression library via LEEs and screening it by expression library immunization in order to identify herpesvirus genes (e.g., HSV-1 genes) that confer protection against or therapy for herpesvirus infection. Additionally, methods may be used to identify and utilize polynucleotides and polypeptides derived from other related organism or by synthesizing a molecule that mimics the polypeptides of identified herpesvirus polypeptides.

I. Herpesviridae

[0065] Members of the Herpesvirus family (Herpesviridae) replicate in the nucleus of a wide range of vertebrate hosts, including eight species isolated in humans, several each in horses, cattle, mice, pigs, chickens, turtles, lizards, fish, and even in some invertebrates, such as oysters. Human herpesvirus infections are endemic and sexual contact is a common method of transmission for several of the viruses including both herpes simplex virus 1 and 2 (HSV-1, HSV-2). The increasing prevalence of genital herpes and corresponding rise of neonatal infection and the implication of Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma herpesvirus as cofactors in human cancers create an urgency for a better vaccination against this virus family.

[0066] All herpesvirus virions have an envelope, a capsid, a tegument, and a core. The core includes a single linear molecule of dsDNA. The capsid surrounds the core and is an icosahedron of approximately 100 nm in diameter. The capsid is constructed of 162 capsomeres consisting of 12 pentavalent capsomers (one at each apex) and 150 hexavalent capsomers. The tegument is located between the capsid and the envelope. The tegument is an amorphous, sometimes asymmetrical, feature of the Herpesvirus family. It consists of viral enzymes, some of which are needed to take control of a host cell's chemical processes and subvert them to virion production, some of which defend against the host cell's immediate responses, and others for which the function is not yet understood. The envelope is the outer layer of the virion and is composed of altered host membrane and a dozen unique viral glycoproteins, which appear in electron micrographs as short spikes embedded in the envelope.

[0067] Herpesvirus genomes range in length from 120 to 230 kilobasepairs (kbp) with base composition from 31% to 75% G+C content and contain 60 to 120 genes. Because replication takes place inside the nucleus, herpesviruses can use both the host's transcription machinery and DNA repair enzymes to support a large genome with complex arrays of genes. Herpesvirus genes are not arranged in operons and in most cases have individual promoters. However, unlike eukaryotic genes, very few herpesvirus genes are spliced. All herpesvirus genomes contain lengthy terminal repeats both direct and inverted. There are six terminal repeat arrangements and understanding how these repeats function in viral success is not completely understood.

[0068] The Herpesvirus family is generally divided into three sub-families, Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae. The Alphaherpesvirus sub-family includes the Simplexviruses (e.g., HSV-1 and HSV2) and the Varicellovirus (e.g., Varicella Zoster Virus, VZV). The Betaherpesvirus sub-family includes Cytomegalovirus (e.g., human herpesvirus 5 (HHV-5) or CMV), Muromegalovirus (e.g., mouse cytomegalovirus 1), and Roseolovirus (e.g. HHV-6 and HHV-7). Finally, the Gammaherpesvirus sub-family includes Lymphocryptovirus (e.g., HHV-4 or EBV) and Rhadinovirus (e.g., HHV-8). A more detailed review of the Herpesvirus Family may be found in Fields Virology (1996), which is incorporated herein by reference.

II. Vaccines

[0069] The concept of vaccination/immunization is based on two fundamental characteristics of the immune system, namely specificity and memory of immune system components. Vaccination/immunization will initiate a response specifically directed to the antigen with which a subject was challenged. Furthermore, a population of memory B and T lymphocytes may be induced. Upon re-exposure to the antigen(s) or the pathogen an antigen(s) was derived from, the immune system will be primed to respond much faster and much more vigorously, thus endowing the vaccinated/immunized subject with immunological protection against a pathogen or disease state. Protection may be augmented by administration of the same or different antigen repeatedly to a subject or by boosting a subject with a vaccine composition.

[0070] Vaccination is the artificial induction of actively-acquired immunity by administration of all or part of a non-pathogenic form or a mimetic of a disease-causing agent. The aim is to prevent a disease or treat a symptom of a disease, so the procedure may also be referred to as prophylactic or therapeutic immunization, respectively. In addition to actively-acquired immunity, passive immunization methods may also be used to provide a therapeutic benefit to a subject, see below.

[0071] In particular, genetic vaccination, also known as DNA immunization, involves administering an antigen-encoding expression vector(s) in vivo, in vitro, or ex vivo to induce the production of a correctly folded antigen(s) within an appropriate organism, tissue, cell or a target cell(s). The introduction of the genetic vaccine will cause an antigen to be expressed within those cells, an antigen typically being part or all of one or more protein or proteins of a pathogen. The processed proteins will typically be displayed on the cellular surface of the transfected cells in conjunction with the Major Histocompatibility Complex (MHC) antigens of the normal cell. The display of these antigenic determinants in association with the MHC antigens is intended to elicit the proliferation of cytotoxic T-lymphocyte clones specific to the determinants. Furthermore, the proteins released by the expressing transfected cells can also be picked up, internalized, or expressed by antigen-presenting cells to trigger a systemic humoral antibody responses.

[0072] A vaccine is a composition including an antigen derived from all or part of a pathogenic agent, or a mimetic thereof that is modified to make it non-pathogenic and suitable for use in vaccination. The term vaccine is derived from Jenner's original vaccine that used cowpoxvirus isolated from cows to immunize humans against smallpox. Vaccines may include polynucleotides, polypeptides, attenuated pathogens, killed (or inactivated) pathogens, inactivated toxins, mimetics of an antigen and/or other antigenic materials that induce an immune response in a subject. These antigens may be presented in various ways to the subject being immunized or treated. Types of vaccines include, but are not limited to genetic vaccines, virosomes, attenuated or inactivated whole organism vaccines, recombinant protein vaccines, conjugate vaccines, transgenic plant vaccines, toxoid vaccines, purified sub-unit vaccines, multiple genetically-engineered vaccines, anti-idiotype vaccines, peptide mimetopes and other vaccine types known in the art.

[0073] An immune response may be an active or a passive immune response. Active immunity develops when the body is exposed to various antigens. It typically involves B or T lymphocytes. B lymphocytes (also called B cells) produce antibodies. Antibodies attach to a specific antigen and make it easier for phagocytes to destroy the antigen. Typically, T lymphocytes (T cells) help B cells make antibodies and other T cells attack antigens directly or kill virus infected cells and may provide some control over the infection. B cells and T cells develop that are specific for a particular antigen or antigen type. Passive immunization generally refers to the administration of preformed antibodies or other binding agents, which bind an antigen(s). One of the various goals of immunization is to provide a certain protection against or treatment for an infection or disease associated with an infection or the presence of a pathogen.

[0074] In certain cases, an immune response may be a result of adoptive immunotherapy. In adoptive immunotherapy, lymphocyte(s) are obtained from a subject and are exposed or pulsed with an antigenic composition in vitro, and then administered back to the subject. The antigenic composition may comprise additional immunostimulatory agents or a nucleic acid encoding such agents, as well as adjuvants or excipients, see below. In certain instances, lymphocyte(s) may be obtained from the blood or other tissues of a subject. Lymphocyte(s) may be peripheral blood lymphocyte(s) and may be administered to the same or different subjects, referred to as autologous or heterologous donors respectively (for exemplary methods or compositions see U.S. Pat. Nos. 5,614,610; 5,766,588; 5,776,451; 5,814,295; 6,004,807 and 6,210,963).

[0075] The present invention includes methods of immunizing, treating or vaccinating a subject by contacting the subject with an antigenic composition comprising a herpesvirus antigen or antigens or a polynucleotide(s) encoding a herpesvirus antigen or antigens. An antigenic composition may comprise a nucleic acid; a polypeptide; an attenuated pathogen, such as a virus, a bacterium, a fungus, or a parasite, which may or may not express a herpesvirus antigen; a prokaryotic cell expressing a herpesvirus antigen; a eukaryotic cell expressing a herpesvirus antigen; a virosome; and the like, or a combination thereof. As used herein, an “antigenic composition” will typically comprise an antigen in a pharmaceutically acceptable formulation.

[0076] Antigen refers to any substance, molecule, or molecule encoding a substance that a host regards as foreign and therefore elicits an immune response, particularly in the form of specific antibodies or T-cells reactive to an antigen. An antigenic composition may further comprise an adjuvant, an immunomodulator, a vaccine vehicle, and/or other excipients, as described herein and is known in the art (for example see Remington's Pharmaceutical Sciences).

[0077] A herpesvirus antigen is an antigen that is derived from any virus that is a member of the Herpesvirus family. In particular embodiments a herpesvirus antigen may be an antigen derived from a HSV-1 or HSV-2 virus.

[0078] Various methods of introducing an antigen or an antigen composition to a subject are known in the art. Vaccination methods include, but are not limited to DNA vaccination or genetic immunization (for examples see U.S. Pat. Nos. 5,589,466, 5,593,972, 6,248,565, 6,339,086, 6,348,449, 6,348,450, 6,359,054, each of which is incorporated herein by reference), edible transgenic plant vaccines (for examples see U.S. Pat. Nos. 5,484,719, 5,612,487, 5,914,123, 6,034,298, 6,136,320, and 6,194,560, each of which is incorporated herein by reference), transcutaneous immunization (Glenn et al., 1999 and U.S. Pat. No. 5,980,898, each of which is incorporated herein by reference), nasal or mucosal immunization (for examples see U.S. Pat. Nos. 4,512,972, 5,429,599, 5,707,644, 5,942,242, each of which is incorporated herein by reference); virosomes (Huang et al., 1979; Hosaka et al., 1983; Kaneda, 2000; U.S. Pat. Nos. 4,148,876; 4,406,885; 4826,687; 5,565,203; 5,910,306; 5,985,318, each of which is incorporated herein by reference), live vector and the like. Antigen delivery methods may also be combined with one or more vaccination regimes.

[0079] Vaccines comprising an antigen, a polypeptide or a polynucleotide encoding an antigen may present an antigen in a variety of contexts for the stimulation of an immune response. Some of the various vaccine contexts include attenuated pathogens, inactivated pathogens, toxoids, conjugates, recombinant vectors, and the like. Many of these vaccines may contain a mixture of antigens derived from the same or different pathogens. Polypeptides of the invention may be mixed with, expressed by or couple to various vaccine compositions. Various vaccine compositions may provide an antigen directly or deliver an antigen producing composition, e.g., an expression construct, to a cell that subsequently produces or expresses an antigen or antigen encoding molecule.

[0080] A. Genetic Vaccines

[0081] Immunization against an antigen or a pathogen may be carried out by inoculating, transfecting, or transducing a cell, a tissue, an organ, or a subject with a nucleic acid encoding an antigen. One or more cells of a subject may then express the antigen encoded by the nucleic acid. Thus, the antigen encoding nucleic acids may comprise a “genetic vaccine” useful for vaccination and immunization of a subject. Expression in vivo of the nucleic acid may be, for example, from a plasmid type vector, a viral vector, a viral/plasmid construct vector, or an LEE or CEE construct.

[0082] In preferred aspects, the nucleic acid comprises a coding region that encodes all or part of an antigenic protein or peptide, or an immunologically functional equivalent thereof. Of course, the nucleic acid may comprise and/or encode additional sequences, including but not limited to those comprising one or more immunomodulators or adjuvants. A nucleic acid may be expressed in an in vivo, ex vivo or in vitro context, and in certain embodiments the nucleic acid comprises a vector for in vivo replication and/or expression. For exemplary compositions and methods see U.S. Pat. Nos. 5,589,466; 6,200,959; and 6,339,068; each of which is incorporated herein by reference.

[0083] B. Polypeptide Vaccines

[0084] In accordance with the present invention, one may utilize antigen compositions containing one or more antigenic polypeptide(s), as well as variants or mimics thereof, to induce an immune response in a subject. Antigenic polypeptides of the invention may be synthesized or purified from a natural or recombinant source and used as a component of a polypeptide vaccine. In various embodiments, polypeptides may include fusion proteins, isolated polypeptides, polypeptides conjugated with other immunogenic molecules or substances, polypeptide mixtures with other immunogenic molecules or substances, and the like (for exemplary methods and/or compositions see U.S. Pat. Nos. 5,976,544; 5,747,526; 5,725,863; and 5,578,453; each of which is incorporated herein by reference).

[0085] C. Purified Sub-Unit Vaccines

[0086] Compositions and methods described herein may be used to isolate a portion of a pathogen for use as a sub-unit vaccine. Sub-unit vaccines may utilize a partially or substantially purified molecule of a pathogen as an antigen. Polynucleotides and/or polypeptides of the invention may serve as a sub-unit vaccine or be used in combination with or be included in a sub-unit vaccine for herpesvirus. Methods of sub-unit vaccine preparation may include the extraction of certain antigenic molecules from a bacteria, virus, parasite and/or other pathogens by known purification methods. The preparation of a sub-unit vaccine may neutralize the pathogenicity of an entire pathogen rendering the vaccine, itself, non-infectious. Examples include influenza vaccine (viral surface hemagglutinin molecule) and the Neisseria meningitidis vaccine (capsular polysaccharide molecules). Advantages include high purity, only rare adverse reaction and highly specific immunity. Protein sub-units may be produced in non-pathogenic microbes by genetic engineering techniques making production much safer.

[0087] D. Conjugate Vaccines

[0088] The compositions and antigens of the invention may be conjugated to other molecules to produce a conjugate vaccine. Polysaccharides found to be poorly immunogenic by themselves have been shown to be quite good immunogens once they are conjugated to an immunogenic protein (U.S. Pat. No. 4,695,624, incorporated herein by reference). Conjugate vaccines may also be used to enhance the immunogenicity of an antigenic polypeptide. Conjugate vaccines utilize the immunologic properties of certain peptides to enhance the immunologic properties of glycolipids, polysaccharides, other polypeptides and the like. Certain embodiments of the invention contemplate using conjugates to enhance the immunogenicity of the polynucleotides and polypeptides of the invention. Examples of conjugate vaccines can be found in U.S. Pat. Nos. 6,309,646; 6,299,881; 6,248,334; 6,207,157; and 5,623,057; each of which is incorporated herein by reference.

[0089] E. Virus-like Particle (VLP) Vaccines

[0090] Polynucleotides and polypeptides of the invention may be used in conjunction with VLP vaccines. In many virus species, virus proteins are capable of assembling in the absence of nucleic acid to form so-called virus-like particles or VLPs. Similarly, the proteins which normally cooperate together with nucleic acid to form the virus core can assemble in the absence of nucleic acid to form so-called core-like particles (CLPs). The terms “virus-like particles” and “core-like particles” will be used to designate assemblages of virus proteins (or modified or chimeric virus proteins) in the absence of a viral genome. The addition of antigenic peptide in the context of these particles may be especially useful in the development of vaccines for oral or other mucosal routes of administration (for examples see U.S. Pat. No. 5,667,782, which is hereby incorporated by reference). In other embodiments of the invention a virosome also may be used. Examples of virosome compositions and methodology can be found in U.S. Pat. Nos. 4,148,876; 4,406,885; 4,826,687; and Kaneda, 2000, each of which is incorporated herein by reference.

[0091] F. Cell Mediated Vaccines

[0092] An alternative method of presenting antigens is to use genetically modified cells as an expression or delivery vehicle for polynucleotides or polypeptides of the invention. For example, cells may be isolated from a subject or another donor and transformed with a genetic construct that expresses an antigen, as described herein. Following selection, antigen-expressing cells are cultured as needed. The cells may then be introduced or reintroduced to a subject, where these cells express an antigen and induce an immune response (see U.S. Pat. Nos. 6,228,640; 5,976,546; and 5,891,432, each of which is incorporated herein by reference).

[0093] In certain embodiments, cell mediated vaccines may include vaccines comprising antigen presenting cells (APC). A cell that displays or presents an antigen normally or preferentially with a class II major histocompatibility molecule or complex to an immune cell is an “antigen presenting cell.” Secreted or soluble molecules, such as for example, cytokines and adjuvants, may also aid or enhance the immune response against an antigen. Such molecules are well known to one of skill in the art, and various examples are described herein.

[0094] The dendritic cell (DC) is a cell type that may be used for cell-mediated vaccination, as they are potent antigen presenting cells, effective in the stimulation of both primary and secondary immune responses (Steinman, 1999; Celluzzi and Falo, 1997). It is contemplated in the present invention that the exposure or transformation of dendritic cells to an antigenic composition of the invention, will typically elicit a potent immune response specific for a virus of the Herpesvirus family, e.g. HSV-1 or HSV-2. In particular embodiments an antigen may be reacted or coated with antibodies prior to presentation to an APC.

[0095] G. Edible Vaccines

[0096] An edible vaccine is a food plant or food-stuff that is used in delivering an antigen that is protective against an infectious disease, a pathogen, an organism, a bacterium, a virus or a non-infectious disease such as an autoimmune disease. In particular, the invention provides for an edible vaccine that induces a state of immunization against a member of the Herpesvirus family. The present invention may also include gene constructs or chimeric gene constructs comprising a coding sequence of at least one of the polypeptides, peptides, or fragments thereof of the invention, plant cells and transgenic plants transformed with said gene constructs or chimeric gene constructs, and methods of preparing an edible vaccine from these plant cells and transgenic plants. For exemplary methods see U.S. Patent publication 20020055618 and U.S. Pat. Nos. 5,914,123; 6,034,298; 6,136,320; 6,444,805; and 6,395,964, which are incorporated herein by reference. The present invention also provides methods of treating disease or infection with edible vaccines and compositions comprising edible vaccines according to the invention.

[0097] Numerous plants may be useful for the production of an edible vaccine, including: tobacco, tomato, potato, eggplant, pepino, yam, soybean, pea, sugar beet, lettuce, bell pepper, celery, carrot, asparagus, onion, grapevine, muskmelon, strawberry, rice, sunflower, rapeseed/canola, wheat, oats, maize, cotton, walnut, spruce/conifer, poplar and apple. An edible vaccine may include a plant cell transformed with a nucleic acid construct comprising a promoter and a sequence encoding a peptide of the invention. The sequence may optionally encode a chimeric protein, comprising, for example, a cholera toxin subunit B peptide fused to the peptide. Plant promoters of the invention include, but are not limited to CaMV 35S, patatin, mas, and granule-bound starch synthase promoters. Additional useful promoters and enhancers are described in WO 99/54452, incorporated herein by reference.

[0098] The edible vaccine of the invention can be administered to a mammal suffering from or at risk of disease or infection. Preferably, an edible vaccine is administered orally, e.g. consuming a transgenic plant of the invention. The transgenic plant can be in the form of a plant part, extract, juice, liquid, powder, or tablet. The edible vaccine can also be administered via an intranasal route.

[0099] H. Live Vector Vaccines

[0100] In another embodiment, a live vector vaccine may be prepared comprising attenuated and/or non-pathogenic micro-organisms, e.g. viruses or bacteria containing polynucleotides or nucleic acids encoding the peptides or antigens of the present invention expressed in the same or different micro-organisms. Live vector vaccines, also called “carrier vaccines” and “live antigen delivery systems”, comprise an exciting and versatile area of vaccinology (Levine et al, 1990; Morris et al., 1992; Barletta et al., 1990; Dougan et al., 1987; and Curtiss et al., 1989; U.S. Pat. Nos. 5,783,196; 5,648,081; and 6,413,768; each of which is incorporated herein by reference). In this approach, a live viral or bacterial vaccine is modified so that it expresses protective foreign antigens of another microorganism, and delivers those antigens to the immune system, thereby stimulating a protective immune response. Live bacterial vectors that are being promulgated include, among others, attenuated Salmonella (Levine et al., 1990; Morris et al., 1992; Dougan et al., 1987; and Curtiss et al., 1989), Bacille Calmette Guerin (Barletta et al., 1990), Yersinia enterocolitica (Van Damme et al., 1992), V. cholerae O1 (Viret et al., 1993)) and E. coli (Hale, 1990). The use of attenuated organisms as live vectors/vaccines expressing protective antigens of relevant pathogens is well-known.

[0101] I. Attenuated Pathogen Vaccines

[0102] In certain embodiments, a herpesvirus antigen may be incorporated in or coupled to an attenuated pathogen or cell, which may encode, express, or is coupled to the antigen. Attenuation may be accomplished by genetic engineering, altering pathogen culture conditions, treatment of the pathogen, such as chemical or heat inactivation or other means. The antigen encoded by an attenuated pathogen is one which when expressed or exposed is capable of inducing an immune response and providing protection and/or therapy in an animal or human against a virus from one or more members of the Herpesvirus family from which the antigen was derived, or from a related organism. Herpesvirus antigens may be introduced into an attenuated pathogen by way of DNA encoding the same. For exemplary methods and compositions see U.S. Pat. Nos. 5,922,326; 5,922,326; 5,607,852 and 6,180,110.

[0103] J. Killed Pathogen Vaccines

[0104] An antigen may also be associated with a killed or inactivated pathogen or cell. Killed pathogen vaccines include preparations of wild-type pathogens, or a closely-related pathogen, that has been treated to make them non-viable (inactivated). Methods of inactivation include heat-killing of a pathogen. One advantage of heat killing is that it leaves no extraneous residue, but may alter protein conformations and hence immunogenic specificity, however it is useful for vaccines in which the immunogenic molecule is a polysaccharide. Alternative methods of killing include chemicals (β-propio-lacone or formaldehyde), which may leave a toxic residue, but does not alter protein conformations significantly and preserves immunogenic specificity. Killed pathogen vaccines may be use in combination with other vaccine vehicles as described herein. For exemplary methods and compositions see U.S. Pat. Nos. 6,303,130, 6,254,873, 6,129,920 and 5,523,088, each of which is incorporated herein by reference.

[0105] K. Humanized Antibodies

[0106] Polypeptides, fragments or mimetics thereof, of the invention may be used to produce anti-idiotypic antibodies for use in a vaccine. In an anti-idiotype vaccine the immunogen is an antibody against the Fab end of a second antibody which was raised against an antigenic molecule of a pathogen. The Fab end of the anti-idiotype antibody will have the same antigenic shape as the antigenic molecule of the pathogen and may then be used as an antigen (see exemplary U.S. Pat. Nos. 5,614,610 and 5,766,588). “Humanized” antibodies for use herein may be antibodies from non-human species wherein one or more selected amino acids have been exchanged for amino acids more commonly observed in human antibodies. This can be readily achieved through the use of routine recombinant technology, particularly site-specific mutagenesis. Humanized antibodies may also be used as a passive immunization agent as described below.

III. Antigen Screening Methods

[0107] Methods of screening for at least one test polypeptide or test polynucleotide encoding a polypeptide for an ability to produce an immune response may comprise (i) obtaining at least one test polypeptide or test polynucleotide by (a) amplifying the polynucleotide by PCR; (b) building the polynucleotide by gene assembly; (c) modifying the amino acid sequence of a known antigenic polypeptide or polynucleotide sequence of a polynucleotide encoding a known antigenic polypeptide; (d) obtaining a homolog of a known antigenic sequence of a polynucleotide encoding such a homolog, or (e) obtaining a homolog of a known antigenic sequence or a polynucleotide encoding such a homolog and modifying the amino acid sequence of the homolog or the polynucleotide sequence of the polynucleotide encoding such a homolog; and (ii) testing the test polypeptide or test polynucleotide under appropriate conditions to determine whether the test polypeptide is antigenic or the test polynucleotide encodes an antigenic polypeptide.

[0108] A method of screening may include identifying a polypeptide by testing mixtures of linear polynucleotides that encode a polypeptide for protection against disease or infection.

[0109] A method of screening may include obtaining a test polypeptide by modifying the amino acid sequence or obtaining a homolog of a least one polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116 or fragment thereof. The method of screening may also include a test polypeptide comprising an amino acid sequence of at least one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116 or fragment thereof, which has been modified.

[0110] In other embodiments the method of screening may also include obtaining a test polynucleotide comprising a polynucleotide encoding a modified amino acid sequence of or a homolog of at least one polypeptide having a sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116 or fragment thereof or obtaining a test polynucleotide comprising modifying the polynucleotide sequence of at least one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 and/or SEQ ID NO:115 or fragment thereof. In various embodiments a method of screening may further comprise identifying at least one test polypeptide as being antigenic or at least one test polynucleotide as encoding an antigenic polypeptide.

[0111] The methods described may include placing an identified antigenic polypeptide or the polynucleotide encoding an antigenic polypeptide in a pharmaceutical composition. The methods may also include using an identified antigenic polypeptide or polynucleotide encoding an antigenic polypeptide to vaccinate a subject. In certain aspects a subject may be vaccinated against a herpesvirus and in particular HSV-1. Additionally, the subject may be vaccinated against a non-herpesvirus disease.

[0112] Additional embodiments include a method of preparing a vaccine including obtaining an antigenic polypeptide or a polynucleotide encoding an antigenic polypeptide, as determined to be antigenic by known screening methods and/or screening methods described herein, and placing a polypeptide or a polynucleotide in a vaccine composition. A vaccine composition may be used in vaccinating a subject by preparing a vaccine as described and vaccinating a subject with the vaccine.

IV. Herpesvirus Antigens

[0113] Antigens of the invention are typically isolated from members of Herpesvirus family, in particular the Alphaherperviruses, namely HSV-1, HSV-2, VZV, and BHV. In particular embodiments, the immunization of vertebrate animals according to the present invention includes a library of herpesvirus coding sequences in expression constructs. In various embodiments, a DNA expression construct may be in the context of a linear expression elements (“LEEs”) and/or circular expression elements (“CEEs”), which typically encompass a complete gene (promoter, coding sequence, and terminator). These LEEs and CEEs can be directly introduced into and expressed in cells or an intact organism to yield expression levels comparable to those from a standard supercoiled, replicative plasmid (Sykes and Johnston, 1999). In specific embodiments, an expression library of HSV (e.g., HSV-1 and HSV-2) is provided. Expression library immunization, ELI herein, is well known in the art (U.S. Pat. No. 5,703,057, specifically incorporated herein by reference). In certain embodiments, the invention provides an ELI method applicable to virtually any pathogen and requires no knowledge of the biological properties of the pathogen. The method operates on the assumption, generally accepted by those skilled in the art, that all the possible polypeptide-based determinants of any pathogen are encoded in its genome. The inventors have previously devised methods of identifying vaccines using a genomic expression library representing all of the polypeptide-based determinants of a pathogen (U.S. Pat. No. 5,703,057). The method uses to its advantage the simplicity of genetic immunization to sort through a genome for immunological reagents in an unbiased, systematic fashion.

[0114] The preparation of an expression library is performed using the techniques and methods familiar to one of skill in the art (Sambrook et al., 2001). The pathogen's genomic sequence, may or may not be known. Thus one obtains DNA (or cDNA), representing substantially the entire genome of the pathogen (e.g., HSV-1). The DNA is broken up, by physical fragmentation or restriction endonuclease, into segments of some length so as to provide a library of about 10⁵ (approximately 18× the genome size) members. The library is then tested by inoculating a subject with purified DNA of the library or sub-library and the subject challenged with a pathogen, wherein immune protection of the subject from pathogen challenge indicates a clone that confers a protective immune response against infection.

[0115] In some embodiments of the invention, a herpesvirus antigen may be obtained by methods comprising: (a) preparing a sequence-directed linear expression element library prepared from nucleic acids (e.g., genomic DNA) of a member of the Herpesvirus family; (b) administering at least one LEE of the library in a pharmaceutically acceptable carrier into an animal; and (c) expressing at least one herpesvirus antigen in the animal. The expression library may comprise at least one or more polynucleotides having a sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 and/or SEQ ID NO:115; a complement, a fragment, or a closely related sequences thereof. The polynucleotides of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:79, SEQ ID NO:83, SEQ ID NO:87, SEQ ID NO:91, SEQ ID NO:95, SEQ ID NO:99, SEQ ID NO:103, SEQ ID NO:107, SEQ ID NO:111, and SEQ ID NO:113 represent exemplary gene fragments identified using ELI and related technology, as described herein. In addition, polynucleotides of SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:31, SEQ ID NO:39, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:55, SEQ ID NO:63, SEQ ID NO:63, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:77, SEQ ID NO:81, SEQ ID NO:85, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:101, SEQ ID NO:105, and SEQ ID NO:115 are representative of exemplary full length gene sequences identified using ELI and related technologies, as described herein. The expression library may be cloned in a genetic immunization vector or any other suitable expression construct. The construct may comprise a gene encoding a mouse ubiquitin polypeptide positioned such that it produces a herpesvirus/mouse ubiquitin/antigen fusion protein designed to link the expression library polynucleotides to the ubiquitin gene. The vector may comprise a promoter operable in eukaryotic cells, for example a CMV promoter, or any other suitable promoter. In such methods, the polynucleotide may be administered by an intramuscular injection, intradermal injection, or epidermal injection or particle bombardment. The polynucleotide may likewise be administered by intravenous, subcutaneous, intralesional, intraperitoneal, oral, other mucosal, or inhaled routes of administration. In some specific, exemplary embodiments, the administration may be via epidermal injection/bombardment of at least 0.0025 μg to 5.0 μg of the polynucleotide. Administration may also be via intramuscular injection of at least 0.1 μg to 50 μg of the polynucleotide. In some cases, a second administration, for example, an intramuscular injection and/or epidermal injection, may be administered at least about two weeks or longer after the first administration. In these methods, the polynucleotide may be, but need not be, cloned into a viral expression vector, for example, a viral expression vector, including adenovirus, herpes-simplex virus, retrovirus or adeno-associated virus vectors. The polynucleotide may also be administered in any other method disclosed herein or known to those of skill in the art.

[0116] In still other embodiments, a herpesvirus antigen(s) maybe obtained by methods comprising: (a) preparing a pharmaceutical composition comprising at least one polynucleotide encoding an Herpesvirus antigen or fragment thereof; (b) administering one or more ORFs of the library in a pharmaceutically acceptable carrier into an animal; and (c) expressing one or more Herpesvirus antigens in the animal. The one or more polynucleotides can be comprised in one or more expression vectors.

[0117] Alternatively, methods of obtaining Herpesvirus antigen(s) may comprise: (a) preparing a pharmaceutical composition of at least one Herpesvirus antigen or an antigenic fragment thereof; and (b) administering the at least one antigen or fragment into an animal. The antigen(s) may be administered by an intramuscular injection, intravenous injection, subcutaneous injection, intradermal injection, epidermal injection, by inhalation, oral, or other mucosal routes.

[0118] Also described herein, are methods of obtaining polynucleotide sequences effective for generating an immune response against members of the Herpesvirus family, in particular HSV-1, in a non-human animal comprising: (a) preparing an expression library from genomic DNA of a virus selected from the Herpesvirus family; (b) administering one or more components of the library in a pharmaceutically acceptable carrier into the animal in an amount effective to induce an immune response; and (c) selecting from the library the polynucleotide sequences that induce an immune response, wherein the immune response in the animal is protective against herpesvirus infection. Such methods may further comprise testing the animal for immune resistance against a herpesvirus infection by challenging the animal with herpesvirus. In some cases, the genomic DNA has been fragmented physically or by restriction enzymes. DNA fragments may be, on average, about 300-1500 base pairs in length. In some cases, each component in the library may comprise a sequence encoding a mouse ubiquitin fusion polypeptide designed to link the expression library polynucleotides to the ubiquitin gene, but this is not required in all cases. In some cases, the library may comprise about 4 to about 400 or more ORFs; in more specific cases, the library could have 1×10⁵ ORFs. In some preferred methods, about 0.01 μg to about 5 μg of DNA, of the open-reading frames is administered into the animal. In some situations the genomic DNA, gene or cDNA is introduced by intramuscular injection or epidermal injection. In some versions of these protocols, the expression library further comprises a promoter operably linked to the DNA that permits expression in a vertebrate animal cell.

[0119] The application also discloses methods of preparing antigens that confer protection against infection in a vertebrate animal comprising the steps of: (a) preparing an ORF expression library from PCR-amplified genomic DNA of a herpes simplex virus; (b) administering one or more ORFs of the library in a pharmaceutically acceptable carrier into the animal in an amount effective to induce an immune response; (c) selecting from the library the polynucleotide sequences that induce an immune response (d) expressing the polynucleotide sequences in cell culture, such as a eukaryotic or prokaryotic expression system; and (e) purifying the polypeptide(s) expressed in the cell culture. Often, these methods further comprise testing the animal for immune resistance against infection by challenging the animal with one or more herpesvirus or other pathogens.

[0120] In yet other embodiments the invention relates to methods of preparing antibodies against a herpesvirus antigen comprising the steps of: (a) identifying an HSV antigen that confers immune resistance against an infection of HSV or other member of the family when challenged with a selected member of the Herpesvirus family; (b) generating an immune response in a vertebrate animal with the antigen identified in step (a); and (c) obtaining antibodies produced in the animal.

[0121] The invention also relates to methods of preparing antibodies against a herpesvirus polypeptide that is immunogenic, but not necessarily protective as a vaccine. For example herpes-specific antibodies might be useful in research analyses, diagnosis or antibody-therapy. Immunizing animals with the identified antigen might produce antibodies, or expressing the gene encoding the antibody could produce them. In other methods of producing herpesvirus antibodies, the identified antigen might be used for panning against a phage library. This procedure would isolate single chain phage-displayed antibodies in vitro.

[0122] A. Nucleic Acids

[0123] The present invention provides compositions comprising herpesvirus polynucleotides and methods of using these compositions to induce a protective immune response in vertebrate animals. In certain embodiments, an animal may be challenged with an herpesvirus infection.

[0124] In various embodiments of the invention, genes and polynucleotides encoding herpesvirus polypeptides, as well as fragments thereof, are provided. In other embodiments, a polynucleotide encoding an herpesvirus polypeptide or a polypeptide fragment may be expressed in prokaryotic or eukaryotic cells. The expressed polypeptides or polypeptide fragments may be purified for use as herpesvirus antigens in the vaccination of vertebrate animals or in generating antibodies immunoreactive with herpesvirus polypeptides or polypeptide fragments.

[0125] The present invention is not limited in scope to the genes of any particular virus of the Herpesvirus family. One of ordinary skill in the art could, using the nucleic acids described herein, readily identify related homologs in the Herpesvirus family. In addition, it should be clear that the present invention is not limited to the specific nucleic acids disclosed herein. As discussed below, a specific “herpesvirus” gene or polynucleotide fragment may contain a variety of different bases and yet still produce a corresponding polypeptide that is functionally indistinguishable, and in some cases structurally indistinguishable, from the polynucleotide sequences disclosed herein.

[0126] 1. Nucleic Acids Encoding Herpesvirus Antigens

[0127] The present invention provides polynucleotides encoding antigenic herpesvirus polypeptides capable of inducing a protective immune response in vertebrate animals and for use as an antigen to generate anti-herpesvirus antibodies or antibodies reactive with other pathogens. In certain instances, it may be desirable to express herpesvirus polynucleotides encoding a particular antigenic herpesvirus polypeptide domain or sequence to be used as a vaccine, in generating anti-herpesvirus antibodies or in generating antibodies reactive with other pathogens. Nucleic acids according to the present invention may encode an entire HSV gene, or any other fragment of the HSV sequences set forth herein. The nucleic acid may be derived from PCR-amplified DNA of a particular organism. In other embodiments, however, the nucleic acid may comprise genomic DNA, complementary DNA (cDNA), or synthetically built DNA. A protein may be derived from the designated sequences for use in a vaccine or in methods for isolating antibodies.

[0128] The term “cDNA” is intended to refer to DNA prepared using messenger RNA (mRNA) as a template. The advantage of using a cDNA, as opposed to DNA amplified or synthesized from a genomic DNA template or a non-processed or partially processed RNA template is that a cDNA primarily contains coding sequences comprising the open reading frame (ORF) of the corresponding protein. There may be times when the full or partial genomic sequence is preferred, such as where the non-coding regions are required for optimal expression.

[0129] In still further embodiments, a herpesvirus polynucleotide from a given species may be represented by natural variants that have slightly different nucleic acid sequences but, nonetheless, encode the same polypeptide (see Table 1 below). In addition, it is contemplated that a given herpesvirus polypeptide from a species may be generated using alternate codons that result in a different nucleic acid sequence but encodes the same polypeptide.

[0130] As used in this application, the term “a nucleic acid encoding a herpesvirus polynucleotide” refers to a nucleic acid molecule that has been isolated free of total cellular nucleic acid. The term “functionally equivalent codon” is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine (Table 1, below), and also refers to codons that encode biologically equivalent amino acids, as discussed in the following pages. TABLE 1 Amino Acids Codons Alanine Ala A GCA GCC GCG GCU Cysteine Cys C UGC UGU Aspartic acid Asp D GAC GAU Glutamic acid Glu E GAA GAG Phenylalanine Phe F UUC UUU Glycine Gly G GGA GGC GGG GGU Histidine His H CAC CAU Isoleucine Ile I AUA AUC AUU Lysine Lys K AAA AAG Leucine Leu L UUA UUG CUA CUC CUG CUU Methionine Met M AUG Asparagine Asn N AAC AAU Proline Pro P CCA CCC CCG CCU Glutamine Gln Q CAA CAG Arginine Arg R AGA AGG CGA CGC CGG CGU Serine Ser S AGC AGU UCA UCC UCG UCU Threonine Thr T ACA ACC ACG ACU Valine Val V GUA GUC GUG GUU Tryptophan Trp W UGG Tyrosine Tyr Y UAC UAU

[0131] Allowing for the degeneracy of the genetic code, sequences are considered essentially the same as those set forth in a herpesvirus gene or polynucleotide that have at least about 50%, usually at least about 60%, more usually about 70%, most usually about 80%, preferably at least about 90% and most preferably about 95% of nucleotides that are identical to the nucleotides of a given herpesvirus gene or polynucleotide. Sequences that are essentially the same as those set forth in a herpesvirus gene or polynucleotide may also be functionally defined as sequences that are capable of hybridizing to a nucleic acid segment containing the complement of a herpesvirus polynucleotide under standard conditions. The term closely related sequences refers to sequences with either substantial sequence similarity or sequence that encode proteins that perform or invoke similar antigenic responses as described herein. The term closely related sequence is used herein to designate a sequence with a minimum of 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% similarity with a polynucleotide or polypeptide with which it is being compared.

[0132] The DNA segments of the present invention include those encoding biologically functional equivalent herpesvirus proteins and peptides, as described above. Such sequences may arise as a consequence of codon redundancy and amino acid functional equivalency that are known to occur naturally within nucleic acid sequences and the proteins thus encoded. Alternatively, functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged. Changes may be engineered through the application of site-directed mutagenesis techniques or may be introduced randomly and screened later for the desired function, as described below.

[0133] 2. Non-bacterially Amplified Nucleic Acids

[0134] A nucleic acid or polynucleotide of the invention may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, or enzymatic production. Non-limiting examples of a synthetic nucleic acid (e.g., a synthetic oligonucleotide), include a nucleic acid made by in vitro chemical synthesis using phosphotriester, phosphite or phosphoramidite chemistry and solid phase techniques such as described in EP 266,032, incorporated herein by reference, or via deoxynucleoside H-phosphonate intermediates as described by Froehler et al., 1986 and U.S. Pat. No. 5,705,629, each incorporated herein by reference. In the methods of the present invention, one or more oligonucleotide or polynucleotide may be used. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Pat. Nos. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, and 5,602,244, each of which is incorporated herein by reference.

[0135] A non-limiting example of an enzymatically produced nucleic acid or polynucleotide includes one produced by enzymes in amplification reactions such as PCR™ (see for example, U.S. Pat. Nos. 4,683,202 and 4,682,195, each incorporated herein by reference), or the synthesis of an oligonucleotide described in U.S. Pat. No. 5,645,897, incorporated herein by reference.

[0136] Another method for nucleic acid or polynucleotide amplification is the ligase chain reaction (“LCR”), disclosed in EPO No. 320 308, incorporated herein by reference in its entirety. In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a single unit. By temperature cycling, as in PCR™, bound ligated units dissociate from the target and then serve as “target sequences” for ligation of excess probe pairs. U.S. Pat. No. 4,883,750 describes a method similar to LCR for binding probe pairs to a target sequence.

[0137] Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting “di-oligonucleotide”, thereby amplifying the di-oligonucleotide, may also be used in the amplification step of the present invention, see Wu et al., (1989), which is incorporated herein by reference in its entirety.

[0138] 3. Oligonucleotides

[0139] Naturally, the present invention also encompasses oligonucleotides that are complementary, or essentially complementary to the sequences of an herpesvirus polynucleotide. Nucleic acid sequences that are “complementary” are those that are capable of base-pairing according to the standard Watson-Crick complementary rules. As used herein, the term “complementary sequences” means nucleic acid sequences that are substantially complementary, as may be assessed by the same nucleotide comparison set forth above, or as defined as being capable of hybridizing to the nucleic acid segment of an herpesvirus polynucleotide under relatively stringent conditions such as those described herein.

[0140] Alternatively, the hybridizing segments may be shorter oligonucleotides. Sequences of 17 bases long should occur only once in the human genome and, therefore, suffice to specify a unique target sequence. Although shorter oligomers are easier to make and increase in vivo accessibility, numerous other factors are involved in determining the specificity of hybridization. Both binding affinity and sequence specificity of an oligonucleotide to its complementary target increases with increasing length. It is contemplated that exemplary oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more base pairs will be used, although others are contemplated. Longer polynucleotides encoding 250, 500, 1000, 1212, 1500, 2000, 2500, 3000 or 3500 bases and longer are contemplated as well. Such oligonucleotides or polynucleotides will typically find use, for example, as probes in Southern and Northern blots and as primers in amplification reactions or for vaccines.

[0141] Suitable hybridization conditions will be well known to those of skill in the art. In certain applications, for example, substitution of amino acids by site-directed mutagenesis, it is appreciated that lower stringency conditions are required. Under these conditions, hybridization may occur even though the sequences of probe and target strand are not perfectly complementary, but are mismatched at one or more positions. Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA. Typically, a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered (see Sambrook et al., 2001).

[0142] One method of using probes and primers of the present invention is in the search for genes related to the polynucleotides of HSV identified as encoding antigenic HSV polypeptides or, more particularly, homologs of HSV from other related viruses. Normally, the target DNA will be a genomic or cDNA library, although screening may involve analysis of RNA molecules. By varying the stringency of hybridization, and the region of the probe, different degrees of homology may be discovered (see Sambrook et al., 2001).

[0143] Another method of using oligonucleotides of the present invention is to design short RNA molecules for specific expression interference in vivo (siRNA).

[0144] B. Polypeptides and Antigens

[0145] For the purposes of the present invention a herpesvirus polypeptide, i.e., a polypeptide derived from a virus of the Herpesvirus family, may be a naturally-occurring polypeptide that has been identified by the methods described herein and extracted using protein extraction techniques well known to those of skill in the art. In particular embodiments, a herpesvirus antigen may be identified by ELI, RELI, or DELI and prepared in a pharmaceutically acceptable carrier for the vaccination of an animal.

[0146] In alternative embodiments, the herpesvirus polypeptide or antigen may be a synthetic peptide. In still other embodiments, the peptide may be a recombinant peptide produced through molecular engineering techniques. The present section describes the methods and compositions involved in producing a composition of herpesvirus polypeptides for use as antigens in the present invention.

[0147] 1. Herpesvirus Polypeptides

[0148] Methods for screening and identifying herpesvirus genes that confer protection against herpesvirus infection are described herein. The herpesvirus polypeptide encoding genes or their corresponding cDNA may be inserted into an appropriate expression vector, LEE or CEE for the production of antigenic herpesvirus polypeptides. In addition, sequence variants of the polypeptide may be prepared. Polypeptide sequence variants may be minor sequence variants of the polypeptide that arise due to natural variation within the population or they may be homologs found in other viruses. They also may be sequences that do not occur naturally, but that are sufficiently similar that they function similarly and/or elicit an immune response that cross-reacts with natural forms of the polypeptide. Sequence variants can be prepared by standard methods of site-directed mutagenesis such as those described in Sambrook et al. 2001.

[0149] Another synthetic or recombinant variation of an antigenic herpesvirus polypeptide is a polyepitope moiety comprising repeats of epitope determinants found naturally in herpesvirus proteins. Such synthetic polyepitope proteins can be made up of several homomeric repeats of any one herpesvirus protein epitope; or may comprise of two or more heteromeric epitopes expressed on one or several herpesvirus protein epitopes.

[0150] Amino acid sequence variants of the polypeptide can be substitutional, insertional or deletion variants. Deletion variants lack one or more residues of the native protein which are not essential for function or immunogenic activity. Another common type of deletion variant is one lacking secretory signal sequences or signal sequences directing a protein to bind to a particular part of a cell.

[0151] Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and may be designed to modulate one or more properties of the polypeptide such as stability against proteolytic cleavage. Substitutions preferably are conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for example, the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.

[0152] Insertional variants include fusion proteins such as those used to allow rapid purification of the polypeptide and also can include hybrid proteins containing sequences from other proteins and polypeptides that are homologs of the polypeptide. For example, an insertional variant could include portions of the amino acid sequence of the polypeptide from one species, together with portions of the homologous polypeptide from another species or subspecies. Other insertional variants can include those in which additional amino acids are introduced within the coding sequence of the polypeptide. These typically are smaller insertions than the fusion proteins described above and are introduced, for example, into a protease cleavage site.

[0153] In one embodiment, major antigenic determinants of the polypeptide may be identified by an empirical approach in which portions of the gene encoding the polypeptide are expressed in a recombinant host, and the resulting proteins tested for their ability to elicit an immune response. For example, the polymerase chain reaction (PCR) can be used to prepare a range of cDNAs encoding peptides lacking successively longer fragments of the C-terminus of the protein. The immunogenic activity of each of these peptides then identifies those fragments or domains of the polypeptide that are essential for this activity. Further studies in which only a small number of amino acids are removed or added at each iteration then allows the location of other antigenic determinants of the polypeptide. Thus, use of the polymerase chain reaction, a technique for amplifying a specific segment of DNA via multiple cycles of denaturation-renaturation, using a thermostable DNA polymerase, deoxyribonucleotides and primer sequences is contemplated in the present invention (Mullis, 1990; Mullis et al., 1992).

[0154] Another embodiment for the preparation of the polypeptides according to the invention is the use of peptide mimetics. Mimetics are molecules that mimic elements of protein secondary structure. Because many proteins exert their biological activity via relatively small regions of their folded surfaces, their actions can be reproduced by much smaller designer (mimetic) molecules that retain the bioactive surfaces and have potentially improved pharmacokinetic/dynamic properties (Fairlie et al., 1998). Methods for mimicking individual elements of secondary structure (helices, turns, strands, sheets) and for assembling their combinations into tertiary structures (helix bundles, multiple loops, helix-loop-helix motifs) have been reviewed (Fairlie et al., 1998; Moore, 1994). Methods for predicting, preparing, modifying, and screening mimetic peptides are described in U.S. Pat. Nos. 5,933,819 and 5,869,451 (each specifically incorporated herein by reference). It is contemplated in the present invention, that peptide mimetics will be useful in screening modulators of an immune response.

[0155] Modifications and changes may be made in the sequence of a gene or polynucleotide and still obtain a molecule that encodes a protein or polypeptide with desirable characteristics. The following is a discussion based upon changing the amino acids of a protein or polypeptide to create an equivalent, or even an improved, second-generation molecule. The amino acid changes may be achieved by changing the codons of the DNA sequence, or by chemical peptide synthesis, according to the following examples.

[0156] For example, certain amino acids may be substituted for other amino acids in a polypeptide structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a polypeptide that defines the biological activity, certain amino acid substitutions can be made in a polypeptide sequence, and its underlying DNA coding sequence, and nevertheless obtain a polypeptide with like or improved properties. It is thus contemplated by the inventor that various changes may be made in the DNA sequences of the polynucleotides and genes of the invention without appreciable loss of their biological utility or activity. Table 1 shows the codons that encode particular amino acids.

[0157] In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

[0158] It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein or polypeptide with similar biological activity. It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

[0159] It is also understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent and immunologically equivalent protein.

[0160] Amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine, as well as others.

[0161] 2. Synthetic Polypeptides

[0162] Contemplated in the present invention are herpesvirus proteins and related peptides for use as antigens. In certain embodiments, the synthesis of an herpesvirus peptide fragment is considered. The peptides of the invention can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, (1984); Tam et al., (1983); Merrifield, (1986); and Barany and Merrifield (1979), each incorporated herein by reference.

[0163] 3. Polypeptide Purification

[0164] Herpesvirus polypeptides of the present invention are typically used as antigens for inducing a protective immune response in an animal and for the preparation of anti-herpesvirus antibodies. Thus, certain aspects of the present invention concern the purification, and in particular embodiments, the substantial purification, of a herpesvirus polypeptide. The term “purified protein or peptide” as used herein, is intended to refer to a composition, isolatable from other components, wherein the protein or peptide is purified to any degree relative to its naturally-obtainable state. A purified protein or peptide therefore also refers to a protein or peptide, free from the environment in which it may naturally occur.

[0165] Generally, “purified” will refer to a protein or peptide composition that has been subjected to fractionation to remove various other components, and which composition substantially retains its expressed biological activity. Where the term “substantially purified” is used, this designation will refer to a composition in which the protein or peptide forms the major component of the composition, such as constituting about 50% or more of the proteins in the composition.

[0166] Various methods for quantifying the degree of purification of the protein or peptide will be known to those of skill in the art in light of the present disclosure. These include, for example, determining the specific activity of an active fraction, or assessing the number of polypeptides within a fraction by SDS/PAGE analysis. A preferred method for assessing the purity of a fraction is to calculate the specific activity of the fraction, to compare it to the specific activity of the initial extract, and to thus calculate the degree of purity, herein assessed by a “-fold purification number.” The actual units used to represent the amount of activity will, of course, be dependent upon the particular assay technique chosen to follow the purification and whether or not the expressed protein or peptide exhibits a detectable activity.

[0167] Various techniques suitable for use in protein purification will be well known to those of skill in the art. These include, for example, precipitation with ammonium sulphate, PEG, antibodies or by heat denaturation, which may be followed by centrifugation; chromatography steps such as ion exchange, gel filtration, reverse phase, hydroxylapatite and affinity chromatography; isoelectric focusing; gel electrophoresis; and combinations of such and other techniques. As is generally known in the art, it is believed that the order of conducting the various purification steps may be changed, or that certain steps may be omitted, and still result in a suitable method for the preparation of a substantially purified protein or peptide.

[0168] There is no general requirement that the protein or peptide always be provided in their most purified state. Indeed, it is contemplated that less substantially purified products will have utility in certain embodiments. Partial purification may be accomplished by using fewer purification steps in combination, or by utilizing different forms of the same general purification scheme. Methods exhibiting a lower degree of relative purification may have advantages in total recovery of protein product, or in maintaining the activity of an expressed protein.

[0169] To purify a desired protein, polypeptide, or peptide, which is a natural or recombinant composition comprising at least some specific proteins, polypeptides, or peptides will be subjected to fractionation to remove various other components from the composition. Various techniques suitable for use in protein purification will be well known to those of skill in the art. The most commonly used separative procedure for chemically synthesized peptides is HPLC chromatography. Other procedures for protein purification include affinity chromatography (e.g., immunoaffinity chromatography) and other methods known in the art. For exemplary methods and a more detailed discussion see Marshak et al. (1996) or Janson and Ryden (1998).

[0170] C. Polynucleotide Delivery

[0171] In certain embodiments of the invention, an expression construct comprising an herpesvirus polynucleotide or polynucleotide segment under the control of a heterologous promoter operable in eukaryotic cells is provided. For example, the delivery of an HSV-1 antigen-encoding expression constructs can be provided in this manner. The general approach in certain aspects of the present invention is to provide a cell with an expression construct encoding a specific protein, polypeptide or peptide fragment, thereby permitting the expression of the antigenic protein, polypeptide or peptide fragment in the cell. Following delivery of the expression construct, the protein, polypeptide or peptide fragment encoded by the expression construct is synthesized by the transcriptional and translational machinery of the cell and/or the vaccine vector. Various compositions and methods for polynucleotide delivery are known (see Sambrook et al., 2001; Liu and Huang, 2002; Ravid et al., 1998; and Balicki and Beutler, 2002, each of which is incorporated herein by reference).

[0172] Viral and non-viral delivery systems are two of the various delivery systems for the delivery of an expression construct encoding an antigenic protein, polypeptide, polypeptide fragment. Both types of delivery systems are well known in the art and are briefly described below. There also are two primary approaches utilized in the delivery of an expression construct for the purposes of genetic immunization; either indirect, ex vivo methods or direct, in vivo methods. Ex vivo gene transfer comprises vector modification of (host) cells in culture and the administration or transplantation of the vector modified cells to a subject. In vivo gene transfer comprises direct introduction of the vaccine vector into the subject to be immunized.

[0173] In various embodiments, a nucleic acid to be expressed may be in the context of a linear expression elements (“LEEs”) and/or circular expression elements (“CEEs”), which typically encompass a complete set of gene expression components (promoter, coding sequence, and terminator). These LEEs and CEEs can be directly introduced into and expressed in cells or an intact organism to yield expression levels comparable to those from a standard supercoiled, replicative plasmid (Sykes and Johnston, 1999). In some alternative methods and compositions of the invention, LEE or CEE allows any open-reading frame (ORF), for example, PCR™ amplified ORFs, to be non-covalently linked to an eukaryotic promoter and terminator. These quickly linked fragments can be directly injected into animals to produce local gene expression. It has also been demonstrated that the ORFs can be injected into mice to produce antibodies to the encoded foreign protein by simply attaching mammalian promoter and terminator sequences.

[0174] In certain embodiments of the invention, the nucleic acid encoding herpesvirus or similar polynucleotide may be stably integrated into the genome of a cell. In yet further embodiments, the nucleic acid may be stably or transiently maintained in a cell as a separate, episomal segment of DNA. Such nucleic acid segments or “episomes” encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. How the expression construct is delivered to a cell and/or where in the cell the nucleic acid remains is dependent on the type of vector employed. The following gene delivery methods provide the framework for choosing and developing the most appropriate gene delivery system for a preferred application.

[0175] 1. Non-Viral Polynucleotide Delivery

[0176] In one embodiment of the invention, a polynucleotide expression construct may include recombinantly-produced DNA plasmids or in vitro-generated DNA. In various embodiments of the invention, an expression construct comprising, for example, a herpesvirus polynucleotide is administered to a subject via injection and/or particle bombardment (e.g., a gene gun). Polynucleotide expression constructs may be transferred into cells by accelerating DNA-coated microprojectiles to a high velocity, allowing the DNA-coated microprojectiles to pierce cell membranes and enter cells. In another preferred embodiment, polynucleotides are administered to a subject by needle injection. Injection of a polynucleotide expression construct may be given by intramuscular, intravenous, subcutaneous, intradermal, or intraperitoneal injection.

[0177] Particle Bombardment depends on the ability to accelerate DNA-coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein et al., 1987). Several devices for accelerating small particles have been developed. The most commonly used forms rely on high-pressure helium gas (Sanford et al., 1991). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

[0178] Transfer of an expression construct comprising herpesvirus or similar polynucleotides of the present invention also may be performed by any of the methods which physically or chemically permeabilize the cell membrane (e.g., calcium phosphate precipitation, DEAE-dextran, electroporation, direct microinjection, DNA-loaded liposomes and lipofectamine-DNA complexes, cell sonication, gene bombardment using high velocity microprojectiles and receptor-mediated transfection. In certain embodiments, the use of lipid formulations and/or nanocapsules is contemplated for the introduction of a herpesvirus polynucleotide, herpesvirus polypeptide, or an expression vector comprising a herpesvirus polynucleotide into host cells (see exemplary methods and compositions in Bangham et al., 1965; Gregoriadis, 1979; Dearner and Uster, 1983; Szoka and Papahadjopoulos 1978; Nicolau et al., 1987 and Watt et al., 1986; each of which is incorporated herein by reference). In another embodiment of the invention, the expression construct may simply consist of naked recombinant DNA, expression cassettes or plasmids.

[0179] 2. Viral Vectors

[0180] In certain embodiments, it is contemplated that a herpesvirus gene or other polynucleotide that confers immune resistance to infection pursuant to the invention may be delivered by a viral vector. The capacity of certain viral vectors to efficiently infect or enter cells, to integrate into a host cell genome and stably express viral genes, have led to the development and application of a number of different viral vector systems (Robbins and Ghivizzani, 1998). Viral systems are currently being developed for use as vectors for ex vivo and in vivo gene transfer. For example, adenovirus, herpes-simplex virus, retrovirus and adeno-associated virus vectors are being evaluated currently for treatment of diseases such as cancer, cystic fibrosis, Gaucher disease, renal disease and arthritis (Robbins and Ghivizzani, 1998; Imai et al., 1998; U.S. Pat. No. 5,670,488).

[0181] In particular embodiments, an adenoviral (U.S. Pat. Nos. 6,383,795; 6,328,958 and 6,287,571, each specifically incorporated herein by reference); retroviral (U.S. Pat. Nos. 5,955,331; 5,888,502; and 5,830,725, each specifically incorporated herein by reference); Herpes-Simplex Viral (U.S. Pat. Nos. 5,879,934 and 5,851,826, each specifically incorporated herein by reference in its entirety); Adeno-associated virus (AAV); poxvirus (e.g., vaccinia virus (Gnant et al., 1999)); alpha virus (e.g., sindbis virus; Semliki forest virus (Lundstrom, 1999)); reovirus (Coffey et al., 1998) and influenza A virus (Neumann et al., 1999); Chimeric poxviral/retroviral vectors (Holzer et al., 1999); adenoviral/retroviral vectors (Feng et al., 1997; Bilbao et al., 1997; Caplen et al., 1999) and adenoviral/adeno-associated viral vectors (Fisher et al., 1996; U.S. Pat. No. 5,871,982), expression vectors are contemplated for the delivery of expression constructs. “Viral expression vector” is meant to include those constructs containing virus sequences sufficient to (a) support packaging of the construct and (b) to ultimately express a tissue or cell-specific construct that has been cloned therein. Virus growth and manipulation is known to those skilled in the art.

[0182] D. Antibodies Reactive to Herpesvirus Antigens.

[0183] In another aspect, the present invention includes antibody compositions that are immunoreactive with a herpesvirus polypeptide of the present invention, or any portion thereof. In still other embodiments, an antigen of the invention may be used to produce antibodies and/or antibody compositions. Antibodies may be specifically or preferentially reactive to herpesvirus polypeptides. Antibodies reactive to herpesvirus include antibodies reactive to HSV, including those directed against an antigen having the sequences as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, fragments, variants, or mimetics thereof, or closely related sequences. The antigens of SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:34, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:66, SEQ ID NO:70, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:80, SEQ ID NO:84, SEQ ID NO:88, SEQ ID NO:92, SEQ ID NO:96, SEQ ID NO:100, SEQ ID NO:104, SEQ ID NO:108, SEQ ID NO:112, and SEQ ID NO:114 are representative of antigenic fragments of HSV polypeptides. Antigens represented in SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:56, SEQ ID NO:64, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:78, SEQ ID NO:82, SEQ ID NO:86, SEQ ID NO:90, SEQ ID NO:94, SEQ ID NO:98, SEQ ID NO:102, SEQ ID NO:106, and SEQ ID NO:116 are exemplary of full length HSV polypeptides from which exemplary antigenic fragments have been identified. The antibodies may be polyclonal or monoclonal and produced by methods known in the art. The antibodies may also be monovalent or bivalent. An antibody may be split by a variety of biological or chemical means. Each half of the antibody can only bind one antigen and, therefore, is defined monovalent. Means for preparing and characterizing antibodies are well known in the art (see, e.g., Harlow and Lane, 1988, which is incorporated herein by reference).

[0184] Peptides corresponding to one or more antigenic determinants of a herpesvirus polypeptide of the present invention may be prepared in order to produce an antibody. Such peptides should generally be at least five or six amino acid residues in length, will preferably be about 10, 15, 20, 25 or about 30 amino acid residues in length, and may contain up to about 35 to 50 residues or so. Synthetic peptides will generally be about 35 residues long, which is the approximate upper length limit of automated peptide synthesis machines, such as those available from Applied Biosystems (Foster City, Calif.). Longer peptides also may be prepared, e.g., by recombinant means. In other methods full or substantially full length polypeptides may be used to produce antibodies of the invention.

[0185] Once a peptide(s) is prepared that contains at least one or more antigenic determinants, the peptide(s) is then employed in the generation of antisera against the polypeptide. Minigenes or gene fusions encoding these determinants also can be constructed and inserted into expression vectors by standard methods, for example, using PCR cloning methodology. The use of peptides for antibody generation or vaccination typically requires conjugation of the peptide to an immunogenic carrier protein, such as hepatitis B surface antigen, keyhole limpet hemocyanin or bovine serum albumin. Methods for performing this conjugation are well known in the art.

[0186] The antibodies used in the methods of the invention include derivatives that are modified, i.e, by the covalent attachment of any type of molecule to the antibody. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, and/or linkage to a cellular ligand or other protein. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, and metabolic synthesis in the presence of tunicamycin. Additionally, the derivative may contain one or more non-classical amino acids.

[0187] For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a constant region derived, from a human immunoglobulin. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, 1985; O1 et al., 1986; Gillies et al. 1989; U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entireties. Humanized antibodies are antibody molecules from non-human species that bind the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. See, e.g., U.S. Pat. No. 5,585,089 and Riechmann et al. (1988), which are incorporated herein by reference in their entireties. Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991; Studnicka et al., 1994; Roguska et al., 1994), and chain shuffling (U.S. Pat. No. 5,565,332), all of which are hereby incorporated by reference in their entireties.

[0188] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See U.S. Pat. Nos. 4,444,887 and 4,710,111; and WO 98/46645; WO 99/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741, each of which is incorporated herein by reference in its entirety.

[0189] Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, 1995. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT applications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; Europrean patent EP 0598877; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598; which are incorporated by reference herein in their entireties. In addition, companies such as Abgenix, Inc. (Freemont, Calif.). Kirin, Inc. (Japan), Medarex (N.J.) and Genpharm (San Jose, Calif.) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

[0190] Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as “guided selection.” In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers et al., 1988).

[0191] The present invention encompasses single domain antibodies, including camelized single domain antibodies (See e.g., Muyldermans et al., 2001; Nuttall et al., 2000; Reichmann and Muyldermans, 1999; WO 94/04678; WO 94/25591; and U.S. Pat. No. 6,005,079; which are incorporated herein by reference in their entireties), In one embodiment, the present invention provides single domain antibodies comprising two VH domains with modifications such that single domain antibodies are formed.

[0192] The methods of the present invention also encompass the use of antibodies or fragments thereof that have half-lives (e.g., serum half-lives) in a mammal, preferably a human, of greater than 15 days, preferably greater than 20 days, greater than 25 days, greater than 30 days, greater, than 35 days, greater than 40 days, greater than 45 days, greater than 2 months, greater than 3 months, greater than 4 months, or greater than 5 months. The increased half-lives of the antibodies of the present invention or fragments thereof in a mammal, preferably a human, results in a higher serum titer of said antibodies or antibody fragments in the mammal, and thus, reduces the frequency of the administration of said antibodies or antibody fragments and/or reduces the concentration of said antibodies or antibody fragments to be administered. Antibodies or fragments thereof having increased in vivo half-lives can be generated by techniques known to those of skill in the art. For example, antibodies or fragments thereof will increased in vivo half-lives can be generated by modifying (e.g., substituting, deleting or adding) amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor. The antibodies of the invention may be engineered by methods described in Ward et al. to increase biological half-lives (see U.S. Pat. No. 6,277,375 B1). For example, antibodies of the invention maybe engineered in the Fc-hinge domain to have increased in vivo or serum half-lives.

[0193] Antibodies or fragments thereof with increased in vivo half-lives can be generated by attaching to the antibodies or antibody fragments polymer molecules such as high molecular weight polyethyleneglycol (PEG). PEG can be attached to said antibodies or antibody fragments with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C-terminus of the antibodies or antibody fragments or via episilon-amino groups present on lysine residues or other chemistry. Linear or branched polymer derivatization that results in minimal loss of biological activity will typically be used. The degree of conjugation will be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies. Unreacted PEG can be separated from antibody-PEG conjugates by, e.g., size exclusion or ion-exchange chromatography.

[0194] The antibodies of the invention may also be modified by the methods and coupling agents described by Davis et al. (U.S. Pat. No. 4,179,337) in order to provide compositions that can be injected into the mammalian circulatory system with substantially no immunogenic response.

[0195] In one aspect, the invention features multispecific, multivalent molecules, which minimally comprise an anti-Fc receptor portion, an anti-target portion and optionally an anti-enhancement factor (anti-EF) portion. In preferred embodiments, the anti-Fc receptor portion is an antibody fragment (e.g., Fab or (Fab′)₂ fragment), the anti-target portion is a ligand or antibody fragment and the anti-EF portion is an antibody directed against a surface protein involved in cytotoxic activity. In a particular embodiment, the recombinant anti-FcR antibodies, or fragments are “humanized” (e.g., have at least a portion of a complementarity determining region (CDR) derived from a non-human antibody (e.g., murine) with the remaining portion(s) being human in origin).

[0196] In various embodiments, the invention includes methods for generating multispecific molecules, e.g., a first specificity for an antigen and a second specificity for a Fc receptor. In one embodiment, both specificities are encoded in the same vector and are expressed and assembled in a host cell. In another embodiment, each specificity is generated recombinantly and the resulting proteins or peptides are conjugated to one another via sulfhydryl bonding of the C-terminus hinge regions of the heavy chain. In a particularly preferred embodiment, the hinge region is modified to contain only one sulfhydryl residue, prior to conjugation. For examples of these and other related methods and compositions see U.S. Pat. Nos. 6,410,690; 6,365,161; 6,303,755; 6,270,765; and 6,258,358 each of which are incorporated herein by reference. The present invention also encompasses the use of antibodies or antibody fragments comprising the amino acid sequence of any of the antibodies of the invention with mutations (e.g., one or more amino acid substitutions) in the framework or variable regions. Preferably, mutations in these antibodies maintain or enhance the avidity and/or affinity of the antibodies for the particular antigen(s) to which they immunospecifically bind. Standard techniques known to those skilled in the art (e.g., immunoassays) can be used to assay the affinity of an antibody for a particular antigen.

[0197] The present invention also encompasses antibodies comprising a modified Fc region. Modifications that affect Fc-mediated effector function are well known in the art (U.S. Pat. No. 6,194,551, which is incorporated herein by reference in its entirety), for example, one or more amino acids alterations (e.g., substitutions) are introduced in the Fc region. The amino acids modified can be, for example, Proline 329, Proline 331, or Lysine 322. Proline 329, 331 and Lysine 322 are preferably replaced with alanine, however, substitution with any other amino acid is contemplated (PCT application WO 00/42072 and U.S. Pat. No. 6,194,551, which are incorporated herein by reference). In one particular embodiment, the modification of the Fc region comprises one or more mutations in the Fc region. In another particular embodiment, the modification in the Fc region has altered antibody-mediated effector function. In another embodiment of the invention, the modification in the Fc region has altered binding to other Fc receptors (e.g., Fc activation receptors). In yet another particular embodiment, the antibodies of the invention comprising a modified Fc region mediate ADCC more effectively. In another embodiment, the modification in the Fc region alters C1q binding activity. In yet a further embodiment, the modification in the Fc region alters complement dependant cytotoxicity.

[0198] The invention also comprises antibodies with altered carbohydrate modifications (e.g., glycosylation, fucosylation, etc.), wherein such modification enhances antibody-mediated effector function. Carbohydrate modifications that lead to altered antibody mediated effector function are well known in the art (for example see Shields et al., 2001; Davies et al., 2001).

[0199] 1. Antibody Conjugates

[0200] The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalent conjugations) to heterologous polypeptides (i.e., an unrelated polypeptide; or portion thereof, preferably at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 amino acids of the polypeptide) to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. Antibodies may be used for example to target heterologous polypeptides to particular cell types, either in vitro or in vivo, by fusing or conjugating the antibodies to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to heterologous polypeptides may also be used in in vitro immunoassays and purification methods using methods known in, the art, see e.g., PCT application WO 93/21232; European patent EP 439,095; Naramura et al., 1994; U.S. Pat. No. 5,474,981; Gillies et al., 1992; and Fell et al., 1991, which are incorporated herein by reference in their entireties.

[0201] Further, an antibody may be conjugated to a therapeutic agent or drug moiety that modifies a given biological response. Therapeutic agents or drug moieties are not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin (i.e., PE-40), or diphtheria toxin, ricin, gelonon, and pokeweed antiviral protein or other toxin, a protein such as tumor necrosis factor, interferons including, but not limited to, alpha-interferon (IFN-α), beta-interferon (IFN-β), nerve growth factor (NGF), platelet derived growth factor (PDGF), tissue plasminogen activator (TPA), an apoptotic agent (e.g., TNF-α, TNF-β, AIM I (PCT application WO 97/33899), AIM II (PCT application WO 97/34911), Fas Ligand (Takahashi et al., 1994), and VEGI (PCT application WO 99/23105), a thrombotic agent or an anti-angiogenic agent (e.g., angiostain or endostatin), or a biological response modifier such as, for example, lymphokine (e.g. interleukm-1 (“IL-1”), interleukin-2 (“IL-2”), interleukm-6 (“IL-6”) granulocyte macrophage colony stimulating factor (“GM-CSF”), and granulocyte colony stimulating factor (“G-CSF”), macrophage colony stimulating factor, (“M-CSF”), or a growth factor (e.g., growth hormone (“GH”); proteases, or ribonucleases.

[0202] Antibodies can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., Chatsworth, Calif.), among others, many of which are commercially available. As described in Gentz et al., 1989, for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin “HA” tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., 1984) and the “flag” tag (Knappik et al., 1994).

[0203] The present invention further includes compositions comprising heterologous polypeptides fused or conjugated to antibody fragments. For example, the heterologous polypeptides may be fused or conjugated to a Fab fragment, Fd fragment, Fv fragment, F(ab)₂ fragment, or portion thereof. Methods for fusing or conjugating polypeptides to antibody portions are known in the art. See for example U.S. Pat. Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 3,447,851; and 5,112,946; Eurppean Patents EP 307,434 and EP 367,166; PCT applications WO 96/04388 and WO 91/06570; Ashkenazi et al., 1991, PNAS 88: 10535-10539; Zheng et al., 1995; and Vil et al., 1992; each of which are incorporated by reference in there entireties).

[0204] Additional fusion proteins may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling; and/or codon-shuffling (collectively referred to as “DNA shuffling”). DNA shuffling may be employed to alter the activities of antibodies of the invention or fragments thereof (e.g., antibodies or fragments thereof with higher affinities and lower dissociation rates), see, generally, U.S. Pat. Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458; and Patten et al., 1997; Harayama, 1998; Hansson et al., 1999; Lorenzo and Blasco, 1998; each of which are hereby incorporated by reference in its entirety. Antibodies or fragments thereof, or the encoded antibodies or fragments thereof, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. One or more portions of a polynucleotide encoding an antibody or antibody fragment, which portions specifically bind to FcγRIIB may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

[0205] The present invention also encompasses antibodies conjugated to a diagnostic or therapeutic agent or any other molecule for which serum half-life is desired to be increased. The antibodies can be used diagnostically to, for example, monitor the development or progression of a disease, disorder or infection as part of a clinical testing procedure, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and non-radioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art, see, for example, U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Such diagnosis and detection can be accomplished by coupling the antibody to detectable substances including, but not limited to, various enzyme, enzymes including, but not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic group complexes such as, but not limited to, streptavidin/biotin and avidin/biotin; fluorescent materials such as, but not limited to umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine, fluorescein, dansyl chloride or phycoerythrin; luminescent material such as, but not limited to, luminol; bioluminescent materials such as, but not limited to, luciferase, luciferin, and aequorin; radioactive material such as, but not limited to, bismuth (²¹³B), carbon (¹⁴C), chromium (⁵¹Cr), cobalt (⁵⁷Co), fluorine (¹⁸F), gadolinium (¹⁵³Gd, ¹⁵⁹Gd), gallium (⁶⁸Ga, ⁶⁷Ga), germanium (⁶⁸Ge), holmium (¹⁶⁶Ho), indium (¹¹⁵In, ¹¹³In, ¹¹²In, ¹¹¹n), iodine (¹³¹I, ¹²⁵I, ¹²³I, ¹²¹), lansthanium (¹⁴⁰La), lutetitium (¹⁷⁷Lu), manganese (⁵⁴Mn), molybdenum (⁹⁹Mo), palladium (¹⁰³Pd), phosphorous (³²p), praseodymium (¹⁴²Pr), promethium (¹⁴⁹Pm), rhenium (¹⁸⁶Re, ¹⁸⁸Re), rhodium (¹⁰⁵Rh), ruthemium (⁹⁷Ru), samarium (¹⁵³Sm), scandium (⁴⁷Sc), selenium (⁷⁵Se), strontium (⁸⁵Sr), sulfur (³⁵S), technetium (⁹⁹Tc), titanium (⁴⁴Ti), tin (¹¹³Sn, ¹¹⁷Sn), tritium (³H), xenon (¹³⁶Xe), ytterbium (¹⁷⁹Yb, ¹⁷⁵Yb), yttrium (⁹⁰Y), zinc (⁶⁵Zn); positron emitting metals using various positron emission tomographies, and non-radioactive paramagnetic metal ions.

[0206] An antibody may be conjugated to a therapeutic moiety such as a. cytotoxin (e.g., a cytostatic or cytocidal agent), a therapeutic agent or a radioactive element (e.g., alpha-emitters, gamma-emitters, etc.). Cytotoxins or cytotoxic agents include any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anrhracindione, mitoxantrone. mithramycin, actinciomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine; cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa Chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II) (DDP) cisplatin.), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin). antibiotics (e.g., dactinomycin (fomerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0207] Moreover, an antibody can be conjugated to therapeutic moieties such as a radioactive materials or macrocyclic chelators useful for conjugating radiometal ions (see above for examples radioactive materials). In certain embodiments, macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) which can be attached to the antibody via a linker molecule. Such linker molecules are commonly known in the art and described in Denardo et al., 1998; Peterson et al., 1999; and Zimmerman et al., 1999, each incorporated by reference in their entireties.

[0208] Techniques for conjugating such therapeutic moieties to antibodies are well known; see, example Arnon et al., 1985; Hellstrom et al., 1987; Thorpe, 1985; Thorpe et al., 1982.

[0209] An antibody or fragment thereof, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

[0210] Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal (U.S. Pat. No. 4,676,980, which is incorporated herein by reference in its entirety.

[0211] Antibodies may also be attached to solid supports that are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

[0212] 2. Anti-Herpesvirus Antibody Generation

[0213] The present invention provides monoclonal antibody compositions that are immunoreactive with a herpesvirus polypeptide. As detailed above, in addition to antibodies generated against a full-length herpesvirus polypeptide, antibodies also may be generated in response to smaller constructs comprising epitope core regions, including wild-type and mutant epitopes. In other embodiments of the invention, the use of anti-herpesvirus single chain antibodies, chimeric antibodies, diabodies and the like are contemplated.

[0214] As used herein, the term “antibody” is intended to refer broadly to any immunologic binding agent such as IgG, IgM, IgA, IgD and IgE. Generally, IgG and/or IgM are preferred because they are the most common antibodies in the physiological situation and because they are most easily made in a laboratory setting.

[0215] However, “humanized” herpesvirus antibodies also are contemplated, as are chimeric antibodies from mouse, rat, goat or other species, fusion proteins, single chain antibodies, diabodies, bispecific antibodies, and other engineered antibodies and fragments thereof. As defined herein, a “humanized” antibody comprises constant regions from a human antibody gene and variable regions from a non-human antibody gene. A “chimeric antibody, comprises constant and variable regions from two genetically distinct individuals. An anti-HSV humanized or chimeric antibody can be genetically engineered to comprise an HSV antigen binding site of a given of molecular weight and biological lifetime, as long as the antibody retains its HSV antigen binding site. Humanized antibodies may be prepared by using following the teachings of U.S. Pat. No. 5,889,157

[0216] The term “antibody” is used to refer to any antibody-like molecule that has an antigen binding region, and includes antibody fragments such as Fab′, Fab, F(ab′)₂, single domain antibodies (DABs), Fv, scFv (single chain Fv), chimeras and the like. Methods and techniques of producing the above antibody-based constructs and fragments are well known in the art (U.S. Pat. Nos. 5,889,157; 5,821,333; and 5,888,773, each specifically incorporated herein by reference). The methods and techniques for preparing and characterizing antibodies are well known in the art (see, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; incorporated herein by reference).

[0217] As also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Suitable molecule adjuvants include all acceptable immunostimulatory compounds, such as cytokines, toxins or synthetic compositions. In addition to adjuvants, it may be desirable to coadminister biologic response modifiers (BRM), which have been shown to upregulate T cell immunity or downregulate suppressor cell activity.

[0218] 3. Detecting Herpesvirus

[0219] The invention also relates to methods of assaying for the presence of herpesvirus infection, in particular HSV-1 or HSV-2 infection, in a patient, subject, vertebrate animal, and/or human comprising: (a) obtaining an antibody, as described above, directed against a herpesvirus antigen of the invention; (b) obtaining a sample from a subject, patient, and/or animal; (c) admixing the antibody with the sample; and (d) assaying the sample for antigen-antibody binding, wherein the antigen-antibody binding indicates herpesvirus infection in the animal. In some cases, the antibody directed against the antigen is further defined as a polyclonal antibody. In other embodiments, an antibody directed against the antigen is further defined as a monoclonal antibody. In some embodiments, an antibody is reactive against an antigen having a sequence as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, fragments, variants, or mimetics thereof, or closely related sequences. The assaying of the sample for antigen-antibody binding may be by precipitation reaction, radioimmunoassay, ELISA, Western blot, immunofluorescence, or any other method known to those of skill in the art.

[0220] In other embodiments, the invention also relates to methods of assaying for the presence of herpesvirus infection or antibodies reactive to herpesvirus, in particular HSV-1 or HSV-2 infection, in a patient, subject, vertebrate animal, and/or human comprising: (a) obtaining a peptide, as described above; (b) obtaining a sample from a subject, patient, and/or animal; (c) admixing the peptide with the sample; and (d) assaying the sample for antigen-antibody binding, wherein the antigen-antibody binding indicates exposure of the animal to herpesvirus. The peptide may have a sequence as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, fragments, variants, or mimetics thereof, or closely related sequences. The assaying of the sample for antigen-antibody binding may be by precipitation reaction, radioimmunoassay, ELISA, Western blot, immunofluorescence, or any other method known to those of skill in the art.

[0221] The invention further relates to methods of assaying for the presence of an HSV infection in an animal comprising: (a) obtaining an oligonucleotide probe comprising a sequence comprised within one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 and/or SEQ ID NO:115, a complement, a fragment, or a closely related sequences thereof; and (b) employing the probe in a PCR or other detection protocol.

[0222] E. Other Binding or Affinity Agents

[0223] Various embodiments of the invention may include the use of alternative binding or affinity agents that preferentially bind nucleic acids and/or polypeptides, including fragments, portions, subdivisions and the like, of nucleic acids or polypeptides, including variants thereof, of the present invention. A binding agent may include nucleic acids, amino acids, synthetic polymers, carbohydrates, lipids, and combinations thereof as long as the compound, molecule, or complex preferentially binds or has a measurable affinity, as determined by methods known in the art, for a nucleic acid or polypeptide of the present invention. The binding affinity of an agent can, for example, be determined by the Scatchard analysis of Munson and Pollard, 1980. Other binding agents may include, but are not limited to nucleic acid aptamers; anticalins or other lipocalin derivatives (for examples see U.S. Pat. Nos. 5,506,121 and 6,103,493; PCT applications WO 99/16873 and WO 00/75308 and the like); synthetic or recombinant antibody derivatives (for examples see U.S. Pat. No. 6,136,313. Exemplary methods and compositions may be found in U.S. Pat. Nos. 5,506,121 and 6,103,493 and PCT applications WO 99/16873 and WO 00/75308 and the like, each of which is incorporated herein by reference. Any binding or affinity agents derived using the compositions of the present invention may be used in therapeutic, prophylactic, vaccination and/or diagnostic methods.

V. Therapeutic Compositions and Methods

[0224] It is further contemplated that the compositions and methods of the invention may be used as a therapeutic composition for viral infections. The therapeutics may be used to treat and/or diagnose viral infection. In certain embodiments, the nucleic acid and/or polypeptides of the invention may be used as a therapeutic agent. In various embodiments of the invention antibodies, binding agents, or affinity agents that recognize and/bind the nucleic acids or polypeptides of the invention may be used as therapeutic agents. These therapeutic compositions may act through mechanisms that include, but are not limited to the induction or stimulation of an active immune response by an organism or subject. Such therapeutic methods include passive immunization, prime-boost immunization, and other methods of using antigens, vaccines, and/or antibodies or other binding agents to protect, prevent, and/or treat infection by a pathogen.

[0225] Antibodies or binding agents of the invention may be conjugated to a therapeutic agent. Therapeutic agents may include, but are not limited to apoptosis-inducing agents, toxins, anti-viral agents, pro-drug converting enzymes and any other therapeutic agent that may aid in the treatment of a viral infection(s). Compositions of the present invention may be used in the targeting of a therapeutic agent to a focus of infection, the method of which may include injecting a patient infected with a pathogen with an effective amount of an antibody-therapeutic agent conjugate. The conjugate may include an immunoreactive composite of one or more chemically-linked antibodies or antibody fragments which specifically binds to a one or more epitopes of one or more pathogens or of an antigen induced by the pathogen or presented by a cell as a result of the fragmentation or destruction of the pathogen at the focus of infection. The antibody conjugate may have a chemically bound therapeutic agent for treating said infection, thus localizing or targeting a therapeutic to the location of a pathogen.

[0226] Reviews of antimicrobial chemotherapy can be found in the chapter by Slack, 1987 and in Section XII, Goodman and Gilman's The Pharmacological Basis of Therapeutics, 1980).

[0227] As indicated in these texts, some antimicrobial agents are selective in their toxicity, since they kill or inhibit the microorganism at concentrations that are tolerated by the host (i.e., the drug acts on microbial structures or biosynthetic pathways that differ from those of the host's cells). Other agents are only capable of temporarily inhibiting the growth of the microbe, which may resume growth when the inhibitor is removed. Often, the ability to kill or inhibit a microbe or parasite is a function of the agent's concentration in the body and its fluids.

[0228] Whereas these principles and the available antimicrobial drugs have been successful for the treatment of many infections, particularly bacterial infections, other infections have been resistant or relatively unresponsive to systemic chemotherapy, e.g., viral infections and certain fungal, protozoan and parasitic infections.

[0229] As used herein, “microbe” denotes virus, bacteria, rickettsia, mycoplasma, protozoa and fungi, while “pathogen” denotes both microbes and infectious multicellular invertebrates, e.g., helminths, spirochetes and the like.

[0230] Virus can infect host cells and “hide” from circulating systemic drugs. Even when viral proliferation is active and the virus is released from host cells, systemic agents can be insufficiently potent at levels which are tolerated by the patient. Thus, the compositions of the invention may be used in targeting therapeutics to the location that will typically be more effective in treating an infection by a pathogen.

[0231] A. Prime-Boost Vaccination Methods

[0232] When one or more compositions of the invention are administered in conjunction with or without adjuvants and/or other excipients, the antigen may be administered before, after, and/or simultaneously with the other antigenic compositions. For instance, the combination of antigens or vaccine compositions may be administered as a priming dose of antigen or vaccine composition. One or more antigen or vaccine composition may then be administered with a boost dose, including the antigen or vaccine composition used as the priming dose. Alternatively, the combination of two or more antigens or vaccine compositions may be administered with a boost dose of antigen. One or more antigen or vaccine composition may then be administered with the prime dose. A “prime dose” is the first dose of antigen administered to a subject. In the case of a subject that has an infection the prime dose may be the initial exposure of the subject to the pathogen and a combination of antigens or vaccine compositions may administered to the subject in a boost dose. A “boost dose” is a second, third, fourth, fifth, sixth, or more dose of the same or different antigen or vaccine composition administered to a subject that has already been exposed to an antigen. In some cases the prime dose may be administered with a combination of antigens or vaccine compositions such that a boost dose is not required to protect a subject at risk of infection from being infected. An antigen may be administered with one or more adjuvants or other excipients individually or in any combination. Adjuvants may be administered prior to, simultaneously with or after administration of one or more antigen(s) or vaccine compositions. It is contemplated that repeated administrations of antigen(s) as well as one or more of the components of a vaccine composition may be given alone or in combination for one or more of the administrations. Antigens need not be from a single pathogen and may be derived from one or more pathogens. The order and composition of a vaccine composition may be readily determined by using known methods in combination with the teachings described herein. Examples of the prime-boost method of vaccination can be found in U.S. Pat. No. 6,210,663, incorporated herein by reference.

[0233] In various embodiment, the time between administration of the priming dose and the boost dose maybe 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or more days, weeks, months, or years. The vaccine compositions include, but are not limited to any of the polynucleotide, polypeptide, and binding agent compositions described herein or combination of any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more of each individual composition.

[0234] B. Passive Immunization

[0235] Methods of passively immunizing an animal or human subject against a preselected ligand or pathogen by administering to the animal or human subject a composition comprising one or more antibodies or affinity agents to an antigen(s) of the present invention are contemplated.

[0236] Immunoglobulin molecules and other affinity or binding agents are capable of binding a preselected antigen and can be efficiently and economically produced synthetically and in plant or animal cells as well as in a variety of animals including, but not limited to horse, pig, rabbit, goat, donkey, mouse, rat, human and other organisms capable of producing natural or recombinant molecules. In certain cases, immunoglobulin molecules may or may not contain sialic acid yet do contain core glycosylated portions and N-acetylglucosamine containing outer branches. In various embodiments, an immunoglobulin molecule either is an IgA, IgM, secretory IgM or secretory IgA.

[0237] Secretory immunoglobulins, such as secretory IgM and secretory IgA may be resistant to proteolysis and denaturation. Contemplated environments for the administration or use of such molecules include acidic environments, protease containing environments, high temperature environments, and other harsh environments. For example, the gastrointestinal tract of an animal is a harsh environment where both proteases and acid are present, see, Kobayishi et al., 1973. Passive immunization of an animal or human subject may be produced by contacting or administering an antibody or binding agent that recognizes an antigen of the present invention by intravascular, intramuscular, oral, intraperitoneal, mucosal, or other methods of administration. Mucosal methods of administration may include administration by the lungs, the digestive tract, the nasopharyngeal cavity, the urogenital system, and the like.

[0238] In various embodiments the antibody or binding agent, such as an immunoglobulin molecule is specific for a preselected antigen. Typically, this antigen is present on a pathogen that causes a disease. One or more antibody or binding agent may be capable of binding to a pathogen(s) and preventing or treating a disease state.

[0239] In certain embodiments, the composition comprising one or more antibody or binding agent is a therapeutic or pharmaceutically acceptable composition. The preparation of therapeutic or pharmaceutically acceptable compositions which contain polypeptides, proteins, or other molecules as active ingredients is well understood in the art and are briefly described herein.

[0240] In certain embodiments, a composition containing one or more antibody or binding agent(s) comprises a molecule that binds specifically or preferentially with a pathogen antigen. Preferentially is used herein to denote that a molecule may bind other antigens or molecules but with a much lower affinity as compared to the affinity for a preferred antigen. Pathogens may be any organism that causes a disease in another organism.

[0241] Antibodies or binding agents specific or preferential for a pathogen may be produced using standard synthetic, recombinant, or antibody production techniques, see, Antibodies: A Laboratory Manual, Harlow et al., eds., Cold Spring Harbor, N.Y. (1988) and alternative affinity or binding agents described herein.

[0242] C. Therapeutic Vaccination

[0243] A promising use of vaccination is the use of therapeutic vaccination to treat or cure established diseases or infections. Methods of therapeutically immunizing an animal or human subject against a preselected ligand or pathogen by contacting or administering to the animal or human subject a composition comprising one or more antigen(s) of the present invention are contemplated. Therapeutic vaccinations may provided relief of complications of, for example, lesions or precursor lesions resulting from herpesvirus infection, and thus represent an alternative to prophylactic intervention. Vaccinations of this type may comprise various polypeptides or polynucleotides as described herein, which are expressed in persistently infected cells. It is assumed that following administration of a vaccination of this type, cytotoxic T-cells might be activated against persistently infected cells in the lesions associated with infection or disease.

[0244] Vaccine candidates of the present invention may be prepared or combined for delivery into an infected subject for the treatment of the infection. It is anticipated that the immune responses raised against these antigens might be capable of eliminating the resident pathogen or preventing or ameliorating disease symptoms associated with herpes reactivation.

VI. Microbial Genomics

[0245] Automated-DNA sequencing has revolutionized the investigation of pathogenic microbes by making the entirety of the information contained within their genomes available for analysis. The availability of genomic and/or proteomic information may be used in context of the invention described herein. In certain embodiments, genomic or proteomic information may be used for the analysis of a pathogenic organism's genome and for identification of polynucleotides or polypeptides encoded by polynucleotides for the purpose of vaccination, vaccine preparation, antibody preparation, and the like. Genomic techniques, methods, and composition have been designed to extract knowledge from sequence data (protein and DNA), microarray data, and other genomic based data. One application of whole-genome-sequence information is investigation of the pathogenic role of microbial genes and their candidacy as a vaccine. The availability of a large number of sequenced microbial genomes allows the systematic study and analysis of microbial genes.

[0246] The genomic sequences of a large number of medically and agriculturally important organisms are or will be known. Genomic technologies are particularly attractive for addressing complex questions that are becoming evident with the increase in sequence information. Many conventional genetic and biochemical approaches have their limitations, especially in regard to some pathogenic organisms.

[0247] The rapidly developing fields of genomics, proteomics and bioinformatics rely on various techniques including, but not limited to, mass spectrometry, high performance chromatography and electrophoresis, protein sequencing and other genomic or proteomic technologies (see Cunningham, 2000 for a general review). Also, development, advancement and integration of proteomics technologies and other areas related to functional genomics, including primary structure determination, chemical modification of proteins, protein-protein crosslinking mass spectrometry, protein purification and characterization and process engineering.

[0248] Genomic applications include, but are not limited to enriched haplotyping, expression analysis, bio-defense and microbial analysis. Using direct, linear readings of long, unbroken segments of DNA, it has the potential to capture comprehensive genetic data, offering researchers a technology to decode genomes, identify genetic variations, and enable pharmacogenomics, drug discovery, population genetics, and agbiotech applications.

[0249] A. Genomic Technologies

[0250] Various genomic methods and techniques may be utilized during the analyses of a pathogen. For example gene synthesis (for exemplary methods see U.S. Pat. Nos. 6,472,184 and 6,110,668); genotyping (for exemplary methods see U.S. Pat. Nos. 5,846,704 and 6,449, 562); library construction (for exemplary methods see U.S. Pat. No. 6,468,765 and Sambrook et al., 2001); oligo synthesis, including modified oligo and RNA oligo synthesis (Ausubel, et al., 1993 or Integrated DNA Technologies, Coralville, Iowa), as well as sequencing and synthesis services that are commercially available (e.g., Qiagen Genomics, Bothell, Wash.; or Cleveland Genomics, Cleveland, Ohio)

[0251] B. Animal Models

[0252] Various assay used to provide information regarding the function of a gene or protein utilize transgenic organisms. Animal models include transgenic animals, transgenic mice, transgenic murine cell lines, transgenic rat cell lines, or transgenic rats.

[0253] C. Array Technology

[0254] Various arrray technologies also are available for genomic and proteomic analyses (Bowtell et al., 2003). Arrays include, but are not limited to Antibody Arrays (BD Biosciences Clontech, Palo Alto, Calif.); cDNA Arrays (Incyte Genomics, St. Louis, Mo.), Microbial Arrays (Sigma-Genosys, The Woodlands, Tex.), Oligo Arrays (QIAGEN Operon, Alameda, Calif.); Protein—DNA Interaction Arrays (BD Biosciences Clontech, Palo Alto, Calif.); Protein Arrays (Ciphergen Biosystems, Inc., Fremont, Calif.); and other types of arrays available from various vendors.

[0255] D. Robotics

[0256] Various robotic or automated machines are typically used in conjunction with high-throughput methods associated with genomics and proteomics. Exemplary robots or machines include Automated Colony Pickers/Arrayers (Biorad, Hercules Calif.; and Genetix, Beaverton Oreg.); Automated Dispensers, Microplate Handlers, Microplate Washers (Beckman Coulter, Fullerton Calif.; Bio-Tek Instruments, Winooski Vt.; and PerkinElmer Life Sciences Inc., Boston Mass.); Automated Nucleic Acid/Protein Analysis (Beckman Coulter, Fullerton Calif.), Automated Nucleic Acid Purification (QIAGEN, Valencia Calif.); Automated Protein Expression Instruments (Roche Applied Science, Indianapolis Ind.); and High Throughput Fluorescence Detection (Cellomics, Inc., Pittsburgh Pa.).

VI. Pharmaceutical Compositions

[0257] Compositions of the present invention comprise an effective amount of a Herpesvirus polynucleotide or variant thereof; an antigenic protein, polypeptide, peptide, or peptide mimetic; anti-herpesvirus antibodies; and the like, which may be dissolved and/or dispersed in a pharmaceutically acceptable carrier and/or aqueous medium. Aqueous compositions of genetic immunization vectors, vaccines and such expressing any of the foregoing are also contemplated.

[0258] A. Pharmaceutical Preparations of Peptides, Nucleic Acids, and Other Active Compounds.

[0259] The herpesvirus polypeptides of the invention and the nucleic acids encoding them may be delivered by any method known to those of skill in the art (see for example, “Remington's Pharmaceutical Sciences” 15th Edition).

[0260] Solutions comprising the compounds of the invention may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The form should usually be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

[0261] For parenteral administration in an aqueous solution, for example, the solution may be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, intratumoral and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure. In terms of using peptide therapeutics as active ingredients, the technology of U.S. Pat. Nos. 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and/or 4,578,770, each incorporated herein by reference, may be used.

[0262] For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA, Center for Biologics Evaluaiton and Research and the Center for Drug Evaluation and Research.

[0263] The phrase “pharmaceutically-acceptable” or “pharmacologically-acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared.

[0264] B. Routes of Delivery/Administration

[0265] Pharmaceutical compositions may be conventionally administered parenterally, by injection, for example, either subcutaneously, intradermally, or intramuscularly. However, any method for administration of a composition is applicable. These include gene gun inoculation of the DNA encoding the peptide(s), oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, transdermal patch application, parenteral delivery, injection, or the like. The polynucleotides and polypeptides of the invention will typically be formulated for parenteral administration, such as injection via the intravenous, intramuscular, sub-cutaneous, intralesional, epidermal, transcutaneous, intraperitoneal routes. Additionally, compositions may be formulated for oral, intravaginal or inhaled delivery.

[0266] Injection of a nucleic acid encoding a herpesvirus polypeptide may be delivered by syringe or any other method used for injection of a solution, as long as the nucleic acid encoding the herpesvirus polypeptide, can pass through the particular gauge of needle required for injection. A novel needleless injection system has recently been described (U.S. Pat. No. 5,846,233) having a nozzle defining an ampule chamber for holding the solution and an energy device for pushing the solution out of the nozzle to the site of delivery. A syringe system has also been described for use in gene therapy that permits multiple injections of predetermined quantities of a solution precisely at any depth (U.S. Pat. No. 5,846,225).

[0267] C. Adjuvants

[0268] Immunogenicity can be significantly improved if the vectors or antigens are co-administered with adjuvants. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses. Adjuvants can stimulate or signal activation of cells or factors of the immune system. Exemplary adjuvants may be found in U.S. Pat. No. 6,406,705, incorporated herein by reference.

[0269] As used herein, the term “adjuvant” refers to an immunological adjuvant. By this is meant a compound that is able to enhance the immune system's response to an immunogenic substance or antigen. The term “immunogenic” refers to a substance or active ingredient which when administered to a subject, either alone or with an adjuvant, induces an immune response in the subject. The term “immune response” includes specific humoral, i.e. antibody, as well as cellular immune responses, the antibodies being serologic as well as secretory and pertaining to the subclasses IgM, IgD, IgG, IgA and IgE as well as all isotypes, allotypes, and subclasses thereof. The term is further intended to include other serum or tissue components. The cellular response includes Type-1 and Type-2 T-helper lymphocytes, cytotoxic T-cells as well as natural killer (NK) cells.

[0270] Furthermore, several other factors relating to adjuvanicity are believed to promote the immunogenicity of antigens. These include (1) rendering antigens particulate, e.g. aluminum salts, (2) polymers or polymerization of antigens, (3) slow antigen release, e.g. emulsions or micro-encapsulation, (4) bacteria and bacterial products, e.g. CFA, (5) other chemical adjuvants, e.g. poly-I:C, dextran sulphate and inulin, (6) cytokines, and (7) antigen targeting to APC.

[0271] General categories of adjuvants that may be used in conjunction with the invention includes, but is not limited to peptides, nucleic acids, cytokines, microbes (bacteria, fungi, parasites), glycoproteins, glycolipids, lipopolysaccharides, emulsions, and the like.

[0272] A combination of adjuvants may be administered simultaneously or sequentially. When adjuvants are administered simultaneously they can be administered in the same or separate formulations, and in the latter case at the same or separate sites, but are administered at the same time. The adjuvants are administered sequentially, when the administration of at least two adjuvants is temporally separated. The separation in time between the administrations of the two adjuvants may be a matter of minutes or it may be longer. The separation in time is less than 14 days, and more preferably less than 7 days, and most preferably less than 1 day. The separation in time may also be with one adjuvant at prime and one at boost, or one at prime and the combination at boost, or the combination at prime and one at boost.

[0273] In some embodiments, the adjuvant is Adjumer™, Adju-Phos, Algal Glucan, Algammulin, Alhydrogel, Antigen Formulation, Avridine®, BAY R1005, Calcitriol, Calcium Phosphate Gel, Cholera holotoxin (CT), Cholera toxin B subunit (CTB), Cholera toxin A1-subunit-Protein A D-fragment fusion protein, CRL1005, Cytokine-containing Liposome, Dimethyldioctadecylammonium bromide, Dehydroepiandrosterone; Dimyristoyl phosphatidylcholine; 1,2-dimyristoyl-sn-3-phosphatidylcholine, Dimyristoyl phosphatidylglycerol, Deoxycholic Acid Sodium Salt; Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, Gamma Inulin, Gerbu Adjuvant, GM-CSF, N-acetylglucosaminyl-(β1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine, Imiquimod, ImmTher™, Interferon-1α, Interleukin-1β, Interleukin-2, Interleukin-7, Interleukin-12, ISCOM™, Iscoprep 7.0.3.™, Liposome, Loxoribine, LT-OA or LT Oral Adjuvant, MF59, MONTANIDE ISA 51, MONTANIDE ISA 720, MPL™, MTP-PE, MTP-PE Liposome, Murametide, Murapalmitine, D-Murapalmitine, NAGO, Non-Ionic Surfactant Vesicle, Pleuran, lactic acid polymer, glycolic acid polymer, Pluronic L121, Polymethyl methacrylate, PODDS™, Poly rA:Poly rU, Polysorbate 80, Protein Cochleate, QS-21, Quil-A, Rehydragel HPA, Rehydragel LV, S-28463, SAF-1, Sclavo peptide, Sendai Proteoliposome, Sendai-containing Lipid Matrix, Span 85, Specol, Squalane, Squalene, Stearyl Tyrosine, Theramide™, Threonyl-MDP, Ty Particle, or Walter Reed Liposome.

[0274] D. Dosage and Schedules of Administration

[0275] The dosage of the polynucleotides and/or polypeptides and dosage schedule may be varied on a subject by subject basis, taking into account, for example, factors such as the weight and age of the subject, the type of disease being treated, the severity of the disease condition, previous or concurrent therapeutic interventions, the manner of administration and the like, which can be readily determined by one of ordinary skill in the art.

[0276] Administration is in any manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and/or immunogenic. The quantity to be administered depends on the subject to be treated, including the capacity of the individual's immune system to synthesize antibodies, and the degree of protection desired. The dosage of the vaccine will depend on the route of administration and will vary according to the size of the host. Precise amounts of an active ingredient required to be administered depend on the judgment of the practitioner.

[0277] In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. One of the various active compounds being a herpesvirus polynucleotide or polypeptide. In other embodiments, an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. However, a suitable dosage range may be, for example, of the order of several hundred micrograms active ingredient per vaccination. In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per vaccination, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, can be administered, based on the numbers described above. A suitable regime for initial administration and booster administrations (e.g., inoculations) are also variable, but are typified by an initial administration followed by subsequent inoculation(s) or other administration(s).

[0278] In many instances, it will be desirable to have multiple administrations of a vaccine, usually not exceeding six vaccinations, more usually not exceeding four vaccinations and preferably one or more, usually at least about three vaccinations. The vaccinations will normally be at from two to twelve week intervals, more usually from three to five week intervals. Periodic boosters after the initial series of immunizations at intervals of 1-5 years, usually three years, will be desirable to maintain protective levels of the antibodies.

[0279] A course of the immunization may be followed by assays for antibodies for the supernatant antigens. The assays may be performed by labeling with conventional labels, such as radionuclides, enzymes, fluorescents, and the like. These techniques are well known and may be found in a wide variety of patents, such as U.S. Pat. Nos. 3,791,932; 4,174,384 and 3,949,064, as illustrative of these types of assays. Other immune assays can be performed and assays of protection from challenge with a nucleic acid can be performed, following immunization.

VII. Kits

[0280] The invention also relates to kits for assaying an HSV infection comprising, in a suitable container: (a) a pharmaceutically acceptable carrier; and (b) an antibody, or other suitable binding agent, directed against an HSV antigen.

[0281] Therapeutic kits of the present invention are kits comprising a herpesvirus (e.g., HSV-1 or HSV-2) polynucleotide or polypeptide or an antibody to the polypeptide. Such kits will generally contain, in a suitable container, a pharmaceutically acceptable formulation of an herpesvirus polynucleotide or polypeptide, or an antibody to the polypeptide, or vector expressing any of the foregoing in a pharmaceutically acceptable formulation. The kit may have a single container, and/or it may have a distinct container for each compound.

[0282] When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred. The herpesvirus polynucleotide or polypeptide, or antibody compositions may also be formulated into a syringeable composition. In which case, the container may itself be a syringe, pipette, and/or other such like apparatus, from which the formulation may be applied to an infected area of the body, injected into an animal, and/or even applied to and/or mixed with the other components of the kit.

[0283] However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container.

[0284] The container will generally include at least one vial, test tube, flask, bottle, syringe and/or other container, into which the herpesvirus polynucleotide or polypeptide, or antibody formulation are placed, preferably, suitably allocated. The kits may also comprise a second container for containing a sterile, pharmaceutically acceptable buffer and/or other diluent.

[0285] The kits of the present invention will also typically include a means for containing the vials in close confinement for commercial sale, such as, injection and/or blow-molded plastic containers into which the desired vials are retained.

[0286] Irrespective of the number and/or type of containers, the kits of the invention may also comprise, and/or be packaged with, an instrument for assisting with the injection/administration and/or placement of the ultimate herpesvirus polynucleotide or polypeptide, or an antibody to the polypeptide within the body of an animal. Such an instrument may be a syringe, pipette, forceps, and/or any such medically approved delivery vehicle.

EXAMPLES

[0287] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example 1 A RELI Screen: Construction of Libraries Expressing Herpes Simples Virus 1 (HSV-1) DNA

[0288] Genomic DNA from the MacIntryre strain of HSV-1 was purified from cultured green monkey kidney cells (VERO-E6). The viral DNA was physically sheared by nebulization, purified and size-selected by electrophoresis through a 1.5% agarose TRIS-borate gel. Fragments from 500 to 2000 base pairs (bp) were excised and electroeluted. The library production protocol was similar to that previously described to generate HIV random expression libraries (Sykes and Johnston, 1999, incorporated herein by reference). However instead of attaching adaptors to the sheared fragments to generate BglII restriction site overhangs, the fragments were enzymatically mended (Klenow and T4 polymerase) to generate blunt-ends. The mended fragments were ligated into two mammailian expression plasmids. The mended fragments were prepared for ligation by linearizing with BglII restriction enzyme, dephosphorylating with alkaline phosphatase, and blunting the 5′-single-strand overhangs with Klenow. The two vectors are designed to express inserts in a mammalian system as fusions with either a secretory peptide sequence from the tissue plasmid activator gene, pCMVitPA (tPA vector) or a mouse ubiquitin subunit, pCMViUB (UB vector).

[0289] Immune analyses of infection and disease resolution have suggested a role for both humoral and cellular responses (Whitley and Miller, 2001), therefore both the tPA and UB vectors were used to drive both MHC II and MHC I presentation, respectively. The two sets of ligated products were used to transform DH5α E. coli and plated onto LB agar with ampicillin at subconfluency. These original library transformants were lifted with toothpicks and used to inoculate individual microtiter-plate cultures containing HYT freezing media (1.6% Bacto-tryptone, 1.0% Bacto-yeast extract, 85.5 mM NaCl, 36 mM K₂HPO₄, 13.2 mM KH₂PO₄, 1.7 mM Sodium citrate, 0.4 mM MgSO₄, 6.8 mM ammonium sulfate, 4.4% wt/vol glycerol) supplemented with 75 μg/mL ampicillin, and were grown overnight at 37° C. Growth and storage of the libraries as mini-cultures served to permanently maintain the original library complexity. Plasmid DNA was purified from several of the mini-cultures and analyzed to verify pathogen identity and to characterize the library. Sequence analysis established that 55% of the library inserts are HSV-1 sequences and that the remaining inserts are monkey-derived DNA, presumably from the culture cells used to propagate the viral stocks.

[0290] The plasmid-transformed bacteria were organized into twelve pools of 384 colonies transformed with the tPA vector ligation and another twelve pools of 384 colonies transformed with the UB vector ligation. A pool was comprised of four 96-well microtiter cultures. A stamping tool was used to inoculate 20×20 cm LB-carbenicillin/lincomycin agar plates with the microtiter cultures for bacterial propagation of the sublibrary plasmids. Plates were incubated at 37° C. overnight and bacterial cells harvested. The mixed-plasmid DNA samples that corresponded to each of the 24 expression library pools were purified with endotoxin-free Qiagen tip-500 column kits (QIAGEN Inc., Valencia, Calif.). The DNA quality and integrity of pool complexities were verified by spectrophotometry, enzyme digestion, and gel electrophoresis. Each of the resulting HSV insert-bearing library clones contains one randomly inserted fragment averaging 900 bp from the 152,000 bp viral genome. Since there are 384 clones in each sub-library pool, with 55% carrying HSV-1 DNA, and only 1 in 6 fragments are properly oriented and framed, one pool could express the average equivalent of 0.2 of the genome's coding sequences: (384×0.55)×900×(⅙)/152,000=0.21 expression equivalents). Together, the two intracellular targeting libraries, comprising a total of 24 sub-libraries, statistically represent 5 genome-expression-equivalents.

Example 2 Immunizations and Challenge-Protection Assays, Round 1

[0291] The twelve sub-library DNAs in the tPA vector and the twelve DNAs in the UB vector were each combined with a plasmid expressing murine GMCSF at {fraction (1/10)} library dose in buffered saline. These inocula were intramuscularly (i.m.) injected into 24 groups of 6-week old hairless mice. Each mouse (4 per group) injected with 50 μg of pooled library plasmids and 5 μg of the genetic adjuvant GMCSF, which was evenly distributed into two quadricep and two tibialis anterior muscles. The animals were administered two boosts with the same inocula at weeks 4 and 8 post-prime then challenged with virus 2 weeks after the last immunization. Exposure to HSV-1 strain 17 syn+ was carried out by pipetting a 50 μl suspension of HSV stock containing 2×10⁵ pfu to an abraded region of shaved dermis. Both the tPA and UB library screens, using two readouts of herpes infection i) infection-induced lesions and ii) animal survival, were monitored for 14 days. Changes in the epithelium were recorded as mild, moderate, or severe. These results are described in FIG. 1. Mice with severe skin lesions and also myelitis were euthanized. FIG. 2 presents the rates of mouse survival post-challenge. Positives were scored based on both readouts: reduced lesions and increased survival relative to control animals (naïcve and irrelevant library-immunized). The two criteria were strongly correlated. Three groups from the tPA library immunizations were scored as positive, corresponding to plasmid pools T1, T3, and T8. Four groups from the UB library immunizations were identified for deconvolution, those given plasmid pools U6, U7, U11, and U12.

Example 3 Library Reductions, Round Two

[0292] To generate the inocula for the second round of sib-testing and positive clone enrichment, the 21 microtiter culture-plates corresponding to the three positively scoring tPA groups and the four positively scoring UB groups were retrieved from the freezer stocks. Using a stamping tool, 20×20 cm LB-carbenicillin/lincomyocin agar plates were inoculated with a set of the bacterial transformants that would define the new pools of library plasmids for round 2 ELI testing. The pool compositions were designed by positioning each transformant into a virtual three-dimensional matrix, and then combining the bacteria according to the virtual planes (FIG. 3). By this pooling method, each transformant was located in three unique pools, corresponding to once in each of three dimensions. The objective was to map our protection assay data onto this grid such that a matrix analysis of the planar intersections would efficiently identified single transformants correlated with protection. The tPA grid was built with 36 groups of 100 to 200 plasmids organized into 12-X, 16-Y, and 8-Z axes. The UB grid was formed with 25 inoculation groups of 300 plasmids representing 6-X, 9-Y, 10-Z axes. Bacterial groups were propagated on the agar plates and cells were harvested. Mixed plasmid samples were purified as described above and the integrity of pool complexities were verified. The GMCSF plasmid was not included in the inocula for this and subsequent rounds of immunization. An adjuvant was deemed less important as pool complexities were reduced and the inventors preferred to avoid any possible adverse effect of inappropriate immune modulation by the cytokine expression. The mouse strain used for the challenge model was BALB/c for round 2 and 3 since the results from this strain and the hairless mice were observed to be similar. Although lesions are more easily assessed in the hairless, both strains are similarly susceptible to lethal HSV infection. Consequently, subsequent protection results obtained using the BALB/c relied on survival readouts without disease monitoring. The animals were immunized with the re-arrayed pools of library plasmids by i.m. injection (50 μg per mouse, as described for round 1), and also by gene gun delivery (1 μg per ear). The challenge procedures were similar to that described for round 1.

[0293] In the screen of the tPA-fused library, boosts were administered at weeks 3 and 10, and animals were exposed to virus 2 weeks after the last immunization. The challenge readout results are graphed in FIG. 4A. The positively scoring pools from round 1 were retested and again conferred protection. Negative control groups were immunized with empty vector or non-immunized (NI) mice. The top surviving test groups within each data set were chosen. Mice immunized with Z-axes pools uniformly displayed lower survival rates than those immunized with the X and Y pools, therefore scoring was less stringent for the Z axes mouse groups. The pools selected as positive corresponded to grid dimensions X1, X8, Y1, Y4, and Y9, Y12, Y14, Y15, and Z2, Z3, Z5, Z7. Their intersections indicated 48 microtiter-well transformants.

[0294] For screening the UB fusion library, mice were immunized at weeks 0, 6 and 12. The lethality results of the viral challenges, administered 3 weeks later, are graphed in FIG. 4B. Survival was monitored twice daily until 10 days post-challenge. Monitoring was not carried as long as the tPA library study because death appeared to level off by day 10 post-infection, although longer monitored may have permitted the NI to display complete death. The survival rates observed on day 9 post-infection were used to select positive groups. Again, the mice immunized with Z-axes pools uniformly displayed lower survival rates. The best surviving groups within each data set were chosen. These groups were immunized with pools of plamids representing matrix planes X1, X2, X5, and Y1, Y2, Y6, Y9, and Z2, Z7, Z9. Their intersections indicated that 90 microtiter-well transformants from the originally designed grid were responsible for the observed improvements in survival.

Example 4 Reduction to Individual Antigen-Encoding Clones

[0295] Each of the library transformants designated by the matrix cross-hairs was individually propagated in liquid culture and the plasmid was purified using a small-scale alkaline lysis kit method (Qiagen, Turbo-preps). Sequencing reactions were performed with primers that hybridize immediately upstream and downstream of the library insert cloning site. Analyses of the sequence data were used to identify inserts that encoded properly fused HSV-1 open-reading-frames (ORFs) greater than 50 amino acids (aa) in length.

[0296] From the group of 48 tPA peptide-fused library clones, 21 carried contaminating mammalian-DNA inserts and another 26 carried non-coding HSV-1 DNA. Six clones encoded HSV-1 ORFs that encoded fragments from the following six proteins:

[0297] 1. US6, glycoprotein D (gD), currently studied as a vaccine candidate. The gD library insert identified in the screen was 1385 bp, and spanned the full-length gene.

[0298] 2. US3, a serine/threonine protein kinase.

[0299] 3. UL17, a viral DNA cleavage and packaging protein.

[0300] 4. UL50, a dUTPase. The insert encodes an open-reading frame greater than 50 aa however it is not in the predicted coding frame.

[0301] 5. US8, glycoprotein E (gE), known to inhibit IgG-mediated immune responses.

[0302] 6. UL28, viral DNA cleavage and packaging protein and a transport protein.

[0303] From the group of 98 UB-fused library clones, 27 carried contaminating mammalian-DNA inserts and 25 were HSV-1 inserts but did not encode an HSV-1 protein fragment. Eight plasmids encoded HSV-1 ORFs corresponding to one or more fragments of the following six proteins:

[0304] 1. Anti-sense of UL29/ICP-8

[0305] 2. UL53, glycoprotein K (gK).

[0306] 3. UL27, glycoprotein B (gB), currently studied as a vaccine candidate.

[0307] 4. UL36, the very large tegument protein.

[0308] 5. UL29/ICP-8, major single-stranded DNA-binding protein.

[0309] 6. UL24, a replication protein.

[0310] Sequencing revealed that three unique library clones carried inserts corresponding to three different regions of the approximately 10 kilobase UL36 gene. Two of these encoded UL36 fragments and one of these was scored as positive. Two ORFs corresponded to the UL29 gene. One of these encoded a fragment of UL29 and the other ORF appears to be fortuitous since the UL29 coding sequence was fused in an inverted orientation.

Example 5 Protection Analysis with Individual Library Clones, RELI Round 3

[0311] Stock bacterial cultures carrying each of tPA and UB library clones indicated above were grown in liquid culture by standard methods and the plasmids were purified with Qiagen endotoxin-free kits. Less library plasmid was used for the single clone inoculations, since the dose of each one was high relative to the earlier rounds. If the total amount of DNA in an inoculum is maintained, then the dose of any one antigen increases as the complexity of the mixture decreases. For round-3 of the tPA screen, inocula for vaccination were prepared by diluting each library plasmid with an equal amount of pUC118, as non-specific carrier DNA to facilitate delivery. In particular, BALB/c mice were injected i.m. with 50 μg of DNA, comprised of 25 μg of one of the protection candidates and 25 μg of pUC118. They were simultaneously administered two 1 μg DNA shots with the gene gun, each comprised of 0.5 μg of same vaccine candidate with 0.5 μg pUC118. The animals were boosted with the same inocula at weeks 5 and 9. Three weeks following the last boost, vaccinated animals were challenged with HSV-1 strain 17 syn⁺. Unfortunately the viral stock was less virulent than anticipated, evidenced by survival of the unimmunized control mice. The animals were re-challenged two-weeks later with a fresh stock of titered HSV-1, and survival was monitored and recorded for 14 days. To confirm that the second challenge had not altered the readout, the tPA-library round-3 study was repeated and similar results were obtained. The survival results are shown in FIG. 5A. Immunization with five of the six clones led to survival rates that were at least twice as high as the negative control groups (non-immunized and irrelevant-antigen immunized). These clones encode gD (US6), a serine/threonine kinase (US3), two viral packaging proteins (UL17 and UL28), and UL50. A positively scored pool from round-2 did not perform as well as the single clone inocula in this study. This may be attributable to the more severe conditions of a double challenge with no adjuvant, and/or its several-hundred fold complexity, and therefore dilution, relative to the single plasmid inocula.

[0312] The UB fusion vector is designed to facilitate proteasome processing and MHC I-stimulated immune responses. The inventors have previously observed that, unlike antibody responses, cellular responses can decline once the optimal dose has been surpassed. Therefore, the inventors chose to imitate the gene dose of each antigen within the sublibrary pools by mixing the single plasmids with pUC 118 into a 200-fold dilution (0.25 μg i.m. and 0.005 μg per gene gun shot). Mice were primed individually with the eight ORF-containing clones, and then boosted twice at weeks 5 and 11 with the same single plasmid inocula. Vaccinated animals were challenged 2 weeks later with HSV1 syn17⁺ as described above. These results showed that the inoculum was not sufficiently lethal. Fresh HSV stocks were prepared and titered, and the challenge was repeated 6 weeks later. Survival was monitored and recorded for 14 days. Presumably as a result of this double challenge, protection levels were generally lower than previously observed. Namely, even the positive control gD-expressing plasmid (pCMVigD), delivered at a full (undiluted) dose, provided only partial protection. The survival percentages on representative days 8, 9, and 14 are plotted in FIG. 5B. Immunization with four clones led to extended survival relative to the non-immunized group. These clones encode fragments of UL27 (gB), UL36.2, UL29, UL24.

Example 6 Comparative Protection Assays of RELI-Identified HSV-1 Gene Fragments

[0313] This study was conducted in order to assess the relative levels of protection conferred by the gene vaccine candidates. All ten library clones that had been identified in the tPA and UB RELI library screens were retested using the original gene-fragment constructs. The plasmids were delivered by gene-gun (2×1 μg) and i.m. (50 μg) routes, into groups of 10 mice each. Several of these gene-fragment inocula led to extended mouse survival, although none performed better than the full-length gD construct. In particular, fragments of UL17, US3, UL50, UL28, and UL36 (UL36.2) showed some protection relative to the non-immunized control mice. These results are presented in FIGS. 6A and 6B. In FIG. 6A, the percentage of each group surviving at representative days 8 through 11 and the endpoint day 14 are shown. In FIG. 6B, an average survival score has been calculated for each group, and plotted alongside the positive and negative control groups, which were immunized with pCMVigD, pCMViLUC, respectively or NI. A score was calculated for each animal by summing the day-numbers post-exposure (days 8 through 14) during which the animal lived. An average score and standard error was calculated for the group and used for graphing. The results show that immunization with US3, UL17, UL28, UL27 (gB), and UL29 generated protection scores with non-overlapping standard errors to that of the NI controls.

Example 7 Analysis of Candidate Antigens for HSV-1 Vaccines

[0314] By utilizing RELI and two intracellular targeting genetic immunization vectors, four viral genes were newly identified as vaccine candidates for including in a subunit-based Herpesvirus vaccine. The libraries comprising round 1 were screened in the presence of GMCSF, while the inocula in rounds 2 and 3 were tested without adjuvant. When retested, the positively scored sub-libraries from round 1 were found also to be protective without GMCSF. The immunization route in round 1 was i.m. injection only, and subsequent rounds included both injection and gene gun delivery. Also the first round was done in Hairless mice while the subsequent rounds were conducted in BALB/c mice. These differences between rounds indicate that the output candidates were capable of conferring protection independent of GMCSF co-delivery, with or without gene gun delivery, and in at least two different mouse model strains.

[0315] In addition to the four unique candidates, both of the two major antigens currently studied as vaccine candidates were identified. In particular, screening the tPA fusion library yielded the full length glycoprotein D gene, and screening the UB fusion library yielded an expressed fragment of the glycoprotein B gene. The fragment carried on this library clone encodes a determinant that has been shown to be immunogenic in infected individuals. The output of known vaccine candidates by the ELI process supports the validity of the unbiased method and suggests the utility of the other output antigens.

[0316] None of the new vaccine candidates from the RELI screens are predominantly surface proteins. Instead enzymes, nuclear proteins, and cytoplasmically-located proteins were discovered. For example, a new candidate from the tPA library screen expresses an N-terminal fragment of US3, serine/threonine protein kinase. In both HSV-1 and 2, the US3 gene is required for the characteristic herpes virus-induced blockage of programmed cell death. Interestingly, one of the other two genes thought to block apoptosis is gD (Whitley and Roizman, 2001). US3-deficient mutant strains replicate normally but are highly attenuated. Despite the reduced virulence these mutants display enhanced immune activity, suggesting a role for US3 in suppressing host immune responses (Inagaki-Ohara et al., 2001). In cytomegalovirus, US3 has been shown to delay the presentation of viral antigens to cytotoxic T cells (Jones et al., 1996). In a screen for human T cell epitopes, a 15 aa peptide mapping to US3 has been identified as stimulating CD4 T cells in an in vitro proliferation assay (U.S. Patent Application 20020090610). To our knowledge, the US3 protein kinase has not been previously predicted to be, or tested as, a vaccine candidate. Two of the other candidates from the tPA-fusion library screen encode fragments of proteins involved in viral DNA cleavage and genome packaging, UL17 and UL28. To our knowledge, neither has been previously implicated as protective antigens. A new candidate derived from the UB library screen is UL29. The UL29 gene product is ICP-8, a single-stranded DNA binding protein required for viral replication. It appears to be involved in recruitment of the helicase-primase complex to DNA lesions (Carrington-Lawrence et.al, 2003). Mutant HSV-2 deficient in UL29 are defective in DNA synthesis and replication (Da Costa et al., 2000). In cytomegalovirus (CMV), the UL36-38 complex synergizes with the US3 protein to regulate transcription of the heat shock protein 70 gene of the host.

[0317] Table 2 provides the sequences and summarizes the lengths of each of the HSV random library fragments that conferred mice protection against challenge in the comparative study. The length of the gene-encoding portion within the random fragment, and the size of the full gene are given. In Table 3, the pooling history of these library clones during the library reduction is described. TABLE 2 The HSV-1 vaccine candidates identified by RELI. Library Coding Full length Gene Insert Insert SEQ ID No. fragment gene Gene SEQ ID No. US6(gD) 1381 SEQ ID NO: 111 1185 1185 SEQ ID NO: 115 US3 974 SEQ ID NO: 103 969 1446 SEQ ID NO: 105 UL17 1425 SEQ ID NO: 33 558 2112 SEQ ID NO: 39 UL28 1815 SEQ ID NO: 57 1815 2358 SEQ ID NO: 63 UL27 (gB) 683 SEQ ID NO: 53 681 2715 SEQ ID NO: 55 UL29 514 SEQ ID NO: 65 513 3591 SEQ ID NO: 67

[0318] TABLE 3 Resident pools of the RELI candidates Derivative Gene Round 1 pool Round 2 pools US6 (gD) T3 T: X1, Y1, Z7 US3 T3 T: X1, Y14, Z2 UL17 T8 T: X1, Y9, Z3 UL28 T8 T: X8, Y14, Z7 UL27 (gB) U7 U: X2, Y6, Z9 UL29 U12 U: X1, Y6, Z7

[0319] Table 4 presents the amino acid similarities and identities of the products encoded by the ELI-identified HSV-1 gene fragments to their homologs in a selection of other herpesviruses. These sequence comparisons may indicate that the HSV-1 homologs could carry protective capacities. For example, gD of BHV has been shown to be protective against BHV, as is its homologue from HSV-1 and HSV-2. Notably, a number of the RELI candidates display herpesvirus similarities/identities that are higher than that of gD. The relatedness also suggests that vaccination with genes or gene products from one virus might heterologously protect against exposure to a different herpesvirus. TABLE 4 Examples of Percent Similarities/Identities of RELI hits to Herpesvirus homologs. Gene fragment HSV2 VZV BHV EHV CMV CHV gD 82/88 25/44 27/39 23/40 30/33 58/72 US3 70/79 44/61 44/62 34/55 26/36 51/64 UL17 84/90 31/53 34/48 31/51 33/43 69/79 UL28 88/91 46/62 51/64 52/67 22/41 81/87 gB 90/95 45/67 45/64 42/58 26/42 77/86 UL29 97/98 48/63 53/67 55/71 26/40 88/91

Example 8 A DELI Screen: Construction of an HSV-1 Gene Library

[0320] Genomic DNA from the MacIntryre strain of HSV-1 was purified from cultured green monkey kidney cells (VERO-E6). The genomic DNA itself would be used as template for polymerase chain reactions. A backup source of template was generated by cloning the genomic DNA into plasmids. In this state, the DNA would have different characteristics (e.g. topology) and be a renewable resource. The two libraries described in example 1 for RELI were also used as an alternative plasmid template for DELI.

[0321] To build an expression library of all HSV-1 genes, a set of two oligonucleotides (oligos) were designed that correspond to the 5′ and 3′ end sequences of each open-reading-frame (ORF) to provide for sequence-directed PCR-amplification of the HSV-1 coding sequences. Each primer was designed to optimize the probability of successful hybridization and to roughly match the melting temperature (T_(m)) of its primer pair. Accommodations were made for repetitive sequences, GC-content, melting temperature, product length, and LEE linking. Genes longer than 1,500 bp were split into sub-gene fragments. To facilitate the attachment of expression elements to the ORFs, each primer was designed with a 15 base deoxyuracil (dU)-containing stretch at its 5′ end, followed by approximately 20 nucleotides of ORF-specific sequence. The dU stretch is comprised a repeated triplet sequence, which contains a dU phosphoramidite, and renders the region sensitive to uracil-DNA-glycosylase (UDG) degradation. The purpose of including this sequence is to generate a single-stranded region by degrading the 5′ stretch and creating a 3′overhang. The sequences of the dU stretches are designed to prevent the ORF from self-annealing, but permit complementary annealing to promoter and terminator expression fragments. Each oligo was designed to ensure that the coding frame of the HSV-1 polypeptide would be maintained. Primer sets to amplify 126 ORFs that would encode for the 77 HSV-1 genes were synthesized on a MerMade IV™ instrument in 96-well formats. The 35 to 37 base oligo products were evaluated for quality by gel electrophoresis, and evaluated for yield by fluorimetry.

[0322] The dU-containing oligo stocks were diluted to 10 μm then combined into ORF primer sets. A reaction master-mix was prepared to PCR-amplify each ORF as follows: 10X PCR buffer with MgCl₂ (Promega), 10 μl 2.5 mM dNTPs 5 μl dH₂0 55.8 μl HSV-1 genomic DNA (1.2 ng/ul) 8.2 μl Taq polymerase (Promega) 1 μl

[0323] ORF-specific primers were separately added to each microtiter well:

[0324] dU primer pair (10 μm) 20 μl

[0325] Reactions were incubated in a thermocycler (Perkin-Elmer) by the following program: 96° C., melting  2 min 94° C., melting 30 sec 55° C., annealing 30 sec 72° C., polymerizing  1 min, 30 sec Cycle 34 times, then 72° C. 10 min

[0326] The high GC-content of the HSV genome (69%) and number of repetitive sequences are believed to have led to the need for extensive PCR testings. Reactions that did not amplify with sufficient specificity or yield were re-prepared and run in a Robocylcer (Strategene, La Jolla, Calif.) temperature gradient program. Optimal amplifications of the 126 primer sets were found to require eight different annealing temperatures that vary from 33° C. to 63° C. In addition, optimal amplification of the ORFs encoding a subset of ORFs, such as the UL36 gene and a portion of the UL29 and UL27 genes, required the addition of 6% DMSO to the reactions. The DMSO-containing samples were the only reactions programmed at the lowest annealing temperature, 33° C. Once appropriate conditions were identified, multiple reactions were prepared to amplify sufficient quantities of each ORF. Identical products were combined and were precipitated by adding 0.3 M sodium acetate and 3 volumes of ethanol. Products were resuspended in water, and a sample (5/100) of each PCR product was analyzed by agarose gel electrophoresis alongside a quantitated 100 bp DNA standard ladder (Promega, Madison, Wis.). Another sample (1/100) was removed to measure DNA concentration with pico-green dye in a Tecan plate-reader (Tecan, Research Triangle Park, N.C.) by fluorimetry using a kinetic measurement program.

Example 9 Arraying of an HSV-1 ORF Library According to Cubic Designations

[0327] The quality- and quantity-controlled ORFs were arrayed into 75 pools (25 X's, 25 Y's, 25 Z's) of 5 ORFs according to their computer-assigned location with in virtual 25×25×25 grid. Each new pool represented the constituents of the x, y, and z planes of the computer-derived three-dimensional matrix. Since each ORF holds a position in all three dimensions, each ORF is contained in three independent pools for subsequent testing. The pooling was accomplished robotically using a BioMek (Beckman, Brea, Calif.) instrument. A program was written that imported the PCR product names and concentrations, and then distributed the each product into three of 75 wells (representing 25 X, 25 Y, and 25 Z pools) such that all ORFs were present at equal molar amounts in each pool. Since the product lengths varied, the total amounts of DNA per well varied from 2.6 to 3.9 μg. The volumes of samples in the wells were raised to a common 150 μl with dH₂O to prepare for the uracil DNA-glycosylase reactions: PCR products 150 μl 10x UDG buffer (NEB) 17.3 μl UDG 6 μl (6 units)

[0328] The reactions were incubated at 37° C. for 40 minutes then the enzyme was inactivated at 65° C. for 10 minutes. The resulting products will carry 15 base single-stranded stretches at both ends. To purify the samples, 200 μl of Magnasil DNA-binding beads (Promega, Madison, Wis.) were added and the samples were vortexed for 30 minutes. After settling, the supernatant was transferred to a separate tube and purification was repeated with 200 μl of fresh beads. Wash solution was added to the beads and vortexed as directed. Beads were washed in 80% ethanol as directed, then dried. Elution buffer was added to beads to recover the PCR products. Volumes were reduced to 50 μl by lyophilization.

Example 10 Preparation of the Arrayed Library for Gene Expression

[0329] Based on numerous genetic immunization studies using both plasmid and LEE based antigen expression, the inventors arrived at pair of expression elements that reliably performed well. The promoter element is a PCR product comprised of the cytomegalovirus immediate early gene promoter, the chimeric intron of pCI, and one of two fusion peptides for intracellular targeting the antigen. The two fusions, as described earlier, are designed to favor either MHC II or MHC I presentation by using i) a secretory leader sequence from human α1-antitrypsin (LS) and ii) a short ubiquitin subunit sequence (UB). The terminator (GHterm) is a PCR product comprised of the human growth hormone transcription termination sequence. To facilitate consistency, these three expression elements were prepared in large batches, with the following 100 μl standard-reaction master-mix: 10x PCR buffer with MgCl₂ (Promega) 10 μl  2.5 mM dNTPS 5 μl ddH₂O to final volume of 100 μl Taq (5 units/μl) (Promega) 1 μl

[0330] The mix was divided into three parts and different sets of template and primer were added to each: For the LS promoter-fusion element (product size is 1.2 kb): Plasmid template pCMViLS 50 ng CMV Fprimer151 1 μg LS dU Rprimer 1.5 μg For the UB promoter-fusion element (product size is 1.34 kb): Plasmid template pCMViUB 50 ng CMV Fprimer151 1 μg UB dU Rprimer 1.5 μg For the GH terminator element (product size is 0.61 kb): Plasmid template pCMVi 50 ng GHterm dU Fprimer 1 μg GHterm Rprimer1590 1.5 μg

[0331] The plasmid templates were genetic immunization vectors without any coding sequences (no insert) that contained either the leader sequence or ubiquitin sequence and the human growth hormone gene terminator. These were linearized by digestion with PvuI restriction enzyme to facilitate PCR-amplification. In each expression element primer set, one primer contains a dU stretch and one primer does not. The sequences of these oligo primers have been previously described (Sykes and Johnston, 1999). For the ORF primer sets, both primers contain dU stretches. Reactions were incubated in a thermocycler (Perkin-Elmer, Boston Mass.) by the following program: 96° C., melting  3 min T*, annealing  1 min, 15 sec 72° C., polymerizing  1 min, 30 sec 94° C., melting 45 sec T*, annealing  1 min, 15 sec 72° C., polymerizing  1 min, 30 sec Cycle 34 times, then 72° C. 10 min

[0332] Multiple 100 μl reactions are prepared at once, and then collected for purification. Sodium acetate is added to a final concentration of 0.3 M, and then the samples are extracted one time with an equal volume of phenol/chloroform. The aqueous was removed into a fresh tube then ethanol precipitated. The pellets were resuspended in water at one-fourth their original volume. The elements were analyzed by gel electrophoresis and concentrations were determined by flurometry.

[0333] The linear expression elements (LEEs) were created by combining the two promoter-fusion elements and the terminator element into each of the pooled ORFs so as to provide equivalent molar ratios of expression elements to ORFs. In particular the molar ratios of the two promoter-fusions to ORF to terminator was calculated so as to be 0.5:0.5:1:1. ORFs (approximately 3.75 μg in 50 μl) 10x Annealing buffer   10 μl 1.25 μg CMViUB 6.25 μl 1.25 μg CMViLS 6.94 μl 1.25 μg GHterm  4.2 μl

[0334] The linking reactions were incubated at 95° C. for 5 minutes then transferred to 65° C. After 1 minute to cool sample, 2M KCl (25.8 μl) was added to a final concentration of 0.5 M. Samples were incubated at 65° C. for 10 minutes, then 37° C. for 15 minutes, and then 25° C. for 10 minutes. To assess linking efficiency 1 μl was removed, diluted 5-fold into TE and loading dye, and then electrophoresed at low voltage on a 0.7% agarose gel.

Example 11 Preparation of the Arrayed LEE Expression Library for Direct Mouse Inoculation

[0335] Inocula for animal immunizations were made by mixing the expression element-linked ORFs (approximately 7.5 μg in 100 μl) with linearized plasmid DNA (pUC118) to total 30 μg of DNA. The EcoRI-digested pUC118 filler served as carrier for more efficient gold precipitation (see below). For each HSV gene pool inoculum, 30 gene-gun doses (bullets) were prepared, such that each shot delivered 250 ng of HSV DNA along with 750 ng of carrier. Gold microparticles with diameters ranging from 1-3 μm (Degusa Inc.) were weighed out dry into multiple microfuge tubes at 75 mg per tube. Particles were washed with approximately 1 ml ddH₂O then removed, cleaned with approximately 1 ml 100% ethanol then removed, and then finally resuspended in 1.25 ml of ddH₂O to obtain a slurry of gold at 60 mg/ml. The slurry was aliquotted at 225 μl per each of 75 microfuge tubes. The tubes were gently spun to pellet gold and then the ddH₂O was removed. To each of the tubes, a 100 μl linking reaction and 22.5 μg of pUC118 was added. The DNA/gold slurry was vortexed and 1 volume (130 μl) of 2.5 M CaCl₂, pH5.2 was added. While vortexing, {fraction (1/10)} vol (26 μl) of 1 M spermidine (free base) was added. The samples were allowed to precipitate on the gold microparticles for 15 min at room temperature, and then spun at room temperature for 1 minute. Supernatants were removed and the gold was washed with 70%, then 100% ethanol three times. The washed samples were combined with 1.8 ml fresh, very dry 100% ethanol and then dried overnight in a dessicator. Gene-gun bullets were prepared as per Helios instructions (BioRad, Inc., Hercules Calif.). Briefly, each 1.8 ml sample was drawn into a syringe and injected into dry plastic tubing that fixed onto a rotating station. DNA attached gold was dried onto the inner surface of the tubing by blowing nitrogen through it. The inventors have adapted the station to accommodate 8 samples at once. Up to 30 bullets were obtained from each batch, and one was used for analysis. A bullet was placed in a tube with TE and loading dye. The solution was then loaded onto an agarose gel for analysis. Prepared bullets were stored in a dessicator until used for immunizations.

Example 12 Mouse Immunizations and HSV-1 Challenge-Protection Assays

[0336] The 75 pools of LEEs expressing 5 HSV ORF and controls were administered to groups of 4 BALB/c mice, as three sets of 25 dimensionally-defined test pools. Positive control groups received a plasmid or LEE expressing the known vaccine candidate glycoprotein D₁ (gD) and negative control groups were non-immunized (NI). Each mouse received a total of 2 μg of DNA delivered on gold microprojectiles with a Helios gene gun. The immunizations were distributed as two 1 μg doses into the skin of the mouse ears. Each test dose was comprised of 250 ng of HSV-1 DNA (and therefore 50 ng of each individual ORF) and 750 ng of pUC118 DNA as filler. Each positive control dose was comprised of 250 ng of pCMVigD or LEE-gD, and 750 ng of pUC118. The animals, were administered two boosts with the same inocula at weeks 4 and 8 post-prime then challenged with virus 3 weeks after the last immunization. Exposure to HSV-1 pathogenic strain 17 syn⁺ was carried out by pipetting a 50 μl suspension of viral stock containing 2×10⁵ plaque-forming-units to an abraded region of shaved dermis. Survival was monitored for 12 to 15 days; disease-induced death began on day 6 and continued through day 12 post-exposure.

[0337] The challenge assay results of the mice immunized with the X, Y, and Z sets of matrix-arrayed library-inocula are depicted in FIG. 7 and FIG. 8. In FIG. 7, the raw survival rates are provided for days 7 through 10, and the endpoint day (last day monitored before sacrifice). In FIG. 8 survival scores are plotted. These scores were derived in order to compare levels of protection between the sets of X, Y, and Z groups. Animal survival data recorded for days 6 through day 12 were used to determine the survival score for each of the 75 study and control groups. An individual animal score was calculated by summing the day-numbers post-exposure (days 6 through 12) for which the animal lived. An average score and standard error was calculated for each group of mice and used for graphing the group results.

Example 13 Matrix Analyses of Protection Data

[0338] In order to analyze the results with respect to a three-dimensional matrix, the average group-survival scores were normalized to that of the positive control group commonly included in each of the X, Y, and Z data sets. The purpose of normalization to a standard (gD control) is to minimize the impact of any unintended differences between the three independently conducted X, Y, and Z challenge studies. A normalized group score of “0” indicates that no mice were alive beyond day 6 post-infection; a group score of “1.0” indicates that the group's survival score was equivalent to that of the positive control mice tested in parallel, which were immunized with a full 250 ng dose of the protective antigen gD. The average normalized survival score of the three groups (X, Y, and Z) of negative control mice was calculated to be 0.166.

[0339] These results of the challenge-protection assays of the 75 study groups were subjected to matrix analyses that permitted protective candidates to be inferred by either i) triangulation or ii) quantitative ranking. For the triangulation method, the survival scores were used to categorize each test group as either positive or negative. An average of 15 of the 25 test groups from each of the three data sets showed group survival scores above the negative controls. Consequently, the top-scoring 15 groups were designated as positives for equilateral matrix analysis, and the ORF-pools used to inoculate these animal groups were pursued. The planar intersections of the positive pools indicated 3,375 loci within the virtual cube that was originally used to design these pools. Since only 127 ORFs were arrayed in a grid with 15,625 possible positions (25×25×25), most loci were not filled, enabling triangulation to pinpoint 23 ORF-containing intersections. The ORFs located at these cross-hairs are resident in each of one positively scoring X, Y, and Z pool, and thereby they were candidates for causing the observed mouse protection. Thus cross-hair triangulation and low occupancy enabled 104 of 127 ORFs to be culled, an 82% reduction of the library. The 23 ORFs, corresponding to 21 different HSV-1 genes including gD, are listed in Table 5. The nucleotide length of the library-tested ORF, the size of the derivative gene, and the grid coordinates of the ORF are provided. Since 15 groups had been chosen from each axis to analyze, it was estimated that approximately 15 ORFs are responsible for the observed protection. Fewer than 15 ORFs may be true candidates if one or more groups were mis-categorized as positive, or if one or more ORF is pooled with another ORF that masked the protective activity. Even though the inventors were testing each ORF in three independent pools of other ORFs, identification by triangulation analysis requires a cross-hair, or positive scores in all three of an ORF's resident pools. TABLE 5 Intersection Analysis By Triangulation Fragment Size Gene Size ORF name (bp) (bp) Resident pools RL1_a_a 339 747 X20, Y1, Z15 UL1_a 588 675 X20, Y1, Z8 UL11_a 249 291 X23, Y6, Z12 UL13_b 801 1557 X09, Y20, Z15 UL15_a_a 309 2208 X21, Y16, Z18 UL16_a_c 309 1122 X6, Y24, Z4 UL17_a 984 2112 X1, Y14, Z4 UL17_b 1053 2112 X11, Y3, Z6 UL18_a 939 957 X22, Y23, Z3 UL21_b 795 1608 X22, Y13, Z3 UL25_a 831 1743 X16, Y20, Z1 UL28_a 1065 2358 X6, Y25, Z18 UL36_b 1320 9495 X17, Y6, Z3 UL37_b 1128 3372 X09, Y11, Z12 UL41_a 1401 1470 X10, Y13, Z04 UL43_a 1182 1305 X21, Y3, Z17 UL44_a 708 1536 X12, Y16, Z5 UL5_a 1290 2649 X12, Y4, Z1 UL52_c 1020 3177 X25, Y25, Z15 UL54_a 702 1539 X09, Y16, Z05 UL54_b 711 1539 X23, Y13, Z23 US5_a 261 279 X10, Y24, Z12 US6_a 1089 1185 X16, Y20, Z6

[0340] Although one of the advantages of the triangulation method is that any pinpointed candidate has been tested in triplicate, the requirement for three positive readouts can also be a disadvantage. In addition it does not enable the inferred protective capacity of one ORF relative to one another in the grid to be discerned. In a second matrix analysis a quantitative ranking was performed that addresses both of these potential pitfalls. The ranking method accommodates for the possibility that a protective ORF may reside in a pool carrying a negative ORF. If the other two resident pools score well, the protective ORF can still be identified based on a favorable three-pool cumulative score. Quantitation also allows the assignment of a score value to each ORF, and thereby derive a rank-sorted list of all the constituent ORFs in the entire genomic grid.

[0341] For the ranking method, each ORF was given a score-value that is based on individual scores of the three groups that had been inoculated with the three pools (one X, one Y, and one Z) containing any particular ORF. The normalized scores of the three X, Y, and Z “coordinates” of every ORF in the grid were summed, averaged, and standard errors were calculated. Table 6 displays a rank-sorted list of ORFs based on average survival scores of their resident pools. ORF fragment length, derivative gene size, and each ORFs grid coordinates are also provided. TABLE 6 Intersection Analysis By Quantitative Ranking, Survival Score Fragment Size ORF name Rank (bp) GeneSize (bp) Resident pools UL16_a_c 1 309 1122 X6, Y24, Z4 UL8_a 2 1039 2253 X17, Y21, Z19 UL18_a 3 939 957 X22, Y23, Z3 UL43_a 4 1182 1305 X21, Y3, Z17 UL17_a 5 984 2112 X1, Y14, Z4 UL21_b 6 795 1608 X22, Y13, Z3 UL52_b_a 7 315 3177 X16, Y12, Z07 UL30_c 8 1249 3708 X08, Y08, Z07 UL41_a 9 1401 1470 X10, Y13, Z04 US6_a 10 1089 1185 X16, Y20, Z6 UL6_b 11 946 2031 X21, Y10, Z17 UL25_a 12 831 1743 X16, Y20, Z1 UL28_b_b 13 312 2358 X04, Y07, Z12 UL15_a_a 14 309 2208 X21, Y16, Z18 UL40_a 15 904 1023 X06, Y09, Z06 RS1_a 16 1273 3897 X22, Y12, Z11 UL47_b 17 973 2082 X22, Y20, Z16 UL26_a 18 877 1908 X12, Y17, Z04 UL37_c 19 1083 3372 X4, Y5, Z23 UL28_a 20 1065 2358 X6, Y25, Z18 UL26.5_a 21 973 990 X21, Y19, Z11 UL49A_a 22 166 276 X24, Y06, Z07 UL17_b 23 1053 2112 X11, Y3, Z6 UL33_a 24 325 393 X08, Y19, Z07 US4_a 25 661 717 X21, Y23, Z21 UL36_d_c 26 426 9495 X19, Y23, Z06 UL5_a 27 1290 2649 X12, Y4, Z1 UL36_g_c 28 426 9495 X22, Y21, Z09 UL55_a 29 478 561 X03, Y02, Z04 UL37_b 30 1128 3372 X09, Y11, Z12 UL13_a 31 799 1557 X04, Y13, Z02 UL29_b 32 1141 3591 X18, Y11, Z06 UL8_b 33 1087 2253 X13, Y08, Z14 US5_a 34 261 279 X10, Y24, Z12

[0342] The ORFs were also rank-sorted based on the p-value calculated by student's t test of the difference between an ORF's survival scores and that of the negative controls. Table 7 enumerates the 34 ORFs displaying p-values of ≦0.05. ORF fragment length, derivative gene size, and each ORF's grid coordinates are also provided. Because 34 ORFs were determined to be above the p-value cut-off used in Table 7, the inventors chose also to arbitrarily list the top 34 ORFs by survival score in Table 6. TABLE 7 Intersection Analysis By Quantitative Ranking, Ttest Fragment Size Gene Size ORF name Rank (bp) (bp) Resident pools UL54_b 1 711 1539 X23, Y13, Z23 UL1_a 2 588 675 X20, Y1, Z8 UL28_a 3 1065 2358 X6, Y25, Z18 RL1_a_a 4 339 747 X20, Y1, Z15 RL2_a_a 5 345 2328 X10, Y14, Z02 UL13_b 6 801 1557 X09, Y20, Z15 UL25_a 7 831 1743 X16, Y20, Z1 US8A_a 8 433 480 X12, Y11, Z02 US6_a 9 1089 1185 X16, Y20, Z6 UL8_b 10 1087 2253 X13, Y08, Z14 UL36_b 11 1320 9495 X17, Y6, Z3 UL18_a 12 939 957 X22, Y23, Z3 UL36_a 13 1353 9495 X11, Y18, Z22 UL43_a 14 1182 1305 X21, Y3, Z17 UL16_a_c 15 309 1122 X6, Y24, Z4 UL31_a 16 907 921 X13, Y21, Z17 UL52_a 17 1018 3177 X11, Y07, Z03 UL52_c 18 1020 3177 X25, Y25, Z15 UL37_b 19 1128 3372 X09, Y11, Z12 UL21_b 20 795 1608 X22, Y13, Z3 UL17_b 21 1053 2112 X11, Y3, Z6 UL49_a 22 841 906 X14, Y01, Z20 UL44_b 23 751 1536 X23, Y02, Z02 UL22_b 24 1186 2517 X10, Y14, Z16 UL51_a 25 685 735 X02, Y14, Z10 UL28_b_b 26 312 2358 X04, Y07, Z12 UL15_a_a 27 309 2208 X21, Y16, Z18 UL36_f_b 28 420 9495 X13, Y06, Z23 UL16_a_b 29 354 1122 X23, Y10, Z03 UL37_c 30 1083 3372 X4, Y5, Z23 US5_a 31 261 279 X10, Y24, Z12 UL39_b 32 1093 3414 X01, Y10, Z18 UL20_a 33 628 669 X11, Y07, Z02 UL11_a 34 249 291 X23, Y6, Z12

[0343] The inventors have found that the cross-hair triangulating and quantitative ranking methods predominantly identify the same ORFs. In particular, all 23 ORFs identified by triangulation were also identified by ranking. However the two quantitative analyses enabled more ORFs to be identified with inferred protective capacities. The most useful distinction between the two analysis approaches is that the cumulative scoring enables all of the herpesvirus coding sequences to be ranked by inferred utility. Table 8 lists the ORFs inferred, based on the preceding analyses of the DELI data, to be candidate vaccines. ORFs identified by at least two of the three analyses are listed as “repeated hits” and the SEQ IDs correspond to these ORFs. TABLE 8 Condensed Output From the DELI Screen Analyses SEQ ID No. for All ORFs Repeated ORFs Repeated ORFs RL1_a_a RL1_a_a SEQ ID NO: 1 RL2_a_a UL1_a SEQ ID NO: 5 RS1_a UL5_a SEQ ID NO: 9 UL1_a UL8_b SEQ ID NO: 13 UL5_a UL11_a SEQ ID NO: 17 UL6_b UL13_b SEQ ID NO: 21 UL8_a UL15_a_a SEQ ID NO: 25 UL8_b UL16_a_c SEQ ID NO: 29 UL11_a UL17_a SEQ ID NO: 35 UL13_a UL17_b SEQ ID NO: 37 UL13_b UL18_a SEQ ID NO: 41 UL15_a_a UL21_b SEQ ID NO: 45 UL16_a_b UL25_a SEQ ID NO: 49 UL16_a_c UL28_a SEQ ID NO: 59 UL17_a UL28_b_b SEQ ID NO: 61 UL17_b UL36_b SEQ ID NO: 69 UL18_a UL37_b SEQ ID NO: 73 UL20_a UL37_c SEQ ID NO: 75 UL21_b UL41_a SEQ ID NO: 79 UL22_b UL43_a SEQ ID NO: 83 UL25_a UL44_a SEQ ID NO: 87 UL26.5_a UL49_a SEQ ID NO: 91 UL26_a UL52_c SEQ ID NO: 95 UL28_a UL54_b SEQ ID NO: 99 UL28_b_b US5_a SEQ ID NO: 107 UL29_b US6_a SEQ ID NO: 113 UL30_c UL31_a UL33_a UL36_a UL36_b UL36_d_c UL36_f_b UL36_g_c UL37_b UL37_c UL39_b UL40_a UL41_a UL43_a UL44_a UL47_b UL49_a UL51_a UL52_a UL52_b_a UL52_c UL54_a UL54_b UL55_a US4_a US5_a US6_a US8A_a

[0344] In Table 9 the derivative genes of the ORFs identified by the three analyses of the DELI data are listed and compared with the results of the RELI screen of randomly-generated HSV-1 gene fragments. The final column provides a list of the 23 genes, corresponding to 26 ORF hits repeatly indicated by the ELI analyses. TABLE 9 Summary Of Genes Identified By Analyses Of The HSV-1 DELI And RELI Screens. Ranking DELI, DELI, Summary Triangulation by by Repeat SEQ ID NOs. RELI DELI Score TTest rank Genes For Repeat Genes UL17 RL1 UL16 UL54 1 RL1 SEQ ID NO: 3 UL24 UL1 UL8 UL1 2 UL1 SEQ ID NO: 7 UL27 UL5 UL18 UL28 3 UL5 SEQ ID NO: 11 UL28 UL11 UL43 RL1 4 UL8 SEQ ID NO: 15 UL29 UL13 UL17 RL2 5 UL11 SEQ ID NO: 19 UL36 UL15 UL21 UL13 6 UL13 SEQ ID NO: 23 UL50 UL16 UL52 UL25 7 UL15 SEQ ID NO: 27 US3 UL17 UL30 US8 8 UL16 SEQ ID NO: 31 US6 UL18 UL41 US6 9 UL17 SEQ ID NO: 39 US8 UL21 US6 UL8 10 UL18 SEQ ID NO: 43 UL25 UL6 UL36 11 UL21 SEQ ID NO: 47 UL28 UL25 UL18 12 UL25 SEQ ID NO: 51 UL36 UL28 UL43 13 UL28 SEQ ID NO: 63 UL37 UL15 UL16 14 UL36 SEQ ID NO: 71 UL41 UL40 UL31 15 UL37 SEQ ID NO: 77 UL43 RS1 UL52 16 UL41 SEQ ID NO: 81 UL44 UL47 UL37 17 UL43 SEQ ID NO: 85 UL52 UL26 UL21 18 UL44 SEQ ID NO: 89 UL54 UL37 UL17 19 UL49 SEQ ID NO: 93 US5 UL26.5 UL49 20 UL52 SEQ ID NO: 97 US6 UL49 UL44 21 UL54 SEQ ID NO: 101 UL33 UL22 22 US5 SEQ ID NO: 109 US4 UL51 23 US6 SEQ ID NO: 115 UL36 UL15 24 UL5 US5 25 UL55 UL39 26 UL13 UL20 27 UL29 UL11 28 US5 29

[0345] An ELI protection study might also have been analyzed without matrix arraying. If the 127 ORFs had been partitioned into pools of 5 ORFs as above, and 15 positive groups were selected as above, then only 40% ((10 negative groups)×(5 ORFs/group))/127) of the unprotective ORFs would have been culled. Each ORF would have been tested only once, in only one ORF mixture.

Example 14 Analysis of DELI-Identified ORFS

[0346] In a directed LEE library screen, 23 HSV-1 ORFs were identified as vaccine candidates by triangulation and another 31 were identified by either/both quantitative scoring and p-value sorting. Among these ORFs is glycoprotein D (gD), a previously studied HSV vaccine candidate that has generated variable results in clinical trials. The gene encoding gD, US6, was identified by all three of our DELI analyses. The second HSV antigen most studied as a possible vaccine component is glycoprotein B (gB). Its absence in our list of ORF candidates can be explained by comparing the ORF design to the known. B-cell determinants of gB. The gene-splitting program for primer design breaks genes greater than 1,500 bp into subgenes, and in particular the 2,715 bp gB gene was arbitrarily divided into two subgene ORFs. ORF “a” ends at amino acid (aa) 461, and ORF “b” starts at aa 444. A prominent H-2d (i.e. BALB/c mice) domain detected by a known neutralizing antibody to HSV-1 spans amino acids 290 to 520 (Navarro et al., 1992). In the RELI screen of the HSV-1 genome, using populations of randomly fragmented ORFs, fragments of both gB and gD were identified as candidate protective ORFs, along with 8 other ORFs. The genes corresponding to 4 of the 8 novel candidates identified by RELI were also identified in the DELI screen (US8, UL17, UL28, and UL29).

[0347] Among the novel candidates, there is also some overlapping results between thr RELI and DELI screens. For example, 5 different ORFs encoding different portions of the very large tegument protein UL36 were inferred to hold some level of protective capacity in the DELI screen. A DNA fragment triangulated with the RELI results encodes a portion of UL36 (aa 338 to 509) that spans 2 of these 5 DELI hits (aa 1 to 461; aa 444 to 897). In another case, both portions of UL17, which was split into 2 ORFs for DELI, were identified in the DELI screen, and a random UL17 fragment was identified by RELI. Likewise, both fragments of the full UL28 gene were identified by DELI, and a random fragment of it was identified by RELI. The remaining ORFs inferred to carry some protective capacity by this screen correspond to a varied set of cytoplasmic, nuclear, and structural genes. The genes indicated by at least two of the three analyses of the DELI screen are listed in Table 10 with the viral products and/or the biological processes that these gene products are known or suggested to be involved in are provided. Categories of gene products multiply hit include DNA packaging, tegument, capsid and immediate early proteins, glycoproteins and components of the helicase-primase complex. A virulence factor, DNAse, metabolic protein, and a few products without know functions are also indicated as candidates. TABLE 10 Name Of HSV-1 Gene Product And/Or Its Known Or Proposed Biological Activity ORF Gene product /activity RL1 ICP34.5, Neurovirulence factor, Inhibition of host protein synthesis UL1 Glycoprotein L Viral spread UL5 Viral genome replication, DNA helicase-primase subunit UL8 Intracellular protein transport UL11 Myristylated tegument protein Viral capsid envelopment UL13 Induction of apoptosis by virus, ATP-binding, protein kinase UL15 Viral DNA packaging protein UL16 DNA packaging, capsid maturation protein UL17 Viral DNA cleavage and packaging UL18 Capsid protein UL21 Cytoskeleton organization and biogenesis UL25 Capsid-associated tegument, viral assembly protein UL28 ICP18.5 Viral DNA packaging protein UL36 ICP1-2, Very large tegument protein Viral egress UL37 Viral budding UL41 Vhs Host defense evasion, Inhibition of cytokine production UL43 Tegument protein UL44 Glycoprotein C Enhancement of virulence UL49 VP22 Cell to cell viral spread UL52 DNA helicase-primase subunit Initiator for ATG codons UL54 ICP27 Perturbation of host cell transcription US5 GJ viral inhibition of apoptosis US6 Glycoprotein D Viral induced cell-cell fusion

[0348] Table 11 presents the nucleotide similarities and identities of the gene products encoded by the HSV-1. ORFs identified in the ELI screen to homologs in other herpesviruses. These sequence comparisons may indicate that the HSV-1 homologs could carry protective capacities. For example the gD gene product of BHV has been shown to be protective against BHV, as is its glycoprotein homologue from HSV-1 and HSV-2. Notably, a number of DELI HSV-1 hits show similarities to other herpesvirus gene products that are significantly higher than that of gD. It also suggests that vaccination with genes from one virus might heterologously protect against exposure to a different herpesvirus. TABLE 11 Examples Of Percent Amino Acid Identities/Similarities To Herpesvirus Homologs. ORF HSV2 VZV BHV EHV CMV CHV RL1aa 41/47 32/39 29/33 29/33 24/26 26/31 UL1a 70/80 29/50 28/33 31/47 26/37 58/66 UL5a 90/92 62/78 64/77 67/81 32/51 85/92 UL8b 78/83 26/42 31/43 29/46 43/46 52/62 UL11a 73/80 34/54 35/45/ 35/52 26/35 59/70 UL13b 80/88 33/54 34/44 34/54 28/41 58/70 UL15aa 96/98 44/67 55/65 56/70 34/46 80/87 UL16ac 72/79 34/50 42/58 42/49 24/34 63/73 UL17a 76/83 35/50 35/44 36/50 24/32 36/48 UL17b 87/90 33/50 39/50 38/55 33/48 74/81 UL18a 92/95 42/61 47/63 43/65 28/42 83/90 UL21b 82/88 — 34/40 27/43 33/46 56/70 UL25a 85/88 42/58 49/60 46/63 29/38 71/80 UL28a 88/90 43/56 49/61 47/60 23/44 83/88 UL28bb  99/100 63/78 68/81 67/85 31/55 93/96 UL36b 80/87 32/47 31/42 30/47 27/40 61/75 UL37b 90/95 32/46 28/43 31/50 28/50 76/83 UL37c 80/85 25/42 27/41 23/41 31/44 66/77 UL41a 85/88 39/56 32/48 33/51 34/44 70/80 UL43a 65/71 28/35 24/30 31/35 25/33 44/52 UL44a 54/61 28/40 23/40 26/37 24/35 37/46 UL49a 68/75 25/32 26/33 32/42 25/35 44/55 UL52c 85/89 48/65 48/63 42/59 31/44 71/80 UL54b 91/94 40/61 46/60 43/62 26/42 70/82 US5a 48/62 39/51 27/30 33/39 29/35 27/41 US6a 83/89 25/44 27/38 27/42 29/41 61/74

[0349] In this study, two different promoter-leader fusions were linked to each of the tested ORF. Since these LEE constructs were co-delivered it cannot be discern whether the secretory or proteasome targeting led to a more protective response. However, the inventors previously have found that simultaneous delivery of ORFs did not interfere with any individual ORF-generated response.

Example 15 Comparison of Directed-LEE Library Screening to the Random ELI Screening Methodology

[0350] In the random ELI (RELI) screening protocol 10 ORFs including fragments of the gB and gD genes from the HSV-1 genome were inferred by matrix triangulation to be candidates for protective antigens. Triangulation of the DELI data revealed 23 ORFs with inferred protective utility. A number of genes in these two output groups overlapped, while others were unique. Table 12 delineates some technical parameters that are likely to have influenced the outcomes of the two ELI studies.

[0351] The results of the two protection studies reflect both these differences and similarities in design. Among the 10 gene fragments identified as protective candidates in the RELI grid, 6 of the derivative genes were also on the list of top 23 genes identified in the DELI protection screen. Among the 6 RELI gene fragments that tested positive when tested individually, all but two of the derivative genes were also identified in the DELI grid. These two outliers were gB and US3. Glycoprotein B (UL27) was identified only in the RELI screen most likely for technical reasons, as described above. Likewise US3 was only identified in the RELI grid, most likely for technical reasons also. In particular, a fragment of US3 was functionally-selected from a population of random subgenes in the RELI study. However in the DELI study, the full-length US3 gene was tested. Recent studies have demonstrated that constructs carrying the full-length sequence are not protective. TABLE 12 Two ELI Screens Compared. RELI DELI Statistically-assumed coverage of Complete, defined coverage genome Plasmid GMCSF was included No adjuvant in round 1 Any particular ORF is tested unknown Each gene tested in triplicate number of times Pools sizes in round 1 of ˜600 Pools sizes of 5 ORFs ORFs expressed in plasmids, with ORFs generated in vitro for LEE potential for cloning biases and expression contamination Each ORF fused to sequences encoding Each ORF fused to both LS either tPA or UB targeting peptides and UB sequences for intracellular targeting Library comprised of random ˜800 bp Library comprised of physically-generated genomic sequence-defined 1500 bp ORFs fragments ORFs delivered biolistically into ears ORFs delivered biolistically and by injection into leg muscles into ears Hairless mice used in round 1 then BALB/c mice only BALB/c for subsequent rounds

Example 16 Testing of Individual DELI ORFS as Vaccine Candidates

[0352] From the qualitative triangulation analysis of the challenge survival assay results, 26 HSV-1 ORFs (from 23 genes) were inferred to carry protective capacities. From this set, 19 ORFs were PCR-amplified and prepared again as LEEs on gold microprojectiles. These antigens were then gene-gun delivered as single genes (200 ng) into groups of 5 BALB/c mice. Each inoculum also contained 800 ng of empty vector DNA, used to facilitate microprojectile preparation. Boosts were administered at weeks 4 and 8, followed by virus exposure at week 11. These mice were lethally challenged with HSV-1 using a scarification route as performed earlier and then survival was monitored twice daily for 14 days. Nine groups of mice survived longer than the positive control group which was administered gD (US6) at the same dose as the test genes. This gD group survived until day 8; those ORFs associated with longer survival are: UL1a, UL11a, UL15a, UL17a, UL18a, UL44a, UL52c, and RL1a. At the completion of the study (14-day endpoint) groups of mice immunized with UL1a, UL11a, and UL17a still maintained a survivor. Other control groups were immunized with a full 1 ug dose of gD, constructed in both an LEE and as a plasmid, and a non-HSV-1 gene, LUC carried in the CpG rich plasmid pCMVi. The survival rates at several days through the monitoring period are plotted in FIG. 9A. Survival scores were calculated for the period from day 8 through 12, and these are graphed in FIG. 9B. Calculating a single survival score for each mouse that integrates the multiple data points through the monitoring period enables group averages and standard errors to be determined. Analysis indicates that immunization with UL1a, UL17a, and UL52c generates survival scores that are non-overlapping with the non-immunized control group. The remaining ORFs from the triangulation and quantitative analyses will be next tested individually.

Example 17 Creation and Testing of Vaccines using Combinations of the ELI-Identified Herpesvirus Nucleic Acid and Amino Acid Sequences

[0353] The Herpesvirus sequences and antigens showing protection may be developed into vaccines for Herpesvirus in humans and animals in the following manner. The genetic-antigens, genetic-antigen fragments, protein antigens or protein antigen fragments may be combined with one another, including the previously identified glycoproteins B and D antigens to produce an improved vaccine. These may be delivered by a combination of modalities, such as genetic, protein, or live-vectors. Alternatively, the functional or sequence homologs of the identified antigen candidates from multiple herpesviruses might be combined to produce broader protection against multiple species in one vaccine.

Example 18 Creation and Testing of Vaccines Against Other Herpesviruses using the Identified Herpesvirus Nucleic Acid and Amino Acid Sequences

[0354] The Herpesvirus sequences and antigens disclosed in this application are envisioned to be used in vaccines for Herpesvirus in humans and commercially important animals. However, these Herpesvirus sequences may be used to create vaccines for other viral species as well. For example, one may use the information gained concerning Herpesvirus to identify a sequence in another viral pathogen that has substantial homology to the Herpesvirus sequences. In many cases, this homology would be expected to be more than a 30% amino acid sequence identity or similarity and could be for only part of a protein, e.g., 30 amino acids, in the other species. The gene encoding such identity/similarity may be isolated and tested as a vaccine candidate in the appropriate model system either as a protein or nucleic acid. Alternatively, the Herpesvirus homologs may be tested directly in an animal species of interest. Given there are a limited number of genes to screen, and that the genes have been demonstrated to be protective in another species the probability of success should be high. Alternatively, proteins or peptides corresponding to the homologs to the Herpesvirus genes may be used to assay in animals or humans for immune responses in people or animals infected with the relevant pathogen. If such immune responses are detected, particularly if they correlated with protection, then the genes, proteins or peptides corresponding to the homologs may be tested directly in animals or humans as vaccines.

Example 19 Creation and Testing of Commercial Vaccines using Herpesvirus Nucleic Acid and Amino Acid Sequences

[0355] The vaccine candidates described herein may be developed into commercial vaccines. For example, the genes identified may be converted to optimized mammalian expression sequences by altering the codons to correspond with a codon preference of an animal to be vaccinated. This is a straightforward procedure, which can be easily done by one of skill in the art. Alternatively, a protective gene vaccine might be sequence-optimized by shuffling homologs from other herpesviruses (Stemmer et al., 1995). This might increase efficacy against HSV-1 exposure and/or provide a vaccine that protects against multiple herpesviruses. The genes may then be tested in the relevant host, for example, humans, for protection against infection. Genetic immunization affords a simple method to test vaccine candidate for efficacy and this form of delivery has been used in a wide variety of animals including humans. Alternatively, the genes may be transferred to another vector, for example, a vaccinia vector, to be tested in a relevant host.

[0356] Alternatively, the corresponding protein, with or without adjuvants may also be tested. These tests may be done on a relatively small number of animals. Once conducted, a decision can be made as to how many of the protective antigens to include in a larger test. Only a subset may be chosen based on the economics of production. A large field trial may be conducted using a preferred formulation. Based on the results of the field trial, possibly done more than once at different locations, a commercial vaccine may then be produced.

Example 20 Creation and Testing of Vaccines Against Other Pathogens using Herpesvirus Nucleic Acid and Amino Acid Sequences

[0357] Since HSV-1 has a similar biology to other herpesviruses, the inventors take advantage of the screening already accomplished on the HSV-1 genome to test other herpesviruses for homologs corresponding to the ones from HSV-1 as vaccine candidates. Those of ordinary skill may expect that, as one moved evolutionarily away from HSV-1, the likelihood that the homologs would protect would presumably decline. Once the homologs have been identified and isolated, they may be tested in the appropriate animal model system for efficacy as a vaccine. For example, other herpesvirus homologs, genes or proteins, may be tested in a mouse herpesvirus model.

[0358] One of ordinary skill has access to herpesvirus sequences disclosed in this specification, or to additional sequences determined to be protective using any of the methods disclosed in this specification, a computer-based search of relevant genetic databases may be run in order to determine homologous sequences in other pathogens. For example, these searches can be run in the BLAST database in GenBank.

[0359] Once a sequence which is homologous to a protective sequence is determined, it is possible to obtain the homologous sequence using any of a number of methods known to those of skill. For example, PCR amplification of a homologous gene(s) from a pathogen from genomic DNA and place the genes in an appropriate genetic immunization vector, such as a plasmid or LEE. These homologous genes may then be tested in an animal model appropriate for the pathogen for which protection is sought, to determine whether homologs of herpesvirus genes will protect a host from challenge with that pathogen.

[0360] It is contemplated that the herpesvirus genes that are disclosed herein as protective, or determined to be protective using the methods disclosed herein, to obtain protective sequences from a first non-herpesvirus organism, then to use the protective sequences from the non-herpesvirus organism to search for homologous sequences in a second non-herpesvirus or herpesvirus organism. So long as a protective herpesvirus sequence is used as the starting point for determining at least one homology in such a chain of searches and testing, such methods are within the scope of this invention.

Example 21 Creation and Testing of Therapeutic Vaccines using Herpesvirus Nucleic Acid and Amino Acid Sequences

[0361] The vaccine candidates described herein may be useful not only prophylactically but also therapeutically. For example, reactivation of latent herpes infections is a significant health issue (Keadle et al., 1997; Nesburn et al., 1998; Nesburn et al., 1994; Nesburn et al., 1998). Vaccine candidates identified in this prophylactic screen are envisioned to be used to immunize HSV infected subjects to eliminate infection or to ameliorate disease symptoms associated with subsequent activation of herpesvirus proliferation.

[0362] Once a subject or patient has been identified as having a herpesvirus infection the vaccination methods and compositions of the invention may be used as a therapy. Methods are known for optimizing the amount, schedule and route of administration, when taken in light of the present specification.

Example 22 Creation and Testing of Therapeutic Antibodies using Herpesvirus Nucleic Acid and Amino Acid Sequences

[0363] The vaccine candidates described herein may be developed for passive immune therapy. Some portion of the protective antigens might lead to immunity via protective antibody responses. These antibodies could be useful as immediate, non-drug, therapeutic products. In passive immunotherapy, treatment may involve the delivery of biologic reagents with established immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate anti-pathogen effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T lymphocytes (for example, CD8⁺ cytotoxic T-lymphocyte, CD4⁺ T-helper), killer cells (such as Natural Killer cells, lymphokine-activated killer cells), B cells, or antigen presenting cells (such as dendritic cells and macrophages) expressing the disclosed antigens. The polypeptides disclosed herein may also be used to generate antibodies or anti-idiotypic antibodies (as in U.S. Pat. No. 4,918,164) for passive immunotherapy.

[0364] In one embodiment, an effector cell is isolated and cultured. Subsequently, the effector cell is exposed or primed with an antigen of the invention. The effector cell is then reintroduced into the subject. In other embodiments, antibodies may be prepared in large quantities outside of the body and introduced into the body of a patient in need of such a treatment.

Example 23 Creation and Testing of Diagnostic or Drug Targets using Herpesvirus Nucleic Acid and Amino Acid Sequences

[0365] The vaccine candidates as described herein may be developed into commercial diagnostic candidates in the following manner. It is envisioned that antigens useful in raising protective immune responses may also engender rapidly detectable host responses that could be useful for identification of pathogen exposure or early-stage infection. In addition these antigens may designate key pathogen targets for developing drug-based inhibition or therapies of infection or disease.

[0366] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

[0367] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

[0368] U.S. Pat. No. 3,447,851

[0369] U.S. Pat. No. 3,791,932

[0370] U.S. Pat. No. 3,949,064

[0371] U.S. Pat. No. 4,148,876

[0372] U.S. Pat. No. 4,148,876

[0373] U.S. Pat. No. 4,174,384

[0374] U.S. Pat. No. 4,179,337

[0375] U.S. Pat. No. 4,406,885

[0376] U.S. Pat. No. 4,406,885

[0377] U.S. Pat. No. 4,444,887

[0378] U.S. Pat. No. 4,512,972

[0379] U.S. Pat. No. 4,554,101

[0380] U.S. Pat. No. 4,578,770

[0381] U.S. Pat. No. 4,596,792

[0382] U.S. Pat. No. 4,599,230

[0383] U.S. Pat. No. 4,599,231

[0384] U.S. Pat. No. 4,601,903

[0385] U.S. Pat. No. 4,608,251

[0386] U.S. Pat. No. 4,676,980

[0387] U.S. Pat. No. 4,695,624

[0388] U.S. Pat. No. 4,710,111

[0389] U.S. Pat. No. 4,741,900

[0390] U.S. Pat. No. 4,816,397

[0391] U.S. Pat. No. 4,816,567

[0392] U.S. Pat. No. 4,826,687

[0393] U.S. Pat. No. 4,826,687

[0394] U.S. Pat. No. 5,112,946

[0395] U.S. Pat. No. 5,225,539

[0396] U.S. Pat. No. 5,336,603

[0397] U.S. Pat. No. 5,349,053

[0398] U.S. Pat. No. 5,359,046

[0399] U.S. Pat. No. 5,413,923

[0400] U.S. Pat. No. 5,429,599

[0401] U.S. Pat. No. 5,474,981

[0402] U.S. Pat. No. 5,474,981

[0403] U.S. Pat. No. 5,484,719

[0404] U.S. Pat. No. 5,506,121

[0405] U.S. Pat. No. 5,506,121

[0406] U.S. Pat. No. 5,523,088

[0407] U.S. Pat. No. 5,530,101

[0408] U.S. Pat. No. 5,545,806

[0409] U.S. Pat. No. 5,565,203

[0410] U.S. Pat. No. 5,565,332

[0411] U.S. Pat. No. 5,569,825

[0412] U.S. Pat. No. 5,578,453

[0413] U.S. Pat. No. 5,585,089

[0414] U.S. Pat. No. 5,585,089

[0415] U.S. Pat. No. 5,589,466

[0416] U.S. Pat. No. 5,589,466

[0417] U.S. Pat. No. 5,593,972

[0418] U.S. Pat. No. 5,605,793

[0419] U.S. Pat. No. 5,607,852

[0420] U.S. Pat. No. 5,612,487

[0421] U.S. Pat. No. 5,614,610

[0422] U.S. Pat. No. 5,614,610

[0423] U.S. Pat. No. 5,622,929

[0424] U.S. Pat. No. 5,623,057

[0425] U.S. Pat. No. 5,625,126

[0426] U.S. Pat. No. 5,633,425

[0427] U.S. Pat. No. 5,648,081

[0428] U.S. Pat. No. 5,661,016

[0429] U.S. Pat. No. 5,667,782

[0430] U.S. Pat. No. 5,670,488

[0431] U.S. Pat. No. 5,703,057

[0432] U.S. Pat. No. 5,707,644

[0433] U.S. Pat. No. 5,725,863

[0434] U.S. Pat. No. 5,747,526

[0435] U.S. Pat. No. 5,766,588

[0436] U.S. Pat. No. 5,766,588

[0437] U.S. Pat. No. 5,776,451

[0438] U.S. Pat. No. 5,783,196

[0439] U.S. Pat. No. 5,807,715

[0440] U.S. Pat. No. 5,811,238

[0441] U.S. Pat. No. 5,814,295

[0442] U.S. Pat. No. 5,814,318

[0443] U.S. Pat. No. 5,821,333

[0444] U.S. Pat. No. 5,830,721

[0445] U.S. Pat. No. 5,830,725

[0446] U.S. Pat. No. 5,834,252

[0447] U.S. Pat. No. 5,837,458

[0448] U.S. Pat. No. 5,846,225

[0449] U.S. Pat. No. 5,846,233

[0450] U.S. Pat. No. 5,851,826

[0451] U.S. Pat. No. 5,869,451

[0452] U.S. Pat. No. 5,871,982

[0453] U.S. Pat. No. 5,879,934

[0454] U.S. Pat. No. 5,885,793

[0455] U.S. Pat. No. 5,888,502

[0456] U.S. Pat. No. 5,888,773

[0457] U.S. Pat. No. 5,889,157

[0458] U.S. Pat. No. 5,889,157

[0459] U.S. Pat. No. 5,891,432

[0460] U.S. Pat. No. 5,910,306

[0461] U.S. Pat. No. 5,914,123

[0462] U.S. Pat. No. 5,916,771

[0463] U.S. Pat. No. 5,922,326

[0464] U.S. Pat. No. 5,922,326

[0465] U.S. Pat. No. 5,933,819

[0466] U.S. Pat. No. 5,939,598

[0467] U.S. Pat. No. 5,942,242

[0468] U.S. Pat. No. 5,955,331

[0469] U.S. Pat. No. 5,976,544

[0470] U.S. Pat. No. 5,976,546

[0471] U.S. Pat. No. 5,980,898

[0472] U.S. Pat. No. 5,985,318

[0473] U.S. Pat. No. 6,004,807

[0474] U.S. Pat. No. 6,005,079

[0475] U.S. Pat. No. 6,034,298

[0476] U.S. Pat. No. 6,103,493

[0477] U.S. Pat. No. 6,103,493

[0478] U.S. Pat. No. 6,129,920

[0479] U.S. Pat. No. 6,136,313

[0480] U.S. Pat. No. 6,136,320

[0481] U.S. Pat. No. 6,180,110

[0482] U.S. Pat. No. 6,194,551

[0483] U.S. Pat. No. 6,194,560

[0484] U.S. Pat. No. 6,200,959

[0485] U.S. Pat. No. 6,207,157

[0486] U.S. Pat. No. 6,210,963

[0487] U.S. Pat. No. 6,228,640

[0488] U.S. Pat. No. 6,248,334

[0489] U.S. Pat. No. 6,248,565

[0490] U.S. Pat. No. 6,254,873

[0491] U.S. Pat. No. 6,277,375 B1

[0492] U.S. Pat. No. 6,287,571

[0493] U.S. Pat. No. 6,299,881

[0494] U.S. Pat. No. 6,303,130

[0495] U.S. Pat. No. 6,309,646

[0496] U.S. Pat. No. 6,328,958

[0497] U.S. Pat. No. 6,339,068

[0498] U.S. Pat. No. 6,339,086

[0499] U.S. Pat. No. 6,348,449

[0500] U.S. Pat. No. 6,348,450

[0501] U.S. Pat. No. 6,359,054

[0502] U.S. Pat. No. 6,383,795

[0503] U.S. Pat. No. 6,406,705

[0504] U.S. Pat. No. 6,413,768

[0505] EP 0598877

[0506] EP 239,400

[0507] EP 307,434

[0508] EP 367,166

[0509] EP 439,095;

[0510] EP 519,596

[0511] EP 592,106

[0512] WO 00/42072

[0513] WO 00/75308

[0514] WO 00/75308

[0515] WO 91/06570

[0516] WO 91/09967

[0517] WO 91/10741

[0518] WO 92/01047

[0519] WO 93/21232

[0520] WO 94/04678

[0521] WO 94/25591

[0522] WO 96/04388

[0523] WO 96/33735

[0524] WO 96/33735

[0525] WO 96/34096

[0526] WO 96/34096

[0527] WO 97/33899

[0528] WO 97/34911

[0529] WO 98/16654

[0530] WO 98/24893

[0531] WO 98/24893

[0532] WO 98/46645

[0533] WO 99/16873

[0534] WO 99/16873

[0535] WO 99/50433

[0536] Ada, Mol. Immunol., 28(3):225-230, 1991.

[0537] Alberti et al., Vaccine, 16(6):608-612, 1998.

[0538] Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1988.

[0539] Arnon et al., In: Monoclonal antibodies and cancer therapy, Reisfeld et al. (eds.), 243-256, Alan R. Liss, Inc., 1985.

[0540] Ashkenazi et al., PNAS, 88:10535-10539, 1991.

[0541] Ausubel, et al., Current Protocols in Molecular Biology, 1993.

[0542] Balicki and Beutler, Medicine, 81(1):69-86. 2002.

[0543] Bangham et al., J. Mol. Biol., 13:238, 1965.

[0544] Barany and Merrifield, In: The peptides, Gross and Meienhofer (eds.), Academic Press, NY, 1-284, 1979.

[0545] Barletta et al., Res. Microbiol, 141:931-940, 1990.

[0546] Barry et al., Nature, 377(6550):632-635, 1995.

[0547] Bernstein and Stanberry, Vaccine, 17(13-14):1681-1689, 1999.

[0548] Bilbao et al., FASEB J., 11 (8):624-634, 1997.

[0549] Bowtell et al., DNA Microarrays: A Molecular Cloning Manual; Cold Spring Harbor Press, 2003

[0550] Brayton et al., Ann. N Y Acad. Sci., 849:369-371, 1998.

[0551] Caplen et al., Gene Ther., 6(3):454-459, 1999.

[0552] Carrington-Lawrence et al., J. Virol., 77(7):4237-4247, 2003.

[0553] Celluzzi and Falo, J. Invest. Dermatol., 108(5):716-720, 1997.

[0554] Coffey et al., Science, 282(5392):1332-1334, 1998.

[0555] Coney et al., Vaccine, 12(16):1545-1550, 1994.

[0556] Cunningham, J Pharmacol Toxicol Methods. July-August;44(1):291-300, 2000.

[0557] Curtiss et al., Curr. Top. Microbiol. Immunol., 146:35-49, 1989.

[0558] Da Costa et al., J. Virol. 4(17):7963-7971, 2000.

[0559] Davies et al., Biotech. and Bioengin., 74(4): 288-294, 2001.

[0560] Deamer and Nichols, Proc. Natl. Acad. Sci. USA, 80(1):165-168, 1983.

[0561] Denardo et al., Clin. Cancer Res., 4:2483-2490, 1998.

[0562] Dougan et al., Para. Immunol., 9:151-160, 1987.

[0563] Farlie et al., Acta Obstet. Gynecol. Scand., 77(1):131-133, 1998.

[0564] Farrell et al., J. Virol., 68(2):927-932, 1994.

[0565] Fell et al., J. Immunol., 146:2446-2452, 1991.

[0566] Feng et al., Nat. Biotechnol., 15(9):866-70, 1997.

[0567] Fields Virology, 3^(rd) Ed., Fields et al., (Eds.) chapter 71, 1996.

[0568] Fisher et al., Hum. Gene Ther., 7(17):2079-2087, 1996.

[0569] Froehler et al., Nucleic Acids Res., 14(13):5399-5407, 1986.

[0570] Gentz et al., Proc. Natl. Acad. Sci. USA, 86:821-824, 1989.

[0571] Gillies et al. J, Immunol. Methods, 125:191-202, 1989.

[0572] Gillies et al., PNAS, 89:1428-1432, 1992.

[0573] Glenn et al., Exp. Opin. Invest. Drugs, 8:797-805, 1999.

[0574] Gnant et al., Cancer Res., 59(14):3396-403, 1999.

[0575] Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th Ed., Goodman et al., (Eds.), 1080-1248; Macmillan Publishing Co., NY, 1980.

[0576] Gregoriadis, Drug Carriers In Biology And Medicine, G. Gregoriadis (ed.), 287-341, 1979.

[0577] Hale, Res. Microbiol., 141(7-8):913-919, 1990.

[0578] Hansson et al., J. Mol. Biol., 287:265, 1999.

[0579] Harayama, Trends Biotechnol., 16:76, 1998.

[0580] Harlow and Lane, In: Antibodies, A Laboratory manual, Cold Spring Harbor Laboratory, 1988.

[0581] Hellstrom et al., In: Controlled drug delivery, 2d Ed., Robinson et al. (eds.), 623-653, Marcel Dekker, Inc., 1987.

[0582] Holzer et al. Virology, 253(1):107-114, 1999.

[0583] Hosaka et al., J. Virol., 46(3):1014-1017, 1983.

[0584] Huang et al., Virology, 97:212-217, 1979.

[0585] Imai et al., Nephrologie, 19(7):397-402, 1998.

[0586] Inagaki-Ohara et al., Vaccine, 20(1-2):98-104, 2001.

[0587] Janson and Ryden, In: Protein purification: principles, high-resolution methods, and applications, 2d Ed., 1998.

[0588] Jespers et al., Bio/technology, 12:899-903, 1988.

[0589] Jones et al., Proc. Natl. Acad. Sci. USA, 93(21):11327-11333, 1996.

[0590] Kaneda, Adv. Drug Deliv. Rev., 43(2-3):197-205, 2000.

[0591] Keadle et al., J. Infectious Dis., 176, 331-338, 1997.

[0592] Klein et al., Nature, 327:70-73, 1987.

[0593] Kleymann et al., Nat. Med., 8(4):392-398, 2002.

[0594] Knappik et al., Biotechniques, 17(4):754-761, 1994.

[0595] Kobayishi et al., Immunochemistry, 10:73, 1973.

[0596] Kyte and Doolittle, J Mol Biol, 157(1):105-32, 1982.

[0597] Leung and Sacks, Drugs, 60(6):1329-1352, 2000.

[0598] Levine et al, Microecol. Ther., 19:23-32, 1990.

[0599] Liu and Huang, J. Control Release, 78(1-3):259-66, 2002.

[0600] Lonberg and Huszar, Int. Rev. Immunol., 13:65-93, 1995.

[0601] Lorenzo and Blasco, BioTechniques, 24:308, 1998.

[0602] Lowrie et al., Vaccine, 12(16):1537-1540, 1994.

[0603] Lundstrom, J. Recept Signal Transduct. Res., 19(1-4):673-686, 1999.

[0604] Manoutcharian et al., Immunol. Lett., 62(3):131-136, 1998.

[0605] Marshak et al., In: Strategies for protein purification and characterization, A Laboratory Course Manual, Cold Spring Harbor Laboratory, 1996.

[0606] Merrifield, Science, 232:341-347, 1986.

[0607] Moore et al., Vaccine, 20(1-2), 2001.

[0608] Moore, Trends Pharmacol. Sci., 15(4):124-129, 1994.

[0609] Morris et al., Gastroenterol, 103:699-702, 1992.

[0610] Morrison, Science, 229:1202, 1985.

[0611] Mullis et al., Biotechnology, 24:17-27, 1992.

[0612] Mullis, Sci. Am., 262(4):56-61, 64-65, 1990.

[0613] Munson and Pollard, Anal. Biochem., 107:220, 1980.

[0614] Muldermans et al., Trends Biochem. Sci., 26:230, 2001.

[0615] Naramura et al., Immunol. Lett., 39:91-99, 1994.

[0616] Navarro et al., Virology, 186(1), 99-112, 1992.

[0617] Nesburn et al., Invest. Ophthal. Visual Sci., 39(7):1163-1170, 1998.

[0618] Nesburn et al., J. Virology, 68(8):5084-5092, 1994.

[0619] Nesburn et al., Virology, 252(1), 200-209, 1998.

[0620] Neumann et al., Proc. Natl. Acad. Sci. USA, 96(16):9345-9350, 1999.

[0621] Nicolau et al., Methods Enzymol., 149:157-176, 1987.

[0622] Nuttall et al., Cur. Pharm. Biotech., 1:253, 2000.

[0623] Ol et al., BioTechniques, 4-214, 1986.

[0624] Padlan, Molec. Immunol., 28(4/5):489-498, 1991.

[0625] Patten et al., Curr. Opinion Biotechnol., 8:724-33, 1997.

[0626] Peterson et al., Bioconjug. Chem., 10:553, 1999.

[0627] Piedrafita et al., J. Immunol., 163(3):1467-1472, 1999.

[0628] Ravid et al., In: DNA transfer to cultured cells, Wiley and Sons, 1998

[0629] Reichmann and Muyldermans, J. Immunol. Meth., 231:25, 1999.

[0630] Remington's Pharmaceutical Sciences, 15^(th) ed., pages 1035-1038 and 1570-1580, Mack Publishing Company, Easton, Pa., 1980.

[0631] Riechmann et al., Nature, 332:323-327, 1988.

[0632] Robbins and Ghivizzani, Trends Biotech., 16(1):35-40, 1998.

[0633] Roguska et al., Proc. Natl. Acad. Sci. USA, 91:969-973, 1994.

[0634] Rouse et al., J. Virol., 68(9):5685-5689, 1994.

[0635] Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory; 3rd edition, 2001.

[0636] Sanford et al., Technique, 3:3-16, 1991.

[0637] Shields et al., J. Biol. Chem., 277(30):26733-26740, 2001.

[0638] Slack, In: Oxford Textbook of Medicine, 2d Ed., Weatherall et al., (Eds.) 1:5.35, Oxford University Press, Oxford/Melbourne/New York, 1987.

[0639] Smooker et al., Vaccine 18:2533-2540, 2000.

[0640] Stanberry et al., Clinical Infect. Dis., 30(3):549-566, 2000.

[0641] Stanberry et al., In: Viral infections of humans: epidemiology and control, Evans et al., (Eds.), Plenum Medical Book Company, NY, 419-454, 1997.

[0642] Steinman et al., Hum Immunol, 60(7):562-567, 1999

[0643] Stemmer et al., Gene, 154(1):49-53, 1995.

[0644] Stewart and Young, In: Solid phase peptide synthesis, 2d. ed., Pierce Chemical Co. 1984.

[0645] Studnicka et al., Protein Eng., 7(6):805-814,1994.

[0646] Sykes and Johnston, DNA Cell. Biol., 18:521-531, 1999.

[0647] Sykes and Johnston, Nat. Biotechnol., 17(4):355-359, 1999.

[0648] Szoka and Papahadjopoulos, Proc. Natl. Acad. Sci. USA, 75:4194-4198, 1978.

[0649] Takahashi et al., J. Immunol., 6:1567-1574, 1994

[0650] Tam et al., J. Am. Chem. Soc., 105:6442, 1983.

[0651] Tang et al., Nature, 356:152-154, 1992.

[0652] Thorpe et al., Immunol. Rev., 65:119-138, 1982.

[0653] Thorpe, In: Monoclonal antibodies '84: Biological and clinical applications, Pinchera et al. (eds.), 475-506, 1985.

[0654] Van Damme et al., Gastroenterology, 103(2):520-531, 1992.

[0655] Vil et al., PNAS, 89:11337-11341, 1992.

[0656] Viret et al., Mol. Microbiol., 7(2):239-252, 1993.

[0657] Watt et al., Proc. Natl Acad. Sci., 83(2):3166-3170, 1986.

[0658] Whitley and Miller, Viral Immunol., 14(2):111-118, 2001.

[0659] Whitley and Miller, Viral. Immunol., 14(2), 111-118, 2001.

[0660] Whitley and Roizman, Lancet., 357(9267):1513-1518, 2001.

[0661] Whitley et al., Clin. Infect. Dis., 26(3):541-553, 1998.

[0662] Wilson et al., Cell, 37:767, 1984.

[0663] Wu et al., Genomics, 4:560-569, 1989.

[0664] Xiang et al., J. Virol, 199(1):132-140, 1994.

[0665] Zheng et al., J. Immunol., 154:5590-5600, 1995.

[0666] Zimmerman et al., Nucl. Med. Biol., 26:943-50, 1999.

1 116 1 342 DNA Herpes Virus 1 gccgtcccaa ccgcacagtc ccaggtaacc tccacgccca actcggaacc cgcggtcagg 60 agcgcgcccg cggccgcccc gccgccgccc cccgccggtg ggcccccgcc ttcttgttcg 120 ctgctgctgc gccagtggct ccacgttccc gagtccgcgt ccgacgacga cgatgacgac 180 gactggccgg acagcccccc gcccgagccg gcgccagagg cccggcccac cgccgccgcc 240 ccccggcccc ggcccccacc gcccggcgtg ggcccggggg gcggggctga cccctcccac 300 cccccctcgc gccccttccg ccttccgccg cgcctcgccc tc 342 2 114 PRT Herpes Virus 2 Ala Val Pro Thr Ala Gln Ser Gln Val Thr Ser Thr Pro Asn Ser Glu 1 5 10 15 Pro Ala Val Arg Ser Ala Pro Ala Ala Ala Pro Pro Pro Pro Pro Ala 20 25 30 Gly Gly Pro Pro Pro Ser Cys Ser Leu Leu Leu Arg Gln Trp Leu His 35 40 45 Val Pro Glu Ser Ala Ser Asp Asp Asp Asp Asp Asp Asp Trp Pro Asp 50 55 60 Ser Pro Pro Pro Glu Pro Ala Pro Glu Ala Arg Pro Thr Ala Ala Ala 65 70 75 80 Pro Arg Pro Arg Pro Pro Pro Pro Gly Val Gly Pro Gly Gly Gly Ala 85 90 95 Asp Pro Ser His Pro Pro Ser Arg Pro Phe Arg Leu Pro Pro Arg Leu 100 105 110 Ala Leu 3 747 DNA Herpes Virus 3 atggcccgcc gccgccgcca tcgcggcccc cgccgccccc ggccgcccgg gcccacgggc 60 gccgtcccaa ccgcacagtc ccaggtaacc tccacgccca actcggaacc cgcggtcagg 120 agcgcgcccg cggccgcccc gccgccgccc cccgccggtg ggcccccgcc ttcttgttcg 180 ctgctgctgc gccagtggct ccacgttccc gagtccgcgt ccgacgacga cgatgacgac 240 gactggccgg acagcccccc gcccgagccg gcgccagagg cccggcccac cgccgccgcc 300 ccccggcccc ggcccccacc gcccggcgtg ggcccggggg gcggggctga cccctcccac 360 cccccctcgc gccccttccg ccttccgccg cgcctcgccc tccgcctgcg cgtcaccgcg 420 gagcacctgg cgcgcctgcg cctgcgacgc gcgggcgggg agggggcgcc ggagcccccc 480 gcgacccccg cgacccccgc gacccccgcg acccccgcga cccccgcgcg ggtgcgcttc 540 tcgccccacg tccgggtgcg ccacctggtg gtctgggcct cggccgcccg cctggcgcgc 600 cgcggctcgt gggcccgcga gcgggccgac cgggctcggt tccggcgccg ggtggcggag 660 gccgaggcgg tcatcgggcc gtgcctgggg cccgaggccc gtgcccgggc cctggcccgc 720 ggagccggcc cggcgaactc ggtctaa 747 4 248 PRT Herpes Virus 4 Met Ala Arg Arg Arg Arg His Arg Gly Pro Arg Arg Pro Arg Pro Pro 1 5 10 15 Gly Pro Thr Gly Ala Val Pro Thr Ala Gln Ser Gln Val Thr Ser Thr 20 25 30 Pro Asn Ser Glu Pro Ala Val Arg Ser Ala Pro Ala Ala Ala Pro Pro 35 40 45 Pro Pro Pro Ala Gly Gly Pro Pro Pro Ser Cys Ser Leu Leu Leu Arg 50 55 60 Gln Trp Leu His Val Pro Glu Ser Ala Ser Asp Asp Asp Asp Asp Asp 65 70 75 80 Asp Trp Pro Asp Ser Pro Pro Pro Glu Pro Ala Pro Glu Ala Arg Pro 85 90 95 Thr Ala Ala Ala Pro Arg Pro Arg Pro Pro Pro Pro Gly Val Gly Pro 100 105 110 Gly Gly Gly Ala Asp Pro Ser His Pro Pro Ser Arg Pro Phe Arg Leu 115 120 125 Pro Pro Arg Leu Ala Leu Arg Leu Arg Val Thr Ala Glu His Leu Ala 130 135 140 Arg Leu Arg Leu Arg Arg Ala Gly Gly Glu Gly Ala Pro Glu Pro Pro 145 150 155 160 Ala Thr Pro Ala Thr Pro Ala Thr Pro Ala Thr Pro Ala Thr Pro Ala 165 170 175 Arg Val Arg Phe Ser Pro His Val Arg Val Arg His Leu Val Val Trp 180 185 190 Ala Ser Ala Ala Arg Leu Ala Arg Arg Gly Ser Trp Ala Arg Glu Arg 195 200 205 Ala Asp Arg Ala Arg Phe Arg Arg Arg Val Ala Glu Ala Glu Ala Val 210 215 220 Ile Gly Pro Cys Leu Gly Pro Glu Ala Arg Ala Arg Ala Leu Ala Arg 225 230 235 240 Gly Ala Gly Pro Ala Asn Ser Val 245 5 591 DNA Herpes Virus 5 ccttcaaccg aatatgttat tcggagtcgg gtggctcgag aggtggggga tatattaaag 60 gtgccttgtg tgccgctccc gtctgacgat cttgattggc gttacgagac cccctcggct 120 ataaactatg ctttgataga cggtatattt ttgcgttatc actgtcccgg attggacacg 180 gtcttgtggg ataggcatgc ccagaaggca tattgggtta accccttttt atttgtggcg 240 ggttttttgg aggacttgag ttaccccgcg tttcctgcca acacccagga aacagaaacg 300 cgcttggccc tttataaaga gatacgccag gcgctggaca gtcgcaagca ggccgccagc 360 cacacacctg tgaaggctgg gtgtgtgaac tttgactatt cgcgcacccg ccgctgtgta 420 gggcgacagg atttgggacc taccaacgga acgtctggac ggaccccggt tctgccgccg 480 gacgatgaag cgggcctgca gccgaagccc ctcaccacgc cgccgcccat catcgccacg 540 tcggacccca ccccgcgacg ggacgccgcc acaaaaagca gacgccgacg a 591 6 197 PRT Herpes Virus 6 Pro Ser Thr Glu Tyr Val Ile Arg Ser Arg Val Ala Arg Glu Val Gly 1 5 10 15 Asp Ile Leu Lys Val Pro Cys Val Pro Leu Pro Ser Asp Asp Leu Asp 20 25 30 Trp Arg Tyr Glu Thr Pro Ser Ala Ile Asn Tyr Ala Leu Ile Asp Gly 35 40 45 Ile Phe Leu Arg Tyr His Cys Pro Gly Leu Asp Thr Val Leu Trp Asp 50 55 60 Arg His Ala Gln Lys Ala Tyr Trp Val Asn Pro Phe Leu Phe Val Ala 65 70 75 80 Gly Phe Leu Glu Asp Leu Ser Tyr Pro Ala Phe Pro Ala Asn Thr Gln 85 90 95 Glu Thr Glu Thr Arg Leu Ala Leu Tyr Lys Glu Ile Arg Gln Ala Leu 100 105 110 Asp Ser Arg Lys Gln Ala Ala Ser His Thr Pro Val Lys Ala Gly Cys 115 120 125 Val Asn Phe Asp Tyr Ser Arg Thr Arg Arg Cys Val Gly Arg Gln Asp 130 135 140 Leu Gly Pro Thr Asn Gly Thr Ser Gly Arg Thr Pro Val Leu Pro Pro 145 150 155 160 Asp Asp Glu Ala Gly Leu Gln Pro Lys Pro Leu Thr Thr Pro Pro Pro 165 170 175 Ile Ile Ala Thr Ser Asp Pro Thr Pro Arg Arg Asp Ala Ala Thr Lys 180 185 190 Ser Arg Arg Arg Arg 195 7 675 DNA Herpes Virus 7 atggggattt tgggttgggt cgggcttatt gccgttgggg ttttgtgtgt gcgggggggc 60 ttgccttcaa ccgaatatgt tattcggagt cgggtggctc gagaggtggg ggatatatta 120 aaggtgcctt gtgtgccgct cccgtctgac gatcttgatt ggcgttacga gaccccctcg 180 gctataaact atgctttgat agacggtata tttttgcgtt atcactgtcc cggattggac 240 acggtcttgt gggataggca tgcccagaag gcatattggg ttaacccctt tttatttgtg 300 gcgggttttt tggaggactt gagttacccc gcgtttcctg ccaacaccca ggaaacagaa 360 acgcgcttgg ccctttataa agagatacgc caggcgctgg acagtcgcaa gcaggccgcc 420 agccacacac ctgtgaaggc tgggtgtgtg aactttgact attcgcgcac ccgccgctgt 480 gtagggcgac aggatttggg acctaccaac ggaacgtctg gacggacccc ggttctgccg 540 ccggacgatg aagcgggcct gcagccgaag cccctcacca cgccgccgcc catcatcgcc 600 acgtcggacc ccaccccgcg acgggacgcc gccacaaaaa gcagacgccg acgaccccac 660 tcccggcgcc tctaa 675 8 224 PRT Herpes Virus 8 Met Gly Ile Leu Gly Trp Val Gly Leu Ile Ala Val Gly Val Leu Cys 1 5 10 15 Val Arg Gly Gly Leu Pro Ser Thr Glu Tyr Val Ile Arg Ser Arg Val 20 25 30 Ala Arg Glu Val Gly Asp Ile Leu Lys Val Pro Cys Val Pro Leu Pro 35 40 45 Ser Asp Asp Leu Asp Trp Arg Tyr Glu Thr Pro Ser Ala Ile Asn Tyr 50 55 60 Ala Leu Ile Asp Gly Ile Phe Leu Arg Tyr His Cys Pro Gly Leu Asp 65 70 75 80 Thr Val Leu Trp Asp Arg His Ala Gln Lys Ala Tyr Trp Val Asn Pro 85 90 95 Phe Leu Phe Val Ala Gly Phe Leu Glu Asp Leu Ser Tyr Pro Ala Phe 100 105 110 Pro Ala Asn Thr Gln Glu Thr Glu Thr Arg Leu Ala Leu Tyr Lys Glu 115 120 125 Ile Arg Gln Ala Leu Asp Ser Arg Lys Gln Ala Ala Ser His Thr Pro 130 135 140 Val Lys Ala Gly Cys Val Asn Phe Asp Tyr Ser Arg Thr Arg Arg Cys 145 150 155 160 Val Gly Arg Gln Asp Leu Gly Pro Thr Asn Gly Thr Ser Gly Arg Thr 165 170 175 Pro Val Leu Pro Pro Asp Asp Glu Ala Gly Leu Gln Pro Lys Pro Leu 180 185 190 Thr Thr Pro Pro Pro Ile Ile Ala Thr Ser Asp Pro Thr Pro Arg Arg 195 200 205 Asp Ala Ala Thr Lys Ser Arg Arg Arg Arg Pro His Ser Arg Arg Leu 210 215 220 9 1292 DNA Herpes Virus 9 cagctagacg gacagaaacc cggcccgccg caccttcagc aacccgggga ccgaccagcc 60 gttccaggga gggccgaggc ctttttaaat tttacgtcta tgcacggggt gcagccaatc 120 cttaagcgca tccgagagct ctcgcaacaa cagctcgacg gagcgcaagt gccccatctg 180 cagtggttcc gggacgtggc ggccttagag tcccccgcag gcctgcccct cagggagttt 240 ccgttcgcgg tgtatcttat caccggcaac gctggctccg gaaagagcac gtgcgtgcag 300 acaatcaacg aggtcttgga ctgtgtggtg acgggcgcca cgcgcattgc ggcccaaaac 360 atgtacgcca aactctcggg cgcctttctc agccgaccca tcaacaccat ctttcatgaa 420 tttgggtttc gcgggaatca cgtccaggcc caactgggac agtacccgta caccctgacc 480 agcaaccccg cctcgctgga ggacctgcag cgacgagatc tgacgtacta ctgggaggtg 540 attttggacc tcacgaagcg cgccctggcc gcctccgggg gcgaggagtt gcggaacgag 600 tttcgcgccc tggccgccct ggaacggacc ctggggttgg ccgagggcgc cctgacgcgg 660 ttggccccgg ccacccacgg ggcgctgccg gcctttaccc gcagcaacgt gatcgtcatc 720 gacgaggccg ggctccttgg gcgtcacctc ctcacggccg tggtgtattg ctggtggatg 780 attaacgccc tgtaccacac cccccagtac gcggcccgcc tgcggcccgt gttggtgtgt 840 gtgggctcgc cgacgcagac ggcgtccctg gagtcgacct tcgagcacca gaaactgcgg 900 tgttccgtcc gccagagcga gaacgtgctc acgtacctca tctgcaaccg cacgctgcgc 960 gagtacgccc gcctctcgta tagctgggcc atttttatta acaacaaacg gtgcgtcgag 1020 cacgagttcg gtaacctcat gaaggtgctg gagtacggcc tgcccatcac cgaggagcac 1080 atgcagttcg tggatcgctt cgtcgtcccg gaaaactaca tcaccaaccc cgccaacctc 1140 cccggctgga cgcggctgtt ctcctcccac aaagaggtga gcgcgtacat ggccaagctc 1200 cacgcctacc tgaaggtgac ccgtgagggg gagttcgtcg tgttcaccct ccccgtgctt 1260 acgttcgtgt cggtcaagga gtttgacgaa ta 1292 10 430 PRT Herpes Virus 10 Gln Leu Asp Gly Gln Lys Pro Gly Pro Pro His Leu Gln Gln Pro Gly 1 5 10 15 Asp Arg Pro Ala Val Pro Gly Arg Ala Glu Ala Phe Leu Asn Phe Thr 20 25 30 Ser Met His Gly Val Gln Pro Ile Leu Lys Arg Ile Arg Glu Leu Ser 35 40 45 Gln Gln Gln Leu Asp Gly Ala Gln Val Pro His Leu Gln Trp Phe Arg 50 55 60 Asp Val Ala Ala Leu Glu Ser Pro Ala Gly Leu Pro Leu Arg Glu Phe 65 70 75 80 Pro Phe Ala Val Tyr Leu Ile Thr Gly Asn Ala Gly Ser Gly Lys Ser 85 90 95 Thr Cys Val Gln Thr Ile Asn Glu Val Leu Asp Cys Val Val Thr Gly 100 105 110 Ala Thr Arg Ile Ala Ala Gln Asn Met Tyr Ala Lys Leu Ser Gly Ala 115 120 125 Phe Leu Ser Arg Pro Ile Asn Thr Ile Phe His Glu Phe Gly Phe Arg 130 135 140 Gly Asn His Val Gln Ala Gln Leu Gly Gln Tyr Pro Tyr Thr Leu Thr 145 150 155 160 Ser Asn Pro Ala Ser Leu Glu Asp Leu Gln Arg Arg Asp Leu Thr Tyr 165 170 175 Tyr Trp Glu Val Ile Leu Asp Leu Thr Lys Arg Ala Leu Ala Ala Ser 180 185 190 Gly Gly Glu Glu Leu Arg Asn Glu Phe Arg Ala Leu Ala Ala Leu Glu 195 200 205 Arg Thr Leu Gly Leu Ala Glu Gly Ala Leu Thr Arg Leu Ala Pro Ala 210 215 220 Thr His Gly Ala Leu Pro Ala Phe Thr Arg Ser Asn Val Ile Val Ile 225 230 235 240 Asp Glu Ala Gly Leu Leu Gly Arg His Leu Leu Thr Ala Val Val Tyr 245 250 255 Cys Trp Trp Met Ile Asn Ala Leu Tyr His Thr Pro Gln Tyr Ala Ala 260 265 270 Arg Leu Arg Pro Val Leu Val Cys Val Gly Ser Pro Thr Gln Thr Ala 275 280 285 Ser Leu Glu Ser Thr Phe Glu His Gln Lys Leu Arg Cys Ser Val Arg 290 295 300 Gln Ser Glu Asn Val Leu Thr Tyr Leu Ile Cys Asn Arg Thr Leu Arg 305 310 315 320 Glu Tyr Ala Arg Leu Ser Tyr Ser Trp Ala Ile Phe Ile Asn Asn Lys 325 330 335 Arg Cys Val Glu His Glu Phe Gly Asn Leu Met Lys Val Leu Glu Tyr 340 345 350 Gly Leu Pro Ile Thr Glu Glu His Met Gln Phe Val Asp Arg Phe Val 355 360 365 Val Pro Glu Asn Tyr Ile Thr Asn Pro Ala Asn Leu Pro Gly Trp Thr 370 375 380 Arg Leu Phe Ser Ser His Lys Glu Val Ser Ala Tyr Met Ala Lys Leu 385 390 395 400 His Ala Tyr Leu Lys Val Thr Arg Glu Gly Glu Phe Val Val Phe Thr 405 410 415 Leu Pro Val Leu Thr Phe Val Ser Val Lys Glu Phe Asp Glu 420 425 430 11 2649 DNA Herpes Virus 11 atggcggcgg ccggcgggga gcgccagcta gacggacaga aacccggccc gccgcacctt 60 cagcaacccg gggaccgacc agccgttcca gggagggccg aggccttttt aaattttacg 120 tctatgcacg gggtgcagcc aatccttaag cgcatccgag agctctcgca acaacagctc 180 gacggagcgc aagtgcccca tctgcagtgg ttccgggacg tggcggcctt agagtccccc 240 gcaggcctgc ccctcaggga gtttccgttc gcggtgtatc ttatcaccgg caacgctggc 300 tccggaaaga gcacgtgcgt gcagacaatc aacgaggtct tggactgtgt ggtgacgggc 360 gccacgcgca ttgcggccca aaacatgtac gccaaactct cgggcgcctt tctcagccga 420 cccatcaaca ccatctttca tgaatttggg tttcgcggga atcacgtcca ggcccaactg 480 ggacagtacc cgtacaccct gaccagcaac cccgcctcgc tggaggacct gcagcgacga 540 gatctgacgt actactggga ggtgattttg gacctcacga agcgcgccct ggccgcctcc 600 gggggcgagg agttgcggaa cgagtttcgc gccctggccg ccctggaacg gaccctgggg 660 ttggccgagg gcgccctgac gcggttggcc ccggccaccc acggggcgct gccggccttt 720 acccgcagca acgtgatcgt catcgacgag gccgggctcc ttgggcgtca cctcctcacg 780 gccgtggtgt attgctggtg gatgattaac gccctgtacc acacccccca gtacgcggcc 840 cgcctgcggc ccgtgttggt gtgtgtgggc tcgccgacgc agacggcgtc cctggagtcg 900 accttcgagc accagaaact gcggtgttcc gtccgccaga gcgagaacgt gctcacgtac 960 ctcatctgca accgcacgct gcgcgagtac gcccgcctct cgtatagctg ggccattttt 1020 attaacaaca aacggtgcgt cgagcacgag ttcggtaacc tcatgaaggt gctggagtac 1080 ggcctgccca tcaccgagga gcacatgcag ttcgtggatc gcttcgtcgt cccggaaaac 1140 tacatcacca accccgccaa cctccccggc tggacgcggc tgttctcctc ccacaaagag 1200 gtgagcgcgt acatggccaa gctccacgcc tacctgaagg tgacccgtga gggggagttc 1260 gtcgtgttca ccctccccgt gcttacgttc gtgtcggtca aggagtttga cgaataccga 1320 cggctgacac accagcccgg cctgacgatt gaaaagtggc tcacggccaa cgccagccgc 1380 atcaccaact actcgcagag ccaggaccag gacgcggggc acatgcgctg cgaggtgcac 1440 agcaaacagc agctggtcgt ggcccgcaac gacgtcactt acgtcctcaa cagccagatc 1500 gcggtgaccg cgcgcctgcg aaaactggtt tttgggttta gtgggacgtt ccgggccttc 1560 gaggcagtgt tgcgtgacga cagctttgta aagactcagg gggagacttc ggtggagttt 1620 gcctacaggt tcctgtcgcg gctcatattt agcgggctta tctcctttta caactttctg 1680 cagcgcccgg gcctggatgc gacccagagg accctcgcct acgcccgcat gggagaacta 1740 acggcggaga ttctgtctct gcgccccaaa tcttcggggg tgccgacgca ggcgtcggta 1800 atggccgacg caggcgcccc cggcgagcgt gcgtttgatt ttaagcaact ggggccgcgg 1860 gacgggggcc cggacgattt tcccgacgac gacctcgacg ttattttcgc ggggctggac 1920 gaacaacagc tcgacgtgtt ttactgccac tacacccccg gggaaccgga gaccaccgcc 1980 gccgttcaca cccagtttgc gctgctgaag cgggccttcc tcgggagatt ccgaatcctc 2040 caagagctct tcggggaggc atttgaagtc gcccccttta gcacgtacgt ggacaacgtt 2100 atcttccggg gctgcgagat gctgaccggc tcgccgcgcg gggggctgat gtccgtcgcc 2160 ctgcagacgg acaattatac gctcatggga tacacgtacg cacgggtgtt tgcctttgcg 2220 gacgagctgc ggaggcggca cgcgacggcc aacgtggccg agttactgga agaggccccc 2280 ctgccttacg tggtcttgcg ggaccaacac ggcttcatgt ccgtcgtcaa caccaacatc 2340 agcgagtttg tcgagtccat tgactctacg gagctggcca tggccataaa cgccgactac 2400 ggcatcagct ccaagcttgc catgaccatc acgcgctccc agggccttag cctggacaag 2460 gtcgccatct gctttacgcc cggcaacctg cgcctcaaca gcgcgtacgt ggccatgtcc 2520 cgcaccacct cctccgaatt ccttcgcatg aacttaaatc cgctccggga gcgccacgag 2580 cgcgatgacg tcattagtga gcacatacta tcggctctgc gcgatccgaa cgtggtcatt 2640 gtctattaa 2649 12 882 PRT Herpes Virus 12 Met Ala Ala Ala Gly Gly Glu Arg Gln Leu Asp Gly Gln Lys Pro Gly 1 5 10 15 Pro Pro His Leu Gln Gln Pro Gly Asp Arg Pro Ala Val Pro Gly Arg 20 25 30 Ala Glu Ala Phe Leu Asn Phe Thr Ser Met His Gly Val Gln Pro Ile 35 40 45 Leu Lys Arg Ile Arg Glu Leu Ser Gln Gln Gln Leu Asp Gly Ala Gln 50 55 60 Val Pro His Leu Gln Trp Phe Arg Asp Val Ala Ala Leu Glu Ser Pro 65 70 75 80 Ala Gly Leu Pro Leu Arg Glu Phe Pro Phe Ala Val Tyr Leu Ile Thr 85 90 95 Gly Asn Ala Gly Ser Gly Lys Ser Thr Cys Val Gln Thr Ile Asn Glu 100 105 110 Val Leu Asp Cys Val Val Thr Gly Ala Thr Arg Ile Ala Ala Gln Asn 115 120 125 Met Tyr Ala Lys Leu Ser Gly Ala Phe Leu Ser Arg Pro Ile Asn Thr 130 135 140 Ile Phe His Glu Phe Gly Phe Arg Gly Asn His Val Gln Ala Gln Leu 145 150 155 160 Gly Gln Tyr Pro Tyr Thr Leu Thr Ser Asn Pro Ala Ser Leu Glu Asp 165 170 175 Leu Gln Arg Arg Asp Leu Thr Tyr Tyr Trp Glu Val Ile Leu Asp Leu 180 185 190 Thr Lys Arg Ala Leu Ala Ala Ser Gly Gly Glu Glu Leu Arg Asn Glu 195 200 205 Phe Arg Ala Leu Ala Ala Leu Glu Arg Thr Leu Gly Leu Ala Glu Gly 210 215 220 Ala Leu Thr Arg Leu Ala Pro Ala Thr His Gly Ala Leu Pro Ala Phe 225 230 235 240 Thr Arg Ser Asn Val Ile Val Ile Asp Glu Ala Gly Leu Leu Gly Arg 245 250 255 His Leu Leu Thr Ala Val Val Tyr Cys Trp Trp Met Ile Asn Ala Leu 260 265 270 Tyr His Thr Pro Gln Tyr Ala Ala Arg Leu Arg Pro Val Leu Val Cys 275 280 285 Val Gly Ser Pro Thr Gln Thr Ala Ser Leu Glu Ser Thr Phe Glu His 290 295 300 Gln Lys Leu Arg Cys Ser Val Arg Gln Ser Glu Asn Val Leu Thr Tyr 305 310 315 320 Leu Ile Cys Asn Arg Thr Leu Arg Glu Tyr Ala Arg Leu Ser Tyr Ser 325 330 335 Trp Ala Ile Phe Ile Asn Asn Lys Arg Cys Val Glu His Glu Phe Gly 340 345 350 Asn Leu Met Lys Val Leu Glu Tyr Gly Leu Pro Ile Thr Glu Glu His 355 360 365 Met Gln Phe Val Asp Arg Phe Val Val Pro Glu Asn Tyr Ile Thr Asn 370 375 380 Pro Ala Asn Leu Pro Gly Trp Thr Arg Leu Phe Ser Ser His Lys Glu 385 390 395 400 Val Ser Ala Tyr Met Ala Lys Leu His Ala Tyr Leu Lys Val Thr Arg 405 410 415 Glu Gly Glu Phe Val Val Phe Thr Leu Pro Val Leu Thr Phe Val Ser 420 425 430 Val Lys Glu Phe Asp Glu Tyr Arg Arg Leu Thr His Gln Pro Gly Leu 435 440 445 Thr Ile Glu Lys Trp Leu Thr Ala Asn Ala Ser Arg Ile Thr Asn Tyr 450 455 460 Ser Gln Ser Gln Asp Gln Asp Ala Gly His Met Arg Cys Glu Val His 465 470 475 480 Ser Lys Gln Gln Leu Val Val Ala Arg Asn Asp Val Thr Tyr Val Leu 485 490 495 Asn Ser Gln Ile Ala Val Thr Ala Arg Leu Arg Lys Leu Val Phe Gly 500 505 510 Phe Ser Gly Thr Phe Arg Ala Phe Glu Ala Val Leu Arg Asp Asp Ser 515 520 525 Phe Val Lys Thr Gln Gly Glu Thr Ser Val Glu Phe Ala Tyr Arg Phe 530 535 540 Leu Ser Arg Leu Ile Phe Ser Gly Leu Ile Ser Phe Tyr Asn Phe Leu 545 550 555 560 Gln Arg Pro Gly Leu Asp Ala Thr Gln Arg Thr Leu Ala Tyr Ala Arg 565 570 575 Met Gly Glu Leu Thr Ala Glu Ile Leu Ser Leu Arg Pro Lys Ser Ser 580 585 590 Gly Val Pro Thr Gln Ala Ser Val Met Ala Asp Ala Gly Ala Pro Gly 595 600 605 Glu Arg Ala Phe Asp Phe Lys Gln Leu Gly Pro Arg Asp Gly Gly Pro 610 615 620 Asp Asp Phe Pro Asp Asp Asp Leu Asp Val Ile Phe Ala Gly Leu Asp 625 630 635 640 Glu Gln Gln Leu Asp Val Phe Tyr Cys His Tyr Thr Pro Gly Glu Pro 645 650 655 Glu Thr Thr Ala Ala Val His Thr Gln Phe Ala Leu Leu Lys Arg Ala 660 665 670 Phe Leu Gly Arg Phe Arg Ile Leu Gln Glu Leu Phe Gly Glu Ala Phe 675 680 685 Glu Val Ala Pro Phe Ser Thr Tyr Val Asp Asn Val Ile Phe Arg Gly 690 695 700 Cys Glu Met Leu Thr Gly Ser Pro Arg Gly Gly Leu Met Ser Val Ala 705 710 715 720 Leu Gln Thr Asp Asn Tyr Thr Leu Met Gly Tyr Thr Tyr Ala Arg Val 725 730 735 Phe Ala Phe Ala Asp Glu Leu Arg Arg Arg His Ala Thr Ala Asn Val 740 745 750 Ala Glu Leu Leu Glu Glu Ala Pro Leu Pro Tyr Val Val Leu Arg Asp 755 760 765 Gln His Gly Phe Met Ser Val Val Asn Thr Asn Ile Ser Glu Phe Val 770 775 780 Glu Ser Ile Asp Ser Thr Glu Leu Ala Met Ala Ile Asn Ala Asp Tyr 785 790 795 800 Gly Ile Ser Ser Lys Leu Ala Met Thr Ile Thr Arg Ser Gln Gly Leu 805 810 815 Ser Leu Asp Lys Val Ala Ile Cys Phe Thr Pro Gly Asn Leu Arg Leu 820 825 830 Asn Ser Ala Tyr Val Ala Met Ser Arg Thr Thr Ser Ser Glu Phe Leu 835 840 845 Arg Met Asn Leu Asn Pro Leu Arg Glu Arg His Glu Arg Asp Asp Val 850 855 860 Ile Ser Glu His Ile Leu Ser Ala Leu Arg Asp Pro Asn Val Val Ile 865 870 875 880 Val Tyr 13 1011 DNA Herpes Virus 13 caactgttag acccgcccgc ggccgtcggg cccgtctgga cggcgcggtt ttgcttcccc 60 ggacttcgcg cccagctcct ggcggccctg gccgacctcg gggggagcgg gctggcggac 120 ccccacggcc ggacgggcct agcaagactg gacgcgctgg tggtggccgc tccctcagag 180 ccctgggccg gggccgtctt ggagcgcctg gtcccggaca cgtgcaacgc ctgccctgcg 240 ctgcggcagc tcctgggtgg ggtaatggcc gccgtctgcc tgcagatcga ggagacggcc 300 agctcggtga agttcgcggt ctgcgggggc gatgggggtg cgttctgggg tgtctttaac 360 gtggaccccc aagacgcgga tgcggcttcc ggggtgatcg aggacgcccg gcgggccatc 420 gagacggccg tgggagccgt gcttagggcc aacgccgtcc ggctgcggca cccactgtgc 480 ctggccctcg agggcgtcta cacccacgca gtcgcctgga gccaggcggg agtgtggttc 540 tggaactccc gcgacaacac tgaccatctt gggggatttc ctctccgcgg gcccgcgtac 600 accacggcgg caggggtcgt acgcgacacg ctgcgacggg tcctgggcct gacaacggca 660 tgcgtgccgg aggaggacgc actcacggcc cggggcctta tggaggacgc ctgcgaccgc 720 cttatcttgg acgcgtttaa taaacggttg gacgcggagt actggagcgt tcgggtgtcc 780 ccctttgagg ccagcgaccc cttgcccccc actgccttcc gcggcggcgc cttgctggac 840 gcagagcact actggcggcg cgtcgtgcgt gtctgtcccg gaggcgggga gtcggtcggc 900 gtccccgtcg atctataccc gcggcccctt gtgctccccc ccgtggactg cgctcatcac 960 ctgcgcgaaa tcctgcgcga gattgagttg gtgtttaccg gggtgctggc g 1011 14 337 PRT Herpes Virus 14 Gln Leu Leu Asp Pro Pro Ala Ala Val Gly Pro Val Trp Thr Ala Arg 1 5 10 15 Phe Cys Phe Pro Gly Leu Arg Ala Gln Leu Leu Ala Ala Leu Ala Asp 20 25 30 Leu Gly Gly Ser Gly Leu Ala Asp Pro His Gly Arg Thr Gly Leu Ala 35 40 45 Arg Leu Asp Ala Leu Val Val Ala Ala Pro Ser Glu Pro Trp Ala Gly 50 55 60 Ala Val Leu Glu Arg Leu Val Pro Asp Thr Cys Asn Ala Cys Pro Ala 65 70 75 80 Leu Arg Gln Leu Leu Gly Gly Val Met Ala Ala Val Cys Leu Gln Ile 85 90 95 Glu Glu Thr Ala Ser Ser Val Lys Phe Ala Val Cys Gly Gly Asp Gly 100 105 110 Gly Ala Phe Trp Gly Val Phe Asn Val Asp Pro Gln Asp Ala Asp Ala 115 120 125 Ala Ser Gly Val Ile Glu Asp Ala Arg Arg Ala Ile Glu Thr Ala Val 130 135 140 Gly Ala Val Leu Arg Ala Asn Ala Val Arg Leu Arg His Pro Leu Cys 145 150 155 160 Leu Ala Leu Glu Gly Val Tyr Thr His Ala Val Ala Trp Ser Gln Ala 165 170 175 Gly Val Trp Phe Trp Asn Ser Arg Asp Asn Thr Asp His Leu Gly Gly 180 185 190 Phe Pro Leu Arg Gly Pro Ala Tyr Thr Thr Ala Ala Gly Val Val Arg 195 200 205 Asp Thr Leu Arg Arg Val Leu Gly Leu Thr Thr Ala Cys Val Pro Glu 210 215 220 Glu Asp Ala Leu Thr Ala Arg Gly Leu Met Glu Asp Ala Cys Asp Arg 225 230 235 240 Leu Ile Leu Asp Ala Phe Asn Lys Arg Leu Asp Ala Glu Tyr Trp Ser 245 250 255 Val Arg Val Ser Pro Phe Glu Ala Ser Asp Pro Leu Pro Pro Thr Ala 260 265 270 Phe Arg Gly Gly Ala Leu Leu Asp Ala Glu His Tyr Trp Arg Arg Val 275 280 285 Val Arg Val Cys Pro Gly Gly Gly Glu Ser Val Gly Val Pro Val Asp 290 295 300 Leu Tyr Pro Arg Pro Leu Val Leu Pro Pro Val Asp Cys Ala His His 305 310 315 320 Leu Arg Glu Ile Leu Arg Glu Ile Glu Leu Val Phe Thr Gly Val Leu 325 330 335 Ala 15 2253 DNA Herpes Virus 15 atggacaccg cagatatcgt gtgggtggag gagagcgtca gcgccattac cctttacgcg 60 gtatggctgc ccccccgcgc tcgcgagtac ttccacgccc tggtgtattt tgtatgtcgc 120 aacgccgcag gggagggtcg cgcgcgcttt gcggaggtct ccgtcaccgc gacggagctg 180 cgggatttct acggctccgc ggacgtctcc gtccaggccg tcgtggcggc cgcccgcgcc 240 gcgacgacgc cggccgcctc cccgctggag cccctggaga acccgactct gtggcgggcg 300 ctgtacgcgt gcgtcctggc ggccctggag cgccagaccg ggccggtggc cctgttcgcc 360 ccgctgcgta tcggctcgga cccacgcacg ggactggtgg tgaaagttga gagagcgtcg 420 tggggcccgc ccgccgcccc tcgcgccgct ctcctggtcg cggaggccaa cattgacatc 480 gaccctatgg ccctggcggc gcgcgttgcc gagcatcccg acgcgcggct ggcgtgggcg 540 cgcctggcgg ccattcgcga caccccccag tgcgcgtccg ccgcttcgct gaccgttaac 600 atcaccaccg gaaccgcgct atttgcgcgc gaataccaga ctcttgcgtt tccgccgatc 660 aagaaggagg gcgcgttcgg ggacctggtc gaggtgtgcg aggtgggcct gcggccacgc 720 gggcacccgc aacgagtcac ggcacgggtg ctgctgcccc gcgattacga ctactttgta 780 agcgccggcg agaagttctc cgcgccggcg ctcgtcgccc ttttccggca gtggcatacc 840 acggtccacg ccgcccccgg ggccctggcc cccgtctttg cctttctggg gcccgagttt 900 gaggtccggg ggggacccgt cccgtacttt gccgtcctgg ggtttccggg ttggcccacg 960 ttcaccgtgc cggccacggc cgagtcggca cgggacctgg tgcgcggggc cgcggccgct 1020 tacgccgcgc tcctgggggc ctggcccgcg gtgggggcca gggtcgtcct ccccccgcga 1080 gcctggcccg gcgtggcctc ggcggcagcc ggatgcctcc tgcccgcggt gcgggaggcg 1140 gtggcgcggt ggcatcccgc cactaaaatc atccaactgt tagacccgcc cgcggccgtc 1200 gggcccgtct ggacggcgcg gttttgcttc cccggacttc gcgcccagct cctggcggcc 1260 ctggccgacc tcggggggag cgggctggcg gacccccacg gccggacggg cctagcaaga 1320 ctggacgcgc tggtggtggc cgctccctca gagccctggg ccggggccgt cttggagcgc 1380 ctggtcccgg acacgtgcaa cgcctgccct gcgctgcggc agctcctggg tggggtaatg 1440 gccgccgtct gcctgcagat cgaggagacg gccagctcgg tgaagttcgc ggtctgcggg 1500 ggcgatgggg gtgcgttctg gggtgtcttt aacgtggacc cccaagacgc ggatgcggct 1560 tccggggtga tcgaggacgc ccggcgggcc atcgagacgg ccgtgggagc cgtgcttagg 1620 gccaacgccg tccggctgcg gcacccactg tgcctggccc tcgagggcgt ctacacccac 1680 gcagtcgcct ggagccaggc gggagtgtgg ttctggaact cccgcgacaa cactgaccat 1740 cttgggggat ttcctctccg cgggcccgcg tacaccacgg cggcaggggt cgtacgcgac 1800 acgctgcgac gggtcctggg cctgacaacg gcatgcgtgc cggaggagga cgcactcacg 1860 gcccggggcc ttatggagga cgcctgcgac cgccttatct tggacgcgtt taataaacgg 1920 ttggacgcgg agtactggag cgttcgggtg tccccctttg aggccagcga ccccttgccc 1980 cccactgcct tccgcggcgg cgccttgctg gacgcagagc actactggcg gcgcgtcgtg 2040 cgtgtctgtc ccggaggcgg ggagtcggtc ggcgtccccg tcgatctata cccgcggccc 2100 cttgtgctcc cccccgtgga ctgcgctcat cacctgcgcg aaatcctgcg cgagattgag 2160 ttggtgttta ccggggtgct ggcgggagta tggggcgagg gggggaagtt tgtgtatccc 2220 tttgacgaca agatgtcgtt tctgtttgcc tga 2253 16 750 PRT Herpes Virus 16 Met Asp Thr Ala Asp Ile Val Trp Val Glu Glu Ser Val Ser Ala Ile 1 5 10 15 Thr Leu Tyr Ala Val Trp Leu Pro Pro Arg Ala Arg Glu Tyr Phe His 20 25 30 Ala Leu Val Tyr Phe Val Cys Arg Asn Ala Ala Gly Glu Gly Arg Ala 35 40 45 Arg Phe Ala Glu Val Ser Val Thr Ala Thr Glu Leu Arg Asp Phe Tyr 50 55 60 Gly Ser Ala Asp Val Ser Val Gln Ala Val Val Ala Ala Ala Arg Ala 65 70 75 80 Ala Thr Thr Pro Ala Ala Ser Pro Leu Glu Pro Leu Glu Asn Pro Thr 85 90 95 Leu Trp Arg Ala Leu Tyr Ala Cys Val Leu Ala Ala Leu Glu Arg Gln 100 105 110 Thr Gly Pro Val Ala Leu Phe Ala Pro Leu Arg Ile Gly Ser Asp Pro 115 120 125 Arg Thr Gly Leu Val Val Lys Val Glu Arg Ala Ser Trp Gly Pro Pro 130 135 140 Ala Ala Pro Arg Ala Ala Leu Leu Val Ala Glu Ala Asn Ile Asp Ile 145 150 155 160 Asp Pro Met Ala Leu Ala Ala Arg Val Ala Glu His Pro Asp Ala Arg 165 170 175 Leu Ala Trp Ala Arg Leu Ala Ala Ile Arg Asp Thr Pro Gln Cys Ala 180 185 190 Ser Ala Ala Ser Leu Thr Val Asn Ile Thr Thr Gly Thr Ala Leu Phe 195 200 205 Ala Arg Glu Tyr Gln Thr Leu Ala Phe Pro Pro Ile Lys Lys Glu Gly 210 215 220 Ala Phe Gly Asp Leu Val Glu Val Cys Glu Val Gly Leu Arg Pro Arg 225 230 235 240 Gly His Pro Gln Arg Val Thr Ala Arg Val Leu Leu Pro Arg Asp Tyr 245 250 255 Asp Tyr Phe Val Ser Ala Gly Glu Lys Phe Ser Ala Pro Ala Leu Val 260 265 270 Ala Leu Phe Arg Gln Trp His Thr Thr Val His Ala Ala Pro Gly Ala 275 280 285 Leu Ala Pro Val Phe Ala Phe Leu Gly Pro Glu Phe Glu Val Arg Gly 290 295 300 Gly Pro Val Pro Tyr Phe Ala Val Leu Gly Phe Pro Gly Trp Pro Thr 305 310 315 320 Phe Thr Val Pro Ala Thr Ala Glu Ser Ala Arg Asp Leu Val Arg Gly 325 330 335 Ala Ala Ala Ala Tyr Ala Ala Leu Leu Gly Ala Trp Pro Ala Val Gly 340 345 350 Ala Arg Val Val Leu Pro Pro Arg Ala Trp Pro Gly Val Ala Ser Ala 355 360 365 Ala Ala Gly Cys Leu Leu Pro Ala Val Arg Glu Ala Val Ala Arg Trp 370 375 380 His Pro Ala Thr Lys Ile Ile Gln Leu Leu Asp Pro Pro Ala Ala Val 385 390 395 400 Gly Pro Val Trp Thr Ala Arg Phe Cys Phe Pro Gly Leu Arg Ala Gln 405 410 415 Leu Leu Ala Ala Leu Ala Asp Leu Gly Gly Ser Gly Leu Ala Asp Pro 420 425 430 His Gly Arg Thr Gly Leu Ala Arg Leu Asp Ala Leu Val Val Ala Ala 435 440 445 Pro Ser Glu Pro Trp Ala Gly Ala Val Leu Glu Arg Leu Val Pro Asp 450 455 460 Thr Cys Asn Ala Cys Pro Ala Leu Arg Gln Leu Leu Gly Gly Val Met 465 470 475 480 Ala Ala Val Cys Leu Gln Ile Glu Glu Thr Ala Ser Ser Val Lys Phe 485 490 495 Ala Val Cys Gly Gly Asp Gly Gly Ala Phe Trp Gly Val Phe Asn Val 500 505 510 Asp Pro Gln Asp Ala Asp Ala Ala Ser Gly Val Ile Glu Asp Ala Arg 515 520 525 Arg Ala Ile Glu Thr Ala Val Gly Ala Val Leu Arg Ala Asn Ala Val 530 535 540 Arg Leu Arg His Pro Leu Cys Leu Ala Leu Glu Gly Val Tyr Thr His 545 550 555 560 Ala Val Ala Trp Ser Gln Ala Gly Val Trp Phe Trp Asn Ser Arg Asp 565 570 575 Asn Thr Asp His Leu Gly Gly Phe Pro Leu Arg Gly Pro Ala Tyr Thr 580 585 590 Thr Ala Ala Gly Val Val Arg Asp Thr Leu Arg Arg Val Leu Gly Leu 595 600 605 Thr Thr Ala Cys Val Pro Glu Glu Asp Ala Leu Thr Ala Arg Gly Leu 610 615 620 Met Glu Asp Ala Cys Asp Arg Leu Ile Leu Asp Ala Phe Asn Lys Arg 625 630 635 640 Leu Asp Ala Glu Tyr Trp Ser Val Arg Val Ser Pro Phe Glu Ala Ser 645 650 655 Asp Pro Leu Pro Pro Thr Ala Phe Arg Gly Gly Ala Leu Leu Asp Ala 660 665 670 Glu His Tyr Trp Arg Arg Val Val Arg Val Cys Pro Gly Gly Gly Glu 675 680 685 Ser Val Gly Val Pro Val Asp Leu Tyr Pro Arg Pro Leu Val Leu Pro 690 695 700 Pro Val Asp Cys Ala His His Leu Arg Glu Ile Leu Arg Glu Ile Glu 705 710 715 720 Leu Val Phe Thr Gly Val Leu Ala Gly Val Trp Gly Glu Gly Gly Lys 725 730 735 Phe Val Tyr Pro Phe Asp Asp Lys Met Ser Phe Leu Phe Ala 740 745 750 17 252 DNA Herpes Virus 17 tgccgaaaca acgtcctcat caccgacgac ggggaggtcg tctcgctgac cgcccacgac 60 tttgacgtcg tggatatcga gtccgaagag gaaggtaatt tctacgtgcc cccggatatg 120 cgcggggtta cgcgggcccc ggggagacag cgcctgcgtt catcggaccc cccctcgcgc 180 cacactcacc ggcggacccc cggaggcgcc tgccccgcca cccagtttcc accccccatg 240 tccgatagcg aa 252 18 84 PRT Herpes Virus 18 Cys Arg Asn Asn Val Leu Ile Thr Asp Asp Gly Glu Val Val Ser Leu 1 5 10 15 Thr Ala His Asp Phe Asp Val Val Asp Ile Glu Ser Glu Glu Glu Gly 20 25 30 Asn Phe Tyr Val Pro Pro Asp Met Arg Gly Val Thr Arg Ala Pro Gly 35 40 45 Arg Gln Arg Leu Arg Ser Ser Asp Pro Pro Ser Arg His Thr His Arg 50 55 60 Arg Thr Pro Gly Gly Ala Cys Pro Ala Thr Gln Phe Pro Pro Pro Met 65 70 75 80 Ser Asp Ser Glu 19 291 DNA Herpes Virus 19 atgggcctct cgttctccgg ggcccggccc tgctgctgcc gaaacaacgt cctcatcacc 60 gacgacgggg aggtcgtctc gctgaccgcc cacgactttg acgtcgtgga tatcgagtcc 120 gaagaggaag gtaatttcta cgtgcccccg gatatgcgcg gggttacgcg ggccccgggg 180 agacagcgcc tgcgttcatc ggaccccccc tcgcgccaca ctcaccggcg gacccccgga 240 ggcgcctgcc ccgccaccca gtttccaccc cccatgtccg atagcgaata a 291 20 96 PRT Herpes Virus 20 Met Gly Leu Ser Phe Ser Gly Ala Arg Pro Cys Cys Cys Arg Asn Asn 1 5 10 15 Val Leu Ile Thr Asp Asp Gly Glu Val Val Ser Leu Thr Ala His Asp 20 25 30 Phe Asp Val Val Asp Ile Glu Ser Glu Glu Glu Gly Asn Phe Tyr Val 35 40 45 Pro Pro Asp Met Arg Gly Val Thr Arg Ala Pro Gly Arg Gln Arg Leu 50 55 60 Arg Ser Ser Asp Pro Pro Ser Arg His Thr His Arg Arg Thr Pro Gly 65 70 75 80 Gly Ala Cys Pro Ala Thr Gln Phe Pro Pro Pro Met Ser Asp Ser Glu 85 90 95 21 801 DNA Herpes Virus 21 atggatgagt cccgcagaca gcgacctgct ggtcatgtgg cagctaacct cagcccccaa 60 ggtgcacgcc aacggtcctt caaggattgg ctcgcatcct acgtacactc caacccccac 120 ggggcctccg ggcgccccag cggcccctct ctccaggacg ccgccgtctc ccgctcctcc 180 cacgggtccc gccaccgatc cggcctccgc gagcggcttc gcgcgggact atcccgatgg 240 cgaatgagcc gctcgtctca tcgccgcgcg tcccccgaga cgcccggtac ggcggccaaa 300 ctgaaccgcc cgcccctgcg cagatcccag gcggcgttaa ccgcaccccc ctcgtccccc 360 tcgcacatcc tcaccctcac gcgcatccgc aagctatgca gccccgtgtt cgccatcaac 420 cccgccctac actacacgac cctcgagatc cccggggccc gaagcttcgg ggggtctggg 480 ggatacggtg acgtccaact gattcgcgaa cataagcttg ccgttaagac cataaaggaa 540 aaggagtggt ttgccgttga gctcatcgcg accctgttgg tcggggagtg cgttctacgc 600 gccggccgca cccacaacat ccgcggcttc atcgcgcccc tcgggttctc gctgcaacaa 660 cgacagatag tgttccccgc gtacgacatg gacctcggta agtatatcgg ccaactggcg 720 tccctgcgca caacaaaccc ctcggtctcg acggccctcc accagtgctt cacggagctg 780 gcccgcgccg ttgtgttttt a 801 22 267 PRT Herpes Virus 22 Met Asp Glu Ser Arg Arg Gln Arg Pro Ala Gly His Val Ala Ala Asn 1 5 10 15 Leu Ser Pro Gln Gly Ala Arg Gln Arg Ser Phe Lys Asp Trp Leu Ala 20 25 30 Ser Tyr Val His Ser Asn Pro His Gly Ala Ser Gly Arg Pro Ser Gly 35 40 45 Pro Ser Leu Gln Asp Ala Ala Val Ser Arg Ser Ser His Gly Ser Arg 50 55 60 His Arg Ser Gly Leu Arg Glu Arg Leu Arg Ala Gly Leu Ser Arg Trp 65 70 75 80 Arg Met Ser Arg Ser Ser His Arg Arg Ala Ser Pro Glu Thr Pro Gly 85 90 95 Thr Ala Ala Lys Leu Asn Arg Pro Pro Leu Arg Arg Ser Gln Ala Ala 100 105 110 Leu Thr Ala Pro Pro Ser Ser Pro Ser His Ile Leu Thr Leu Thr Arg 115 120 125 Ile Arg Lys Leu Cys Ser Pro Val Phe Ala Ile Asn Pro Ala Leu His 130 135 140 Tyr Thr Thr Leu Glu Ile Pro Gly Ala Arg Ser Phe Gly Gly Ser Gly 145 150 155 160 Gly Tyr Gly Asp Val Gln Leu Ile Arg Glu His Lys Leu Ala Val Lys 165 170 175 Thr Ile Lys Glu Lys Glu Trp Phe Ala Val Glu Leu Ile Ala Thr Leu 180 185 190 Leu Val Gly Glu Cys Val Leu Arg Ala Gly Arg Thr His Asn Ile Arg 195 200 205 Gly Phe Ile Ala Pro Leu Gly Phe Ser Leu Gln Gln Arg Gln Ile Val 210 215 220 Phe Pro Ala Tyr Asp Met Asp Leu Gly Lys Tyr Ile Gly Gln Leu Ala 225 230 235 240 Ser Leu Arg Thr Thr Asn Pro Ser Val Ser Thr Ala Leu His Gln Cys 245 250 255 Phe Thr Glu Leu Ala Arg Ala Val Val Phe Leu 260 265 23 1557 DNA Herpes Virus 23 atggatgagt cccgcagaca gcgacctgct ggtcatgtgg cagctaacct cagcccccaa 60 ggtgcacgcc aacggtcctt caaggattgg ctcgcatcct acgtacactc caacccccac 120 ggggcctccg ggcgccccag cggcccctct ctccaggacg ccgccgtctc ccgctcctcc 180 cacgggtccc gccaccgatc cggcctccgc gagcggcttc gcgcgggact atcccgatgg 240 cgaatgagcc gctcgtctca tcgccgcgcg tcccccgaga cgcccggtac ggcggccaaa 300 ctgaaccgcc cgcccctgcg cagatcccag gcggcgttaa ccgcaccccc ctcgtccccc 360 tcgcacatcc tcaccctcac gcgcatccgc aagctatgca gccccgtgtt cgccatcaac 420 cccgccctac actacacgac cctcgagatc cccggggccc gaagcttcgg ggggtctggg 480 ggatacggtg acgtccaact gattcgcgaa cataagcttg ccgttaagac cataaaggaa 540 aaggagtggt ttgccgttga gctcatcgcg accctgttgg tcggggagtg cgttctacgc 600 gccggccgca cccacaacat ccgcggcttc atcgcgcccc tcgggttctc gctgcaacaa 660 cgacagatag tgttccccgc gtacgacatg gacctcggta agtatatcgg ccaactggcg 720 tccctgcgca caacaaaccc ctcggtctcg acggccctcc accagtgctt cacggagctg 780 gcccgcgccg ttgtgttttt aaacaccacc tgcgggatca gccacctgga tatcaagtgc 840 gccaacatcc tcgtcatgct gcggtcggac gccgtctcgc tccggcgggc cgtcctcgcc 900 gactttagcc tcgtcaccct caactccaac tccacgatcg cccgggggca gttttgcctc 960 caggagccgg acctcaagtc cccccggatg tttggcatgc ccaccgccct aaccacagcc 1020 aactttcaca ccctggtggg tcacgggtat aaccagcccc cggagctgtt ggtgaaatac 1080 cttaacaacg aacgggccga atttaccaac caccgcctga agcacgacgt cgggttagcg 1140 gttgacctgt acgccctggg ccagacgctg ctggagttgg tggttagcgt gtacgtcgcc 1200 ccgagcctgg gcgtacccgt gacccggttt cccggttacc agtattttaa caaccagctg 1260 tcgccggact tcgccctggc cctgctcgcc tatcgctgcg tgctgcaccc agccctgttt 1320 gtcaactcgg ccgagaccaa cacccacggc ctggcgtatg acgtcccaga gggcatccgg 1380 cgccacctcc gcaatcccaa gattcggcgc gcgtttacgg atcggtgtat aaattaccag 1440 cacacacaca aggcgatact gtcgtcggtg gcgctgcctc ccgagcttaa gcctctcctg 1500 gtgctggtgt cccgcctgtg tcacaccaac ccgtgcgcgc ggcacgcgct gtcgtga 1557 24 518 PRT Herpes Virus 24 Met Asp Glu Ser Arg Arg Gln Arg Pro Ala Gly His Val Ala Ala Asn 1 5 10 15 Leu Ser Pro Gln Gly Ala Arg Gln Arg Ser Phe Lys Asp Trp Leu Ala 20 25 30 Ser Tyr Val His Ser Asn Pro His Gly Ala Ser Gly Arg Pro Ser Gly 35 40 45 Pro Ser Leu Gln Asp Ala Ala Val Ser Arg Ser Ser His Gly Ser Arg 50 55 60 His Arg Ser Gly Leu Arg Glu Arg Leu Arg Ala Gly Leu Ser Arg Trp 65 70 75 80 Arg Met Ser Arg Ser Ser His Arg Arg Ala Ser Pro Glu Thr Pro Gly 85 90 95 Thr Ala Ala Lys Leu Asn Arg Pro Pro Leu Arg Arg Ser Gln Ala Ala 100 105 110 Leu Thr Ala Pro Pro Ser Ser Pro Ser His Ile Leu Thr Leu Thr Arg 115 120 125 Ile Arg Lys Leu Cys Ser Pro Val Phe Ala Ile Asn Pro Ala Leu His 130 135 140 Tyr Thr Thr Leu Glu Ile Pro Gly Ala Arg Ser Phe Gly Gly Ser Gly 145 150 155 160 Gly Tyr Gly Asp Val Gln Leu Ile Arg Glu His Lys Leu Ala Val Lys 165 170 175 Thr Ile Lys Glu Lys Glu Trp Phe Ala Val Glu Leu Ile Ala Thr Leu 180 185 190 Leu Val Gly Glu Cys Val Leu Arg Ala Gly Arg Thr His Asn Ile Arg 195 200 205 Gly Phe Ile Ala Pro Leu Gly Phe Ser Leu Gln Gln Arg Gln Ile Val 210 215 220 Phe Pro Ala Tyr Asp Met Asp Leu Gly Lys Tyr Ile Gly Gln Leu Ala 225 230 235 240 Ser Leu Arg Thr Thr Asn Pro Ser Val Ser Thr Ala Leu His Gln Cys 245 250 255 Phe Thr Glu Leu Ala Arg Ala Val Val Phe Leu Asn Thr Thr Cys Gly 260 265 270 Ile Ser His Leu Asp Ile Lys Cys Ala Asn Ile Leu Val Met Leu Arg 275 280 285 Ser Asp Ala Val Ser Leu Arg Arg Ala Val Leu Ala Asp Phe Ser Leu 290 295 300 Val Thr Leu Asn Ser Asn Ser Thr Ile Ala Arg Gly Gln Phe Cys Leu 305 310 315 320 Gln Glu Pro Asp Leu Lys Ser Pro Arg Met Phe Gly Met Pro Thr Ala 325 330 335 Leu Thr Thr Ala Asn Phe His Thr Leu Val Gly His Gly Tyr Asn Gln 340 345 350 Pro Pro Glu Leu Leu Val Lys Tyr Leu Asn Asn Glu Arg Ala Glu Phe 355 360 365 Thr Asn His Arg Leu Lys His Asp Val Gly Leu Ala Val Asp Leu Tyr 370 375 380 Ala Leu Gly Gln Thr Leu Leu Glu Leu Val Val Ser Val Tyr Val Ala 385 390 395 400 Pro Ser Leu Gly Val Pro Val Thr Arg Phe Pro Gly Tyr Gln Tyr Phe 405 410 415 Asn Asn Gln Leu Ser Pro Asp Phe Ala Leu Ala Leu Leu Ala Tyr Arg 420 425 430 Cys Val Leu His Pro Ala Leu Phe Val Asn Ser Ala Glu Thr Asn Thr 435 440 445 His Gly Leu Ala Tyr Asp Val Pro Glu Gly Ile Arg Arg His Leu Arg 450 455 460 Asn Pro Lys Ile Arg Arg Ala Phe Thr Asp Arg Cys Ile Asn Tyr Gln 465 470 475 480 His Thr His Lys Ala Ile Leu Ser Ser Val Ala Leu Pro Pro Glu Leu 485 490 495 Lys Pro Leu Leu Val Leu Val Ser Arg Leu Cys His Thr Asn Pro Cys 500 505 510 Ala Arg His Ala Leu Ser 515 25 312 DNA Herpes Virus 25 cagcagtacc tggagcgcct cgagaaacag aggcaactta aggtgggcgc ggacgaggcg 60 tcggcgggcc tcaccatggg cggcgatgcc ctacgagtgc cctttttaga tttcgcgacc 120 gcgaccccca agcgccacca gaccgtggtc cctggcgtcg ggacgctcca cgactgctgc 180 gagcactcgc cgctcttctc ggccgtggcg cggcggctgc tgtttaatag cctggtgccg 240 gcgcaactaa aggggcgtga tttcgggggc gaccacacgg ccaagctgga attcctggcc 300 cccgagttgg ta 312 26 104 PRT Herpes Virus 26 Gln Gln Tyr Leu Glu Arg Leu Glu Lys Gln Arg Gln Leu Lys Val Gly 1 5 10 15 Ala Asp Glu Ala Ser Ala Gly Leu Thr Met Gly Gly Asp Ala Leu Arg 20 25 30 Val Pro Phe Leu Asp Phe Ala Thr Ala Thr Pro Lys Arg His Gln Thr 35 40 45 Val Val Pro Gly Val Gly Thr Leu His Asp Cys Cys Glu His Ser Pro 50 55 60 Leu Phe Ser Ala Val Ala Arg Arg Leu Leu Phe Asn Ser Leu Val Pro 65 70 75 80 Ala Gln Leu Lys Gly Arg Asp Phe Gly Gly Asp His Thr Ala Lys Leu 85 90 95 Glu Phe Leu Ala Pro Glu Leu Val 100 27 2208 DNA Herpes Virus 27 atgtttggtc agcagctggc gtccgacgtc cagcagtacc tggagcgcct cgagaaacag 60 aggcaactta aggtgggcgc ggacgaggcg tcggcgggcc tcaccatggg cggcgatgcc 120 ctacgagtgc cctttttaga tttcgcgacc gcgaccccca agcgccacca gaccgtggtc 180 cctggcgtcg ggacgctcca cgactgctgc gagcactcgc cgctcttctc ggccgtggcg 240 cggcggctgc tgtttaatag cctggtgccg gcgcaactaa aggggcgtga tttcgggggc 300 gaccacacgg ccaagctgga attcctggcc cccgagttgg tacgggcggt ggcgcgactg 360 cggtttaagg agtgcgcgcc ggcggacgtg gtgcctcagc gtaacgccta ctatagcgtt 420 ctgaatacgt ttcaggccct ccaccgctcc gaagcctttc gccagctggt gcactttgtg 480 cgggactttg cccagctgct caaaacctcc ttccgggcct ccagcctcac ggagaccacg 540 ggccccccca aaaaacgggc caaggtggac gtggccaccc acggccggac gtacggcacg 600 ctggagctgt tccaaaaaat gatccttatg cacgccacct actttctggc cgccgtgctc 660 ctcggggacc acgcggagca ggtcaacacg ttcctgcgtc tcgtgtttga gatccccctg 720 tttagcgacg cggccgtgcg ccacttccgc cagcgcgcca ccgtgtttct cgtcccccgg 780 cgccacggca agacctggtt tctggtgccc ctcatcgcgc tgtcgctggc ctcctttcgg 840 gggatcaaga tcggctacac ggcgcacatc cgcaaggcga ccgagccggt gtttgaggag 900 atcgacgcct gcctgcgggg ctggttcggt tcggcccgag tggaccacgt taaaggggaa 960 accatctcct tctcgtttcc ggacgggtcg cgcagtacca tcgtgtttgc ctccagccac 1020 aacacaaacg gaatccgagg ccaggacttt aacctgctct ttgtcgacga ggccaacttt 1080 attcgcccgg atgcggtcca gacgattatg ggctttctca accaggccaa ctgcaagatt 1140 atcttcgtgt cgtccaccaa caccgggaag gccagtacga gctttttgta caacctccgc 1200 ggggccgcag acgagcttct caacgtggtg acctatatat gcgatgatca catgccgagg 1260 gtggtgacgc acacaaacgc cacggcctgt tcttgttata tcctcaacaa gcccgttttc 1320 atcacgatgg acggggcggt tcgccggacc gccgatttgt ttctggccga ttccttcatg 1380 caggagatca tcgggggcca ggccagggag accggcgacg accggcccgt tctgaccaag 1440 tctgcggggg agcggtttct gttgtaccgc ccctcgacca ccaccaacag cggcctcatg 1500 gcccccgatt tgtacgtgta cgtggatccc gcgttcacgg ccaacacccg agcctccggg 1560 accggcgtcg ctgtcgtcgg gcggtaccgc gacgattata tcatcttcgc cctggagcac 1620 ttttttctcc gcgcgctcac gggctcggcc cccgccgaca tcgcccgctg cgtcgtccac 1680 agtctgacgc aggtcctggc cctgcatccc ggggcgtttc gcggcgtccg ggtggcggtc 1740 gagggaaata gcagccagga ctcggccgtc gccatcgcca cgcacgtgca cacagagatg 1800 caccgcctac tggcctcgga gggggccgac gcgggctcgg gccccgagct tctcttctac 1860 cactgcgagc ctcccgggag cgcggtgctg tacccctttt tcctgctcaa caaacagaag 1920 acgcccgcct ttgaacactt tattaaaaag tttaactccg ggggcgtcat ggcctcccag 1980 gagatcgttt ccgcgacggt gcgcctgcag accgacccgg tcgagtatct gctcgagcag 2040 ctaaataacc tcaccgaaac cgtctccccc aacactgacg tccgtacgta ttccggaaaa 2100 cggaacggcg cctcggatga ccttatggtc gccgtcatta tggccatcta cctcgcggcc 2160 caggccggac ctccgcacac attcgctcct atcacacgcg tctcgtga 2208 28 735 PRT Herpes Virus 28 Met Phe Gly Gln Gln Leu Ala Ser Asp Val Gln Gln Tyr Leu Glu Arg 1 5 10 15 Leu Glu Lys Gln Arg Gln Leu Lys Val Gly Ala Asp Glu Ala Ser Ala 20 25 30 Gly Leu Thr Met Gly Gly Asp Ala Leu Arg Val Pro Phe Leu Asp Phe 35 40 45 Ala Thr Ala Thr Pro Lys Arg His Gln Thr Val Val Pro Gly Val Gly 50 55 60 Thr Leu His Asp Cys Cys Glu His Ser Pro Leu Phe Ser Ala Val Ala 65 70 75 80 Arg Arg Leu Leu Phe Asn Ser Leu Val Pro Ala Gln Leu Lys Gly Arg 85 90 95 Asp Phe Gly Gly Asp His Thr Ala Lys Leu Glu Phe Leu Ala Pro Glu 100 105 110 Leu Val Arg Ala Val Ala Arg Leu Arg Phe Lys Glu Cys Ala Pro Ala 115 120 125 Asp Val Val Pro Gln Arg Asn Ala Tyr Tyr Ser Val Leu Asn Thr Phe 130 135 140 Gln Ala Leu His Arg Ser Glu Ala Phe Arg Gln Leu Val His Phe Val 145 150 155 160 Arg Asp Phe Ala Gln Leu Leu Lys Thr Ser Phe Arg Ala Ser Ser Leu 165 170 175 Thr Glu Thr Thr Gly Pro Pro Lys Lys Arg Ala Lys Val Asp Val Ala 180 185 190 Thr His Gly Arg Thr Tyr Gly Thr Leu Glu Leu Phe Gln Lys Met Ile 195 200 205 Leu Met His Ala Thr Tyr Phe Leu Ala Ala Val Leu Leu Gly Asp His 210 215 220 Ala Glu Gln Val Asn Thr Phe Leu Arg Leu Val Phe Glu Ile Pro Leu 225 230 235 240 Phe Ser Asp Ala Ala Val Arg His Phe Arg Gln Arg Ala Thr Val Phe 245 250 255 Leu Val Pro Arg Arg His Gly Lys Thr Trp Phe Leu Val Pro Leu Ile 260 265 270 Ala Leu Ser Leu Ala Ser Phe Arg Gly Ile Lys Ile Gly Tyr Thr Ala 275 280 285 His Ile Arg Lys Ala Thr Glu Pro Val Phe Glu Glu Ile Asp Ala Cys 290 295 300 Leu Arg Gly Trp Phe Gly Ser Ala Arg Val Asp His Val Lys Gly Glu 305 310 315 320 Thr Ile Ser Phe Ser Phe Pro Asp Gly Ser Arg Ser Thr Ile Val Phe 325 330 335 Ala Ser Ser His Asn Thr Asn Gly Ile Arg Gly Gln Asp Phe Asn Leu 340 345 350 Leu Phe Val Asp Glu Ala Asn Phe Ile Arg Pro Asp Ala Val Gln Thr 355 360 365 Ile Met Gly Phe Leu Asn Gln Ala Asn Cys Lys Ile Ile Phe Val Ser 370 375 380 Ser Thr Asn Thr Gly Lys Ala Ser Thr Ser Phe Leu Tyr Asn Leu Arg 385 390 395 400 Gly Ala Ala Asp Glu Leu Leu Asn Val Val Thr Tyr Ile Cys Asp Asp 405 410 415 His Met Pro Arg Val Val Thr His Thr Asn Ala Thr Ala Cys Ser Cys 420 425 430 Tyr Ile Leu Asn Lys Pro Val Phe Ile Thr Met Asp Gly Ala Val Arg 435 440 445 Arg Thr Ala Asp Leu Phe Leu Ala Asp Ser Phe Met Gln Glu Ile Ile 450 455 460 Gly Gly Gln Ala Arg Glu Thr Gly Asp Asp Arg Pro Val Leu Thr Lys 465 470 475 480 Ser Ala Gly Glu Arg Phe Leu Leu Tyr Arg Pro Ser Thr Thr Thr Asn 485 490 495 Ser Gly Leu Met Ala Pro Asp Leu Tyr Val Tyr Val Asp Pro Ala Phe 500 505 510 Thr Ala Asn Thr Arg Ala Ser Gly Thr Gly Val Ala Val Val Gly Arg 515 520 525 Tyr Arg Asp Asp Tyr Ile Ile Phe Ala Leu Glu His Phe Phe Leu Arg 530 535 540 Ala Leu Thr Gly Ser Ala Pro Ala Asp Ile Ala Arg Cys Val Val His 545 550 555 560 Ser Leu Thr Gln Val Leu Ala Leu His Pro Gly Ala Phe Arg Gly Val 565 570 575 Arg Val Ala Val Glu Gly Asn Ser Ser Gln Asp Ser Ala Val Ala Ile 580 585 590 Ala Thr His Val His Thr Glu Met His Arg Leu Leu Ala Ser Glu Gly 595 600 605 Ala Asp Ala Gly Ser Gly Pro Glu Leu Leu Phe Tyr His Cys Glu Pro 610 615 620 Pro Gly Ser Ala Val Leu Tyr Pro Phe Phe Leu Leu Asn Lys Gln Lys 625 630 635 640 Thr Pro Ala Phe Glu His Phe Ile Lys Lys Phe Asn Ser Gly Gly Val 645 650 655 Met Ala Ser Gln Glu Ile Val Ser Ala Thr Val Arg Leu Gln Thr Asp 660 665 670 Pro Val Glu Tyr Leu Leu Glu Gln Leu Asn Asn Leu Thr Glu Thr Val 675 680 685 Ser Pro Asn Thr Asp Val Arg Thr Tyr Ser Gly Lys Arg Asn Gly Ala 690 695 700 Ser Asp Asp Leu Met Val Ala Val Ile Met Ala Ile Tyr Leu Ala Ala 705 710 715 720 Gln Ala Gly Pro Pro His Thr Phe Ala Pro Ile Thr Arg Val Ser 725 730 735 29 312 DNA Herpes Virus 29 aacgcactgt ggctctcctc cgtcgtaacg gagtcctgtc cctgcgtcgc cccgtgtctg 60 tgggccaaga tggcccagtg taccctggcg gtccaggggg atgctagcct gtgtccgctt 120 ctctttggcc atcccgtgga tacggtcacc ctgctgcagg ccccccgccg tccttgcatc 180 acggaccgtc tgcaagaggt cgtcggggga cggtgcggcg cggacaacat ccccccgacc 240 agcgccgggt ggcgcctgtg tgtcttctct tcgtacatca gtcgcctatt tgctacgagt 300 tgccccaccg tt 312 30 104 PRT Herpes Virus 30 Asn Ala Leu Trp Leu Ser Ser Val Val Thr Glu Ser Cys Pro Cys Val 1 5 10 15 Ala Pro Cys Leu Trp Ala Lys Met Ala Gln Cys Thr Leu Ala Val Gln 20 25 30 Gly Asp Ala Ser Leu Cys Pro Leu Leu Phe Gly His Pro Val Asp Thr 35 40 45 Val Thr Leu Leu Gln Ala Pro Arg Arg Pro Cys Ile Thr Asp Arg Leu 50 55 60 Gln Glu Val Val Gly Gly Arg Cys Gly Ala Asp Asn Ile Pro Pro Thr 65 70 75 80 Ser Ala Gly Trp Arg Leu Cys Val Phe Ser Ser Tyr Ile Ser Arg Leu 85 90 95 Phe Ala Thr Ser Cys Pro Thr Val 100 31 1122 DNA Herpes Virus 31 atggcgcagc tgggaccccg gcggcccctg gcgccgcctg gtcccccggg gaccttgccc 60 cggccggatt cccgggccgg agctcgcggc acgcgcgata gagtcgacga cctggggacg 120 gacgtcgact ctatcgcgcg cattgtcaac tccgtctttg tgtggcgcgt cgttcgggcg 180 gacgagcggc tcaagatctt tcggtgtcta acggtcctca ccgagcctct gtgtcaggtg 240 gcccttccta acccagaccc cgggcgcgcc ctcttctgcg agatttttct gtatctgacg 300 cgccccaagg cgctgcggtt gcccccgaac accttctttg ccctcttttt ctttaaccgc 360 gagcgccgct actgcgcgat cgtccacctc cggagcgtga cgcaccccct gaccccgctc 420 ctgtgcaccc tcacgttcgc acgcatacgg gcggccaccc ccccggagga aacccccgac 480 ccaaccaccg aacagctcgc ggaggagcca gtggtcggcg agctggatgg cgcgtatctg 540 gtccccgcga agaccccccc ggagccgggc gcgtgctgcg ccttgggccc gggggcctgg 600 tggcacctcc ccagcggcca gatctactgc tgggccatgg acagcgacct ggggtcgctc 660 tgtccaccgg gaagcagggc ccgccatctg ggatggctcc tggccaggat caccaaccac 720 ccggggggct gcgagtcctg cgccccgccg ccccacatcg attccgccaa cgcactgtgg 780 ctctcctccg tcgtaacgga gtcctgtccc tgcgtcgccc cgtgtctgtg ggccaagatg 840 gcccagtgta ccctggcggt ccagggggat gctagcctgt gtccgcttct ctttggccat 900 cccgtggata cggtcaccct gctgcaggcc ccccgccgtc cttgcatcac ggaccgtctg 960 caagaggtcg tcgggggacg gtgcggcgcg gacaacatcc ccccgaccag cgccgggtgg 1020 cgcctgtgtg tcttctcttc gtacatcagt cgcctatttg ctacgagttg ccccaccgtt 1080 gcccgggccg ttgcccgggc ctcctcaagc gatcccgaat aa 1122 32 373 PRT Herpes Virus 32 Met Ala Gln Leu Gly Pro Arg Arg Pro Leu Ala Pro Pro Gly Pro Pro 1 5 10 15 Gly Thr Leu Pro Arg Pro Asp Ser Arg Ala Gly Ala Arg Gly Thr Arg 20 25 30 Asp Arg Val Asp Asp Leu Gly Thr Asp Val Asp Ser Ile Ala Arg Ile 35 40 45 Val Asn Ser Val Phe Val Trp Arg Val Val Arg Ala Asp Glu Arg Leu 50 55 60 Lys Ile Phe Arg Cys Leu Thr Val Leu Thr Glu Pro Leu Cys Gln Val 65 70 75 80 Ala Leu Pro Asn Pro Asp Pro Gly Arg Ala Leu Phe Cys Glu Ile Phe 85 90 95 Leu Tyr Leu Thr Arg Pro Lys Ala Leu Arg Leu Pro Pro Asn Thr Phe 100 105 110 Phe Ala Leu Phe Phe Phe Asn Arg Glu Arg Arg Tyr Cys Ala Ile Val 115 120 125 His Leu Arg Ser Val Thr His Pro Leu Thr Pro Leu Leu Cys Thr Leu 130 135 140 Thr Phe Ala Arg Ile Arg Ala Ala Thr Pro Pro Glu Glu Thr Pro Asp 145 150 155 160 Pro Thr Thr Glu Gln Leu Ala Glu Glu Pro Val Val Gly Glu Leu Asp 165 170 175 Gly Ala Tyr Leu Val Pro Ala Lys Thr Pro Pro Glu Pro Gly Ala Cys 180 185 190 Cys Ala Leu Gly Pro Gly Ala Trp Trp His Leu Pro Ser Gly Gln Ile 195 200 205 Tyr Cys Trp Ala Met Asp Ser Asp Leu Gly Ser Leu Cys Pro Pro Gly 210 215 220 Ser Arg Ala Arg His Leu Gly Trp Leu Leu Ala Arg Ile Thr Asn His 225 230 235 240 Pro Gly Gly Cys Glu Ser Cys Ala Pro Pro Pro His Ile Asp Ser Ala 245 250 255 Asn Ala Leu Trp Leu Ser Ser Val Val Thr Glu Ser Cys Pro Cys Val 260 265 270 Ala Pro Cys Leu Trp Ala Lys Met Ala Gln Cys Thr Leu Ala Val Gln 275 280 285 Gly Asp Ala Ser Leu Cys Pro Leu Leu Phe Gly His Pro Val Asp Thr 290 295 300 Val Thr Leu Leu Gln Ala Pro Arg Arg Pro Cys Ile Thr Asp Arg Leu 305 310 315 320 Gln Glu Val Val Gly Gly Arg Cys Gly Ala Asp Asn Ile Pro Pro Thr 325 330 335 Ser Ala Gly Trp Arg Leu Cys Val Phe Ser Ser Tyr Ile Ser Arg Leu 340 345 350 Phe Ala Thr Ser Cys Pro Thr Val Ala Arg Ala Val Ala Arg Ala Ser 355 360 365 Ser Ser Asp Pro Glu 370 33 1425 DNA Herpes Virus 33 tggttggggg aggtgaccag gcgcttcccc attctcctcg agaacctgat gcgcgccgtc 60 gaggggaccg cccccgacgc cttttttcac accgcgtatg ccctggccgt cctggcacac 120 ctggggggac ggggcggtcg ggggcggcgg gtcgtcccgc tcggcgacga cctcccggcc 180 cgctttgccg actccgacgg ccattacgtt tttgactact acagcacaag cggagacacg 240 ctgcggctta acaatcgtcc aatcgccgtg gcgatggatg gtgacgtcag taaacgcgag 300 cagagtaaat gtcgcttcat ggaggccgtc ccctccacag ccccacgcag ggtctgcgag 360 caatacctgc ccggggaaag ctacgcctac ctctgcctgg ggtttaatcg ccgcctctgt 420 ggcatagttg tctttcccgg cggctttgcg ttcaccatta acatcgcggc ctaccttagc 480 ctctcggacc ccgtcgcgcg ggccgctgtc cttaggtttt gtcgcaaggt gtcgtccggg 540 aacggccggt ctcgctagcg ggcgccttcc cccggccacc tcgcccaccc actcctcccc 600 gcgccgttgg cccccgcctc tggggtttgc cctccccccg cccccggcat ggcgcagctg 660 ggaccccggc ggcccctggc gccgcctggt cccccgggga ccttgccccg gccggattcc 720 cgggccggag ctcgcggcac gcgcgataga gtcgacgacc tggggacgga cgtcgactct 780 atcgcgcgca ttgtcaactc cgtctttgtg tggcgcgtcg ttcgggcgga cgagcggctc 840 aagatctttc ggtgtctaac ggtcctcacc gagcctctgt gtcaggtggc ccttcctaac 900 ccagaccccg ggcgcgccct cttctgcgag atttttctgt atctgacgcg ccccaaggcg 960 ctgcggttgc ccccgaacac cttctttgcc ctctttttct ttaaccgcga gcgccgctac 1020 tgcgcgatcg tccacctccg gagcgtgacg caccccctga ccccgctcct gtgcaccctc 1080 acgttcgcac gcatacgggc ggccaccccc ccggaggaaa cccccgaccc aaccaccgaa 1140 cagctcgcgg aggagccagt ggtcggcgag ctggatggcg cgtatctggt ccccgcgaag 1200 acccccccgg agccgggcgc gtgctgcgcc ttgggcccgg gggcctggtg gcacctcccc 1260 agcggccaga tctactgctg ggccatggac agcgacctgg ggtcgctctg tccaccggga 1320 agcagggccc gccatctggg atggctcctg gccaggatca ccaaccaccc ggggggctgc 1380 gagtcctgcg ccccgccgcc ccacatcgat tccgccaacg cactg 1425 34 185 PRT Herpes Virus 34 Trp Leu Gly Glu Val Thr Arg Arg Phe Pro Ile Leu Leu Glu Asn Leu 1 5 10 15 Met Arg Ala Val Glu Gly Thr Ala Pro Asp Ala Phe Phe His Thr Ala 20 25 30 Tyr Ala Leu Ala Val Leu Ala His Leu Gly Gly Arg Gly Gly Arg Gly 35 40 45 Arg Arg Val Val Pro Leu Gly Asp Asp Leu Pro Ala Arg Phe Ala Asp 50 55 60 Ser Asp Gly His Tyr Val Phe Asp Tyr Tyr Ser Thr Ser Gly Asp Thr 65 70 75 80 Leu Arg Leu Asn Asn Arg Pro Ile Ala Val Ala Met Asp Gly Asp Val 85 90 95 Ser Lys Arg Glu Gln Ser Lys Cys Arg Phe Met Glu Ala Val Pro Ser 100 105 110 Thr Ala Pro Arg Arg Val Cys Glu Gln Tyr Leu Pro Gly Glu Ser Tyr 115 120 125 Ala Tyr Leu Cys Leu Gly Phe Asn Arg Arg Leu Cys Gly Ile Val Val 130 135 140 Phe Pro Gly Gly Phe Ala Phe Thr Ile Asn Ile Ala Ala Tyr Leu Ser 145 150 155 160 Leu Ser Asp Pro Val Ala Arg Ala Ala Val Leu Arg Phe Cys Arg Lys 165 170 175 Val Ser Ser Gly Asn Gly Arg Ser Arg 180 185 35 1068 DNA Herpes Virus 35 gccaacgagg tccagacgat ctcggccacg gcccgggtcg gccctcggtc tttggttcac 60 gtcatcatat ccagcgagtg cctggcggcc gcgggaatcc ctctggccgc cctgatgcgc 120 ggccgccccg gactcgggac ggccgcaaac ttccaggtcg aaatccagac tcgggctcat 180 gccaccggcg actgtacccc gtggtgcacg gcgtttgccg cctacgtgcc cgcggatgcg 240 gtgggggagc ttctggcccc cgtcgtgccg gcacaccctg gcctccttcc gcgtgcgtcc 300 agcgccgggg ggttgttcgt ctccctgccc gtggtgtgtg acgcgcaggg cgtctatgac 360 ccgtacgccg tggcggcgct gcgccttgcg tggggctcgg gggcgagctg tgcccgcgtg 420 attctgttta gttacgacga gctcgtcccc cccaacacgc gctacgcggc cgacagcacg 480 cgcatcatgc gcgtctgtcg gcatttgtgc cgctacgtcg ctctgcttgg cgccgccgcc 540 ccgccggccg cgaaggaggc tgcggcccac ctgtccatgg gtctggggga aagcgcgtcc 600 ccgcgtccgc agcccttggc ccggccccac gcgggggcgc ccgcagaccc gcccatcgtc 660 ggggcgtccg acccccccat ctccccggag gagcagctga cggcccccgg cggcgacacg 720 accgcggccc aggacgtgtc catcgcacag gagaacgagg agatcctcgc gttggttcag 780 cgggcagtgc aggacgtcac ccgccgccac ccggtccgag cgcggaccgg gcgtgcggcc 840 tgtggcgttg catcggggct acgccagggc gccctggttc accaggccgt cagcgggggc 900 gccatggggg cggctgacgc agatgcggtg ctggcgggtc tggagccccc cggcgggggc 960 cgctttgtgg ccccagcgcc ccacgggccc gggggcgagg acatcctgaa cgacgttcta 1020 acccttaccc ctggtaccgc aaagccgcgg tcgctggtcg agtggttg 1068 36 356 PRT Herpes Virus 36 Ala Asn Glu Val Gln Thr Ile Ser Ala Thr Ala Arg Val Gly Pro Arg 1 5 10 15 Ser Leu Val His Val Ile Ile Ser Ser Glu Cys Leu Ala Ala Ala Gly 20 25 30 Ile Pro Leu Ala Ala Leu Met Arg Gly Arg Pro Gly Leu Gly Thr Ala 35 40 45 Ala Asn Phe Gln Val Glu Ile Gln Thr Arg Ala His Ala Thr Gly Asp 50 55 60 Cys Thr Pro Trp Cys Thr Ala Phe Ala Ala Tyr Val Pro Ala Asp Ala 65 70 75 80 Val Gly Glu Leu Leu Ala Pro Val Val Pro Ala His Pro Gly Leu Leu 85 90 95 Pro Arg Ala Ser Ser Ala Gly Gly Leu Phe Val Ser Leu Pro Val Val 100 105 110 Cys Asp Ala Gln Gly Val Tyr Asp Pro Tyr Ala Val Ala Ala Leu Arg 115 120 125 Leu Ala Trp Gly Ser Gly Ala Ser Cys Ala Arg Val Ile Leu Phe Ser 130 135 140 Tyr Asp Glu Leu Val Pro Pro Asn Thr Arg Tyr Ala Ala Asp Ser Thr 145 150 155 160 Arg Ile Met Arg Val Cys Arg His Leu Cys Arg Tyr Val Ala Leu Leu 165 170 175 Gly Ala Ala Ala Pro Pro Ala Ala Lys Glu Ala Ala Ala His Leu Ser 180 185 190 Met Gly Leu Gly Glu Ser Ala Ser Pro Arg Pro Gln Pro Leu Ala Arg 195 200 205 Pro His Ala Gly Ala Pro Ala Asp Pro Pro Ile Val Gly Ala Ser Asp 210 215 220 Pro Pro Ile Ser Pro Glu Glu Gln Leu Thr Ala Pro Gly Gly Asp Thr 225 230 235 240 Thr Ala Ala Gln Asp Val Ser Ile Ala Gln Glu Asn Glu Glu Ile Leu 245 250 255 Ala Leu Val Gln Arg Ala Val Gln Asp Val Thr Arg Arg His Pro Val 260 265 270 Arg Ala Arg Thr Gly Arg Ala Ala Cys Gly Val Ala Ser Gly Leu Arg 275 280 285 Gln Gly Ala Leu Val His Gln Ala Val Ser Gly Gly Ala Met Gly Ala 290 295 300 Ala Asp Ala Asp Ala Val Leu Ala Gly Leu Glu Pro Pro Gly Gly Gly 305 310 315 320 Arg Phe Val Ala Pro Ala Pro His Gly Pro Gly Gly Glu Asp Ile Leu 325 330 335 Asn Asp Val Leu Thr Leu Thr Pro Gly Thr Ala Lys Pro Arg Ser Leu 340 345 350 Val Glu Trp Leu 355 37 1056 DNA Herpes Virus 37 gttctaaccc ttacccctgg taccgcaaag ccgcggtcgc tggtcgagtg gttggatcgc 60 ggatgggaag ccctggccgg cggcgaccgg ccggactggc tgtggagccg tcgttctatc 120 tccgtggtcc tgcgccacca ctacggaacc aagcagcgct tcgtcgtcgt ctcctacgag 180 aactccgtgg cgtggggcgg gcgacgcgcc cgccctccgc tgctgtcctc ggcgctggcc 240 acggccctga ccgaggcctg cgccgcagaa cgcgtcgtgc gcccccacca gctgtctccc 300 gctgggcagg cggagctgct gctacgcttt cccgcgctcg aggtgcccct gcgccacccg 360 cgccccgtcc tgccgccctt tgacatcgcc gccgaggtcg cctttaccgc gcgcatacat 420 ctggcgtgcc tccgggccct gggccaggcc atccgggccg cgcttcaggg cggcccgcga 480 atctcacagc gcctgcgcta tgactttggc cccgaccaac gcgcgtggtt gggggaggtg 540 accaggcgct tccccattct cctcgagaac ctgatgcgcg ccgtcgaggg gaccgccccc 600 gacgcctttt ttcacaccgc gtatgccctg gccgtcctgg cacacctggg gggacggggc 660 ggtcgggggc ggcgggtcgt cccgctcggc gacgacctcc cggcccgctt tgccgactcc 720 gacggccatt acgtttttga ctactacagc acaagcggag acacgctgcg gcttaacaat 780 cgtccaatcg ccgtggcgat ggatggtgac gtcagtaaac gcgagcagag taaatgtcgc 840 ttcatggagg ccgtcccctc cacagcccca cgcagggtct gcgagcaata cctgcccggg 900 gaaagctacg cctacctctg cctggggttt aatcgccgcc tctgtggcat agttgtcttt 960 cccggcggct ttgcgttcac cattaacatc gcggcctacc ttagcctctc ggaccccgtc 1020 gcgcgggccg ctgtccttag gttttgtcgc aaggtg 1056 38 352 PRT Herpes Virus 38 Val Leu Thr Leu Thr Pro Gly Thr Ala Lys Pro Arg Ser Leu Val Glu 1 5 10 15 Trp Leu Asp Arg Gly Trp Glu Ala Leu Ala Gly Gly Asp Arg Pro Asp 20 25 30 Trp Leu Trp Ser Arg Arg Ser Ile Ser Val Val Leu Arg His His Tyr 35 40 45 Gly Thr Lys Gln Arg Phe Val Val Val Ser Tyr Glu Asn Ser Val Ala 50 55 60 Trp Gly Gly Arg Arg Ala Arg Pro Pro Leu Leu Ser Ser Ala Leu Ala 65 70 75 80 Thr Ala Leu Thr Glu Ala Cys Ala Ala Glu Arg Val Val Arg Pro His 85 90 95 Gln Leu Ser Pro Ala Gly Gln Ala Glu Leu Leu Leu Arg Phe Pro Ala 100 105 110 Leu Glu Val Pro Leu Arg His Pro Arg Pro Val Leu Pro Pro Phe Asp 115 120 125 Ile Ala Ala Glu Val Ala Phe Thr Ala Arg Ile His Leu Ala Cys Leu 130 135 140 Arg Ala Leu Gly Gln Ala Ile Arg Ala Ala Leu Gln Gly Gly Pro Arg 145 150 155 160 Ile Ser Gln Arg Leu Arg Tyr Asp Phe Gly Pro Asp Gln Arg Ala Trp 165 170 175 Leu Gly Glu Val Thr Arg Arg Phe Pro Ile Leu Leu Glu Asn Leu Met 180 185 190 Arg Ala Val Glu Gly Thr Ala Pro Asp Ala Phe Phe His Thr Ala Tyr 195 200 205 Ala Leu Ala Val Leu Ala His Leu Gly Gly Arg Gly Gly Arg Gly Arg 210 215 220 Arg Val Val Pro Leu Gly Asp Asp Leu Pro Ala Arg Phe Ala Asp Ser 225 230 235 240 Asp Gly His Tyr Val Phe Asp Tyr Tyr Ser Thr Ser Gly Asp Thr Leu 245 250 255 Arg Leu Asn Asn Arg Pro Ile Ala Val Ala Met Asp Gly Asp Val Ser 260 265 270 Lys Arg Glu Gln Ser Lys Cys Arg Phe Met Glu Ala Val Pro Ser Thr 275 280 285 Ala Pro Arg Arg Val Cys Glu Gln Tyr Leu Pro Gly Glu Ser Tyr Ala 290 295 300 Tyr Leu Cys Leu Gly Phe Asn Arg Arg Leu Cys Gly Ile Val Val Phe 305 310 315 320 Pro Gly Gly Phe Ala Phe Thr Ile Asn Ile Ala Ala Tyr Leu Ser Leu 325 330 335 Ser Asp Pro Val Ala Arg Ala Ala Val Leu Arg Phe Cys Arg Lys Val 340 345 350 39 2112 DNA Herpes Virus 39 atgaacgcgc acttggccaa cgaggtccag acgatctcgg ccacggcccg ggtcggccct 60 cggtctttgg ttcacgtcat catatccagc gagtgcctgg cggccgcggg aatccctctg 120 gccgccctga tgcgcggccg ccccggactc gggacggccg caaacttcca ggtcgaaatc 180 cagactcggg ctcatgccac cggcgactgt accccgtggt gcacggcgtt tgccgcctac 240 gtgcccgcgg atgcggtggg ggagcttctg gcccccgtcg tgccggcaca ccctggcctc 300 cttccgcgtg cgtccagcgc cggggggttg ttcgtctccc tgcccgtggt gtgtgacgcg 360 cagggcgtct atgacccgta cgccgtggcg gcgctgcgcc ttgcgtgggg ctcgggggcg 420 agctgtgccc gcgtgattct gtttagttac gacgagctcg tcccccccaa cacgcgctac 480 gcggccgaca gcacgcgcat catgcgcgtc tgtcggcatt tgtgccgcta cgtcgctctg 540 cttggcgccg ccgccccgcc ggccgcgaag gaggctgcgg cccacctgtc catgggtctg 600 ggggaaagcg cgtccccgcg tccgcagccc ttggcccggc cccacgcggg ggcgcccgca 660 gacccgccca tcgtcggggc gtccgacccc cccatctccc cggaggagca gctgacggcc 720 cccggcggcg acacgaccgc ggcccaggac gtgtccatcg cacaggagaa cgaggagatc 780 ctcgcgttgg ttcagcgggc agtgcaggac gtcacccgcc gccacccggt ccgagcgcgg 840 accgggcgtg cggcctgtgg cgttgcatcg gggctacgcc agggcgccct ggttcaccag 900 gccgtcagcg ggggcgccat gggggcggct gacgcagatg cggtgctggc gggtctggag 960 ccccccggcg ggggccgctt tgtggcccca gcgccccacg ggcccggggg cgaggacatc 1020 ctgaacgacg ttctaaccct tacccctggt accgcaaagc cgcggtcgct ggtcgagtgg 1080 ttggatcgcg gatgggaagc cctggccggc ggcgaccggc cggactggct gtggagccgt 1140 cgttctatct ccgtggtcct gcgccaccac tacggaacca agcagcgctt cgtcgtcgtc 1200 tcctacgaga actccgtggc gtggggcggg cgacgcgccc gccctccgct gctgtcctcg 1260 gcgctggcca cggccctgac cgaggcctgc gccgcagaac gcgtcgtgcg cccccaccag 1320 ctgtctcccg ctgggcaggc ggagctgctg ctacgctttc ccgcgctcga ggtgcccctg 1380 cgccacccgc gccccgtcct gccgcccttt gacatcgccg ccgaggtcgc ctttaccgcg 1440 cgcatacatc tggcgtgcct ccgggccctg ggccaggcca tccgggccgc gcttcagggc 1500 ggcccgcgaa tctcacagcg cctgcgctat gactttggcc ccgaccaacg cgcgtggttg 1560 ggggaggtga ccaggcgctt ccccattctc ctcgagaacc tgatgcgcgc cgtcgagggg 1620 accgcccccg acgccttttt tcacaccgcg tatgccctgg ccgtcctggc acacctgggg 1680 ggacggggcg gtcgggggcg gcgggtcgtc ccgctcggcg acgacctccc ggcccgcttt 1740 gccgactccg acggccatta cgtttttgac tactacagca caagcggaga cacgctgcgg 1800 cttaacaatc gtccaatcgc cgtggcgatg gatggtgacg tcagtaaacg cgagcagagt 1860 aaatgtcgct tcatggaggc cgtcccctcc acagccccac gcagggtctg cgagcaatac 1920 ctgcccgggg aaagctacgc ctacctctgc ctggggttta atcgccgcct ctgtggcata 1980 gttgtctttc ccggcggctt tgcgttcacc attaacatcg cggcctacct tagcctctcg 2040 gaccccgtcg cgcgggccgc tgtccttagg ttttgtcgca aggtgtcgtc cgggaacggc 2100 cggtctcgct ag 2112 40 703 PRT Herpes Virus 40 Met Asn Ala His Leu Ala Asn Glu Val Gln Thr Ile Ser Ala Thr Ala 1 5 10 15 Arg Val Gly Pro Arg Ser Leu Val His Val Ile Ile Ser Ser Glu Cys 20 25 30 Leu Ala Ala Ala Gly Ile Pro Leu Ala Ala Leu Met Arg Gly Arg Pro 35 40 45 Gly Leu Gly Thr Ala Ala Asn Phe Gln Val Glu Ile Gln Thr Arg Ala 50 55 60 His Ala Thr Gly Asp Cys Thr Pro Trp Cys Thr Ala Phe Ala Ala Tyr 65 70 75 80 Val Pro Ala Asp Ala Val Gly Glu Leu Leu Ala Pro Val Val Pro Ala 85 90 95 His Pro Gly Leu Leu Pro Arg Ala Ser Ser Ala Gly Gly Leu Phe Val 100 105 110 Ser Leu Pro Val Val Cys Asp Ala Gln Gly Val Tyr Asp Pro Tyr Ala 115 120 125 Val Ala Ala Leu Arg Leu Ala Trp Gly Ser Gly Ala Ser Cys Ala Arg 130 135 140 Val Ile Leu Phe Ser Tyr Asp Glu Leu Val Pro Pro Asn Thr Arg Tyr 145 150 155 160 Ala Ala Asp Ser Thr Arg Ile Met Arg Val Cys Arg His Leu Cys Arg 165 170 175 Tyr Val Ala Leu Leu Gly Ala Ala Ala Pro Pro Ala Ala Lys Glu Ala 180 185 190 Ala Ala His Leu Ser Met Gly Leu Gly Glu Ser Ala Ser Pro Arg Pro 195 200 205 Gln Pro Leu Ala Arg Pro His Ala Gly Ala Pro Ala Asp Pro Pro Ile 210 215 220 Val Gly Ala Ser Asp Pro Pro Ile Ser Pro Glu Glu Gln Leu Thr Ala 225 230 235 240 Pro Gly Gly Asp Thr Thr Ala Ala Gln Asp Val Ser Ile Ala Gln Glu 245 250 255 Asn Glu Glu Ile Leu Ala Leu Val Gln Arg Ala Val Gln Asp Val Thr 260 265 270 Arg Arg His Pro Val Arg Ala Arg Thr Gly Arg Ala Ala Cys Gly Val 275 280 285 Ala Ser Gly Leu Arg Gln Gly Ala Leu Val His Gln Ala Val Ser Gly 290 295 300 Gly Ala Met Gly Ala Ala Asp Ala Asp Ala Val Leu Ala Gly Leu Glu 305 310 315 320 Pro Pro Gly Gly Gly Arg Phe Val Ala Pro Ala Pro His Gly Pro Gly 325 330 335 Gly Glu Asp Ile Leu Asn Asp Val Leu Thr Leu Thr Pro Gly Thr Ala 340 345 350 Lys Pro Arg Ser Leu Val Glu Trp Leu Asp Arg Gly Trp Glu Ala Leu 355 360 365 Ala Gly Gly Asp Arg Pro Asp Trp Leu Trp Ser Arg Arg Ser Ile Ser 370 375 380 Val Val Leu Arg His His Tyr Gly Thr Lys Gln Arg Phe Val Val Val 385 390 395 400 Ser Tyr Glu Asn Ser Val Ala Trp Gly Gly Arg Arg Ala Arg Pro Pro 405 410 415 Leu Leu Ser Ser Ala Leu Ala Thr Ala Leu Thr Glu Ala Cys Ala Ala 420 425 430 Glu Arg Val Val Arg Pro His Gln Leu Ser Pro Ala Gly Gln Ala Glu 435 440 445 Leu Leu Leu Arg Phe Pro Ala Leu Glu Val Pro Leu Arg His Pro Arg 450 455 460 Pro Val Leu Pro Pro Phe Asp Ile Ala Ala Glu Val Ala Phe Thr Ala 465 470 475 480 Arg Ile His Leu Ala Cys Leu Arg Ala Leu Gly Gln Ala Ile Arg Ala 485 490 495 Ala Leu Gln Gly Gly Pro Arg Ile Ser Gln Arg Leu Arg Tyr Asp Phe 500 505 510 Gly Pro Asp Gln Arg Ala Trp Leu Gly Glu Val Thr Arg Arg Phe Pro 515 520 525 Ile Leu Leu Glu Asn Leu Met Arg Ala Val Glu Gly Thr Ala Pro Asp 530 535 540 Ala Phe Phe His Thr Ala Tyr Ala Leu Ala Val Leu Ala His Leu Gly 545 550 555 560 Gly Arg Gly Gly Arg Gly Arg Arg Val Val Pro Leu Gly Asp Asp Leu 565 570 575 Pro Ala Arg Phe Ala Asp Ser Asp Gly His Tyr Val Phe Asp Tyr Tyr 580 585 590 Ser Thr Ser Gly Asp Thr Leu Arg Leu Asn Asn Arg Pro Ile Ala Val 595 600 605 Ala Met Asp Gly Asp Val Ser Lys Arg Glu Gln Ser Lys Cys Arg Phe 610 615 620 Met Glu Ala Val Pro Ser Thr Ala Pro Arg Arg Val Cys Glu Gln Tyr 625 630 635 640 Leu Pro Gly Glu Ser Tyr Ala Tyr Leu Cys Leu Gly Phe Asn Arg Arg 645 650 655 Leu Cys Gly Ile Val Val Phe Pro Gly Gly Phe Ala Phe Thr Ile Asn 660 665 670 Ile Ala Ala Tyr Leu Ser Leu Ser Asp Pro Val Ala Arg Ala Ala Val 675 680 685 Leu Arg Phe Cys Arg Lys Val Ser Ser Gly Asn Gly Arg Ser Arg 690 695 700 41 942 DNA Herpes Virus 41 gacggctttg aaactgacat cgcgataccc tcgggcatct cgcgccccga tgcggcggcg 60 ctgcagcgct gcgaagggcg ggtggtattc ctgccgacca tccgccggca actgacgctg 120 gccgacgtgg cgcacgaatc cttcgtctcc ggaggcgtca gtcccgacac gttggggttg 180 ttgctggcgt accgaaggcg cttccccgcg gtcatcaccc gggtgcttcc cacgcgaatc 240 gtcgcctgcc ccctggacgt gggcctcacc cacgccggca ccgttaacct tcgcaacacc 300 tcccccgtag atctctgtaa cggggacccc atcagcctcg tcccgcccgt gttcgagggc 360 caagcgacgg acgtgcgcct ggattcgctg gacctcacgt tgcggtttcc cgttccgctt 420 ccatcgcccc tggcgcgcga aatcgtggcg cggctcgtgg ccaggggcat ccgggacctg 480 aaccccagcc ccagaaaccc cggagggctg ccagacctca acgtgctgta ctacaacggg 540 agtcgcctct cgctgctggc ggacgtccaa caactcggtc ccgtaaacgc cgagctgcga 600 tcgctggtcc ttaacatggt ttactcgatc acggagggaa ccaccatcat ccttacgcta 660 atcccccggc tctttgcgct aagtgcccag gacgggtacg tgaacgctct actgcagatg 720 cagagtgtca cgcgggaggc cgcccagctc attcaccccg aagccccggc cctgatgcag 780 gatggagagc gaaggctgcc gctttacgag gcgctcgtcg cctggctgac ccacgcgggc 840 caactaggag acaccttggc cctggctccc gtggttcggg tgtgcacctt tgacggcgcg 900 gccgttgtgc ggtccggaga catggccccc gttatacgct at 942 42 314 PRT Herpes Virus 42 Asp Gly Phe Glu Thr Asp Ile Ala Ile Pro Ser Gly Ile Ser Arg Pro 1 5 10 15 Asp Ala Ala Ala Leu Gln Arg Cys Glu Gly Arg Val Val Phe Leu Pro 20 25 30 Thr Ile Arg Arg Gln Leu Thr Leu Ala Asp Val Ala His Glu Ser Phe 35 40 45 Val Ser Gly Gly Val Ser Pro Asp Thr Leu Gly Leu Leu Leu Ala Tyr 50 55 60 Arg Arg Arg Phe Pro Ala Val Ile Thr Arg Val Leu Pro Thr Arg Ile 65 70 75 80 Val Ala Cys Pro Leu Asp Val Gly Leu Thr His Ala Gly Thr Val Asn 85 90 95 Leu Arg Asn Thr Ser Pro Val Asp Leu Cys Asn Gly Asp Pro Ile Ser 100 105 110 Leu Val Pro Pro Val Phe Glu Gly Gln Ala Thr Asp Val Arg Leu Asp 115 120 125 Ser Leu Asp Leu Thr Leu Arg Phe Pro Val Pro Leu Pro Ser Pro Leu 130 135 140 Ala Arg Glu Ile Val Ala Arg Leu Val Ala Arg Gly Ile Arg Asp Leu 145 150 155 160 Asn Pro Ser Pro Arg Asn Pro Gly Gly Leu Pro Asp Leu Asn Val Leu 165 170 175 Tyr Tyr Asn Gly Ser Arg Leu Ser Leu Leu Ala Asp Val Gln Gln Leu 180 185 190 Gly Pro Val Asn Ala Glu Leu Arg Ser Leu Val Leu Asn Met Val Tyr 195 200 205 Ser Ile Thr Glu Gly Thr Thr Ile Ile Leu Thr Leu Ile Pro Arg Leu 210 215 220 Phe Ala Leu Ser Ala Gln Asp Gly Tyr Val Asn Ala Leu Leu Gln Met 225 230 235 240 Gln Ser Val Thr Arg Glu Ala Ala Gln Leu Ile His Pro Glu Ala Pro 245 250 255 Ala Leu Met Gln Asp Gly Glu Arg Arg Leu Pro Leu Tyr Glu Ala Leu 260 265 270 Val Ala Trp Leu Thr His Ala Gly Gln Leu Gly Asp Thr Leu Ala Leu 275 280 285 Ala Pro Val Val Arg Val Cys Thr Phe Asp Gly Ala Ala Val Val Arg 290 295 300 Ser Gly Asp Met Ala Pro Val Ile Arg Tyr 305 310 43 957 DNA Herpes Virus 43 atgctggcgg acggctttga aactgacatc gcgataccct cgggcatctc gcgccccgat 60 gcggcggcgc tgcagcgctg cgaagggcgg gtggtattcc tgccgaccat ccgccggcaa 120 ctgacgctgg ccgacgtggc gcacgaatcc ttcgtctccg gaggcgtcag tcccgacacg 180 ttggggttgt tgctggcgta ccgaaggcgc ttccccgcgg tcatcacccg ggtgcttccc 240 acgcgaatcg tcgcctgccc cctggacgtg ggcctcaccc acgccggcac cgttaacctt 300 cgcaacacct cccccgtaga tctctgtaac ggggacccca tcagcctcgt cccgcccgtg 360 ttcgagggcc aagcgacgga cgtgcgcctg gattcgctgg acctcacgtt gcggtttccc 420 gttccgcttc catcgcccct ggcgcgcgaa atcgtggcgc ggctcgtggc caggggcatc 480 cgggacctga accccagccc cagaaacccc ggagggctgc cagacctcaa cgtgctgtac 540 tacaacggga gtcgcctctc gctgctggcg gacgtccaac aactcggtcc cgtaaacgcc 600 gagctgcgat cgctggtcct taacatggtt tactcgatca cggagggaac caccatcatc 660 cttacgctaa tcccccggct ctttgcgcta agtgcccagg acgggtacgt gaacgctcta 720 ctgcagatgc agagtgtcac gcgggaggcc gcccagctca ttcaccccga agccccggcc 780 ctgatgcagg atggagagcg aaggctgccg ctttacgagg cgctcgtcgc ctggctgacc 840 cacgcgggcc aactaggaga caccttggcc ctggctcccg tggttcgggt gtgcaccttt 900 gacggcgcgg ccgttgtgcg gtccggagac atggcccccg ttatacgcta tccctaa 957 44 318 PRT Herpes Virus 44 Met Leu Ala Asp Gly Phe Glu Thr Asp Ile Ala Ile Pro Ser Gly Ile 1 5 10 15 Ser Arg Pro Asp Ala Ala Ala Leu Gln Arg Cys Glu Gly Arg Val Val 20 25 30 Phe Leu Pro Thr Ile Arg Arg Gln Leu Thr Leu Ala Asp Val Ala His 35 40 45 Glu Ser Phe Val Ser Gly Gly Val Ser Pro Asp Thr Leu Gly Leu Leu 50 55 60 Leu Ala Tyr Arg Arg Arg Phe Pro Ala Val Ile Thr Arg Val Leu Pro 65 70 75 80 Thr Arg Ile Val Ala Cys Pro Leu Asp Val Gly Leu Thr His Ala Gly 85 90 95 Thr Val Asn Leu Arg Asn Thr Ser Pro Val Asp Leu Cys Asn Gly Asp 100 105 110 Pro Ile Ser Leu Val Pro Pro Val Phe Glu Gly Gln Ala Thr Asp Val 115 120 125 Arg Leu Asp Ser Leu Asp Leu Thr Leu Arg Phe Pro Val Pro Leu Pro 130 135 140 Ser Pro Leu Ala Arg Glu Ile Val Ala Arg Leu Val Ala Arg Gly Ile 145 150 155 160 Arg Asp Leu Asn Pro Ser Pro Arg Asn Pro Gly Gly Leu Pro Asp Leu 165 170 175 Asn Val Leu Tyr Tyr Asn Gly Ser Arg Leu Ser Leu Leu Ala Asp Val 180 185 190 Gln Gln Leu Gly Pro Val Asn Ala Glu Leu Arg Ser Leu Val Leu Asn 195 200 205 Met Val Tyr Ser Ile Thr Glu Gly Thr Thr Ile Ile Leu Thr Leu Ile 210 215 220 Pro Arg Leu Phe Ala Leu Ser Ala Gln Asp Gly Tyr Val Asn Ala Leu 225 230 235 240 Leu Gln Met Gln Ser Val Thr Arg Glu Ala Ala Gln Leu Ile His Pro 245 250 255 Glu Ala Pro Ala Leu Met Gln Asp Gly Glu Arg Arg Leu Pro Leu Tyr 260 265 270 Glu Ala Leu Val Ala Trp Leu Thr His Ala Gly Gln Leu Gly Asp Thr 275 280 285 Leu Ala Leu Ala Pro Val Val Arg Val Cys Thr Phe Asp Gly Ala Ala 290 295 300 Val Val Arg Ser Gly Asp Met Ala Pro Val Ile Arg Tyr Pro 305 310 315 45 798 DNA Herpes Virus 45 cctccgccaa acaacaccga ctcgagttcc ctggtgcccg gggcccagga ttccgccccg 60 cccggcccca cgctaaggga gctgtggtgg gtgttttatg ccgcagaccg ggcgctggag 120 gagccccgcg ccgactctgg cctcacccgc gaggaggtac gtgccgtacg tgggttccgg 180 gagcaggcgt ggaaactgtt tggctccgcg ggggccccgc gggcgtttat cggggccgcg 240 ttgggcctga gccccctcca aaagctagcc gtttactact atatcatcca ccgagagagg 300 cgcctgtccc ccttccccgc gctagtccgg ctcgtaggcc ggtacacaca gcgccacggc 360 ctgtacgtcc ctcggcccga cgacccagtc ttggccgatg ccatcaacgg gctgtttcgc 420 gacgcgctgg cggccggaac cacagccgag cagctcctca tgttcgacct tctcccccca 480 aaggacgtgc cggtgggaag cgacgtgcag gccgacagca ccgctctgct gcgctttata 540 gaatcgcaac gtctcgccgt ccccgggggg gtgatctccc ccgagcacgt cgcgtacctt 600 ggtgcgttcc tgagcgtgct gtacgctggc cgcgggcgca tgtccgcagc cacgcacacc 660 gcgcggctga caggggtgac ctccctggtg ctagcggtgg gtgacgtgga ccgtctttcc 720 gcgtttgacc gcggagcggc gggcgcggcc agccgcacgc gggccgccgg gtacctggat 780 gtgcttctta ccgttcgt 798 46 266 PRT Herpes Virus 46 Pro Pro Pro Asn Asn Thr Asp Ser Ser Ser Leu Val Pro Gly Ala Gln 1 5 10 15 Asp Ser Ala Pro Pro Gly Pro Thr Leu Arg Glu Leu Trp Trp Val Phe 20 25 30 Tyr Ala Ala Asp Arg Ala Leu Glu Glu Pro Arg Ala Asp Ser Gly Leu 35 40 45 Thr Arg Glu Glu Val Arg Ala Val Arg Gly Phe Arg Glu Gln Ala Trp 50 55 60 Lys Leu Phe Gly Ser Ala Gly Ala Pro Arg Ala Phe Ile Gly Ala Ala 65 70 75 80 Leu Gly Leu Ser Pro Leu Gln Lys Leu Ala Val Tyr Tyr Tyr Ile Ile 85 90 95 His Arg Glu Arg Arg Leu Ser Pro Phe Pro Ala Leu Val Arg Leu Val 100 105 110 Gly Arg Tyr Thr Gln Arg His Gly Leu Tyr Val Pro Arg Pro Asp Asp 115 120 125 Pro Val Leu Ala Asp Ala Ile Asn Gly Leu Phe Arg Asp Ala Leu Ala 130 135 140 Ala Gly Thr Thr Ala Glu Gln Leu Leu Met Phe Asp Leu Leu Pro Pro 145 150 155 160 Lys Asp Val Pro Val Gly Ser Asp Val Gln Ala Asp Ser Thr Ala Leu 165 170 175 Leu Arg Phe Ile Glu Ser Gln Arg Leu Ala Val Pro Gly Gly Val Ile 180 185 190 Ser Pro Glu His Val Ala Tyr Leu Gly Ala Phe Leu Ser Val Leu Tyr 195 200 205 Ala Gly Arg Gly Arg Met Ser Ala Ala Thr His Thr Ala Arg Leu Thr 210 215 220 Gly Val Thr Ser Leu Val Leu Ala Val Gly Asp Val Asp Arg Leu Ser 225 230 235 240 Ala Phe Asp Arg Gly Ala Ala Gly Ala Ala Ser Arg Thr Arg Ala Ala 245 250 255 Gly Tyr Leu Asp Val Leu Leu Thr Val Arg 260 265 47 1608 DNA Herpes Virus 47 atggagctta gctacgccac caccatgcac taccgggacg ttgtgtttta cgtcacaacg 60 gaccgaaacc gggcctactt tgtgtgcggg gggtgtgttt attccgtggg gcggccgtgt 120 gcctcgcagc ccggggagat tgccaagttt ggtctggtcg ttcgagggac aggcccagac 180 gaccgcgtgg tcgccaacta tgtacgaagc gagctccgac aacgcggcct gcaggacgtg 240 cgtcccattg gggaggacga ggtgtttctg gacagcgtgt gtcttctaaa cccgaacgtg 300 agctccgagc tggatgtgat taacacgaac gacgtggaag tgctggacga atgtctggcc 360 gagtactgca cctcgctgcg aaccagcccg ggtgtgctaa tatccgggct gcgcgtgcgg 420 gcgcaggaca gaatcatcga gttgtttgaa cacccaacga tagtcaacgt ttcctcgcac 480 tttgtgtata ccccgtcccc atacgtgttc gccctggccc aggcgcacct cccccggctc 540 ccgagctcgc tggaggccct ggtgagcggc ctgtttgacg gcatccccgc cccacgccag 600 ccacttgacg cccacaaccc gcgcacggat gtggttatca cgggccgccg cgccccacga 660 cccatcgccg ggtcgggggc ggggtcgggg ggcgcgggcg ccaagcgggc caccgtcagc 720 gagttcgtgc aagtcaaaca cattgaccgc gtgggccccg ctggcgtttc gccggcgcct 780 ccgccaaaca acaccgactc gagttccctg gtgcccgggg cccaggattc cgccccgccc 840 ggccccacgc taagggagct gtggtgggtg ttttatgccg cagaccgggc gctggaggag 900 ccccgcgccg actctggcct cacccgcgag gaggtacgtg ccgtacgtgg gttccgggag 960 caggcgtgga aactgtttgg ctccgcgggg gccccgcggg cgtttatcgg ggccgcgttg 1020 ggcctgagcc ccctccaaaa gctagccgtt tactactata tcatccaccg agagaggcgc 1080 ctgtccccct tccccgcgct agtccggctc gtaggccggt acacacagcg ccacggcctg 1140 tacgtccctc ggcccgacga cccagtcttg gccgatgcca tcaacgggct gtttcgcgac 1200 gcgctggcgg ccggaaccac agccgagcag ctcctcatgt tcgaccttct ccccccaaag 1260 gacgtgccgg tgggaagcga cgtgcaggcc gacagcaccg ctctgctgcg ctttatagaa 1320 tcgcaacgtc tcgccgtccc cgggggggtg atctcccccg agcacgtcgc gtaccttggt 1380 gcgttcctga gcgtgctgta cgctggccgc gggcgcatgt ccgcagccac gcacaccgcg 1440 cggctgacag gggtgacctc cctggtgcta gcggtgggtg acgtggaccg tctttccgcg 1500 tttgaccgcg gagcggcggg cgcggccagc cgcacgcggg ccgccgggta cctggatgtg 1560 cttcttaccg ttcgtctcgc tcgctcccaa cacggacagt ctgtgtaa 1608 48 535 PRT Herpes Virus 48 Met Glu Leu Ser Tyr Ala Thr Thr Met His Tyr Arg Asp Val Val Phe 1 5 10 15 Tyr Val Thr Thr Asp Arg Asn Arg Ala Tyr Phe Val Cys Gly Gly Cys 20 25 30 Val Tyr Ser Val Gly Arg Pro Cys Ala Ser Gln Pro Gly Glu Ile Ala 35 40 45 Lys Phe Gly Leu Val Val Arg Gly Thr Gly Pro Asp Asp Arg Val Val 50 55 60 Ala Asn Tyr Val Arg Ser Glu Leu Arg Gln Arg Gly Leu Gln Asp Val 65 70 75 80 Arg Pro Ile Gly Glu Asp Glu Val Phe Leu Asp Ser Val Cys Leu Leu 85 90 95 Asn Pro Asn Val Ser Ser Glu Leu Asp Val Ile Asn Thr Asn Asp Val 100 105 110 Glu Val Leu Asp Glu Cys Leu Ala Glu Tyr Cys Thr Ser Leu Arg Thr 115 120 125 Ser Pro Gly Val Leu Ile Ser Gly Leu Arg Val Arg Ala Gln Asp Arg 130 135 140 Ile Ile Glu Leu Phe Glu His Pro Thr Ile Val Asn Val Ser Ser His 145 150 155 160 Phe Val Tyr Thr Pro Ser Pro Tyr Val Phe Ala Leu Ala Gln Ala His 165 170 175 Leu Pro Arg Leu Pro Ser Ser Leu Glu Ala Leu Val Ser Gly Leu Phe 180 185 190 Asp Gly Ile Pro Ala Pro Arg Gln Pro Leu Asp Ala His Asn Pro Arg 195 200 205 Thr Asp Val Val Ile Thr Gly Arg Arg Ala Pro Arg Pro Ile Ala Gly 210 215 220 Ser Gly Ala Gly Ser Gly Gly Ala Gly Ala Lys Arg Ala Thr Val Ser 225 230 235 240 Glu Phe Val Gln Val Lys His Ile Asp Arg Val Gly Pro Ala Gly Val 245 250 255 Ser Pro Ala Pro Pro Pro Asn Asn Thr Asp Ser Ser Ser Leu Val Pro 260 265 270 Gly Ala Gln Asp Ser Ala Pro Pro Gly Pro Thr Leu Arg Glu Leu Trp 275 280 285 Trp Val Phe Tyr Ala Ala Asp Arg Ala Leu Glu Glu Pro Arg Ala Asp 290 295 300 Ser Gly Leu Thr Arg Glu Glu Val Arg Ala Val Arg Gly Phe Arg Glu 305 310 315 320 Gln Ala Trp Lys Leu Phe Gly Ser Ala Gly Ala Pro Arg Ala Phe Ile 325 330 335 Gly Ala Ala Leu Gly Leu Ser Pro Leu Gln Lys Leu Ala Val Tyr Tyr 340 345 350 Tyr Ile Ile His Arg Glu Arg Arg Leu Ser Pro Phe Pro Ala Leu Val 355 360 365 Arg Leu Val Gly Arg Tyr Thr Gln Arg His Gly Leu Tyr Val Pro Arg 370 375 380 Pro Asp Asp Pro Val Leu Ala Asp Ala Ile Asn Gly Leu Phe Arg Asp 385 390 395 400 Ala Leu Ala Ala Gly Thr Thr Ala Glu Gln Leu Leu Met Phe Asp Leu 405 410 415 Leu Pro Pro Lys Asp Val Pro Val Gly Ser Asp Val Gln Ala Asp Ser 420 425 430 Thr Ala Leu Leu Arg Phe Ile Glu Ser Gln Arg Leu Ala Val Pro Gly 435 440 445 Gly Val Ile Ser Pro Glu His Val Ala Tyr Leu Gly Ala Phe Leu Ser 450 455 460 Val Leu Tyr Ala Gly Arg Gly Arg Met Ser Ala Ala Thr His Thr Ala 465 470 475 480 Arg Leu Thr Gly Val Thr Ser Leu Val Leu Ala Val Gly Asp Val Asp 485 490 495 Arg Leu Ser Ala Phe Asp Arg Gly Ala Ala Gly Ala Ala Ser Arg Thr 500 505 510 Arg Ala Ala Gly Tyr Leu Asp Val Leu Leu Thr Val Arg Leu Ala Arg 515 520 525 Ser Gln His Gly Gln Ser Val 530 535 49 834 DNA Herpes Virus 49 gattcccgaa acttcatcac ccccgagttc ccccgggact tttggatgtc gcccgtcttt 60 aacctccccc gggagacggc ggcggagcag gtggtcgtcc tacaggccca gcgcacagcg 120 gctgccgctg ccctggagaa cgccgccatg caggcggccg agctccccgt cgatatcgag 180 cgccggttac gcccgatcga acggaacgtg cacgagatcg caggcgccct ggaggcgctg 240 gagacggcgg cggccgccgc cgaagaggcg gatgccgcgc gcggggatga gccggcgggt 300 gggggcgacg ggggggcgcc cccgggtctg gccgtcgcgg agatggaggt ccagatcgtg 360 cgcaacgacc cgccgctacg atacgacacc aacctccccg tggatctgct acacatggtg 420 tacgcgggcc gcggggcgac cggctcgtcg ggggtggtgt tcgggacctg gtaccgcact 480 atccaggacc gcaccatcac ggactttccc ctgaccaccc gcagtgccga ctttcgggac 540 ggccgtatgt ccaagacctt catgacggcg ctggtactgt ccctgcaggc gtgcggccgg 600 ctgtatgtgg gccagcgcca ctattccgcc ttcgagtgcg ccgtgttgtg tctctacctg 660 ctgtaccgaa acacgcacgg ggccgccgac gatagcgacc gcgctccggt cacgttcggg 720 gatctgctgg gccggctgcc ccgctacctg gcgtgcctgg ccgcggtgat cgggaccgag 780 ggcggccggc cacagtaccg ctaccgcgac gacaagctcc ccaagacgca gttc 834 50 278 PRT Herpes Virus 50 Asp Ser Arg Asn Phe Ile Thr Pro Glu Phe Pro Arg Asp Phe Trp Met 1 5 10 15 Ser Pro Val Phe Asn Leu Pro Arg Glu Thr Ala Ala Glu Gln Val Val 20 25 30 Val Leu Gln Ala Gln Arg Thr Ala Ala Ala Ala Ala Leu Glu Asn Ala 35 40 45 Ala Met Gln Ala Ala Glu Leu Pro Val Asp Ile Glu Arg Arg Leu Arg 50 55 60 Pro Ile Glu Arg Asn Val His Glu Ile Ala Gly Ala Leu Glu Ala Leu 65 70 75 80 Glu Thr Ala Ala Ala Ala Ala Glu Glu Ala Asp Ala Ala Arg Gly Asp 85 90 95 Glu Pro Ala Gly Gly Gly Asp Gly Gly Ala Pro Pro Gly Leu Ala Val 100 105 110 Ala Glu Met Glu Val Gln Ile Val Arg Asn Asp Pro Pro Leu Arg Tyr 115 120 125 Asp Thr Asn Leu Pro Val Asp Leu Leu His Met Val Tyr Ala Gly Arg 130 135 140 Gly Ala Thr Gly Ser Ser Gly Val Val Phe Gly Thr Trp Tyr Arg Thr 145 150 155 160 Ile Gln Asp Arg Thr Ile Thr Asp Phe Pro Leu Thr Thr Arg Ser Ala 165 170 175 Asp Phe Arg Asp Gly Arg Met Ser Lys Thr Phe Met Thr Ala Leu Val 180 185 190 Leu Ser Leu Gln Ala Cys Gly Arg Leu Tyr Val Gly Gln Arg His Tyr 195 200 205 Ser Ala Phe Glu Cys Ala Val Leu Cys Leu Tyr Leu Leu Tyr Arg Asn 210 215 220 Thr His Gly Ala Ala Asp Asp Ser Asp Arg Ala Pro Val Thr Phe Gly 225 230 235 240 Asp Leu Leu Gly Arg Leu Pro Arg Tyr Leu Ala Cys Leu Ala Ala Val 245 250 255 Ile Gly Thr Glu Gly Gly Arg Pro Gln Tyr Arg Tyr Arg Asp Asp Lys 260 265 270 Leu Pro Lys Thr Gln Phe 275 51 1743 DNA Herpes Virus 51 atggacccgt actgcccatt tgacgctctg gacgtctggg aacacaggcg cttcatagtc 60 gccgattccc gaaacttcat cacccccgag ttcccccggg acttttggat gtcgcccgtc 120 tttaacctcc cccgggagac ggcggcggag caggtggtcg tcctacaggc ccagcgcaca 180 gcggctgccg ctgccctgga gaacgccgcc atgcaggcgg ccgagctccc cgtcgatatc 240 gagcgccggt tacgcccgat cgaacggaac gtgcacgaga tcgcaggcgc cctggaggcg 300 ctggagacgg cggcggccgc cgccgaagag gcggatgccg cgcgcgggga tgagccggcg 360 ggtgggggcg acgggggggc gcccccgggt ctggccgtcg cggagatgga ggtccagatc 420 gtgcgcaacg acccgccgct acgatacgac accaacctcc ccgtggatct gctacacatg 480 gtgtacgcgg gccgcggggc gaccggctcg tcgggggtgg tgttcgggac ctggtaccgc 540 actatccagg accgcaccat cacggacttt cccctgacca cccgcagtgc cgactttcgg 600 gacggccgta tgtccaagac cttcatgacg gcgctggtac tgtccctgca ggcgtgcggc 660 cggctgtatg tgggccagcg ccactattcc gccttcgagt gcgccgtgtt gtgtctctac 720 ctgctgtacc gaaacacgca cggggccgcc gacgatagcg accgcgctcc ggtcacgttc 780 ggggatctgc tgggccggct gccccgctac ctggcgtgcc tggccgcggt gatcgggacc 840 gagggcggcc ggccacagta ccgctaccgc gacgacaagc tccccaagac gcagttcgcg 900 gccggcgggg gccgctacga acacggagcg ctggcgtcgc acatcgtgat cgccacgctg 960 atgcaccacg gggtgctccc ggcggccccg ggggacgtcc cccgggacgc gagtacccac 1020 gttaaccccg acggcgtggc gcaccacgac gacataaacc gcgccgccgc cgcgttcctc 1080 agccggggcc acaacctatt cctgtgggag gaccagactc tgctgcgggc aaccgcgaac 1140 accataacgg ccctgggcgt tatccagcgg ctcctcgcga acggcaacgt gtacgcggac 1200 cgcctcaaca accgcctgca gctgggcatg ctgatccccg gagccgtccc ttcggaggcc 1260 atcgcccgtg gggcctccgg gtccgactcg ggggccatca agagcggaga caacaatctg 1320 gaggcgctat gtgccaatta cgtgcttccg ctgtaccggg ccgacccggc ggtcgagctg 1380 acccagctgt ttcccggcct ggccgccctg tgtcttgacg cccaggcggg gcggccggtc 1440 gggtcgacgc ggcgggtggt ggatatgtca tcgggggccc gccaggcggc gctggtgcgc 1500 ctcaccgccc tggaactcat caaccgcacc cgcacaaacc ccacccctgt gggggaggtt 1560 atccacgccc acgacgccct ggcgatccaa tacgaacagg ggcttggcct gctggcgcag 1620 caggcacgca ttggcttggg ctccaacacc aagcgtttct ccgcgttcaa cgttagcagc 1680 gactacgaca tgttgtactt tttatgtctg gggttcattc cacagtacct gtcggcggtt 1740 tag 1743 52 580 PRT Herpes Virus 52 Met Asp Pro Tyr Cys Pro Phe Asp Ala Leu Asp Val Trp Glu His Arg 1 5 10 15 Arg Phe Ile Val Ala Asp Ser Arg Asn Phe Ile Thr Pro Glu Phe Pro 20 25 30 Arg Asp Phe Trp Met Ser Pro Val Phe Asn Leu Pro Arg Glu Thr Ala 35 40 45 Ala Glu Gln Val Val Val Leu Gln Ala Gln Arg Thr Ala Ala Ala Ala 50 55 60 Ala Leu Glu Asn Ala Ala Met Gln Ala Ala Glu Leu Pro Val Asp Ile 65 70 75 80 Glu Arg Arg Leu Arg Pro Ile Glu Arg Asn Val His Glu Ile Ala Gly 85 90 95 Ala Leu Glu Ala Leu Glu Thr Ala Ala Ala Ala Ala Glu Glu Ala Asp 100 105 110 Ala Ala Arg Gly Asp Glu Pro Ala Gly Gly Gly Asp Gly Gly Ala Pro 115 120 125 Pro Gly Leu Ala Val Ala Glu Met Glu Val Gln Ile Val Arg Asn Asp 130 135 140 Pro Pro Leu Arg Tyr Asp Thr Asn Leu Pro Val Asp Leu Leu His Met 145 150 155 160 Val Tyr Ala Gly Arg Gly Ala Thr Gly Ser Ser Gly Val Val Phe Gly 165 170 175 Thr Trp Tyr Arg Thr Ile Gln Asp Arg Thr Ile Thr Asp Phe Pro Leu 180 185 190 Thr Thr Arg Ser Ala Asp Phe Arg Asp Gly Arg Met Ser Lys Thr Phe 195 200 205 Met Thr Ala Leu Val Leu Ser Leu Gln Ala Cys Gly Arg Leu Tyr Val 210 215 220 Gly Gln Arg His Tyr Ser Ala Phe Glu Cys Ala Val Leu Cys Leu Tyr 225 230 235 240 Leu Leu Tyr Arg Asn Thr His Gly Ala Ala Asp Asp Ser Asp Arg Ala 245 250 255 Pro Val Thr Phe Gly Asp Leu Leu Gly Arg Leu Pro Arg Tyr Leu Ala 260 265 270 Cys Leu Ala Ala Val Ile Gly Thr Glu Gly Gly Arg Pro Gln Tyr Arg 275 280 285 Tyr Arg Asp Asp Lys Leu Pro Lys Thr Gln Phe Ala Ala Gly Gly Gly 290 295 300 Arg Tyr Glu His Gly Ala Leu Ala Ser His Ile Val Ile Ala Thr Leu 305 310 315 320 Met His His Gly Val Leu Pro Ala Ala Pro Gly Asp Val Pro Arg Asp 325 330 335 Ala Ser Thr His Val Asn Pro Asp Gly Val Ala His His Asp Asp Ile 340 345 350 Asn Arg Ala Ala Ala Ala Phe Leu Ser Arg Gly His Asn Leu Phe Leu 355 360 365 Trp Glu Asp Gln Thr Leu Leu Arg Ala Thr Ala Asn Thr Ile Thr Ala 370 375 380 Leu Gly Val Ile Gln Arg Leu Leu Ala Asn Gly Asn Val Tyr Ala Asp 385 390 395 400 Arg Leu Asn Asn Arg Leu Gln Leu Gly Met Leu Ile Pro Gly Ala Val 405 410 415 Pro Ser Glu Ala Ile Ala Arg Gly Ala Ser Gly Ser Asp Ser Gly Ala 420 425 430 Ile Lys Ser Gly Asp Asn Asn Leu Glu Ala Leu Cys Ala Asn Tyr Val 435 440 445 Leu Pro Leu Tyr Arg Ala Asp Pro Ala Val Glu Leu Thr Gln Leu Phe 450 455 460 Pro Gly Leu Ala Ala Leu Cys Leu Asp Ala Gln Ala Gly Arg Pro Val 465 470 475 480 Gly Ser Thr Arg Arg Val Val Asp Met Ser Ser Gly Ala Arg Gln Ala 485 490 495 Ala Leu Val Arg Leu Thr Ala Leu Glu Leu Ile Asn Arg Thr Arg Thr 500 505 510 Asn Pro Thr Pro Val Gly Glu Val Ile His Ala His Asp Ala Leu Ala 515 520 525 Ile Gln Tyr Glu Gln Gly Leu Gly Leu Leu Ala Gln Gln Ala Arg Ile 530 535 540 Gly Leu Gly Ser Asn Thr Lys Arg Phe Ser Ala Phe Asn Val Ser Ser 545 550 555 560 Asp Tyr Asp Met Leu Tyr Phe Leu Cys Leu Gly Phe Ile Pro Gln Tyr 565 570 575 Leu Ser Ala Val 580 53 683 DNA Herpes Virus 53 gtgtacccgt acgacgagtt tgtgttggcg actggcgact ttgtgtacat gtccccgttt 60 tacggctacc gggaggggtc gcacaccgaa cacaccagct acgccgccga ccgcttcaag 120 caggtcgacg gcttctacgc gcgcgacctc accaccaagg cccgggccac ggcgccgacc 180 acccggaacc tgctcacgac ccccaagttc accgtggcct gggactgggt gccaaagcgc 240 ccgtcggtct gcaccatgac caagtggcag gaggtggacg agatgctgcg ctccgagtac 300 ggcggctcct tccgattctc ttccgacgcc atatccacca ccttcaccac caacctgacc 360 gagtacccgc tctcgcgcgt ggacctgggg gactgcatcg gcaaggacgc ccgcgacgcc 420 atggaccgca tcttcgcccg caggtacaac gcgacgcaca tcaaggtggg ccagccgcag 480 tactacctgg ccaatggggg ctttctgatc gcgtaccagc cccttctcag caacacgctc 540 gcggagctgt acgtgcggga acacctccgc gagcagagcc gcaagccccc aaaccccacg 600 cccccgccgc ccggggccag cgccaacgcg tccgtggagc gcatcaagac cacctcctcc 660 atcgagttcg ccaggctgca gtt 683 54 227 PRT Herpes Virus 54 Val Tyr Pro Tyr Asp Glu Phe Val Leu Ala Thr Gly Asp Phe Val Tyr 1 5 10 15 Met Ser Pro Phe Tyr Gly Tyr Arg Glu Gly Ser His Thr Glu His Thr 20 25 30 Ser Tyr Ala Ala Asp Arg Phe Lys Gln Val Asp Gly Phe Tyr Ala Arg 35 40 45 Asp Leu Thr Thr Lys Ala Arg Ala Thr Ala Pro Thr Thr Arg Asn Leu 50 55 60 Leu Thr Thr Pro Lys Phe Thr Val Ala Trp Asp Trp Val Pro Lys Arg 65 70 75 80 Pro Ser Val Cys Thr Met Thr Lys Trp Gln Glu Val Asp Glu Met Leu 85 90 95 Arg Ser Glu Tyr Gly Gly Ser Phe Arg Phe Ser Ser Asp Ala Ile Ser 100 105 110 Thr Thr Phe Thr Thr Asn Leu Thr Glu Tyr Pro Leu Ser Arg Val Asp 115 120 125 Leu Gly Asp Cys Ile Gly Lys Asp Ala Arg Asp Ala Met Asp Arg Ile 130 135 140 Phe Ala Arg Arg Tyr Asn Ala Thr His Ile Lys Val Gly Gln Pro Gln 145 150 155 160 Tyr Tyr Leu Ala Asn Gly Gly Phe Leu Ile Ala Tyr Gln Pro Leu Leu 165 170 175 Ser Asn Thr Leu Ala Glu Leu Tyr Val Arg Glu His Leu Arg Glu Gln 180 185 190 Ser Arg Lys Pro Pro Asn Pro Thr Pro Pro Pro Pro Gly Ala Ser Ala 195 200 205 Asn Ala Ser Val Glu Arg Ile Lys Thr Thr Ser Ser Ile Glu Phe Ala 210 215 220 Arg Leu Gln 225 55 2715 DNA Herpes Virus 55 atgcgccagg gcgcccccgc gcgggggcgc cggtggttcg tcgtatgggc gctcttgggg 60 ttgacgctgg gggtcctggt ggcgtcggcg gctccgagtt cccccggcac gcctggggtc 120 gcggccgcga cccaggcggc gaacgggggc cctgccactc cggcgccgcc cgcccctggc 180 gcccccccaa cgggggaccc gaaaccgaag aagaacagaa aaccgaaacc cccaaagccg 240 ccgcgccccg ccggcgacaa cgcgaccgtc gccgcgggcc acgccaccct gcgcgagcac 300 ctgcgggaca tcaaggcgga gaacaccgat gcaaactttt acgtgtgccc accccccacg 360 ggcgccacgg tggtgcagtt cgagcagccg cgccgctgcc cgacccggcc cgagggtcag 420 aactacacgg agggcatcgc ggtggtcttc aaggagaaca tcgccccgta caagttcaag 480 gccaccatgt actacaaaga cgtcaccgtt tcgcaggtgt ggttcggcca ccgctactcc 540 cagtttatgg ggatctttga ggaccgcgcc cccgtcccct tcgaggaggt gatcgacaag 600 atcaacgcca agggggtctg tcggtccacg gccaagtacg tgcgcaacaa cctggagacc 660 accgcgtttc accgggacga ccacgagacc gacatggagc tgaaaccggc caacgccgcg 720 acccgcacga gccggggctg gcacaccacc gacctcaagt acaacccctc gcgggtggag 780 gcgttccacc ggtacgggac gacggtaaac tgcatcgtcg aggaggtgga cgcgcgctcg 840 gtgtacccgt acgacgagtt tgtgttggcg actggcgact ttgtgtacat gtccccgttt 900 tacggctacc gggaggggtc gcacaccgaa cacaccagct acgccgccga ccgcttcaag 960 caggtcgacg gcttctacgc gcgcgacctc accaccaagg cccgggccac ggcgccgacc 1020 acccggaacc tgctcacgac ccccaagttc accgtggcct gggactgggt gccaaagcgc 1080 ccgtcggtct gcaccatgac caagtggcag gaggtggacg agatgctgcg ctccgagtac 1140 ggcggctcct tccgattctc ttccgacgcc atatccacca ccttcaccac caacctgacc 1200 gagtacccgc tctcgcgcgt ggacctgggg gactgcatcg gcaaggacgc ccgcgacgcc 1260 atggaccgca tcttcgcccg caggtacaac gcgacgcaca tcaaggtggg ccagccgcag 1320 tactacctgg ccaatggggg ctttctgatc gcgtaccagc cccttctcag caacacgctc 1380 gcggagctgt acgtgcggga acacctccgc gagcagagcc gcaagccccc aaaccccacg 1440 cccccgccgc ccggggccag cgccaacgcg tccgtggagc gcatcaagac cacctcctcc 1500 atcgagttcg ccaggctgca gtttacgtac aaccacatac agcgccatgt caacgatatg 1560 ttgggccgcg ttgccatcgc gtggtgcgag ctgcagaatc acgagctgac cctgtggaac 1620 gaggcccgca agctgaaccc caacgccatc gcctcggcca ccgtgggccg gcgggtgagc 1680 gcgcggatgc tcggcgacgt gatggccgtc tccacgtgcg tgccggtcgc cgcggacaac 1740 gtgatcgtcc aaaactcgat gcgcatcagc tcgcggcccg gggcctgcta cagccgcccc 1800 ctggtcagct ttcggtacga agaccagggc ccgttggtcg aggggcagct gggggagaac 1860 aacgagctgc ggctgacgcg cgatgcgatc gagccgtgca ccgtgggaca ccggcgctac 1920 ttcaccttcg gtgggggcta cgtgtacttc gaggagtacg cgtactccca ccagctgagc 1980 cgcgccgaca tcaccaccgt cagcaccttc atcgacctca acatcaccat gctggaggat 2040 cacgagtttg tccccctgga ggtgtacacc cgccacgaga tcaaggacag cggcctgctg 2100 gactacacgg aggtccagcg ccgcaaccag ctgcacgacc tgcgcttcgc cgacatcgac 2160 acggtcatcc acgccgacgc caacgccgcc atgtttgcgg gcctgggcgc gttcttcgag 2220 gggatgggcg acctggggcg cgcggtcggc aaggtggtga tgggcatcgt gggcggcgtg 2280 gtatcggccg tgtcgggcgt gtcctccttc atgtccaacc cctttggggc gctggccgtg 2340 ggtctgttgg tcctggccgg cctggcggcg gccttcttcg cctttcgcta cgtcatgcgg 2400 ctgcagagca accccatgaa ggccctgtac ccgctaacca ccaaggagct caagaacccc 2460 accaacccgg acgcgtccgg ggagggcgag gagggcggcg actttgacga ggccaagcta 2520 gccgaggccc gggagatgat acggtacatg gccctggtgt ctgccatgga gcgcacggaa 2580 cacaaggcca agaagaaggg cacgagcgcg ctgctcagcg ccaaggtcac cgacatggtc 2640 atgcgcaagc gccgcaacac caactacacc caagttccca acaaagacgg tgacgccgac 2700 gaggacgacc tgtga 2715 56 904 PRT Herpes Virus 56 Met Arg Gln Gly Ala Pro Ala Arg Gly Cys Arg Trp Phe Val Val Trp 1 5 10 15 Ala Leu Leu Gly Leu Thr Leu Gly Val Leu Val Ala Ser Ala Ala Pro 20 25 30 Ser Ser Pro Gly Thr Pro Gly Val Ala Ala Ala Thr Gln Ala Ala Asn 35 40 45 Gly Gly Pro Ala Thr Pro Ala Pro Pro Ala Leu Gly Ala Ala Pro Thr 50 55 60 Gly Asp Pro Lys Pro Lys Lys Asn Lys Lys Pro Lys Asn Pro Thr Pro 65 70 75 80 Pro Arg Pro Ala Gly Asp Asn Ala Thr Val Ala Ala Gly His Ala Thr 85 90 95 Leu Arg Glu His Leu Arg Asp Ile Lys Ala Glu Asn Thr Asp Ala Asn 100 105 110 Phe Tyr Val Cys Pro Pro Pro Thr Gly Ala Thr Val Val Gln Phe Glu 115 120 125 Gln Pro Arg Arg Cys Pro Thr Arg Pro Glu Gly Gln Asn Tyr Thr Glu 130 135 140 Gly Ile Ala Val Val Phe Lys Glu Asn Ile Ala Pro Tyr Lys Phe Lys 145 150 155 160 Ala Thr Met Tyr Tyr Lys Asp Val Thr Val Ser Gln Val Trp Phe Gly 165 170 175 His Arg Tyr Ser Gln Phe Met Gly Ile Phe Glu Asp Arg Ala Pro Val 180 185 190 Pro Phe Glu Glu Val Ile Asp Lys Ile Asn Ala Lys Gly Val Cys Arg 195 200 205 Ser Thr Ala Lys Tyr Val Arg Asn Asn Leu Glu Thr Thr Ala Phe His 210 215 220 Arg Asp Asp His Glu Thr Asp Met Glu Leu Lys Pro Ala Asn Ala Ala 225 230 235 240 Thr Arg Thr Ser Arg Gly Trp His Thr Thr Asp Leu Lys Tyr Asn Pro 245 250 255 Ser Arg Val Glu Ala Phe His Arg Tyr Gly Thr Thr Val Asn Cys Ile 260 265 270 Val Glu Glu Val Asp Ala Arg Ser Val Tyr Pro Tyr Asp Glu Phe Val 275 280 285 Leu Ala Thr Gly Asp Phe Val Tyr Met Ser Pro Phe Tyr Gly Tyr Arg 290 295 300 Glu Gly Ser His Thr Glu His Thr Ser Tyr Ala Ala Asp Arg Phe Lys 305 310 315 320 Gln Val Asp Gly Phe Tyr Ala Arg Asp Leu Thr Thr Lys Ala Arg Ala 325 330 335 Thr Ala Pro Thr Thr Arg Asn Leu Leu Thr Thr Pro Lys Phe Thr Val 340 345 350 Ala Trp Asp Trp Val Pro Lys Arg Pro Ser Val Cys Thr Met Thr Lys 355 360 365 Trp Gln Glu Val Asp Glu Met Leu Arg Ser Glu Tyr Gly Gly Ser Phe 370 375 380 Arg Phe Ser Ser Asp Ala Ile Ser Thr Thr Phe Thr Thr Asn Leu Thr 385 390 395 400 Glu Tyr Pro Leu Ser Arg Val Asp Leu Gly Asp Cys Ile Gly Lys Asp 405 410 415 Ala Arg Asp Ala Met Asp Arg Ile Phe Ala Arg Arg Tyr Asn Ala Thr 420 425 430 His Ile Lys Val Gly Gln Pro Gln Tyr Tyr Leu Ala Asn Gly Gly Phe 435 440 445 Leu Ile Ala Tyr Gln Pro Leu Leu Ser Asn Thr Leu Ala Glu Leu Tyr 450 455 460 Val Arg Glu His Leu Arg Glu Gln Ser Arg Lys Pro Pro Asn Pro Thr 465 470 475 480 Pro Pro Pro Pro Gly Ala Ser Ala Asn Ala Ser Val Glu Arg Ile Lys 485 490 495 Thr Thr Ser Ser Ile Glu Phe Ala Arg Leu Gln Phe Thr Tyr Asn His 500 505 510 Ile Gln Arg His Val Asn Asp Met Leu Gly Arg Val Ala Ile Ala Trp 515 520 525 Cys Glu Leu Gln Asn His Glu Leu Thr Leu Trp Asn Glu Ala Arg Lys 530 535 540 Leu Asn Pro Asn Ala Ile Ala Ser Ala Thr Val Gly Arg Arg Val Ser 545 550 555 560 Ala Arg Met Leu Gly Asp Val Met Ala Val Ser Thr Cys Val Pro Val 565 570 575 Ala Ala Asp Asn Val Ile Val Gln Asn Ser Met Arg Ile Ser Ser Arg 580 585 590 Pro Gly Ala Cys Tyr Ser Arg Pro Leu Val Ser Phe Arg Tyr Glu Asp 595 600 605 Gln Gly Pro Leu Val Glu Gly Gln Leu Gly Glu Asn Asn Glu Leu Arg 610 615 620 Leu Thr Arg Asp Ala Ile Glu Pro Cys Thr Val Gly His Arg Arg Tyr 625 630 635 640 Phe Thr Phe Gly Gly Gly Tyr Val Tyr Phe Glu Glu Ser Ala Tyr Ser 645 650 655 His Gln Leu Ser Arg Ala Asp Ile Thr Thr Val Ser Thr Phe Ile Asp 660 665 670 Leu Asn Ile Thr Met Leu Glu Asp His Glu Phe Val Pro Leu Glu Val 675 680 685 Tyr Thr Arg His Glu Ile Lys Asp Ser Gly Leu Leu Asp Tyr Thr Glu 690 695 700 Val Gln Arg Arg Asn Gln Leu His Asp Leu Arg Phe Ala Asp Ile Asp 705 710 715 720 Thr Val Ile His Ala Asp Ala Asn Ala Ala Met Phe Ala Gly Leu Gly 725 730 735 Ala Phe Phe Glu Gly Met Gly Asp Leu Gly Arg Ala Val Gly Lys Val 740 745 750 Val Met Gly Ile Val Gly Gly Val Val Ser Ala Val Ser Gly Val Ser 755 760 765 Ser Phe Met Ser Asn Pro Phe Gly Ala Leu Ala Val Gly Leu Leu Val 770 775 780 Leu Ala Gly Leu Ala Ala Ala Phe Phe Ala Phe Arg Tyr Val Met Arg 785 790 795 800 Leu Gln Ser Asn Pro Met Lys Ala Leu Tyr Pro Leu Thr Thr Lys Glu 805 810 815 Leu Lys Asn Pro Thr Asn Pro Asp Ala Ser Gly Glu Gly Glu Glu Gly 820 825 830 Gly Asp Phe Asp Glu Ala Lys Leu Ala Glu Ala Arg Glu Met Ile Arg 835 840 845 Tyr Met Ala Leu Val Ser Ala Met Glu Arg Thr Glu His Lys Ala Lys 850 855 860 Lys Lys Gly Thr Ser Ala Leu Leu Ser Ala Lys Val Thr Asp Met Val 865 870 875 880 Met Arg Lys Arg Arg Asn Thr Asn Tyr Thr Gln Val Pro Asn Lys Asp 885 890 895 Gly Asp Ala Asp Glu Asp Asp Leu 900 57 1814 DNA Herpes Virus 57 ctgctagagt acgcgtggcg cgagggcgag cggctcctgg gcagcctgga gacgttcgcg 60 accgcgggag acgtcgcggc gtttttcacg gagaccatgg gcctggcccg accctgtccg 120 tatcaccaac gggtcaggct ggatacgtat ggcgggaccg tccatatgga gctgtgtttc 180 ctgcacgacg tcgagaactt tctaaagcag ctaaactact gccacctcat caccccctcg 240 cgcggcgcca ccgccgcgct ggagcgcgtt cgggagttta tggtgggggc ggtggggtcg 300 ggccttatcg tccccccgga gcttagcgac ccgtcccacc cctgcgcggt ctgtttcgag 360 gaactgtgtg tgacggcgaa ccagggggcg acgatcgccc gccgcctggc ggaccgtatc 420 tgtaaccacg tcacccagca ggcgcaggtg cggctggacg ccaacgagct gcggcggtac 480 ctgccccacg ccgccgggct gtcggacgcc gaccgcgcgc gggcgctctc cgtgttggac 540 catgcgctgg cccggaccgc ggggggcgac gggcagcccc acccgtcgcc cgagaacgac 600 tcggtccgca aggaggccga cgccctgctg gaggcgcacg acgtgtttca ggccaccacg 660 cccggcctgt acgccatcag cgaattgcga ttctggctcg cgtccggcga ccgcgccggc 720 cagaccacca tggacgcgtt tgccagcaac ctgaccgcgc tggcgcggcg cgagttgcag 780 caggagaccg ccgcggtggc cgtggaactg gcgctgttcg ggcggcgggc ggagcatttc 840 gatcgcgcgt tcgggagcca cctggcggcg ctggatatgg tggacgccct aataatcggc 900 ggtcaggcca cgtcacccga cgatcagatc gaggcgctca tccgcgcgtg ctacgaccac 960 cacctgacga cgccgctctt gcggcgcctc gtcagccccg aacagtgcga cgaggaggcg 1020 ctgcgtcgcg tgctggcgcg catgggggcg gggggcgcgg cggacgcgcc caagggcggc 1080 gcgggccccg acgacgacgg ggaccgtgtc gccgtagagg aaggggcacg ggggttggga 1140 gctcccgggg gcgggggcga ggacgaagac cgtcgccgcg ggcccggggg gcaggggccc 1200 gagacgtggg gggacatcgc cacgcaagcg gccgcggacg tgcgggagcg acggcggctg 1260 tacgcggacc gcctgacgaa gcggtcgttg gccagcctgg ggcgctgcgt ccgcgagcag 1320 cgcggggagc tcgagaagat gctgcgggtc agcgtccacg gcgaggtgct gcccgcgacg 1380 ttcgccgcgg tcgccaacgg ctttgcggcg cgcgcgcgct tctgcgccct gacggcgggc 1440 gcgggcacgg tcatcgacaa ccgctcggcg ccgggcgtgt tcgacgcgca ccggttcatg 1500 cgagcgtctc tcctgcgaca ccaggtggac ccggccctgc tccccagcat cacccatcgc 1560 ttcttcgagc tcgtcaacgg gcccctcttt gatcactcca cccacagctt cgcccagccc 1620 cccaacaccg cgctgtatta cagcgtcgag aacgtggggc tcctgccgca cctgaaggag 1680 gagctcgccc ggttcatcat gggggcgggg ggctcgggtg ctgattgggc cgtcagcgaa 1740 tttcagaggt tttactgttt tgacggcatt tccggaataa cgcccactca gcgcgccgcc 1800 tggcgatata ttcg 1814 58 604 PRT Herpes Virus 58 Leu Leu Glu Tyr Ala Trp Arg Glu Gly Glu Arg Leu Leu Gly Ser Leu 1 5 10 15 Glu Thr Phe Ala Thr Ala Gly Asp Val Ala Ala Phe Phe Thr Glu Thr 20 25 30 Met Gly Leu Ala Arg Pro Cys Pro Tyr His Gln Arg Val Arg Leu Asp 35 40 45 Thr Tyr Gly Gly Thr Val His Met Glu Leu Cys Phe Leu His Asp Val 50 55 60 Glu Asn Phe Leu Lys Gln Leu Asn Tyr Cys His Leu Ile Thr Pro Ser 65 70 75 80 Arg Gly Ala Thr Ala Ala Leu Glu Arg Val Arg Glu Phe Met Val Gly 85 90 95 Ala Val Gly Ser Gly Leu Ile Val Pro Pro Glu Leu Ser Asp Pro Ser 100 105 110 His Pro Cys Ala Val Cys Phe Glu Glu Leu Cys Val Thr Ala Asn Gln 115 120 125 Gly Ala Thr Ile Ala Arg Arg Leu Ala Asp Arg Ile Cys Asn His Val 130 135 140 Thr Gln Gln Ala Gln Val Arg Leu Asp Ala Asn Glu Leu Arg Arg Tyr 145 150 155 160 Leu Pro His Ala Ala Gly Leu Ser Asp Ala Asp Arg Ala Arg Ala Leu 165 170 175 Ser Val Leu Asp His Ala Leu Ala Arg Thr Ala Gly Gly Asp Gly Gln 180 185 190 Pro His Pro Ser Pro Glu Asn Asp Ser Val Arg Lys Glu Ala Asp Ala 195 200 205 Leu Leu Glu Ala His Asp Val Phe Gln Ala Thr Thr Pro Gly Leu Tyr 210 215 220 Ala Ile Ser Glu Leu Arg Phe Trp Leu Ala Ser Gly Asp Arg Ala Gly 225 230 235 240 Gln Thr Thr Met Asp Ala Phe Ala Ser Asn Leu Thr Ala Leu Ala Arg 245 250 255 Arg Glu Leu Gln Gln Glu Thr Ala Ala Val Ala Val Glu Leu Ala Leu 260 265 270 Phe Gly Arg Arg Ala Glu His Phe Asp Arg Ala Phe Gly Ser His Leu 275 280 285 Ala Ala Leu Asp Met Val Asp Ala Leu Ile Ile Gly Gly Gln Ala Thr 290 295 300 Ser Pro Asp Asp Gln Ile Glu Ala Leu Ile Arg Ala Cys Tyr Asp His 305 310 315 320 His Leu Thr Thr Pro Leu Leu Arg Arg Leu Val Ser Pro Glu Gln Cys 325 330 335 Asp Glu Glu Ala Leu Arg Arg Val Leu Ala Arg Met Gly Ala Gly Gly 340 345 350 Ala Ala Asp Ala Pro Lys Gly Gly Ala Gly Pro Asp Asp Asp Gly Asp 355 360 365 Arg Val Ala Val Glu Glu Gly Ala Arg Gly Leu Gly Ala Pro Gly Gly 370 375 380 Gly Gly Glu Asp Glu Asp Arg Arg Arg Gly Pro Gly Gly Gln Gly Pro 385 390 395 400 Glu Thr Trp Gly Asp Ile Ala Thr Gln Ala Ala Ala Asp Val Arg Glu 405 410 415 Arg Arg Arg Leu Tyr Ala Asp Arg Leu Thr Lys Arg Ser Leu Ala Ser 420 425 430 Leu Gly Arg Cys Val Arg Glu Gln Arg Gly Glu Leu Glu Lys Met Leu 435 440 445 Arg Val Ser Val His Gly Glu Val Leu Pro Ala Thr Phe Ala Ala Val 450 455 460 Ala Asn Gly Phe Ala Ala Arg Ala Arg Phe Cys Ala Leu Thr Ala Gly 465 470 475 480 Ala Gly Thr Val Ile Asp Asn Arg Ser Ala Pro Gly Val Phe Asp Ala 485 490 495 His Arg Phe Met Arg Ala Ser Leu Leu Arg His Gln Val Asp Pro Ala 500 505 510 Leu Leu Pro Ser Ile Thr His Arg Phe Phe Glu Leu Val Asn Gly Pro 515 520 525 Leu Phe Asp His Ser Thr His Ser Phe Ala Gln Pro Pro Asn Thr Ala 530 535 540 Leu Tyr Tyr Ser Val Glu Asn Val Gly Leu Leu Pro His Leu Lys Glu 545 550 555 560 Glu Leu Ala Arg Phe Ile Met Gly Ala Gly Gly Ser Gly Ala Asp Trp 565 570 575 Ala Val Ser Glu Phe Gln Arg Phe Tyr Cys Phe Asp Gly Ile Ser Gly 580 585 590 Ile Thr Pro Thr Gln Arg Ala Ala Trp Arg Tyr Ile 595 600 59 1068 DNA Herpes Virus 59 tatgtgtttc agatagagct gctccggcgg tgcgaccccc acatcggacg ggggaagctc 60 ccccaactga agctgaacgc gcttcaggtg cgggcgctgc ggcgtcgtct gaggccgggc 120 ctggaggccc aggccggggc ctttctcacc ccgctgtcgg tcaccctgga gttgctgcta 180 gagtacgcgt ggcgcgaggg cgagcggctc ctgggcagcc tggagacgtt cgcgaccgcg 240 ggagacgtcg cggcgttttt cacggagacc atgggcctgg cccgaccctg tccgtatcac 300 caacgggtca ggctggatac gtatggcggg accgtccata tggagctgtg tttcctgcac 360 gacgtcgaga actttctaaa gcagctaaac tactgccacc tcatcacccc ctcgcgcggc 420 gccaccgccg cgctggagcg cgttcgggag tttatggtgg gggcggtggg gtcgggcctt 480 atcgtccccc cggagcttag cgacccgtcc cacccctgcg cggtctgttt cgaggaactg 540 tgtgtgacgg cgaaccaggg ggcgacgatc gcccgccgcc tggcggaccg tatctgtaac 600 cacgtcaccc agcaggcgca ggtgcggctg gacgccaacg agctgcggcg gtacctgccc 660 cacgccgccg ggctgtcgga cgccgaccgc gcgcgggcgc tctccgtgtt ggaccatgcg 720 ctggcccgga ccgcgggggg cgacgggcag ccccacccgt cgcccgagaa cgactcggtc 780 cgcaaggagg ccgacgccct gctggaggcg cacgacgtgt ttcaggccac cacgcccggc 840 ctgtacgcca tcagcgaatt gcgattctgg ctcgcgtccg gcgaccgcgc cggccagacc 900 accatggacg cgtttgccag caacctgacc gcgctggcgc ggcgcgagtt gcagcaggag 960 accgccgcgg tggccgtgga actggcgctg ttcgggcggc gggcggagca tttcgatcgc 1020 gcgttcggga gccacctggc ggcgctggat atggtggacg ccctaata 1068 60 356 PRT Herpes Virus 60 Tyr Val Phe Gln Ile Glu Leu Leu Arg Arg Cys Asp Pro His Ile Gly 1 5 10 15 Arg Gly Lys Leu Pro Gln Leu Lys Leu Asn Ala Leu Gln Val Arg Ala 20 25 30 Leu Arg Arg Arg Leu Arg Pro Gly Leu Glu Ala Gln Ala Gly Ala Phe 35 40 45 Leu Thr Pro Leu Ser Val Thr Leu Glu Leu Leu Leu Glu Tyr Ala Trp 50 55 60 Arg Glu Gly Glu Arg Leu Leu Gly Ser Leu Glu Thr Phe Ala Thr Ala 65 70 75 80 Gly Asp Val Ala Ala Phe Phe Thr Glu Thr Met Gly Leu Ala Arg Pro 85 90 95 Cys Pro Tyr His Gln Arg Val Arg Leu Asp Thr Tyr Gly Gly Thr Val 100 105 110 His Met Glu Leu Cys Phe Leu His Asp Val Glu Asn Phe Leu Lys Gln 115 120 125 Leu Asn Tyr Cys His Leu Ile Thr Pro Ser Arg Gly Ala Thr Ala Ala 130 135 140 Leu Glu Arg Val Arg Glu Phe Met Val Gly Ala Val Gly Ser Gly Leu 145 150 155 160 Ile Val Pro Pro Glu Leu Ser Asp Pro Ser His Pro Cys Ala Val Cys 165 170 175 Phe Glu Glu Leu Cys Val Thr Ala Asn Gln Gly Ala Thr Ile Ala Arg 180 185 190 Arg Leu Ala Asp Arg Ile Cys Asn His Val Thr Gln Gln Ala Gln Val 195 200 205 Arg Leu Asp Ala Asn Glu Leu Arg Arg Tyr Leu Pro His Ala Ala Gly 210 215 220 Leu Ser Asp Ala Asp Arg Ala Arg Ala Leu Ser Val Leu Asp His Ala 225 230 235 240 Leu Ala Arg Thr Ala Gly Gly Asp Gly Gln Pro His Pro Ser Pro Glu 245 250 255 Asn Asp Ser Val Arg Lys Glu Ala Asp Ala Leu Leu Glu Ala His Asp 260 265 270 Val Phe Gln Ala Thr Thr Pro Gly Leu Tyr Ala Ile Ser Glu Leu Arg 275 280 285 Phe Trp Leu Ala Ser Gly Asp Arg Ala Gly Gln Thr Thr Met Asp Ala 290 295 300 Phe Ala Ser Asn Leu Thr Ala Leu Ala Arg Arg Glu Leu Gln Gln Glu 305 310 315 320 Thr Ala Ala Val Ala Val Glu Leu Ala Leu Phe Gly Arg Arg Ala Glu 325 330 335 His Phe Asp Arg Ala Phe Gly Ser His Leu Ala Ala Leu Asp Met Val 340 345 350 Asp Ala Leu Ile 355 61 369 DNA Herpes Virus 61 gagaagatgc tgcgggtcag cgtccacggc gaggtgctgc ccgcgacgtt cgccgcggtc 60 gccaacggct ttgcggcgcg cgcgcgcttc tgcgccctga cggcgggcgc gggcacggtc 120 atcgacaacc gctcggcgcc gggcgtgttc gacgcgcacc ggttcatgcg agcgtctctc 180 ctgcgacacc aggtggaccc ggccctgctc cccagcatca cccatcgctt cttcgagctc 240 gtcaacgggc ccctctttga tcactccacc cacagcttcg cccagccccc caacaccgcg 300 ctgtattaca gcgtcgagaa cgtggggctc ctgccgcacc tgaaggagga gctcgcccgg 360 ttcatcatg 369 62 123 PRT Herpes Virus 62 Glu Lys Met Leu Arg Val Ser Val His Gly Glu Val Leu Pro Ala Thr 1 5 10 15 Phe Ala Ala Val Ala Asn Gly Phe Ala Ala Arg Ala Arg Phe Cys Ala 20 25 30 Leu Thr Ala Gly Ala Gly Thr Val Ile Asp Asn Arg Ser Ala Pro Gly 35 40 45 Val Phe Asp Ala His Arg Phe Met Arg Ala Ser Leu Leu Arg His Gln 50 55 60 Val Asp Pro Ala Leu Leu Pro Ser Ile Thr His Arg Phe Phe Glu Leu 65 70 75 80 Val Asn Gly Pro Leu Phe Asp His Ser Thr His Ser Phe Ala Gln Pro 85 90 95 Pro Asn Thr Ala Leu Tyr Tyr Ser Val Glu Asn Val Gly Leu Leu Pro 100 105 110 His Leu Lys Glu Glu Leu Ala Arg Phe Ile Met 115 120 63 2358 DNA Herpes Virus 63 atggccgccc cggtgtccga gcccaccgtg gcccgtcaaa agttgttagc cctgctcggg 60 caggtgcaga cctatgtgtt tcagatagag ctgctccggc ggtgcgaccc ccacatcgga 120 cgggggaagc tcccccaact gaagctgaac gcgcttcagg tgcgggcgct gcggcgtcgt 180 ctgaggccgg gcctggaggc ccaggccggg gcctttctca ccccgctgtc ggtcaccctg 240 gagttgctgc tagagtacgc gtggcgcgag ggcgagcggc tcctgggcag cctggagacg 300 ttcgcgaccg cgggagacgt cgcggcgttt ttcacggaga ccatgggcct ggcccgaccc 360 tgtccgtatc accaacgggt caggctggat acgtatggcg ggaccgtcca tatggagctg 420 tgtttcctgc acgacgtcga gaactttcta aagcagctaa actactgcca cctcatcacc 480 ccctcgcgcg gcgccaccgc cgcgctggag cgcgttcggg agtttatggt gggggcggtg 540 gggtcgggcc ttatcgtccc cccggagctt agcgacccgt cccacccctg cgcggtctgt 600 ttcgaggaac tgtgtgtgac ggcgaaccag ggggcgacga tcgcccgccg cctggcggac 660 cgtatctgta accacgtcac ccagcaggcg caggtgcggc tggacgccaa cgagctgcgg 720 cggtacctgc cccacgccgc cgggctgtcg gacgccgacc gcgcgcgggc gctctccgtg 780 ttggaccatg cgctggcccg gaccgcgggg ggcgacgggc agccccaccc gtcgcccgag 840 aacgactcgg tccgcaagga ggccgacgcc ctgctggagg cgcacgacgt gtttcaggcc 900 accacgcccg gcctgtacgc catcagcgaa ttgcgattct ggctcgcgtc cggcgaccgc 960 gccggccaga ccaccatgga cgcgtttgcc agcaacctga ccgcgctggc gcggcgcgag 1020 ttgcagcagg agaccgccgc ggtggccgtg gaactggcgc tgttcgggcg gcgggcggag 1080 catttcgatc gcgcgttcgg gagccacctg gcggcgctgg atatggtgga cgccctaata 1140 atcggcggtc aggccacgtc acccgacgat cagatcgagg cgctcatccg cgcgtgctac 1200 gaccaccacc tgacgacgcc gctcttgcgg cgcctcgtca gccccgaaca gtgcgacgag 1260 gaggcgctgc gtcgcgtgct ggcgcgcatg ggggcggggg gcgcggcgga cgcgcccaag 1320 ggcggcgcgg gccccgacga cgacggggac cgtgtcgccg tagaggaagg ggcacggggg 1380 ttgggagctc ccgggggcgg gggcgaggac gaagaccgtc gccgcgggcc cggggggcag 1440 gggcccgaga cgtgggggga catcgccacg caagcggccg cggacgtgcg ggagcgacgg 1500 cggctgtacg cggaccgcct gacgaagcgg tcgttggcca gcctggggcg ctgcgtccgc 1560 gagcagcgcg gggagctcga gaagatgctg cgggtcagcg tccacggcga ggtgctgccc 1620 gcgacgttcg ccgcggtcgc caacggcttt gcggcgcgcg cgcgcttctg cgccctgacg 1680 gcgggcgcgg gcacggtcat cgacaaccgc tcggcgccgg gcgtgttcga cgcgcaccgg 1740 ttcatgcgag cgtctctcct gcgacaccag gtggacccgg ccctgctccc cagcatcacc 1800 catcgcttct tcgagctcgt caacgggccc ctctttgatc actccaccca cagcttcgcc 1860 cagcccccca acaccgcgct gtattacagc gtcgagaacg tggggctcct gccgcacctg 1920 aaggaggagc tcgcccggtt catcatgggg gcggggggct cgggtgctga ttgggccgtc 1980 agcgaatttc agaggtttta ctgttttgac ggcatttccg gaataacgcc cactcagcgc 2040 gccgcctggc gatatattcg cgagctgatt atcgccacca cactctttgc ctcggtctac 2100 cggtgcgggg agctcgagtt gcgccgcccg gactgcagcc gcccgacctc cgaaggtcgt 2160 taccgttacc cgcccggcgt atatctcacg tacgactccg actgtccgct ggtggccatc 2220 gtcgagagcg cccccgacgg ctgtatcggc ccccggtcgg tcgtggtcta cgaccgagac 2280 gttttctcga tcctctactc ggtcctccag cacctcgccc ccaggctacc tgacgggggg 2340 cacgacgggc ccccgtag 2358 64 785 PRT Herpes Virus 64 Met Ala Ala Pro Val Ser Glu Pro Thr Val Ala Arg Gln Lys Leu Leu 1 5 10 15 Ala Leu Leu Gly Gln Val Gln Thr Tyr Val Phe Gln Ile Glu Leu Leu 20 25 30 Arg Arg Cys Asp Pro His Ile Gly Arg Gly Lys Leu Pro Gln Leu Lys 35 40 45 Leu Asn Ala Leu Gln Val Arg Ala Leu Arg Arg Arg Leu Arg Pro Gly 50 55 60 Leu Glu Ala Gln Ala Gly Ala Phe Leu Thr Pro Leu Ser Val Thr Leu 65 70 75 80 Glu Leu Leu Leu Glu Tyr Ala Trp Arg Glu Gly Glu Arg Leu Leu Gly 85 90 95 Ser Leu Glu Thr Phe Ala Thr Ala Gly Asp Val Ala Ala Phe Phe Thr 100 105 110 Glu Thr Met Gly Leu Ala Arg Pro Cys Pro Tyr His Gln Arg Val Arg 115 120 125 Leu Asp Thr Tyr Gly Gly Thr Val His Met Glu Leu Cys Phe Leu His 130 135 140 Asp Val Glu Asn Phe Leu Lys Gln Leu Asn Tyr Cys His Leu Ile Thr 145 150 155 160 Pro Ser Arg Gly Ala Thr Ala Ala Leu Glu Arg Val Arg Glu Phe Met 165 170 175 Val Gly Ala Val Gly Ser Gly Leu Ile Val Pro Pro Glu Leu Ser Asp 180 185 190 Pro Ser His Pro Cys Ala Val Cys Phe Glu Glu Leu Cys Val Thr Ala 195 200 205 Asn Gln Gly Ala Thr Ile Ala Arg Arg Leu Ala Asp Arg Ile Cys Asn 210 215 220 His Val Thr Gln Gln Ala Gln Val Arg Leu Asp Ala Asn Glu Leu Arg 225 230 235 240 Arg Tyr Leu Pro His Ala Ala Gly Leu Ser Asp Ala Asp Arg Ala Arg 245 250 255 Ala Leu Ser Val Leu Asp His Ala Leu Ala Arg Thr Ala Gly Gly Asp 260 265 270 Gly Gln Pro His Pro Ser Pro Glu Asn Asp Ser Val Arg Lys Glu Ala 275 280 285 Asp Ala Leu Leu Glu Ala His Asp Val Phe Gln Ala Thr Thr Pro Gly 290 295 300 Leu Tyr Ala Ile Ser Glu Leu Arg Phe Trp Leu Ala Ser Gly Asp Arg 305 310 315 320 Ala Gly Gln Thr Thr Met Asp Ala Phe Ala Ser Asn Leu Thr Ala Leu 325 330 335 Ala Arg Arg Glu Leu Gln Gln Glu Thr Ala Ala Val Ala Val Glu Leu 340 345 350 Ala Leu Phe Gly Arg Arg Ala Glu His Phe Asp Arg Ala Phe Gly Ser 355 360 365 His Leu Ala Ala Leu Asp Met Val Asp Ala Leu Ile Ile Gly Gly Gln 370 375 380 Ala Thr Ser Pro Asp Asp Gln Ile Glu Ala Leu Ile Arg Ala Cys Tyr 385 390 395 400 Asp His His Leu Thr Thr Pro Leu Leu Arg Arg Leu Val Ser Pro Glu 405 410 415 Gln Cys Asp Glu Glu Ala Leu Arg Arg Val Leu Ala Arg Met Gly Ala 420 425 430 Gly Gly Ala Ala Asp Ala Pro Lys Gly Gly Ala Gly Pro Asp Asp Asp 435 440 445 Gly Asp Arg Val Ala Val Glu Glu Gly Ala Arg Gly Leu Gly Ala Pro 450 455 460 Gly Gly Gly Gly Glu Asp Glu Asp Arg Arg Arg Gly Pro Gly Gly Gln 465 470 475 480 Gly Pro Glu Thr Trp Gly Asp Ile Ala Thr Gln Ala Ala Ala Asp Val 485 490 495 Arg Glu Arg Arg Arg Leu Tyr Ala Asp Arg Leu Thr Lys Arg Ser Leu 500 505 510 Ala Ser Leu Gly Arg Cys Val Arg Glu Gln Arg Gly Glu Leu Glu Lys 515 520 525 Met Leu Arg Val Ser Val His Gly Glu Val Leu Pro Ala Thr Phe Ala 530 535 540 Ala Val Ala Asn Gly Phe Ala Ala Arg Ala Arg Phe Cys Ala Leu Thr 545 550 555 560 Ala Gly Ala Gly Thr Val Ile Asp Asn Arg Ser Ala Pro Gly Val Phe 565 570 575 Asp Ala His Arg Phe Met Arg Ala Ser Leu Leu Arg His Gln Val Asp 580 585 590 Pro Ala Leu Leu Pro Ser Ile Thr His Arg Phe Phe Glu Leu Val Asn 595 600 605 Gly Pro Leu Phe Asp His Ser Thr His Ser Phe Ala Gln Pro Pro Asn 610 615 620 Thr Ala Leu Tyr Tyr Ser Val Glu Asn Val Gly Leu Leu Pro His Leu 625 630 635 640 Lys Glu Glu Leu Ala Arg Phe Ile Met Gly Ala Gly Gly Ser Gly Ala 645 650 655 Asp Trp Ala Val Ser Glu Phe Gln Arg Phe Tyr Cys Phe Asp Gly Ile 660 665 670 Ser Gly Ile Thr Pro Thr Gln Arg Ala Ala Trp Arg Tyr Ile Arg Glu 675 680 685 Leu Ile Ile Ala Thr Thr Leu Phe Ala Ser Val Tyr Arg Cys Gly Glu 690 695 700 Leu Glu Leu Arg Arg Pro Asp Cys Ser Arg Pro Thr Ser Glu Gly Arg 705 710 715 720 Tyr Arg Tyr Pro Pro Gly Val Tyr Leu Thr Tyr Asp Ser Asp Cys Pro 725 730 735 Leu Val Ala Ile Val Glu Ser Ala Pro Asp Gly Cys Ile Gly Pro Arg 740 745 750 Ser Val Val Val Tyr Asp Arg Asp Val Phe Ser Ile Leu Tyr Ser Val 755 760 765 Leu Gln His Leu Ala Pro Arg Leu Pro Asp Gly Gly His Asp Gly Pro 770 775 780 Pro 785 65 514 DNA Herpes Virus 65 tacctggcgc gcgccgcggg actcgtgggg gccatggtat ttagcaccaa ctcggccctc 60 catctcaccg aggtggacga cgccggcccg gcggacccaa aggaccacag caaaccctcc 120 ttttaccgct tcttcctcgt gcccgggacc cacgtggcgg ccaacccaca ggtggaccgc 180 gagggacacg tggtgcccgg gttcgagggt cggcccaccg cgcccctcgt cggcggaacc 240 caggaatttg ccggcgagca cctggccatg ctgtgtgggt tttccccggc gctgctggcc 300 aagatgctgt tttacctgga gcgctgcgac ggcggcgtga tcgtcgggcg ccaggagatg 360 gacgtgtttc gatacgtcgc ggactccaac cagaccgacg tgccctgtaa cctatgcacc 420 ttcgacacgc gccacgcctg cgtacacacg acgctcatgc gcctccgggc gcgccatcca 480 aagttcgcca gcgccgcccg cggagccatc ggcg 514 66 171 PRT Herpes Virus 66 Tyr Leu Ala Arg Ala Ala Gly Leu Val Gly Ala Met Val Phe Ser Thr 1 5 10 15 Asn Ser Ala Leu His Leu Thr Glu Val Asp Asp Ala Gly Pro Ala Asp 20 25 30 Pro Lys Asp His Ser Lys Pro Ser Phe Tyr Arg Phe Phe Leu Val Pro 35 40 45 Gly Thr His Val Ala Ala Asn Pro Gln Val Asp Arg Glu Gly His Val 50 55 60 Val Pro Gly Phe Glu Gly Arg Pro Thr Ala Pro Leu Val Gly Gly Thr 65 70 75 80 Gln Glu Phe Ala Gly Glu His Leu Ala Met Leu Cys Gly Phe Ser Pro 85 90 95 Ala Leu Leu Ala Lys Met Leu Phe Tyr Leu Glu Arg Cys Asp Gly Gly 100 105 110 Val Ile Val Gly Arg Gln Glu Met Asp Val Phe Arg Tyr Val Ala Asp 115 120 125 Ser Asn Gln Thr Asp Val Pro Cys Asn Leu Cys Thr Phe Asp Thr Arg 130 135 140 His Ala Cys Val His Thr Thr Leu Met Arg Leu Arg Ala Arg His Pro 145 150 155 160 Lys Phe Ala Ser Ala Ala Arg Gly Ala Ile Gly 165 170 67 3591 DNA Herpes Virus 67 atggagacaa agcccaagac ggcaaccacc atcaaggtcc cccccgggcc cctgggatac 60 gtgtacgctc gcgcgtgtcc gtccgaaggc atcgagcttc tggcgttact gtcggcacgc 120 agcggcgatt ccgacgtcgc cgtggcgccc ctggtcgtgg gcctgaccgt ggagagcggc 180 tttgaggcca acgtggccgt ggtcgtgggt tctcgcacga cggggctcgg gggtaccgcg 240 gtgtccctga aactgacgcc ctcgcactac agctcgtccg tgtacgtctt tcacggcggc 300 cggcacctgg accccagcac ccaggccccg aacctgacgc gactttgcga gcgggcacgc 360 cgccattttg gcttttcgga ctacaccccc cggcccggcg acctcaaaca cgagacgacg 420 ggggaggcgc tgtgtgagcg cctcggcctg gacccggacc gcgccctcct gtatctggtc 480 gttaccgagg gcttcaagga ggccgtgtgc atcaacaaca cctttctgca cctgggaggc 540 tcggacaagg taaccatagg cggggcggag gtgcaccgca tacccgtgta cccgttgcag 600 ctgttcatgc cggattttag ccgtgtcatc gcagagccgt tcaacgccaa ccaccgatcg 660 atcggggaga aatttaccta cccgcttccg ttttttaacc gccccctcaa ccgcctcctg 720 ttcgaggcgg tcgtgggacc cgccgccgtg gcactgcgat gccgaaacgt ggacgccgtg 780 gcccgcgcgg ccgcccacct ggcgtttgac gaaaaccacg agggcgccgc cctccccgcc 840 gacattacgt tcacggcctt cgaagccagc cagggtaaga ccccgcgggg cgggcgcgac 900 ggcggcggca agggcgcggc gggcgggttc gaacagcgcc tggcctccgt catggccgga 960 gacgccgccc tggccctcga gtctatcgtg tcgatggccg tctttgacga gccgcccacc 1020 gacatctccg cgtggccgct gttcgagggc caggacacgg ccgcggcccg cgccaacgcc 1080 gtcggggcgt acctggcgcg cgccgcggga ctcgtggggg ccatggtatt tagcaccaac 1140 tcggccctcc atctcaccga ggtggacgac gccggcccgg cggacccaaa ggaccacagc 1200 aaaccctcct tttaccgctt cttcctcgtg cccgggaccc acgtggcggc caacccacag 1260 gtggaccgcg agggacacgt ggtgcccggg ttcgagggtc ggcccaccgc gcccctcgtc 1320 ggcggaaccc aggaatttgc cggcgagcac ctggccatgc tgtgtgggtt ttccccggcg 1380 ctgctggcca agatgctgtt ttacctggag cgctgcgacg gcgccgtgat cgtcgggcgc 1440 caggagatgg acgtgtttcg atacgtcgcg gactccaacc agaccgacgt gccctgtaac 1500 ctatgcacct tcgacacgcg ccacgcctgc gtacacacga cgctcatgcg cctccgggcg 1560 cgccatccaa agttcgccag cgccgcccgc ggagccatcg gcgtcttcgg gaccatgaac 1620 agcatgtaca gcgactgcga cgtgctggga aactacgccg ccttctcggc cctgaagcgc 1680 gcggacggat ccgagaccgc ccggaccatc atgcaggaga cgtaccgcgc ggcgaccgag 1740 cgcgtcatgg ccgaactcga gaccctgcag tacgtggacc aggcggtccc cacggccatg 1800 gggcggctgg agaccatcat caccaaccgc gaggccctgc atacggtggt gaacaacgtc 1860 aggcaggtcg tggaccgcga ggtggagcag ctgatgcgca acctggtgga ggggaggaac 1920 ttcaagtttc gcgacggtct gggcgaggcc aaccacgcca tgtccctgac gctggacccg 1980 tacgcgtgcg ggccgtgccc cctgcttcag cttctcgggc ggcgatccaa cctcgccgtg 2040 taccaggacc tggccctgag tcagtgccac ggggtgttcg ccgggcagtc ggtcgagggg 2100 cgcaactttc gcaatcaatt ccaaccggtg ctgcggcggc gcgtgatgga catgtttaac 2160 aacgggtttc tgtcggccaa aacgctgacg gtcgcgctct cggagggggc ggctatctgc 2220 gcccccagcc taacggccgg ccagacggcc cccgccgaga gcagcttcga gggcgacgtt 2280 gcccgcgtga ccctggggtt tcccaaggag ctgcgcgtca agagccgcgt gttgttcgcg 2340 ggcgcgagcg ccaacgcgtc cgaggccgcc aaggcgcggg tcgccagcct ccagagcgcc 2400 taccagaagc ccgacaagcg cgtggacatc ctcctcggac cgctgggctt tctgctgaag 2460 cagttccacg cggccatctt ccccaacggc aagcccccgg ggtccaacca gccgaacccg 2520 cagtggttct ggacggccct ccaacgcaac cagcttcccg cccggctcct gtcgcgcgag 2580 gacatcgaga ccatcgcgtt cattaaaaag ttttccctgg actacggcgc gataaacttt 2640 attaacctgg cccccaacaa cgtgagcgag ctggcgatgt actacatggc aaaccagatt 2700 ctgcggtact gcgatcactc gacatacttc atcaacaccc ttacggccat catcgcgggg 2760 tcccgccgtc cccccagcgt gcaggctgcg gccgcgtggt ccgcgcaggg cggggcgggc 2820 ctggaggccg gggcccgcgc gctgatggac gccgtggacg cgcatccggg cgcgtggacg 2880 tccatgttcg ccagctgcaa cctgctgcgg cccgtcatgg cggcgcgccc catggtcgtg 2940 ttggggttga gcatcagcaa gtactacggc atggccggca acgaccgtgt gtttcaggcc 3000 gggaactggg ccagcctgat gggcggcaaa aacgcgtgcc cgctccttat ttttgaccgc 3060 acccgcaagt tcgtcctggc ctgtccccgg gccgggtttg tgtgcgcggc ctcaagcctc 3120 ggcggcggag cgcacgaaag ctcgctgtgc gagcagctcc ggggcattat ctccgagggc 3180 ggggcggccg tcgccagtag cgtgttcgtg gcgaccgtga aaagcctggg gccccgcacc 3240 cagcagctgc agatcgagga ctggctggcg ctcctggagg acgagtacct aagcgaggag 3300 atgatggagc tgaccgcgcg tgccctggag cgcggcaacg gcgagtggtc gacggacgcg 3360 gccctggagg tggcgcacga ggccgaggcc ctagtcagcc aactcggcaa cgccggggag 3420 gtgtttaact ttggggattt tggctgcgag gacgacaacg cgacgccgtt cggcggcccg 3480 ggggccccgg gaccggcatt tgccggccgc aaacgggcgt tccacgggga tgacccgttt 3540 ggggaggggc cccccgacaa aaagggagac ctgacgttgg atatgctgtg a 3591 68 1196 PRT Herpes Virus 68 Met Glu Thr Lys Pro Lys Thr Ala Thr Thr Ile Lys Val Pro Pro Gly 1 5 10 15 Pro Leu Gly Tyr Val Tyr Ala Arg Ala Cys Pro Ser Glu Gly Ile Glu 20 25 30 Leu Leu Ala Leu Leu Ser Ala Arg Ser Gly Asp Ala Asp Val Ala Val 35 40 45 Ala Pro Leu Val Val Gly Leu Thr Val Glu Ser Gly Phe Glu Ala Asn 50 55 60 Val Ala Val Val Val Gly Ser Arg Thr Thr Gly Leu Gly Gly Thr Ala 65 70 75 80 Val Ser Leu Lys Leu Thr Pro Ser His Tyr Ser Ser Ser Val Tyr Val 85 90 95 Phe His Gly Gly Arg His Leu Asp Pro Ser Thr Gln Ala Pro Asn Leu 100 105 110 Thr Arg Leu Cys Glu Arg Ala Arg Arg His Phe Gly Phe Ser Asp Tyr 115 120 125 Thr Pro Arg Pro Gly Asp Leu Lys His Glu Thr Thr Gly Glu Ala Leu 130 135 140 Cys Glu Arg Leu Gly Leu Asp Pro Asp Arg Ala Leu Leu Tyr Leu Val 145 150 155 160 Val Thr Glu Gly Phe Lys Glu Ala Val Cys Ile Asn Asn Thr Phe Leu 165 170 175 His Leu Gly Gly Ser Asp Lys Val Thr Ile Gly Gly Ala Glu Val His 180 185 190 Arg Ile Pro Val Tyr Pro Leu Gln Leu Phe Met Pro Asp Phe Ser Arg 195 200 205 Val Ile Ala Glu Pro Phe Asn Ala Asn His Arg Ser Ile Gly Glu Asn 210 215 220 Phe Thr Tyr Pro Leu Pro Phe Phe Asn Arg Pro Leu Asn Arg Leu Leu 225 230 235 240 Phe Glu Ala Val Val Gly Pro Ala Ala Val Ala Leu Arg Cys Arg Asn 245 250 255 Val Asp Ala Val Ala Arg Ala Ala Ala His Leu Ala Phe Asp Glu Asn 260 265 270 His Glu Gly Ala Ala Leu Pro Ala Asp Ile Thr Phe Thr Ala Phe Glu 275 280 285 Ala Ser Gln Gly Lys Thr Pro Arg Gly Gly Arg Asp Gly Gly Gly Lys 290 295 300 Gly Pro Ala Gly Gly Phe Glu Gln Arg Leu Ala Ser Val Met Ala Gly 305 310 315 320 Asp Ala Ala Leu Ala Leu Glu Ser Ile Val Ser Met Ala Val Phe Asp 325 330 335 Glu Pro Pro Thr Asp Ile Ser Ala Trp Pro Leu Cys Glu Gly Gln Asp 340 345 350 Thr Ala Ala Ala Arg Ala Asn Ala Val Gly Ala Tyr Leu Ala Arg Ala 355 360 365 Ala Gly Leu Val Gly Ala Met Val Phe Ser Thr Asn Ser Ala Leu His 370 375 380 Leu Thr Glu Val Asp Asp Ala Gly Pro Ala Asp Pro Lys Asp His Ser 385 390 395 400 Lys Pro Ser Phe Tyr Arg Phe Phe Leu Val Pro Gly Thr His Val Ala 405 410 415 Ala Asn Pro Gln Val Asp Arg Glu Gly His Val Val Pro Gly Phe Glu 420 425 430 Gly Arg Pro Thr Ala Pro Leu Val Gly Gly Thr Gln Glu Phe Ala Gly 435 440 445 Glu His Leu Ala Met Leu Cys Gly Phe Ser Pro Ala Leu Leu Ala Lys 450 455 460 Met Leu Phe Tyr Leu Glu Arg Cys Asp Gly Gly Val Ile Val Gly Arg 465 470 475 480 Gln Glu Met Asp Val Phe Arg Tyr Val Ala Asp Ser Asn Gln Thr Asp 485 490 495 Val Pro Cys Asn Leu Cys Thr Phe Asp Thr Arg His Ala Cys Val His 500 505 510 Thr Thr Leu Met Arg Leu Arg Ala Arg His Pro Lys Phe Ala Ser Ala 515 520 525 Ala Arg Gly Ala Ile Gly Val Phe Gly Thr Met Asn Ser Met Tyr Ser 530 535 540 Asp Cys Asp Val Leu Gly Asn Tyr Ala Ala Phe Ser Ala Leu Lys Arg 545 550 555 560 Ala Asp Gly Ser Glu Thr Ala Arg Thr Ile Met Gln Glu Thr Tyr Arg 565 570 575 Ala Ala Thr Glu Arg Val Met Ala Glu Leu Glu Thr Leu Gln Tyr Val 580 585 590 Asp Gln Ala Val Pro Thr Ala Met Gly Arg Leu Glu Thr Ile Ile Thr 595 600 605 Asn Arg Glu Ala Leu His Thr Val Val Asn Asn Val Arg Gln Val Val 610 615 620 Asp Arg Glu Val Glu Gln Leu Met Arg Asn Leu Val Glu Gly Arg Asn 625 630 635 640 Phe Lys Phe Arg Asp Gly Leu Gly Glu Ala Asn His Ala Met Ser Leu 645 650 655 Thr Leu Asp Pro Tyr Ala Cys Gly Pro Cys Pro Leu Leu Gln Leu Leu 660 665 670 Gly Arg Arg Ser Asn Leu Ala Val Tyr Gln Asp Leu Ala Leu Ser Gln 675 680 685 Cys His Gly Val Phe Ala Gly Gln Ser Val Glu Gly Arg Asn Phe Arg 690 695 700 Asn Gln Phe Gln Pro Val Leu Arg Arg Arg Val Met Asp Met Phe Asn 705 710 715 720 Asn Gly Phe Leu Ser Ala Lys Thr Leu Thr Val Ala Leu Ser Glu Gly 725 730 735 Ala Ala Ile Cys Ala Pro Ser Leu Thr Ala Gly Gln Thr Ala Pro Ala 740 745 750 Glu Ser Ser Phe Glu Gly Asp Val Ala Arg Val Thr Leu Gly Phe Pro 755 760 765 Lys Glu Leu Arg Val Lys Ser Arg Val Leu Phe Ala Gly Ala Ser Ala 770 775 780 Asn Ala Ser Glu Ala Ala Lys Ala Arg Val Ala Ser Leu Gln Ser Ala 785 790 795 800 Tyr Gln Lys Pro Asp Lys Arg Val Asp Ile Leu Leu Gly Pro Leu Gly 805 810 815 Phe Leu Leu Lys Gln Phe His Ala Ala Ile Phe Pro Asn Gly Lys Pro 820 825 830 Pro Gly Ser Asn Gln Pro Asn Pro Gln Trp Phe Trp Thr Ala Leu Gln 835 840 845 Arg Asn Gln Leu Pro Ala Arg Leu Leu Ser Arg Glu Asp Ile Glu Thr 850 855 860 Ile Ala Phe Ile Lys Lys Phe Ser Leu Asp Tyr Gly Ala Ile Asn Phe 865 870 875 880 Ile Asn Leu Ala Pro Asn Asn Val Ser Glu Leu Ala Met Tyr Tyr Met 885 890 895 Ala Asn Gln Ile Leu Arg Tyr Cys Asp His Ser Thr Tyr Phe Ile Asn 900 905 910 Thr Leu Thr Ala Ile Ile Ala Gly Ser Arg Arg Pro Pro Ser Val Gln 915 920 925 Ala Ala Ala Ala Trp Ser Ala Gln Gly Gly Ala Gly Leu Glu Ala Gly 930 935 940 Ala Arg Ala Leu Met Asp Ala Val Asp Ala His Pro Gly Ala Trp Thr 945 950 955 960 Ser Met Phe Ala Ser Cys Asn Leu Leu Arg Pro Val Met Ala Ala Arg 965 970 975 Pro Met Val Val Leu Gly Leu Ser Ile Ser Lys Tyr Tyr Gly Met Ala 980 985 990 Gly Asn Asp Arg Val Phe Gln Ala Gly Asn Trp Ala Ser Leu Met Gly 995 1000 1005 Gly Lys Asn Ala Cys Pro Leu Leu Ile Phe Asp Arg Thr Arg Lys Phe 1010 1015 1020 Val Leu Ala Cys Pro Arg Ala Gly Phe Val Cys Ala Ala Ser Asn Leu 1025 1030 1035 1040 Gly Gly Gly Ala His Glu Ser Ser Leu Cys Glu Gln Leu Arg Gly Ile 1045 1050 1055 Ile Ser Glu Gly Gly Ala Ala Val Ala Ser Ser Val Phe Val Ala Thr 1060 1065 1070 Val Lys Ser Leu Gly Pro Arg Thr Gln Gln Leu Gln Ile Glu Asp Trp 1075 1080 1085 Leu Ala Leu Leu Glu Asp Glu Tyr Leu Ser Glu Glu Met Met Glu Leu 1090 1095 1100 Thr Ala Arg Ala Leu Glu Arg Gly Asn Gly Glu Trp Ser Thr Asp Ala 1105 1110 1115 1120 Ala Leu Glu Val Ala His Glu Ala Glu Ala Leu Val Ser Gln Leu Gly 1125 1130 1135 Asn Ala Gly Glu Val Phe Asn Phe Gly Asp Phe Gly Cys Glu Asp Asp 1140 1145 1150 Asn Ala Thr Pro Phe Gly Gly Pro Gly Ala Pro Gly Pro Ala Phe Ala 1155 1160 1165 Gly Arg Lys Arg Ala Phe His Gly Asp Asp Pro Phe Gly Glu Gly Pro 1170 1175 1180 Pro Asp Lys Lys Gly Asp Leu Thr Leu Asp Met Leu 1185 1190 1195 69 1323 DNA Herpes Virus 69 aaaaccaaga agaaatccac ccccaaaggc aaaacccccg tcggggccgc ggtccccgcc 60 tccgttccgg agcctgtcct cgcctcggca ccccccgacc cggccgggcc gccggtcgcc 120 gaggcgggcg aggacgacgg gcccacggtt ccggcgtcct cacaggccct cgaggcgctg 180 aagactcgcc gctcgcccga gcccccgggc gcagacctcg cccagctgtt cgaggcccac 240 ccaaacgtgg ccgccacggc ggttaagttc accgcgtgct ccgccgccct ggcccgcgag 300 gtcgccgcgt gttcgcggct caccatcagc gccttacggt cgccgtatcc ggcctctccg 360 gggctgctgg agctctgtgt tatttttttc tttgaacgcg tcctcgcctt tctcatcgag 420 aacggggccc ggacgcacac ccaggccggg gtggccggcc cggccgccgc cctgctggag 480 tttaccctga acatgctgcc ctggaaaacg gccgtggggg actttctggc ctccacgcgc 540 ctgagcctgg ccgacgtggc cgcccatctg cccctcgtcc agcacgtgct ggacgaaaac 600 tctctgatcg gtcgcctggc gctggcgaag ctgatccttg tggctaggga tgtcattcgg 660 gagacggacg ccttttacgg ggaactcgcg gacctggagc tgcagcttcg cgcggccccg 720 ccggccaatc tgtatacacg cctcggcgag tggcttctgg agcgctcgca ggcccacccg 780 gacacccttt ttgcccccgc caccccgacg cacccagaac cgcttctgta tagagtccag 840 gctctggcca aatttgcccg tggcgaagag attagggtgg aggcggagga tcgccagatg 900 cgcgaggccc tcgacgccct cgctcgcggg gtcgacgcgg tctcacagca cgccgggccc 960 ctcggcgtaa tgcccgcccc ggccggggcg gccccgcagg gggctccgcg cccacccccc 1020 ctgggccccg aggccgttca ggttcggctg gaggaggtgc ggacccaggc ccgtcgggcg 1080 atcgagggcg cggttaagga gtacttttac cggggggccg tatacagcgc caaggctcta 1140 caggccagcg acaacaacga ccgccggttt cacgtggctt cggccgccgt cgtgcccgtg 1200 gtccagctgc tcgagtccct gcctgtcttc gaccagcaca cgcgggacat cgcgcagcgc 1260 gccgccattc ccgccccgcc cccgatcgcg accagcccca cggccatcct gttgcgggat 1320 ctg 1323 70 441 PRT Herpes Virus 70 Lys Thr Lys Lys Lys Ser Thr Pro Lys Gly Lys Thr Pro Val Gly Ala 1 5 10 15 Ala Val Pro Ala Ser Val Pro Glu Pro Val Leu Ala Ser Ala Pro Pro 20 25 30 Asp Pro Ala Gly Pro Pro Val Ala Glu Ala Gly Glu Asp Asp Gly Pro 35 40 45 Thr Val Pro Ala Ser Ser Gln Ala Leu Glu Ala Leu Lys Thr Arg Arg 50 55 60 Ser Pro Glu Pro Pro Gly Ala Asp Leu Ala Gln Leu Phe Glu Ala His 65 70 75 80 Pro Asn Val Ala Ala Thr Ala Val Lys Phe Thr Ala Cys Ser Ala Ala 85 90 95 Leu Ala Arg Glu Val Ala Ala Cys Ser Arg Leu Thr Ile Ser Ala Leu 100 105 110 Arg Ser Pro Tyr Pro Ala Ser Pro Gly Leu Leu Glu Leu Cys Val Ile 115 120 125 Phe Phe Phe Glu Arg Val Leu Ala Phe Leu Ile Glu Asn Gly Ala Arg 130 135 140 Thr His Thr Gln Ala Gly Val Ala Gly Pro Ala Ala Ala Leu Leu Glu 145 150 155 160 Phe Thr Leu Asn Met Leu Pro Trp Lys Thr Ala Val Gly Asp Phe Leu 165 170 175 Ala Ser Thr Arg Leu Ser Leu Ala Asp Val Ala Ala His Leu Pro Leu 180 185 190 Val Gln His Val Leu Asp Glu Asn Ser Leu Ile Gly Arg Leu Ala Leu 195 200 205 Ala Lys Leu Ile Leu Val Ala Arg Asp Val Ile Arg Glu Thr Asp Ala 210 215 220 Phe Tyr Gly Glu Leu Ala Asp Leu Glu Leu Gln Leu Arg Ala Ala Pro 225 230 235 240 Pro Ala Asn Leu Tyr Thr Arg Leu Gly Glu Trp Leu Leu Glu Arg Ser 245 250 255 Gln Ala His Pro Asp Thr Leu Phe Ala Pro Ala Thr Pro Thr His Pro 260 265 270 Glu Pro Leu Leu Tyr Arg Val Gln Ala Leu Ala Lys Phe Ala Arg Gly 275 280 285 Glu Glu Ile Arg Val Glu Ala Glu Asp Arg Gln Met Arg Glu Ala Leu 290 295 300 Asp Ala Leu Ala Arg Gly Val Asp Ala Val Ser Gln His Ala Gly Pro 305 310 315 320 Leu Gly Val Met Pro Ala Pro Ala Gly Ala Ala Pro Gln Gly Ala Pro 325 330 335 Arg Pro Pro Pro Leu Gly Pro Glu Ala Val Gln Val Arg Leu Glu Glu 340 345 350 Val Arg Thr Gln Ala Arg Arg Ala Ile Glu Gly Ala Val Lys Glu Tyr 355 360 365 Phe Tyr Arg Gly Ala Val Tyr Ser Ala Lys Ala Leu Gln Ala Ser Asp 370 375 380 Asn Asn Asp Arg Arg Phe His Val Ala Ser Ala Ala Val Val Pro Val 385 390 395 400 Val Gln Leu Leu Glu Ser Leu Pro Val Phe Asp Gln His Thr Arg Asp 405 410 415 Ile Ala Gln Arg Ala Ala Ile Pro Ala Pro Pro Pro Ile Ala Thr Ser 420 425 430 Pro Thr Ala Ile Leu Leu Arg Asp Leu 435 440 71 9495 DNA Herpes Virus 71 atgggtggcg gaaacaacac taaccccggg ggtccggtcc ataaacaggc cgggtctctg 60 gccagcaggg cacatatgat cgcgggcacc ccaccgcact ccacgatgga acgcgggggg 120 gatcgcgaca tcgtggtcac cggtgctcgg aaccagttcg cgcccgacct ggagccgggg 180 gggtcggtat cgtgcatgcg ctcgtcgctg tcctttctca gcctcatatt tgatgtgggc 240 cctcgcgacg tcctgtccgc ggaggccatc gagggatgtt tggtcgaggg gggcgagtgg 300 acgcgcgcga ccgcgggccc tgggccgccg cgcatgtgtt cgatcgtcga gctccccaac 360 ttcctcgagt acccaggggc gcgcggcgga ctgcgctgtg tcttctcgcg cgtatacggc 420 gaggtgggct tcttcgggga gcccgcggcg ggcctgctgg agacacaatg ccccgcacac 480 acgttcttcg ccggcccgtg ggccctgcgc cccctgtcgt acacgctcct aaccattggc 540 cccctaggga tggggctgtt cagggacggc gacaccgcat acctttttga cccgcacggc 600 cttccggagg gcacccccgc gttcatcgcc aaagtgcggg cgggggacat gtatccatac 660 ctgacgtatt acacccgcga tcgcccggac gtacggtggg cgggagccat ggtgtttttc 720 gtgccgtcgg gcccggaacc cgcggctcct gcggacttga cggccgcggc tctgcatctt 780 tacggggcca gcgagactta cctgcaggac gaagcgttca gcgaacggcg cgtggccatc 840 acgcaccccc tgcggggcga gatcgcgggc ctgggggagc cctgcgtcgg cgtgggcccc 900 cgggaggggg tagggggccc ggggccacac ccgcccacag ccgcccagtc gccgccaccg 960 acccgggccc gtcgcgacga cagggcctcc gagacatccc gggggacggc cggtccgtcg 1020 gcaaaaccag aggccaagcg cccgaatcgg gcgcccgacg atgtatgggc ggtggccctg 1080 aagggtaccc cacccacgga tcccccctcc gccgacccac cctccgccga cccaccctcc 1140 gcgatcccac caccgcctcc ctccgccccc aagacccccg ccgcagaggc ggccgaagaa 1200 gatgacgacg acatgcgggt cctggagatg ggcgtcgtcc cggttggtcg gcaccgggca 1260 cgctactcgg ccggccttcc caagcgccgc cgacccacct ggactccgcc ttccagcgtc 1320 gaagacctga cttcggggga gaaaacgaaa cgctcggccc cccctgccaa aaccaagaag 1380 aaatccaccc ccaaaggcaa aacccccgtc ggggccgcgg tccccgcctc cgttccggag 1440 cctgtcctcg cctcggcacc ccccgacccg gccgggccgc cggtcgccga ggcgggcgag 1500 gacgacgggc ccacggttcc ggcgtcctca caggccctcg aggcgctgaa gactcgccgc 1560 tcgcccgagc ccccgggcgc agacctcgcc cagctgttcg aggcccaccc aaacgtggcc 1620 gccacggcgg ttaagttcac cgcgtgctcc gccgccctgg cccgcgaggt cgccgcgtgt 1680 tcgcggctca ccatcagcgc cttacggtcg ccgtatccgg cctctccggg gctgctggag 1740 ctctgtgtta tttttttctt tgaacgcgtc ctcgcctttc tcatcgagaa cggggcccgg 1800 acgcacaccc aggccggggt ggccggcccg gccgccgccc tgctggagtt taccctgaac 1860 atgctgccct ggaaaacggc cgtgggggac tttctggcct ccacgcgcct gagcctggcc 1920 gacgtggccg cccatctgcc cctcgtccag cacgtgctgg acgaaaactc tctgatcggt 1980 cgcctggcgc tggcgaagct gatccttgtg gctagggatg tcattcggga gacggacgcc 2040 ttttacgggg aactcgcgga cctggagctg cagcttcgcg cggccccgcc ggccaatctg 2100 tatacacgcc tcggcgagtg gcttctggag cgctcgcagg cccacccgga cacccttttt 2160 gcccccgcca ccccgacgca cccagaaccg cttctgtata gagtccaggc tctggccaaa 2220 tttgcccgtg gcgaagagat tagggtggag gcggaggatc gccagatgcg cgaggccctc 2280 gacgccctcg ctcgcggggt cgacgcggtc tcacagcacg ccgggcccct cggcgtaatg 2340 cccgccccgg ccggggcggc cccgcagggg gctccgcgcc caccccccct gggccccgag 2400 gccgttcagg ttcggctgga ggaggtgcgg acccaggccc gtcgggcgat cgagggcgcg 2460 gttaaggagt acttttaccg gggggccgta tacagcgcca aggctctaca ggccagcgac 2520 aacaacgacc gccggtttca cgtggcttcg gccgccgtcg tgcccgtggt ccagctgctc 2580 gagtccctgc ctgtcttcga ccagcacacg cgggacatcg cgcagcgcgc cgccattccc 2640 gccccgcccc cgatcgcgac cagccccacg gccatcctgt tgcgggatct gatccagcgg 2700 ggccagacgc tggacgcccc cgaggacctg gcggcctggc tctccgtcct gacggacgcc 2760 gccaaccaag ggctgataga acgcaagcca ctggacgagc tggcgcgcag catccgcgac 2820 attaacgacc aacaggcgcg ccgcagctcg ggtctggccg agctgcggcg cttcgacgcc 2880 ctagatgcgg ccctgggcca gcagctggac agcgacgcgg cctttgttcc tgcgcccggc 2940 gcgtcgccct accccgacga cggcgggctg tcgccagagg ccacgcgcat ggccgaggaa 3000 gcgctgcggc aggcgcgggc catggatgcc gccaagctga cggcagagct cgcccccgat 3060 gcgcgtgccc gtttgcggga gcgcgcgcgc tccctggagg caatgctcga gggagcgcgg 3120 gagcgggcga aggtggcccg cgacgcccgg gagaagttct tgcacaaact ccagggggtc 3180 ctgcgccccc tccctgactt tgtggggcta aaggcctgtc cggccgtcct ggcgaccctg 3240 cgggcctccc tgccggcggg ctggtcggac ctccccgagg ccgttcgggg ggcgccccct 3300 gaggttacgg cggcgctgcg ggcggacatg tgggggctgc tggggcagta ccgagatgcc 3360 ctggagcacc cgactccgga cacggcgacg gctctgtctg gcttgcatcc cagcttcgtg 3420 gtggtgctga agaacctgtt cgccgacgcc ccagagactc cgtttctctt gcagttcttc 3480 gccgatcacg ccccgatcat agcccacgcc gtctcgaacg ccatcaacgc cggcagcgcc 3540 gccgtcgcaa cggcagaccc tgcgtcgacg gtggatgcgg ccgtgcgggc gcaccgcgtc 3600 ctggtcgacg cggtgacggc cctgggcgcg gccgccagcg acccggcctc ccccctggcc 3660 ttcctagcgg ccatggccga cagcgccgcg ggatacgtca aggcgactcg gttggccctg 3720 gacgcgcggg tggccatcgc ccagctcacg accttagggt cggctgccgc cgaccttgtc 3780 gtccaggtgc gccgggccgc caaccaaccg gagggagagc atgcctccct gatccaggcc 3840 gcgacgcgcg cgaccaccgg cgcgcgggaa agcctcgcgg gccacgaggg caggttcggg 3900 ggcctgttgc acgccgaagg gacggccggg gaccactccc ccagcgggcg cgccctgcag 3960 gagctgggaa aggtcatcgg cgccacgcga cgccgcgccg acgaacttga ggccgccacc 4020 gccgacctca gagagaagat ggcggcccag cgcgcccgca gtagccacga gcgctgggcc 4080 gccgacgtgg aggccgtgct ggaccgcgtg gaaagcggtg ccgagtttga cgtggtcgag 4140 ctccgtcgcc tgcaggcgct ggcgggcacg cacggctaca acccccggga cttccgaaag 4200 cgggccgaac aggcgctggg aaccaacgcc aaggcggtga cccttgccct ggagacggcc 4260 cttgcgttta acccatacac ccccgagaac cagcgccacc ccatgctccc cccgctcgca 4320 gccattcacc gcatcgactg gagcgcggcc ttcggggccg cggccgacac gtacgccgac 4380 atgtttcggg tggacaccga gcccctggcg cggcttctgc ggctggcggg ggggctgctg 4440 gagcgggccc aggcgaacga cgggtttatc gactaccacg aggccgtcct acacctgtcg 4500 gaagacttgg ggggcgtgcc ggccctgcgc cagtacgtgc cgttttttca aaagggctac 4560 gccgagtacg tggatatccg cgatcgcctg gacgccctcc gggccgacgc gcggcgcgcg 4620 atcggaagcg tggcgctgga cctggccgcc gccgcggagg agatatccgc ggtgcgcaac 4680 gacccggcgg cggccgccga gcttgtccgg gcaggggtca ccctgccctg cccgagcgag 4740 gacgcgctgg tggcgtgcgt ggcggcgctg gagcgcgtgg accagagccc cgtgaaggac 4800 acggcgtacg cgcactacgt cgcattcgtg acccgacagg acctggccga taccaaggac 4860 gccgtggtgc gcgccaaaca gcagcgcgcc gaagccaccg agcgggtcac ggcggggctg 4920 cgggaggtgc tggccgcgcg cgagcgccgg gcccagctcg aggccgaggg tctggccaat 4980 ctgaagaccc tgctgaaggt ggtcgccgtc ccggcgaccg tggccaagac gctggaccag 5040 gcgcgctcgg cggaggagat cgcggatcag gtcgaaattc tggtggacca gacggagaag 5100 gcgcgcgagc tcgacgtgca ggcggtcgcc tggttggaac atgcccagcg tacctttgag 5160 acgcacccgc taagcgcggc cagcggcgac ggcccgggcc tcctgacgcg acagggcgcg 5220 cgcctgcagg cgctcttcga cacccgtcgc cgcgtcgagg ccctgcggag gtctctcgag 5280 gaggccgagg cggagtggga cgaggtatgg ggtcgcttcg gccgcgttcg cgggggggcc 5340 tggaaatcgc ccgagggatt tcgcgcggca tgcgagcagc ttcgcgccct gcaggacacc 5400 accaacactg tgtcggggct gcgagcccag cgggactacg agcgccttcc cgccaagtac 5460 cagggcgtcc tgggcgccaa gagcgccgag cgggccgggg ccgtggagga gctcgggggg 5520 cgcgtggccc aacacgccga cctgagcgcc cggctgcggg acgaggtggt gccaagggtg 5580 gcctgggaga tgaactttga caccctgggg ggcctgttgg cggaattcga cgcggtggcc 5640 ggggacctgg ccccatgggc ggtggaggag ttccggggcg cgcgggagct catccaacgc 5700 cgcatgggct tatatagcgc gtacgccaag gccacaggcc agacgggcgc gggcgcggcg 5760 gccgcgcccg cgcccctgct cgtggatctt cgcgccctag acgcccgcgc ccgggcgtcc 5820 gccccacccg gccaagaggc cgacccgcag atgctgcgcc gccggggcga ggcgtacctg 5880 cgagtgagcg gaggcccggg gcccctggtg ctgcgcgagg ccaccagtac gctggatcgg 5940 ccgttcgccc ccagcttttt ggtcccggat ggaacgccac tgcagtacgc gctctgcttc 6000 ccggccgtga ccgacaagct cggcgcgctg ctgatgtgtc ccgaggcggc atgcattcgc 6060 cccccgcttc cgacggacac cctggagtcg gcctcgaccg tcacggccat gtacgtcctc 6120 accgtcatca accggcttca gctggccctc agcgacgccc aggccgccaa ctttcagctc 6180 ttcggacgct ttgtgcgcca ccgccaggcg agatgggggg cctcgatgga tgcggcggcc 6240 gagctctacg tcgccctcgt cgcgaccact ctcacgcgcg agtttgggtg tcgctgggcc 6300 cagctggaat gggggggtga cgcggcggcc ccggggccgc cgctcggacc ccagagctcc 6360 actaggcacc gcgtttcctt taacgagaac gacgtgctgg tggcgctggt ggccagctcc 6420 ccggaacaca tttacacctt ttggcgcctg gatctggttc gccaacacga gtacatgcat 6480 ctcaccctcc cccgtgcgtt tcagaacgca gcagattcca tgctattcgt gcagcgcctg 6540 accccgcatc cagacgcccg catccgcgtg ctgccagcgt tttcggccgg aggccctccg 6600 acccggggcc tcatgttcgg cacgcggctg gcagactggc gccgcggcaa gttgtccgaa 6660 accgaccccc tggcgccctg gcgctcggtc cccgagctgg gaaccgagcg cggcgccgcg 6720 ctgggaaagc tgagtcccgc ccaggcgctg gcggcggtga gcgtcctcgg gcgcatgtgt 6780 ctcccaagca ccgctctggt cgctctttgg acctgcatgt ttccggacga ctacacagag 6840 tatgacagtt tcgacgccct tctgaccgcg cgtctggaat ctgggcagac gctgagcccc 6900 tcgggggggc gcgaggcgtc accccccgct ccccccaacg ccctctaccg gcccacgggc 6960 cagcacgtcg ccgtgccggc cgccgccacc caccgcaccc ccgcggcgcg cgttacggcc 7020 atggacctgg tgctggcggc agtgctcctg ggcgcgcccg tcgtcgtggc gctccgcaac 7080 accacggcct tttcccgcga gtcggagctg gagctgtgtc tcacgctgtt tgactcacgc 7140 gctcgcgggc cggacgccgc cttgcgcgat gccgtgtcgt ccgacatcga gacgtgggcc 7200 gtccgcctcc tgcacgccga cctgaacccg atcgaaaacg cgtgtctggc ggcacagctc 7260 ccgcgcctgt ccgcgctcat cgccgagcgg cccctcgccc ggggcccgcc gtgtctggtg 7320 ctcgtggaca tctccatgac cccggtcgcg gtgttgtggg aaaacccgga cccccccggc 7380 ccccccgacg tgcggtttgt tggcagcgag gccaccgagg agctcccgtt tgtggcgggc 7440 ggcgaggacg tcctcgccgc cagcgccacc gacgaggacc ccttcctcgc gcgagctatc 7500 ctcgggcggc cgttcgacgc ctccctcctg tcgggggagc tattcccggg gcatccggtg 7560 taccagcgcg cccccgacga ccagagcccc tcggtcccaa acccgacccc cggccctgtg 7620 gaccttgttg gggcggaggg ctcgttgggg cccggaagcc tggcccccac gctattcacc 7680 gacgccaccc ccggcgagcc cgtcccccct cgcatgtggg catggattca cggcctggag 7740 gagctcgcgt ctgacgactc cggcggcccc gcgcccctcc ttgccccgga ccccctttcg 7800 cccaccgccg atcagtccgt ccccacgtcc cagtgtgcac cgcggccccc tgggccggca 7860 gtcacggctc gcgaagcacg accgggcgtc ccggccgaaa gcacgcggcc ggcgcccgtg 7920 ggcccccgcg acgacttccg gcgcttgccg tccccccaaa gttccccggc gccccccgat 7980 gccaccgccc cccgcccccc cgcctcctcc cgcgcttctg ccgcttcttc gtccgggtcg 8040 cgcgcgcgcc gacaccgccg ggcacgctcc ctggcgcgcg ccacccaggc ttccgcgacc 8100 acccagggtt ggcggccgcc tgccctcccc gacacggtcg ccccggttac cgatttcgcg 8160 cgccccccgg cccctcccaa acccccagag ccagcgcccc acgctttggt gtctggtgtg 8220 cccctcccgc tcgggcccca ggccgccggc caggcttctc ccgctctccc tatcgatccc 8280 gttccgcccc cggtcgcaac cggcacggtt ttgcccgggg gcgaaaaccg ccgccccccg 8340 ctaacctcgg gtcccgcgcc aacccccccc agggttcccg taggcgggcc gcagcggcgc 8400 cttacgcgcc ccgctgtcgc gtcgctgtcc gaatcgcggg aatccctccc ttcaccctgg 8460 gaccccgccg accccacggc ccctgtttta ggccgcaacc cggccgagcc gacctcatcc 8520 tctcccgcag gtccctctcc cccgcctccc gcggtccaac ccgtcgcccc gcccccgacg 8580 tcaggcccgc cccccacata cttgacgctg gagggcggtg ttgcgcccgg aggcccggtt 8640 tcccgccgcc ccactacacg gcagccggtg gccacgccca ccacatctgc gcgcccccgg 8700 gggcatttga ccgtcagccg cctgtccgcg ccccaacccc agccccagcc ccagccccag 8760 ccccagcccc agccccagcc ccagccccag ccccagcccc agccccagcc ccagccccag 8820 ccccagcccc agccccaacc ccaaccccag ccccaacccc aaccccaacc ccagccccaa 8880 ccccagcccc aaccccagcc ccaaccccag ccccaacccc agccccaacc ccagccccaa 8940 aacgggcatg tagcacccgg ggagtatccg gcggttcggt tccgggcacc gcaaaaccgc 9000 ccatccgtcc cggcttccgc gtcttccaca aatccacgca cgggcagctc cttgtctggg 9060 gtgtcttcgt gggcatcctc cctcgcgcta cacatcgacg ctaccccccc gcccgtgtcg 9120 ctgcttcaga ccctgtatgt ctctgacgac gaagactccg acgccacctc gttgttcctc 9180 tcggattccg aggccgaggc gctcgaccca ctccctgggg aaccacactc ccccataacc 9240 aacgaaccat tcagtgcgtt atccgccgat gactcccaag aggtgacgcg cttacaattc 9300 ggccccccgc ccgtatcggc aaacgcagtt ctgtcgcgac gctacgtgca acgcaccggt 9360 cgtagcgccc tggcggtact gatccgcgcc tgttaccgcc tacaacagca gttacagcgg 9420 acccgccggg cgctgcttca tcacagcgac gccgtgctga ccagcctaca tcacgtgcgc 9480 atgttactgg gctag 9495 72 3164 PRT Herpes Virus 72 Met Gly Gly Gly Asn Asn Thr Asn Pro Gly Gly Pro Val His Lys Gln 1 5 10 15 Ala Gly Ser Leu Ala Ser Arg Ala His Met Ile Ala Gly Thr Pro Pro 20 25 30 His Ser Thr Met Glu Arg Gly Gly Asp Arg Asp Ile Val Val Thr Gly 35 40 45 Ala Arg Asn Gln Phe Ala Pro Asp Leu Glu Pro Gly Gly Ser Val Ser 50 55 60 Cys Met Arg Ser Ser Leu Ser Phe Leu Ser Leu Ile Phe Asp Val Gly 65 70 75 80 Pro Arg Asp Val Leu Ser Ala Glu Ala Ile Glu Gly Cys Leu Val Glu 85 90 95 Gly Gly Glu Trp Thr Arg Ala Thr Ala Gly Pro Gly Pro Pro Arg Met 100 105 110 Cys Ser Ile Val Glu Leu Pro Asn Phe Leu Glu Tyr Pro Gly Ala Arg 115 120 125 Gly Gly Leu Arg Cys Val Phe Ser Arg Val Tyr Gly Glu Val Gly Phe 130 135 140 Phe Gly Glu Pro Ala Ala Gly Leu Leu Glu Thr Gln Cys Pro Ala His 145 150 155 160 Thr Phe Phe Ala Gly Pro Trp Ala Leu Arg Pro Leu Ser Tyr Thr Leu 165 170 175 Leu Thr Ile Gly Pro Leu Gly Met Gly Leu Phe Arg Asp Gly Asp Thr 180 185 190 Ala Tyr Leu Phe Asp Pro His Gly Leu Pro Glu Gly Thr Pro Ala Phe 195 200 205 Ile Ala Lys Val Arg Ala Gly Asp Met Tyr Pro Tyr Leu Thr Tyr Tyr 210 215 220 Thr Arg Asp Arg Pro Asp Val Arg Trp Ala Gly Ala Met Val Phe Phe 225 230 235 240 Val Pro Ser Gly Pro Glu Pro Ala Ala Pro Ala Asp Leu Thr Ala Ala 245 250 255 Ala Leu His Leu Tyr Gly Ala Ser Glu Thr Tyr Leu Gln Asp Glu Ala 260 265 270 Phe Ser Glu Arg Arg Val Ala Ile Thr His Pro Leu Arg Gly Glu Ile 275 280 285 Ala Gly Leu Gly Glu Pro Cys Val Gly Val Gly Pro Arg Glu Gly Val 290 295 300 Gly Gly Pro Gly Pro His Pro Pro Thr Ala Ala Gln Ser Pro Pro Pro 305 310 315 320 Thr Arg Ala Arg Arg Asp Asp Arg Ala Ser Glu Thr Ser Arg Gly Thr 325 330 335 Ala Gly Pro Ser Ala Lys Pro Glu Ala Lys Arg Pro Asn Arg Ala Pro 340 345 350 Asp Asp Val Trp Ala Val Ala Leu Lys Gly Thr Pro Pro Thr Asp Pro 355 360 365 Pro Ser Ala Asp Pro Pro Ser Ala Asp Pro Pro Ser Ala Ile Pro Pro 370 375 380 Pro Pro Pro Ser Ala Pro Lys Thr Pro Ala Ala Glu Ala Ala Glu Glu 385 390 395 400 Asp Asp Asp Asp Met Arg Val Leu Glu Met Gly Val Val Pro Val Gly 405 410 415 Arg His Arg Ala Arg Tyr Ser Ala Gly Leu Pro Lys Arg Arg Arg Pro 420 425 430 Thr Trp Thr Pro Pro Ser Ser Val Glu Asp Leu Thr Ser Gly Glu Lys 435 440 445 Thr Lys Arg Ser Ala Pro Pro Ala Lys Thr Lys Lys Lys Ser Thr Pro 450 455 460 Lys Gly Lys Thr Pro Val Gly Ala Ala Val Pro Ala Ser Val Pro Glu 465 470 475 480 Pro Val Leu Ala Ser Ala Pro Pro Asp Pro Ala Gly Pro Pro Val Ala 485 490 495 Glu Ala Gly Glu Asp Asp Gly Pro Thr Val Pro Ala Ser Ser Gln Ala 500 505 510 Leu Glu Ala Leu Lys Thr Arg Arg Ser Pro Glu Pro Pro Gly Ala Asp 515 520 525 Leu Ala Gln Leu Phe Glu Ala His Pro Asn Val Ala Ala Thr Ala Val 530 535 540 Lys Phe Thr Ala Cys Ser Ala Ala Leu Ala Arg Glu Val Ala Ala Cys 545 550 555 560 Ser Arg Leu Thr Ile Ser Ala Leu Arg Ser Pro Tyr Pro Ala Ser Pro 565 570 575 Gly Leu Leu Glu Leu Cys Val Ile Phe Phe Phe Glu Arg Val Leu Ala 580 585 590 Phe Leu Ile Glu Asn Gly Ala Arg Thr His Thr Gln Ala Gly Val Ala 595 600 605 Gly Pro Ala Ala Ala Leu Leu Glu Phe Thr Leu Asn Met Leu Pro Trp 610 615 620 Lys Thr Ala Val Gly Asp Phe Leu Ala Ser Thr Arg Leu Ser Leu Ala 625 630 635 640 Asp Val Ala Ala His Leu Pro Leu Val Gln His Val Leu Asp Glu Asn 645 650 655 Ser Leu Ile Gly Arg Leu Ala Leu Ala Lys Leu Ile Leu Val Ala Arg 660 665 670 Asp Val Ile Arg Glu Thr Asp Ala Phe Tyr Gly Glu Leu Ala Asp Leu 675 680 685 Glu Leu Gln Leu Arg Ala Ala Pro Pro Ala Asn Leu Tyr Thr Arg Leu 690 695 700 Gly Glu Trp Leu Leu Glu Arg Ser Gln Ala His Pro Asp Thr Leu Phe 705 710 715 720 Ala Pro Ala Thr Pro Thr His Pro Glu Pro Leu Leu Tyr Arg Val Gln 725 730 735 Ala Leu Ala Lys Phe Ala Arg Gly Glu Glu Ile Arg Val Glu Ala Glu 740 745 750 Asp Arg Gln Met Arg Glu Ala Leu Asp Ala Leu Ala Arg Gly Val Asp 755 760 765 Ala Val Ser Gln His Ala Gly Pro Leu Gly Val Met Pro Ala Pro Ala 770 775 780 Gly Ala Ala Pro Gln Gly Ala Pro Arg Pro Pro Pro Leu Gly Pro Glu 785 790 795 800 Ala Val Gln Val Arg Leu Glu Glu Val Arg Thr Gln Ala Arg Arg Ala 805 810 815 Ile Glu Gly Ala Val Lys Glu Tyr Phe Tyr Arg Gly Ala Val Tyr Ser 820 825 830 Ala Lys Ala Leu Gln Ala Ser Asp Asn Asn Asp Arg Arg Phe His Val 835 840 845 Ala Ser Ala Ala Val Val Pro Val Val Gln Leu Leu Glu Ser Leu Pro 850 855 860 Val Phe Asp Gln His Thr Arg Asp Ile Ala Gln Arg Ala Ala Ile Pro 865 870 875 880 Ala Pro Pro Pro Ile Ala Thr Ser Pro Thr Ala Ile Leu Leu Arg Asp 885 890 895 Leu Ile Gln Arg Gly Gln Thr Leu Asp Ala Pro Glu Asp Leu Ala Ala 900 905 910 Trp Leu Ser Val Leu Thr Asp Ala Ala Asn Gln Gly Leu Ile Glu Arg 915 920 925 Lys Pro Leu Asp Glu Leu Ala Arg Ser Ile Arg Asp Ile Asn Asp Gln 930 935 940 Gln Ala Arg Arg Ser Ser Gly Leu Ala Glu Leu Arg Arg Phe Asp Ala 945 950 955 960 Leu Asp Ala Ala Leu Gly Gln Gln Leu Asp Ser Asp Ala Ala Phe Val 965 970 975 Pro Ala Pro Gly Ala Ser Pro Tyr Pro Asp Asp Gly Gly Leu Ser Pro 980 985 990 Glu Ala Thr Arg Met Ala Glu Glu Ala Leu Arg Gln Ala Arg Ala Met 995 1000 1005 Asp Ala Ala Lys Leu Thr Ala Glu Leu Ala Pro Asp Ala Arg Ala Arg 1010 1015 1020 Leu Arg Glu Arg Ala Arg Ser Leu Glu Ala Met Leu Glu Gly Ala Arg 1025 1030 1035 1040 Glu Arg Ala Lys Val Ala Arg Asp Ala Arg Glu Lys Phe Leu His Lys 1045 1050 1055 Leu Gln Gly Val Leu Arg Pro Leu Pro Asp Phe Val Gly Leu Lys Ala 1060 1065 1070 Cys Pro Ala Val Leu Ala Thr Leu Arg Ala Ser Leu Pro Ala Gly Trp 1075 1080 1085 Ser Asp Leu Pro Glu Ala Val Arg Gly Ala Pro Pro Glu Val Thr Ala 1090 1095 1100 Ala Leu Arg Ala Asp Met Trp Gly Leu Leu Gly Gln Tyr Arg Asp Ala 1105 1110 1115 1120 Leu Glu His Pro Thr Pro Asp Thr Ala Thr Ala Leu Ser Gly Leu His 1125 1130 1135 Pro Ser Phe Val Val Val Leu Lys Asn Leu Phe Ala Asp Ala Pro Glu 1140 1145 1150 Thr Pro Phe Leu Leu Gln Phe Phe Ala Asp His Ala Pro Ile Ile Ala 1155 1160 1165 His Ala Val Ser Asn Ala Ile Asn Ala Gly Ser Ala Ala Val Ala Thr 1170 1175 1180 Ala Asp Pro Ala Ser Thr Val Asp Ala Ala Val Arg Ala His Arg Val 1185 1190 1195 1200 Leu Val Asp Ala Val Thr Ala Leu Gly Ala Ala Ala Ser Asp Pro Ala 1205 1210 1215 Ser Pro Leu Ala Phe Leu Ala Ala Met Ala Asp Ser Ala Ala Gly Tyr 1220 1225 1230 Val Lys Ala Thr Arg Leu Ala Leu Asp Ala Arg Val Ala Ile Ala Gln 1235 1240 1245 Leu Thr Thr Leu Gly Ser Ala Ala Ala Asp Leu Val Val Gln Val Arg 1250 1255 1260 Arg Ala Ala Asn Gln Pro Glu Gly Glu His Ala Ser Leu Ile Gln Ala 1265 1270 1275 1280 Ala Thr Arg Ala Thr Thr Gly Ala Arg Glu Ser Leu Ala Gly His Glu 1285 1290 1295 Gly Arg Phe Gly Gly Leu Leu His Ala Glu Gly Thr Ala Gly Asp His 1300 1305 1310 Ser Pro Ser Gly Arg Ala Leu Gln Glu Leu Gly Lys Val Ile Gly Ala 1315 1320 1325 Thr Arg Arg Arg Ala Asp Glu Leu Glu Ala Ala Thr Ala Asp Leu Arg 1330 1335 1340 Glu Lys Met Ala Ala Gln Arg Ala Arg Ser Ser His Glu Arg Trp Ala 1345 1350 1355 1360 Ala Asp Val Glu Ala Val Leu Asp Arg Val Glu Ser Gly Ala Glu Phe 1365 1370 1375 Asp Val Val Glu Leu Arg Arg Leu Gln Ala Leu Ala Gly Thr His Gly 1380 1385 1390 Tyr Asn Pro Arg Asp Phe Arg Lys Arg Ala Glu Gln Ala Leu Gly Thr 1395 1400 1405 Asn Ala Lys Ala Val Thr Leu Ala Leu Glu Thr Ala Leu Ala Phe Asn 1410 1415 1420 Pro Tyr Thr Pro Glu Asn Gln Arg His Pro Met Leu Pro Pro Leu Ala 1425 1430 1435 1440 Ala Ile His Arg Ile Asp Trp Ser Ala Ala Phe Gly Ala Ala Ala Asp 1445 1450 1455 Thr Tyr Ala Asp Met Phe Arg Val Asp Thr Glu Pro Leu Ala Arg Leu 1460 1465 1470 Leu Arg Leu Ala Gly Gly Leu Leu Glu Arg Ala Gln Ala Asn Asp Gly 1475 1480 1485 Phe Ile Asp Tyr His Glu Ala Val Leu His Leu Ser Glu Asp Leu Gly 1490 1495 1500 Gly Val Pro Ala Leu Arg Gln Tyr Val Pro Phe Phe Gln Lys Gly Tyr 1505 1510 1515 1520 Ala Glu Tyr Val Asp Ile Arg Asp Arg Leu Asp Ala Leu Arg Ala Asp 1525 1530 1535 Ala Arg Arg Ala Ile Gly Ser Val Ala Leu Asp Leu Ala Ala Ala Ala 1540 1545 1550 Glu Glu Ile Ser Ala Val Arg Asn Asp Pro Ala Ala Ala Ala Glu Leu 1555 1560 1565 Val Arg Ala Gly Val Thr Leu Pro Cys Pro Ser Glu Asp Ala Leu Val 1570 1575 1580 Ala Cys Val Ala Ala Leu Glu Arg Val Asp Gln Ser Pro Val Lys Asp 1585 1590 1595 1600 Thr Ala Tyr Ala His Tyr Val Ala Phe Val Thr Arg Gln Asp Leu Ala 1605 1610 1615 Asp Thr Lys Asp Ala Val Val Arg Ala Lys Gln Gln Arg Ala Glu Ala 1620 1625 1630 Thr Glu Arg Val Thr Ala Gly Leu Arg Glu Val Leu Ala Ala Arg Glu 1635 1640 1645 Arg Arg Ala Gln Leu Glu Ala Glu Gly Leu Ala Asn Leu Lys Thr Leu 1650 1655 1660 Leu Lys Val Val Ala Val Pro Ala Thr Val Ala Lys Thr Leu Asp Gln 1665 1670 1675 1680 Ala Arg Ser Ala Glu Glu Ile Ala Asp Gln Val Glu Ile Leu Val Asp 1685 1690 1695 Gln Thr Glu Lys Ala Arg Glu Leu Asp Val Gln Ala Val Ala Trp Leu 1700 1705 1710 Glu His Ala Gln Arg Thr Phe Glu Thr His Pro Leu Ser Ala Ala Ser 1715 1720 1725 Gly Asp Gly Pro Gly Leu Leu Thr Arg Gln Gly Ala Arg Leu Gln Ala 1730 1735 1740 Leu Phe Asp Thr Arg Arg Arg Val Glu Ala Leu Arg Arg Ser Leu Glu 1745 1750 1755 1760 Glu Ala Glu Ala Glu Trp Asp Glu Val Trp Gly Arg Phe Gly Arg Val 1765 1770 1775 Arg Gly Gly Ala Trp Lys Ser Pro Glu Gly Phe Arg Ala Ala Cys Glu 1780 1785 1790 Gln Leu Arg Ala Leu Gln Asp Thr Thr Asn Thr Val Ser Gly Leu Arg 1795 1800 1805 Ala Gln Arg Asp Tyr Glu Arg Leu Pro Ala Lys Tyr Gln Gly Val Leu 1810 1815 1820 Gly Ala Lys Ser Ala Glu Arg Ala Gly Ala Val Glu Glu Leu Gly Gly 1825 1830 1835 1840 Arg Val Ala Gln His Ala Asp Leu Ser Ala Arg Leu Arg Asp Glu Val 1845 1850 1855 Val Pro Arg Val Ala Trp Glu Met Asn Phe Asp Thr Leu Gly Gly Leu 1860 1865 1870 Leu Ala Glu Phe Asp Ala Val Ala Gly Asp Leu Ala Pro Trp Ala Val 1875 1880 1885 Glu Glu Phe Arg Gly Ala Arg Glu Leu Ile Gln Arg Arg Met Gly Leu 1890 1895 1900 Tyr Ser Ala Tyr Ala Lys Ala Thr Gly Gln Thr Gly Ala Gly Ala Ala 1905 1910 1915 1920 Ala Ala Pro Ala Pro Leu Leu Val Asp Leu Arg Ala Leu Asp Ala Arg 1925 1930 1935 Ala Arg Ala Ser Ala Pro Pro Gly Gln Glu Ala Asp Pro Gln Met Leu 1940 1945 1950 Arg Arg Arg Gly Glu Ala Tyr Leu Arg Val Ser Gly Gly Pro Gly Pro 1955 1960 1965 Leu Val Leu Arg Glu Ala Thr Ser Thr Leu Asp Arg Pro Phe Ala Pro 1970 1975 1980 Ser Phe Leu Val Pro Asp Gly Thr Pro Leu Gln Tyr Ala Leu Cys Phe 1985 1990 1995 2000 Pro Ala Val Thr Asp Lys Leu Gly Ala Leu Leu Met Cys Pro Glu Ala 2005 2010 2015 Ala Cys Ile Arg Pro Pro Leu Pro Thr Asp Thr Leu Glu Ser Ala Ser 2020 2025 2030 Thr Val Thr Ala Met Tyr Val Leu Thr Val Ile Asn Arg Leu Gln Leu 2035 2040 2045 Ala Leu Ser Asp Ala Gln Ala Ala Asn Phe Gln Leu Phe Gly Arg Phe 2050 2055 2060 Val Arg His Arg Gln Ala Arg Trp Gly Ala Ser Met Asp Ala Ala Ala 2065 2070 2075 2080 Glu Leu Tyr Val Ala Leu Val Ala Thr Thr Leu Thr Arg Glu Phe Gly 2085 2090 2095 Cys Arg Trp Ala Gln Leu Glu Trp Gly Gly Asp Ala Ala Ala Pro Gly 2100 2105 2110 Pro Pro Leu Gly Pro Gln Ser Ser Thr Arg His Arg Val Ser Phe Asn 2115 2120 2125 Glu Asn Asp Val Leu Val Ala Leu Val Ala Ser Ser Pro Glu His Ile 2130 2135 2140 Tyr Thr Phe Trp Arg Leu Asp Leu Val Arg Gln His Glu Tyr Met His 2145 2150 2155 2160 Leu Thr Leu Pro Arg Ala Phe Gln Asn Ala Ala Asp Ser Met Leu Phe 2165 2170 2175 Val Gln Arg Leu Thr Pro His Pro Asp Ala Arg Ile Arg Val Leu Pro 2180 2185 2190 Ala Phe Ser Ala Gly Gly Pro Pro Thr Arg Gly Leu Met Phe Gly Thr 2195 2200 2205 Arg Leu Ala Asp Trp Arg Arg Gly Lys Leu Ser Glu Thr Asp Pro Leu 2210 2215 2220 Ala Pro Trp Arg Ser Val Pro Glu Leu Gly Thr Glu Arg Gly Ala Ala 2225 2230 2235 2240 Leu Gly Lys Leu Ser Pro Ala Gln Ala Leu Ala Ala Val Ser Val Leu 2245 2250 2255 Gly Arg Met Cys Leu Pro Ser Thr Ala Leu Val Ala Leu Trp Thr Cys 2260 2265 2270 Met Phe Pro Asp Asp Tyr Thr Glu Tyr Asp Ser Phe Asp Ala Leu Leu 2275 2280 2285 Thr Ala Arg Leu Glu Ser Gly Gln Thr Leu Ser Pro Ser Gly Gly Arg 2290 2295 2300 Glu Ala Ser Pro Pro Ala Pro Pro Asn Ala Leu Tyr Arg Pro Thr Gly 2305 2310 2315 2320 Gln His Val Ala Val Pro Ala Ala Ala Thr His Arg Thr Pro Ala Ala 2325 2330 2335 Arg Val Thr Ala Met Asp Leu Val Leu Ala Ala Val Leu Leu Gly Ala 2340 2345 2350 Pro Val Val Val Ala Leu Arg Asn Thr Thr Ala Phe Ser Arg Glu Ser 2355 2360 2365 Glu Leu Glu Leu Cys Leu Thr Leu Phe Asp Ser Arg Ala Arg Gly Pro 2370 2375 2380 Asp Ala Ala Leu Arg Asp Ala Val Ser Ser Asp Ile Glu Thr Trp Ala 2385 2390 2395 2400 Val Arg Leu Leu His Ala Asp Leu Asn Pro Ile Glu Asn Ala Cys Leu 2405 2410 2415 Ala Ala Gln Leu Pro Arg Leu Ser Ala Leu Ile Ala Glu Arg Pro Leu 2420 2425 2430 Ala Arg Gly Pro Pro Cys Leu Val Leu Val Asp Ile Ser Met Thr Pro 2435 2440 2445 Val Ala Val Leu Trp Glu Asn Pro Asp Pro Pro Gly Pro Pro Asp Val 2450 2455 2460 Arg Phe Val Gly Ser Glu Ala Thr Glu Glu Leu Pro Phe Val Ala Gly 2465 2470 2475 2480 Gly Glu Asp Val Leu Ala Ala Ser Ala Thr Asp Glu Asp Pro Phe Leu 2485 2490 2495 Ala Arg Ala Ile Leu Gly Arg Pro Phe Asp Ala Ser Leu Leu Ser Gly 2500 2505 2510 Glu Leu Phe Pro Gly His Pro Val Tyr Gln Arg Ala Pro Asp Asp Gln 2515 2520 2525 Ser Pro Ser Val Pro Asn Pro Thr Pro Gly Pro Val Asp Leu Val Gly 2530 2535 2540 Ala Glu Gly Ser Leu Gly Pro Gly Ser Leu Ala Pro Thr Leu Phe Thr 2545 2550 2555 2560 Asp Ala Thr Pro Gly Glu Pro Val Pro Pro Arg Met Trp Ala Trp Ile 2565 2570 2575 His Gly Leu Glu Glu Leu Ala Ser Asp Asp Ser Gly Gly Pro Ala Pro 2580 2585 2590 Leu Leu Ala Pro Asp Pro Leu Ser Pro Thr Ala Asp Gln Ser Val Pro 2595 2600 2605 Thr Ser Gln Cys Ala Pro Arg Pro Pro Gly Pro Ala Val Thr Ala Arg 2610 2615 2620 Glu Ala Arg Pro Gly Val Pro Ala Glu Ser Thr Arg Pro Ala Pro Val 2625 2630 2635 2640 Gly Pro Arg Asp Asp Phe Arg Arg Leu Pro Ser Pro Gln Ser Ser Pro 2645 2650 2655 Ala Pro Pro Asp Ala Thr Ala Pro Arg Pro Pro Ala Ser Ser Arg Ala 2660 2665 2670 Ser Ala Ala Ser Ser Ser Gly Ser Arg Ala Arg Arg His Arg Arg Ala 2675 2680 2685 Arg Ser Leu Ala Arg Ala Thr Gln Ala Ser Ala Thr Thr Gln Gly Trp 2690 2695 2700 Arg Pro Pro Ala Leu Pro Asp Thr Val Ala Pro Val Thr Asp Phe Ala 2705 2710 2715 2720 Arg Pro Pro Ala Pro Pro Lys Pro Pro Glu Pro Ala Pro His Ala Leu 2725 2730 2735 Val Ser Gly Val Pro Leu Pro Leu Gly Pro Gln Ala Ala Gly Gln Ala 2740 2745 2750 Ser Pro Ala Leu Pro Ile Asp Pro Val Pro Pro Pro Val Ala Thr Gly 2755 2760 2765 Thr Val Leu Pro Gly Gly Glu Asn Arg Arg Pro Pro Leu Thr Ser Gly 2770 2775 2780 Pro Ala Pro Thr Pro Pro Arg Val Pro Val Gly Gly Pro Gln Arg Arg 2785 2790 2795 2800 Leu Thr Arg Pro Ala Val Ala Ser Leu Ser Glu Ser Arg Glu Ser Leu 2805 2810 2815 Pro Ser Pro Trp Asp Pro Ala Asp Pro Thr Ala Pro Val Leu Gly Arg 2820 2825 2830 Asn Pro Ala Glu Pro Thr Ser Ser Ser Pro Ala Gly Pro Ser Pro Pro 2835 2840 2845 Pro Pro Ala Val Gln Pro Val Ala Pro Pro Pro Thr Ser Gly Pro Pro 2850 2855 2860 Pro Thr Tyr Leu Thr Leu Glu Gly Gly Val Ala Pro Gly Gly Pro Val 2865 2870 2875 2880 Ser Arg Arg Pro Thr Thr Arg Gln Pro Val Ala Thr Pro Thr Thr Ser 2885 2890 2895 Ala Arg Pro Arg Gly His Leu Thr Val Ser Arg Leu Ser Ala Pro Gln 2900 2905 2910 Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln 2915 2920 2925 Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln 2930 2935 2940 Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln 2945 2950 2955 2960 Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln Pro Gln 2965 2970 2975 Pro Gln Pro Gln Asn Gly His Val Ala Pro Gly Glu Tyr Pro Ala Val 2980 2985 2990 Arg Phe Arg Ala Pro Gln Asn Arg Pro Ser Val Pro Ala Ser Ala Ser 2995 3000 3005 Ser Thr Asn Pro Arg Thr Gly Ser Ser Leu Ser Gly Val Ser Ser Trp 3010 3015 3020 Ala Ser Ser Leu Ala Leu His Ile Asp Ala Thr Pro Pro Pro Val Ser 3025 3030 3035 3040 Leu Leu Gln Thr Leu Tyr Val Ser Asp Asp Glu Asp Ser Asp Ala Thr 3045 3050 3055 Ser Leu Phe Leu Ser Asp Ser Glu Ala Glu Ala Leu Asp Pro Leu Pro 3060 3065 3070 Gly Glu Pro His Ser Pro Ile Thr Asn Glu Pro Phe Ser Ala Leu Ser 3075 3080 3085 Ala Asp Asp Ser Gln Glu Val Thr Arg Leu Gln Phe Gly Pro Pro Pro 3090 3095 3100 Val Ser Ala Asn Ala Val Leu Ser Arg Arg Tyr Val Gln Arg Thr Gly 3105 3110 3115 3120 Arg Ser Ala Leu Ala Val Leu Ile Arg Ala Cys Tyr Arg Leu Gln Gln 3125 3130 3135 Gln Leu Gln Arg Thr Arg Arg Ala Leu Leu His His Ser Asp Ala Val 3140 3145 3150 Leu Thr Ser Leu His His Val Arg Met Leu Leu Gly 3155 3160 73 1128 DNA Herpes Virus 73 ttccagcctg ccgtctccag cctgctgcag ctcggggagc agccctccgc cggcgcccag 60 cagcggctgc tggctctgct gcagcagacg tggacgttga tccagaatac caattcgccc 120 tccgtggtga tcaacaccct gatcgacgct gggttcacgc cctcgcactg cacgcactac 180 ctttcggccc tggaggggtt tctggcggcg ggcgtccccg cgcggacgcc caccggccac 240 ggactcggcg aagtccagca gctctttggg tgcattgccc tcgcggggtc gaacgtgttt 300 gggttggcgc gggaatacgg gtactatgcc aactacgtaa aaactttcag gcgggtccag 360 ggcgccagcg agcacacgca cgggcggctc tgcgaggcgg tcggcctgtc ggggggcgtt 420 ctaagccaga cgctggcgcg tatcatgggt ccggccgtgc cgacggaaca tctggcgagc 480 ctgcggcggg cgctcgtggg ggagtttgag acggccgagc gccgctttag ttccggtcaa 540 cccagccttc tccgcgagac ggcgctcatc tggatcgacg tgtatggtca gacccactgg 600 gacatcaccc ccaccacccc ggccacgccg ctgtccgcgc ttctccccgt cgggcagccc 660 agccacgccc cctctgtcca cctggccgcg gcgacccaga tccgcttccc cgccctcgag 720 ggcattcacc ccaacgtcct cgccgacccg ggcttcgtcc cctacgttct ggccctggtg 780 gtcggggacg cgctgagggc cacgtgtagc gcggcctacc ttccccgccc ggtcgagttc 840 gccctgcgtg tgttggcctg ggcccgggac tttgggctgg gctatctccc cacggttgag 900 ggccatcgca ccaaactggg cgcgctgatc accctcctcg aaccggccgc ccggggcggc 960 ctcggcccca ctatgcagat ggccgacaac atagagcagc tgctccggga gctgtacgtg 1020 atctccaggg gtgccgtcga gcagctgcgg cccctggtcc agctgcagcc ccccccgccc 1080 cccgaggtgg gcaccagcct cctgttgatt agcatgtacg ccctggcc 1128 74 376 PRT Herpes Virus 74 Phe Gln Pro Ala Val Ser Ser Leu Leu Gln Leu Gly Glu Gln Pro Ser 1 5 10 15 Ala Gly Ala Gln Gln Arg Leu Leu Ala Leu Leu Gln Gln Thr Trp Thr 20 25 30 Leu Ile Gln Asn Thr Asn Ser Pro Ser Val Val Ile Asn Thr Leu Ile 35 40 45 Asp Ala Gly Phe Thr Pro Ser His Cys Thr His Tyr Leu Ser Ala Leu 50 55 60 Glu Gly Phe Leu Ala Ala Gly Val Pro Ala Arg Thr Pro Thr Gly His 65 70 75 80 Gly Leu Gly Glu Val Gln Gln Leu Phe Gly Cys Ile Ala Leu Ala Gly 85 90 95 Ser Asn Val Phe Gly Leu Ala Arg Glu Tyr Gly Tyr Tyr Ala Asn Tyr 100 105 110 Val Lys Thr Phe Arg Arg Val Gln Gly Ala Ser Glu His Thr His Gly 115 120 125 Arg Leu Cys Glu Ala Val Gly Leu Ser Gly Gly Val Leu Ser Gln Thr 130 135 140 Leu Ala Arg Ile Met Gly Pro Ala Val Pro Thr Glu His Leu Ala Ser 145 150 155 160 Leu Arg Arg Ala Leu Val Gly Glu Phe Glu Thr Ala Glu Arg Arg Phe 165 170 175 Ser Ser Gly Gln Pro Ser Leu Leu Arg Glu Thr Ala Leu Ile Trp Ile 180 185 190 Asp Val Tyr Gly Gln Thr His Trp Asp Ile Thr Pro Thr Thr Pro Ala 195 200 205 Thr Pro Leu Ser Ala Leu Leu Pro Val Gly Gln Pro Ser His Ala Pro 210 215 220 Ser Val His Leu Ala Ala Ala Thr Gln Ile Arg Phe Pro Ala Leu Glu 225 230 235 240 Gly Ile His Pro Asn Val Leu Ala Asp Pro Gly Phe Val Pro Tyr Val 245 250 255 Leu Ala Leu Val Val Gly Asp Ala Leu Arg Ala Thr Cys Ser Ala Ala 260 265 270 Tyr Leu Pro Arg Pro Val Glu Phe Ala Leu Arg Val Leu Ala Trp Ala 275 280 285 Arg Asp Phe Gly Leu Gly Tyr Leu Pro Thr Val Glu Gly His Arg Thr 290 295 300 Lys Leu Gly Ala Leu Ile Thr Leu Leu Glu Pro Ala Ala Arg Gly Gly 305 310 315 320 Leu Gly Pro Thr Met Gln Met Ala Asp Asn Ile Glu Gln Leu Leu Arg 325 330 335 Glu Leu Tyr Val Ile Ser Arg Gly Ala Val Glu Gln Leu Arg Pro Leu 340 345 350 Val Gln Leu Gln Pro Pro Pro Pro Pro Glu Val Gly Thr Ser Leu Leu 355 360 365 Leu Ile Ser Met Tyr Ala Leu Ala 370 375 75 1083 DNA Herpes Virus 75 ctgattcgcc aactggagga cgccatcgtg ctgctgcggc tgcacatgcg cacgctctcc 60 gcctttttcg agtgtcggtt cgagagcgac gggcgccgcc tgtatgcggt ggtcggggac 120 acgcccgacc gcctggggcc ctggcccccc gaggccatgg gggacgcggt gagtcagtac 180 tgcagcatgt atcacgacgc caagcgcgcg ctggtcgcgt ccctcgcgag cctgcgttcc 240 gtcatcaccg aaaccacggc gcacctgggg gtgtgcgacg agctggcggc ccaggtgtcg 300 cacgaggaca acgtgctggc cgtggtccgg cgcgaaattc acgggtttct gtccgtcgtg 360 tccggcattc acgcccgggc gtcgaagctg ctgtcgggag accaggtccc cgggttttgc 420 ttcatgggtc agtttctagc gcgctggcgg cgtctgtcgg cctgctatca agccgcgcgc 480 gcggccgcgg gacccgagcc cgtggccgag tttgtccagg aactccacga cacgtggaag 540 ggcctgcaga cggagcgcgc cgtggtcgtg gcgcccttgg tcagctcggc cgaccagcgc 600 gccgcggcca tccgagaggt aatggcgcat gcgcccgagg acgccccccc gcaaagcccc 660 gcggccgacc gcgtcgtgct tacgagccgt cgcgacctag gggcctgggg ggactacagc 720 ctcggccccc tgggccagac gaccgcggtt ccggactccg tggatctgtc tcgccagggg 780 ctggccgtta cgctgagtat ggattggtta ctgatgaacg agctcctgcg ggtcaccgac 840 ggcgtgtttc gcgcttccgc gtttcgtccg ttagccggac cggagtctcc cagggacctg 900 gaggtccgcg acgccggaaa cagtctcccc gcgcctatgc ccatggacgc acagaagccg 960 gaggcctatg ggcacggccc acgccaggcg gaccgcgagg gggcgcctca ttccaacacc 1020 cccgtcgagg acgacgagat gatcccggag gacaccgtcg cgccacccac ggacttgccg 1080 tta 1083 76 361 PRT Herpes Virus 76 Leu Ile Arg Gln Leu Glu Asp Ala Ile Val Leu Leu Arg Leu His Met 1 5 10 15 Arg Thr Leu Ser Ala Phe Phe Glu Cys Arg Phe Glu Ser Asp Gly Arg 20 25 30 Arg Leu Tyr Ala Val Val Gly Asp Thr Pro Asp Arg Leu Gly Pro Trp 35 40 45 Pro Pro Glu Ala Met Gly Asp Ala Val Ser Gln Tyr Cys Ser Met Tyr 50 55 60 His Asp Ala Lys Arg Ala Leu Val Ala Ser Leu Ala Ser Leu Arg Ser 65 70 75 80 Val Ile Thr Glu Thr Thr Ala His Leu Gly Val Cys Asp Glu Leu Ala 85 90 95 Ala Gln Val Ser His Glu Asp Asn Val Leu Ala Val Val Arg Arg Glu 100 105 110 Ile His Gly Phe Leu Ser Val Val Ser Gly Ile His Ala Arg Ala Ser 115 120 125 Lys Leu Leu Ser Gly Asp Gln Val Pro Gly Phe Cys Phe Met Gly Gln 130 135 140 Phe Leu Ala Arg Trp Arg Arg Leu Ser Ala Cys Tyr Gln Ala Ala Arg 145 150 155 160 Ala Ala Ala Gly Pro Glu Pro Val Ala Glu Phe Val Gln Glu Leu His 165 170 175 Asp Thr Trp Lys Gly Leu Gln Thr Glu Arg Ala Val Val Val Ala Pro 180 185 190 Leu Val Ser Ser Ala Asp Gln Arg Ala Ala Ala Ile Arg Glu Val Met 195 200 205 Ala His Ala Pro Glu Asp Ala Pro Pro Gln Ser Pro Ala Ala Asp Arg 210 215 220 Val Val Leu Thr Ser Arg Arg Asp Leu Gly Ala Trp Gly Asp Tyr Ser 225 230 235 240 Leu Gly Pro Leu Gly Gln Thr Thr Ala Val Pro Asp Ser Val Asp Leu 245 250 255 Ser Arg Gln Gly Leu Ala Val Thr Leu Ser Met Asp Trp Leu Leu Met 260 265 270 Asn Glu Leu Leu Arg Val Thr Asp Gly Val Phe Arg Ala Ser Ala Phe 275 280 285 Arg Pro Leu Ala Gly Pro Glu Ser Pro Arg Asp Leu Glu Val Arg Asp 290 295 300 Ala Gly Asn Ser Leu Pro Ala Pro Met Pro Met Asp Ala Gln Lys Pro 305 310 315 320 Glu Ala Tyr Gly His Gly Pro Arg Gln Ala Asp Arg Glu Gly Ala Pro 325 330 335 His Ser Asn Thr Pro Val Glu Asp Asp Glu Met Ile Pro Glu Asp Thr 340 345 350 Val Ala Pro Pro Thr Asp Leu Pro Leu 355 360 77 3372 DNA Herpes Virus 77 atggcagacc gcggtctccc gtccgaggcc cccgtcgtca cgacctcacc cgccggtccg 60 ccctcggacg gacctatgca gcgcctattg gcgagcctag ccggccttcg ccaaccgcca 120 acccccacgg ccgagacggc aaacggggcg gacgacccgg cgtttctggc cacggccaag 180 ctgcgcgccg ccatggcggc gtttctgttg tcgggaacgg ccatcgcccc ggcagacgcg 240 cgggactgct ggcggccgct gctggaacac ctgtgcgcgc tccaccgggc ccacgggctt 300 ccggagacgg cgctcttggc cgagaacctc cccgggttgc tcgtacaccg cttggtggtg 360 gctctccccg aggcccccga ccaggccttc cgggagatgg aggtcatcaa ggacaccatc 420 ctcgcggtca ccggctccga cacgtcccat gcgctggatt ccgccggcct gcgcaccgcg 480 gcggccctgg ggccggtccg cgtccgccag tgcgccgtgg agtggataga ccgctggcaa 540 accgtcacca agagctgctt ggccatgagc ccgcggacct ccatcgaggc ccttggggag 600 acgtcgctca agatggcgcc ggtcccgttg gggcagccca gcgcgaacct taccaccccg 660 gcgtacagcc tgctcttccc cgccccgttc gtgcaagagg gcctccggtt cttggccctg 720 gtgagtaatc gggtgacgct gttctcggcg cacctccagc gcatagacga cgcgaccctc 780 actcccctca cacgggccct ctttacgttg gccctggtgg acgagtacct gacgaccccc 840 gagcgggggg ctgtggtccc gccgcccctg ttggcgcagt ttcagcacac cgtgcgggag 900 atcgacccgg ccataatgat tccgccgctc gaggccaaca agatggttcg cagccgcgag 960 gaggtgcgcg tgtcgacggc cctcagccgc gtcagcccgc gctcggcctg tgcgcccccg 1020 gggacgctaa tggcgcgcgt gcggacggac gtggccgtgt ttgatcccga cgtgccgttc 1080 ctgagttcgt cggcactggc agtcttccag cctgccgtct ccagcctgct gcagctcggg 1140 gagcagccct ccgccggcgc ccagcagcgg ctgctggctc tgctgcagca gacgtggacg 1200 ttgatccaga ataccaattc gccctccgtg gtgatcaaca ccctgatcga cgctgggttc 1260 acgccctcgc actgcacgca ctacctttcg gccctggagg ggtttctggc ggcgggcgtc 1320 cccgcgcgga cgcccaccgg ccacggactc ggcgaagtcc agcagctctt tgggtgcatt 1380 gccctcgcgg ggtcgaacgt gtttgggttg gcgcgggaat acgggtacta tgccaactac 1440 gtaaaaactt tcaggcgggt ccagggcgcc agcgagcaca cgcacgggcg gctctgcgag 1500 gcggtcggcc tgtcgggggg cgttctaagc cagacgctgg cgcgtatcat gggtccggcc 1560 gtgccgacgg aacatctggc gagcctgcgg cgggcgctcg tgggggagtt tgagacggcc 1620 gagcgccgct ttagttccgg tcaacccagc cttctccgcg agacggcgct catctggatc 1680 gacgtgtatg gtcagaccca ctgggacatc acccccacca ccccggccac gccgctgtcc 1740 gcgcttctcc ccgtcgggca gcccagccac gccccctctg tccacctggc cgcggcgacc 1800 cagatccgct tccccgccct cgagggcatt caccccaacg tcctcgccga cccgggcttc 1860 gtcccctacg ttctggccct ggtggtcggg gacgcgctga gggccacgtg tagcgcggcc 1920 taccttcccc gcccggtcga gttcgccctg cgtgtgttgg cctgggcccg ggactttggg 1980 ctgggctatc tccccacggt tgagggccat cgcaccaaac tgggcgcgct gatcaccctc 2040 ctcgaaccgg ccgcccgggg cggcctcggc cccactatgc agatggccga caacatagag 2100 cagctgctcc gggagctgta cgtgatctcc aggggtgccg tcgagcagct gcggcccctg 2160 gtccagctgc agcccccccc gccccccgag gtgggcacca gcctcctgtt gattagcatg 2220 tacgccctgg ccgcccgggg ggtgctgcag gacctcgccg agcgcgcaga ccccctgatt 2280 cgccaactgg aggacgccat cgtgctgctg cggctgcaca tgcgcacgct ctccgccttt 2340 ttcgagtgtc ggttcgagag cgacgggcgc cgcctgtatg cggtggtcgg ggacacgccc 2400 gaccgcctgg ggccctggcc ccccgaggcc atgggggacg cggtgagtca gtactgcagc 2460 atgtatcacg acgccaagcg cgcgctggtc gcgtccctcg cgagcctgcg ttccgtcatc 2520 accgaaacca cggcgcacct gggggtgtgc gacgagctgg cggcccaggt gtcgcacgag 2580 gacaacgtgc tggccgtggt ccggcgcgaa attcacgggt ttctgtccgt cgtgtccggc 2640 attcacgccc gggcgtcgaa gctgctgtcg ggagaccagg tccccgggtt ttgcttcatg 2700 ggtcagtttc tagcgcgctg gcggcgtctg tcggcctgct atcaagccgc gcgcgcggcc 2760 gcgggacccg agcccgtggc cgagtttgtc caggaactcc acgacacgtg gaagggcctg 2820 cagacggagc gcgccgtggt cgtggcgccc ttggtcagct cggccgacca gcgcgccgcg 2880 gccatccgag aggtaatggc gcatgcgccc gaggacgccc ccccgcaaag ccccgcggcc 2940 gaccgcgtcg tgcttacgag ccgtcgcgac ctaggggcct ggggggacta cagcctcggc 3000 cccctgggcc agacgaccgc ggttccggac tccgtggatc tgtctcgcca ggggctggcc 3060 gttacgctga gtatggattg gttactgatg aacgagctcc tgcgggtcac cgacggcgtg 3120 tttcgcgctt ccgcgtttcg tccgttagcc ggaccggagt ctcccaggga cctggaggtc 3180 cgcgacgccg gaaacagtct ccccgcgcct atgcccatgg acgcacagaa gccggaggcc 3240 tatgggcacg gcccacgcca ggcggaccgc gagggggcgc ctcattccaa cacccccgtc 3300 gaggacgacg agatgatccc ggaggacacc gtcgcgccac ccacggactt gccgttaact 3360 agttaccaat aa 3372 78 1123 PRT Herpes Virus 78 Met Ala Asp Arg Gly Leu Pro Ser Glu Ala Pro Val Val Thr Thr Ser 1 5 10 15 Pro Ala Gly Pro Pro Ser Asp Gly Pro Met Gln Arg Leu Leu Ala Ser 20 25 30 Leu Ala Gly Leu Arg Gln Pro Pro Thr Pro Thr Ala Glu Thr Ala Asn 35 40 45 Gly Ala Asp Asp Pro Ala Phe Leu Ala Thr Ala Lys Leu Arg Ala Ala 50 55 60 Met Ala Ala Phe Leu Leu Ser Gly Thr Ala Ile Ala Pro Ala Asp Ala 65 70 75 80 Arg Asp Cys Trp Arg Pro Leu Leu Glu His Leu Cys Ala Leu His Arg 85 90 95 Ala His Gly Leu Pro Glu Thr Ala Leu Leu Ala Glu Asn Leu Pro Gly 100 105 110 Leu Leu Val His Arg Leu Val Val Ala Leu Pro Glu Ala Pro Asp Gln 115 120 125 Ala Phe Arg Glu Met Glu Val Ile Lys Asp Thr Ile Leu Ala Val Thr 130 135 140 Gly Ser Asp Thr Ser His Ala Leu Asp Ser Ala Gly Leu Arg Thr Ala 145 150 155 160 Ala Ala Leu Gly Pro Val Arg Val Arg Gln Cys Ala Val Glu Trp Ile 165 170 175 Asp Arg Trp Gln Thr Val Thr Lys Ser Cys Leu Ala Met Ser Pro Arg 180 185 190 Thr Ser Ile Glu Ala Leu Gly Glu Thr Ser Leu Lys Met Ala Pro Val 195 200 205 Pro Leu Gly Gln Pro Ser Ala Asn Leu Thr Thr Pro Ala Tyr Ser Leu 210 215 220 Leu Phe Pro Ala Pro Phe Val Gln Glu Gly Leu Arg Phe Leu Ala Leu 225 230 235 240 Val Ser Asn Arg Val Thr Leu Phe Ser Ala His Leu Gln Arg Ile Asp 245 250 255 Asp Ala Thr Leu Thr Pro Leu Thr Arg Ala Leu Phe Thr Leu Ala Leu 260 265 270 Val Asp Glu Tyr Leu Thr Thr Pro Glu Arg Gly Ala Val Val Pro Pro 275 280 285 Pro Leu Leu Ala Gln Phe Gln His Thr Val Arg Glu Ile Asp Pro Ala 290 295 300 Ile Met Ile Pro Pro Leu Glu Ala Asn Lys Met Val Arg Ser Arg Glu 305 310 315 320 Glu Val Arg Val Ser Thr Ala Leu Ser Arg Val Ser Pro Arg Ser Ala 325 330 335 Cys Ala Pro Pro Gly Thr Leu Met Ala Arg Val Arg Thr Asp Val Ala 340 345 350 Val Phe Asp Pro Asp Val Pro Phe Leu Ser Ser Ser Ala Leu Ala Val 355 360 365 Phe Gln Pro Ala Val Ser Ser Leu Leu Gln Leu Gly Glu Gln Pro Ser 370 375 380 Ala Gly Ala Gln Gln Arg Leu Leu Ala Leu Leu Gln Gln Thr Trp Thr 385 390 395 400 Leu Ile Gln Asn Thr Asn Ser Pro Ser Val Val Ile Asn Thr Leu Ile 405 410 415 Asp Ala Gly Phe Thr Pro Ser His Cys Thr His Tyr Leu Ser Ala Leu 420 425 430 Glu Gly Phe Leu Ala Ala Gly Val Pro Ala Arg Thr Pro Thr Gly His 435 440 445 Gly Leu Gly Glu Val Gln Gln Leu Phe Gly Cys Ile Ala Leu Ala Gly 450 455 460 Ser Asn Val Phe Gly Leu Ala Arg Glu Tyr Gly Tyr Tyr Ala Asn Tyr 465 470 475 480 Val Lys Thr Phe Arg Arg Val Gln Gly Ala Ser Glu His Thr His Gly 485 490 495 Arg Leu Cys Glu Ala Val Gly Leu Ser Gly Gly Val Leu Ser Gln Thr 500 505 510 Leu Ala Arg Ile Met Gly Pro Ala Val Pro Thr Glu His Leu Ala Ser 515 520 525 Leu Arg Arg Ala Leu Val Gly Glu Phe Glu Thr Ala Glu Arg Arg Phe 530 535 540 Ser Ser Gly Gln Pro Ser Leu Leu Arg Glu Thr Ala Leu Ile Trp Ile 545 550 555 560 Asp Val Tyr Gly Gln Thr His Trp Asp Ile Thr Pro Thr Thr Pro Ala 565 570 575 Thr Pro Leu Ser Ala Leu Leu Pro Val Gly Gln Pro Ser His Ala Pro 580 585 590 Ser Val His Leu Ala Ala Ala Thr Gln Ile Arg Phe Pro Ala Leu Glu 595 600 605 Gly Ile His Pro Asn Val Leu Ala Asp Pro Gly Phe Val Pro Tyr Val 610 615 620 Leu Ala Leu Val Val Gly Asp Ala Leu Arg Ala Thr Cys Ser Ala Ala 625 630 635 640 Tyr Leu Pro Arg Pro Val Glu Phe Ala Leu Arg Val Leu Ala Trp Ala 645 650 655 Arg Asp Phe Gly Leu Gly Tyr Leu Pro Thr Val Glu Gly His Arg Thr 660 665 670 Lys Leu Gly Ala Leu Ile Thr Leu Leu Glu Pro Ala Ala Arg Gly Gly 675 680 685 Leu Gly Pro Thr Met Gln Met Ala Asp Asn Ile Glu Gln Leu Leu Arg 690 695 700 Glu Leu Tyr Val Ile Ser Arg Gly Ala Val Glu Gln Leu Arg Pro Leu 705 710 715 720 Val Gln Leu Gln Pro Pro Pro Pro Pro Glu Val Gly Thr Ser Leu Leu 725 730 735 Leu Ile Ser Met Tyr Ala Leu Ala Ala Arg Gly Val Leu Gln Asp Leu 740 745 750 Ala Glu Arg Ala Asp Pro Leu Ile Arg Gln Leu Glu Asp Ala Ile Val 755 760 765 Leu Leu Arg Leu His Met Arg Thr Leu Ser Ala Phe Phe Glu Cys Arg 770 775 780 Phe Glu Ser Asp Gly Arg Arg Leu Tyr Ala Val Val Gly Asp Thr Pro 785 790 795 800 Asp Arg Leu Gly Pro Trp Pro Pro Glu Ala Met Gly Asp Ala Val Ser 805 810 815 Gln Tyr Cys Ser Met Tyr His Asp Ala Lys Arg Ala Leu Val Ala Ser 820 825 830 Leu Ala Ser Leu Arg Ser Val Ile Thr Glu Thr Thr Ala His Leu Gly 835 840 845 Val Cys Asp Glu Leu Ala Ala Gln Val Ser His Glu Asp Asn Val Leu 850 855 860 Ala Val Val Arg Arg Glu Ile His Gly Phe Leu Ser Val Val Ser Gly 865 870 875 880 Ile His Ala Arg Ala Ser Lys Leu Leu Ser Gly Asp Gln Val Pro Gly 885 890 895 Phe Cys Phe Met Gly Gln Phe Leu Ala Arg Trp Arg Arg Leu Ser Ala 900 905 910 Cys Tyr Gln Ala Ala Arg Ala Ala Ala Gly Pro Glu Pro Val Ala Glu 915 920 925 Phe Val Gln Glu Leu His Asp Thr Trp Lys Gly Leu Gln Thr Glu Arg 930 935 940 Ala Val Val Val Ala Pro Leu Val Ser Ser Ala Asp Gln Arg Ala Ala 945 950 955 960 Ala Ile Arg Glu Val Met Ala His Ala Pro Glu Asp Ala Pro Pro Gln 965 970 975 Ser Pro Ala Ala Asp Arg Val Val Leu Thr Ser Arg Arg Asp Leu Gly 980 985 990 Ala Trp Gly Asp Tyr Ser Leu Gly Pro Leu Gly Gln Thr Thr Ala Val 995 1000 1005 Pro Asp Ser Val Asp Leu Ser Arg Gln Gly Leu Ala Val Thr Leu Ser 1010 1015 1020 Met Asp Trp Leu Leu Met Asn Glu Leu Leu Arg Val Thr Asp Gly Val 1025 1030 1035 1040 Phe Arg Ala Ser Ala Phe Arg Pro Leu Ala Gly Pro Glu Ser Pro Arg 1045 1050 1055 Asp Leu Glu Val Arg Asp Ala Gly Asn Ser Leu Pro Ala Pro Met Pro 1060 1065 1070 Met Asp Ala Gln Lys Pro Glu Ala Tyr Gly His Gly Pro Arg Gln Ala 1075 1080 1085 Asp Arg Glu Gly Ala Pro His Ser Asn Thr Pro Val Glu Asp Asp Glu 1090 1095 1100 Met Ile Pro Glu Asp Thr Val Ala Pro Pro Thr Asp Leu Pro Leu Thr 1105 1110 1115 1120 Ser Tyr Gln 79 1401 DNA Herpes Virus 79 ttgttcggga tgatgaagtt tgcccacaca caccatctgg tcaagcgccg gggccttggg 60 gccccggccg ggtacttcac ccccattgcc gtggacctgt ggaacgtcat gtacacgttg 120 gtggtcaaat atcagcgccg ataccccagt tacgaccgcg aggccattac gctacactgc 180 ctctgtcgct tattaaaggt gtttacccaa aagtcccttt tccccatctt cgttaccgat 240 cgcggggtca attgtatgga gccggttgtg tttggagcca aggccatcct ggcccgcacg 300 acggcccagt gccggacgga cgaggaggcc agtgacgtgg acgcctctcc accgccttcc 360 cccatcaccg actccagacc cagctctgcc ttttccaaca tgcgccggcg cggcacctct 420 ctggcctcgg ggacccgggg gacggccggg tccggagccg cgctgccgtc cgccgcgccc 480 tcgaagccgg ccctgcgtct ggcgcatctg ttctgtattc gcgttctccg ggccctgggg 540 tacgcctaca ttaactcggg tcagctggag gcggacgatg cctgcgccaa cctctatcac 600 accaacacgg tcgcgtacgt gtacaccacg gacactgacc tcctgttgat gggctgtgat 660 attgtgttgg atattagcgc ctgctacatt cccacgatca actgtcgcga tatactaaag 720 tactttaaga tgagctaccc ccagttcctg gccctctttg tccgctgcca caccgacctc 780 catcccaata acacctacgc ctccgtggag gatgtgctgc gcgaatgtca ctggaccccc 840 ccgagtcgct ctcagacccg gcgggccatc cgccgggaac acaccagctc gcgctccacg 900 gaaaccaggc cccctctgcc gccggccgcc ggcggcaccg agacgcgcgt ctcgtggacc 960 gaaattctaa cccaacagat cgccggcgga tacgaagacg acgaggacct ccccctggat 1020 ccccgggacg ttaccggggg ccaccccggc cccaggtcgt cctcctcgga gatactcacc 1080 ccgcccgagc tcgtccaggt cccgaacgcg cagctgctgg aagagcaccg cagttatgtg 1140 gccaacccgc gacgccacgt catccacgac gccccagagt ccctggactg gctccccgat 1200 cccatgacca tcaccgagct ggtggaacac cgctacatta agtacgtcat atcgcttatc 1260 ggccccaagg agcgggggcc gtggactctt ctgaaacgcc tgcctatcta ccaggacatc 1320 cgcgacgaaa acctggcgcg atctatcgtg acccggcata tcacggcccc tgatatcgcc 1380 gacaggtttc tggagcagtt g 1401 80 467 PRT Herpes Virus 80 Leu Phe Gly Met Met Lys Phe Ala His Thr His His Leu Val Lys Arg 1 5 10 15 Arg Gly Leu Gly Ala Pro Ala Gly Tyr Phe Thr Pro Ile Ala Val Asp 20 25 30 Leu Trp Asn Val Met Tyr Thr Leu Val Val Lys Tyr Gln Arg Arg Tyr 35 40 45 Pro Ser Tyr Asp Arg Glu Ala Ile Thr Leu His Cys Leu Cys Arg Leu 50 55 60 Leu Lys Val Phe Thr Gln Lys Ser Leu Phe Pro Ile Phe Val Thr Asp 65 70 75 80 Arg Gly Val Asn Cys Met Glu Pro Val Val Phe Gly Ala Lys Ala Ile 85 90 95 Leu Ala Arg Thr Thr Ala Gln Cys Arg Thr Asp Glu Glu Ala Ser Asp 100 105 110 Val Asp Ala Ser Pro Pro Pro Ser Pro Ile Thr Asp Ser Arg Pro Ser 115 120 125 Ser Ala Phe Ser Asn Met Arg Arg Arg Gly Thr Ser Leu Ala Ser Gly 130 135 140 Thr Arg Gly Thr Ala Gly Ser Gly Ala Ala Leu Pro Ser Ala Ala Pro 145 150 155 160 Ser Lys Pro Ala Leu Arg Leu Ala His Leu Phe Cys Ile Arg Val Leu 165 170 175 Arg Ala Leu Gly Tyr Ala Tyr Ile Asn Ser Gly Gln Leu Glu Ala Asp 180 185 190 Asp Ala Cys Ala Asn Leu Tyr His Thr Asn Thr Val Ala Tyr Val Tyr 195 200 205 Thr Thr Asp Thr Asp Leu Leu Leu Met Gly Cys Asp Ile Val Leu Asp 210 215 220 Ile Ser Ala Cys Tyr Ile Pro Thr Ile Asn Cys Arg Asp Ile Leu Lys 225 230 235 240 Tyr Phe Lys Met Ser Tyr Pro Gln Phe Leu Ala Leu Phe Val Arg Cys 245 250 255 His Thr Asp Leu His Pro Asn Asn Thr Tyr Ala Ser Val Glu Asp Val 260 265 270 Leu Arg Glu Cys His Trp Thr Pro Pro Ser Arg Ser Gln Thr Arg Arg 275 280 285 Ala Ile Arg Arg Glu His Thr Ser Ser Arg Ser Thr Glu Thr Arg Pro 290 295 300 Pro Leu Pro Pro Ala Ala Gly Gly Thr Glu Thr Arg Val Ser Trp Thr 305 310 315 320 Glu Ile Leu Thr Gln Gln Ile Ala Gly Gly Tyr Glu Asp Asp Glu Asp 325 330 335 Leu Pro Leu Asp Pro Arg Asp Val Thr Gly Gly His Pro Gly Pro Arg 340 345 350 Ser Ser Ser Ser Glu Ile Leu Thr Pro Pro Glu Leu Val Gln Val Pro 355 360 365 Asn Ala Gln Leu Leu Glu Glu His Arg Ser Tyr Val Ala Asn Pro Arg 370 375 380 Arg His Val Ile His Asp Ala Pro Glu Ser Leu Asp Trp Leu Pro Asp 385 390 395 400 Pro Met Thr Ile Thr Glu Leu Val Glu His Arg Tyr Ile Lys Tyr Val 405 410 415 Ile Ser Leu Ile Gly Pro Lys Glu Arg Gly Pro Trp Thr Leu Leu Lys 420 425 430 Arg Leu Pro Ile Tyr Gln Asp Ile Arg Asp Glu Asn Leu Ala Arg Ser 435 440 445 Ile Val Thr Arg His Ile Thr Ala Pro Asp Ile Ala Asp Arg Phe Leu 450 455 460 Glu Gln Leu 465 81 1470 DNA Herpes Virus 81 atgggtttgt tcgggatgat gaagtttgcc cacacacacc atctggtcaa gcgccggggc 60 cttggggccc cggccgggta cttcaccccc attgccgtgg acctgtggaa cgtcatgtac 120 acgttggtgg tcaaatatca gcgccgatac cccagttacg accgcgaggc cattacgcta 180 cactgcctct gtcgcttatt aaaggtgttt acccaaaagt cccttttccc catcttcgtt 240 accgatcgcg gggtcaattg tatggagccg gttgtgtttg gagccaaggc catcctggcc 300 cgcacgacgg cccagtgccg gacggacgag gaggccagtg acgtggacgc ctctccaccg 360 ccttccccca tcaccgactc cagacccagc tctgcctttt ccaacatgcg ccggcgcggc 420 acctctctgg cctcggggac ccgggggacg gccgggtccg gagccgcgct gccgtccgcc 480 gcgccctcga agccggccct gcgtctggcg catctgttct gtattcgcgt tctccgggcc 540 ctggggtacg cctacattaa ctcgggtcag ctggaggcgg acgatgcctg cgccaacctc 600 tatcacacca acacggtcgc gtacgtgtac accacggaca ctgacctcct gttgatgggc 660 tgtgatattg tgttggatat tagcgcctgc tacattccca cgatcaactg tcgcgatata 720 ctaaagtact ttaagatgag ctacccccag ttcctggccc tctttgtccg ctgccacacc 780 gacctccatc ccaataacac ctacgcctcc gtggaggatg tgctgcgcga atgtcactgg 840 acccccccga gtcgctctca gacccggcgg gccatccgcc gggaacacac cagctcgcgc 900 tccacggaaa ccaggccccc tctgccgccg gccgccggcg gcaccgagac gcgcgtctcg 960 tggaccgaaa ttctaaccca acagatcgcc ggcggatacg aagacgacga ggacctcccc 1020 ctggatcccc gggacgttac cgggggccac cccggcccca ggtcgtcctc ctcggagata 1080 ctcaccccgc ccgagctcgt ccaggtcccg aacgcgcagc tgctggaaga gcaccgcagt 1140 tatgtggcca acccgcgacg ccacgtcatc cacgacgccc cagagtccct ggactggctc 1200 cccgatccca tgaccatcac cgagctggtg gaacaccgct acattaagta cgtcatatcg 1260 cttatcggcc ccaaggagcg ggggccgtgg actcttctga aacgcctgcc tatctaccag 1320 gacatccgcg acgaaaacct ggcgcgatct atcgtgaccc ggcatatcac ggcccctgat 1380 atcgccgaca ggtttctgga gcagttgcgg acccaggccc ccccacccgc gttctacaag 1440 gacgtcctgg ccaaattctg ggacgagtag 1470 82 489 PRT Herpes Virus 82 Met Gly Leu Phe Gly Met Met Lys Phe Ala His Thr His His Leu Val 1 5 10 15 Lys Arg Arg Gly Leu Gly Ala Pro Ala Gly Tyr Phe Thr Pro Ile Ala 20 25 30 Val Asp Leu Trp Asn Val Met Tyr Thr Leu Val Val Lys Tyr Gln Arg 35 40 45 Arg Tyr Pro Ser Tyr Asp Arg Glu Ala Ile Thr Leu His Cys Leu Cys 50 55 60 Arg Leu Leu Lys Val Phe Thr Gln Lys Ser Leu Phe Pro Ile Phe Val 65 70 75 80 Thr Asp Arg Gly Val Asn Cys Met Glu Pro Val Val Phe Gly Ala Lys 85 90 95 Ala Ile Leu Ala Arg Thr Thr Ala Gln Cys Arg Thr Asp Glu Glu Ala 100 105 110 Ser Asp Val Asp Ala Ser Pro Pro Pro Ser Pro Ile Thr Asp Ser Arg 115 120 125 Pro Ser Ser Ala Phe Ser Asn Met Arg Arg Arg Gly Thr Ser Leu Ala 130 135 140 Ser Gly Thr Arg Gly Thr Ala Gly Ser Gly Ala Ala Leu Pro Ser Ala 145 150 155 160 Ala Pro Ser Lys Pro Ala Leu Arg Leu Ala His Leu Phe Cys Ile Arg 165 170 175 Val Leu Arg Ala Leu Gly Tyr Ala Tyr Ile Asn Ser Gly Gln Leu Glu 180 185 190 Ala Asp Asp Ala Cys Ala Asn Leu Tyr His Thr Asn Thr Val Ala Tyr 195 200 205 Val Tyr Thr Thr Asp Thr Asp Leu Leu Leu Met Gly Cys Asp Ile Val 210 215 220 Leu Asp Ile Ser Ala Cys Tyr Ile Pro Thr Ile Asn Cys Arg Asp Ile 225 230 235 240 Leu Lys Tyr Phe Lys Met Ser Tyr Pro Gln Phe Leu Ala Leu Phe Val 245 250 255 Arg Cys His Thr Asp Leu His Pro Asn Asn Thr Tyr Ala Ser Val Glu 260 265 270 Asp Val Leu Arg Glu Cys His Trp Thr Pro Pro Ser Arg Ser Gln Thr 275 280 285 Arg Arg Ala Ile Arg Arg Glu His Thr Ser Ser Arg Ser Thr Glu Thr 290 295 300 Arg Pro Pro Leu Pro Pro Ala Ala Gly Gly Thr Glu Thr Arg Val Ser 305 310 315 320 Trp Thr Glu Ile Leu Thr Gln Gln Ile Ala Gly Gly Tyr Glu Asp Asp 325 330 335 Glu Asp Leu Pro Leu Asp Pro Arg Asp Val Thr Gly Gly His Pro Gly 340 345 350 Pro Arg Ser Ser Ser Ser Glu Ile Leu Thr Pro Pro Glu Leu Val Gln 355 360 365 Val Pro Asn Ala Gln Leu Leu Glu Glu His Arg Ser Tyr Val Ala Asn 370 375 380 Pro Arg Arg His Val Ile His Asp Ala Pro Glu Ser Leu Asp Trp Leu 385 390 395 400 Pro Asp Pro Met Thr Ile Thr Glu Leu Val Glu His Arg Tyr Ile Lys 405 410 415 Tyr Val Ile Ser Leu Ile Gly Pro Lys Glu Arg Gly Pro Trp Thr Leu 420 425 430 Leu Lys Arg Leu Pro Ile Tyr Gln Asp Ile Arg Asp Glu Asn Leu Ala 435 440 445 Arg Ser Ile Val Thr Arg His Ile Thr Ala Pro Asp Ile Ala Asp Arg 450 455 460 Phe Leu Glu Gln Leu Arg Thr Gln Ala Pro Pro Pro Ala Phe Tyr Lys 465 470 475 480 Asp Val Leu Ala Lys Phe Trp Asp Glu 485 83 1257 DNA Herpes Virus 83 gtgacggaac caccccgcgt gccatcacgg ccaaggcgcg ggatgctccg caacgacagc 60 caccgggccg tgtccccgga ggacggccag ggacgggtcg acgacggacg gccacacctc 120 gcgtgcgtgg gggccctggc gcgggggttc atgcatatct ggcttcaggc cgccacgctg 180 ggttttgcgg gatcggtcgt tatgtcgcgc gggccgtacg cgaatgccgc gtctggggcg 240 ttcgccgtcg ggtgcgccgt gctgggcttt atgcgcgcac cccctcccct cgcgcggccc 300 accgcgcgga tatacgcctg gctcaaactg gcggccggtg gagcggccct tgttctgtgg 360 agtctcgggg agcccggcac gcagccgggg gccccggccc cgggcccggc cacccagtgc 420 ctggcactgg gcgccgccta tgcggcgctc ctggtgctcg ccgatgacgt ctatccgctc 480 tttctcctcg ccccggggcc cctgttcgtc ggcaccctgg ggatggtcgt cggcgggctg 540 acgatcggag gcagcgcgcg ctactggtgg atcggtgggc ccgccgcggc cgccctggcc 600 gcggcggtgt tggcgggccc gggggcgacc accgccaggg actgcttttc cagggcttgc 660 cccgaccacc gccgcgtctg tgtcatcacc gcaggcgagt ctctttcccg ccgccccccg 720 gaggacccag agcgacccgg ggttcccggg cccccgtccc ccccgacccc ccaacgatcc 780 cacgggccgc cggccgatga ggtcgcaccg gccagggtcg cgcggcccga aaacgtctgg 840 gtgcccgtgg tcacctttct gggggcgggc gcgcttgccg tcaagacggt gcgagaacat 900 gcccggggaa cgccgggccc gggcctgccg ctgtggcccc aggtgtttct cggaggccat 960 gtggcggtgg ccctgacgga gctgtgtcag gcgcttccgc cctgggacct tacggacccg 1020 ctgctgtttg ttcacgccgg actgcaggtc atcaacctcg ggttggtgtt tcggttttcc 1080 gaggttgtcg tgtatgcggc gctagggggt gccgtgtgga tttcgttggc gcaggtgctg 1140 gggctccggc gtcgcctgca caggaaggac cccggggacg gggcccggtt ggcggcgacg 1200 cttcggggcc tcttcttctc cgtgtacgcg ctggggtttg gggtgggggt gctgctg 1257 84 419 PRT Herpes Virus 84 Val Thr Glu Pro Pro Arg Val Pro Ser Arg Pro Arg Arg Gly Met Leu 1 5 10 15 Arg Asn Asp Ser His Arg Ala Val Ser Pro Glu Asp Gly Gln Gly Arg 20 25 30 Val Asp Asp Gly Arg Pro His Leu Ala Cys Val Gly Ala Leu Ala Arg 35 40 45 Gly Phe Met His Ile Trp Leu Gln Ala Ala Thr Leu Gly Phe Ala Gly 50 55 60 Ser Val Val Met Ser Arg Gly Pro Tyr Ala Asn Ala Ala Ser Gly Ala 65 70 75 80 Phe Ala Val Gly Cys Ala Val Leu Gly Phe Met Arg Ala Pro Pro Pro 85 90 95 Leu Ala Arg Pro Thr Ala Arg Ile Tyr Ala Trp Leu Lys Leu Ala Ala 100 105 110 Gly Gly Ala Ala Leu Val Leu Trp Ser Leu Gly Glu Pro Gly Thr Gln 115 120 125 Pro Gly Ala Pro Ala Pro Gly Pro Ala Thr Gln Cys Leu Ala Leu Gly 130 135 140 Ala Ala Tyr Ala Ala Leu Leu Val Leu Ala Asp Asp Val Tyr Pro Leu 145 150 155 160 Phe Leu Leu Ala Pro Gly Pro Leu Phe Val Gly Thr Leu Gly Met Val 165 170 175 Val Gly Gly Leu Thr Ile Gly Gly Ser Ala Arg Tyr Trp Trp Ile Gly 180 185 190 Gly Pro Ala Ala Ala Ala Leu Ala Ala Ala Val Leu Ala Gly Pro Gly 195 200 205 Ala Thr Thr Ala Arg Asp Cys Phe Ser Arg Ala Cys Pro Asp His Arg 210 215 220 Arg Val Cys Val Ile Thr Ala Gly Glu Ser Leu Ser Arg Arg Pro Pro 225 230 235 240 Glu Asp Pro Glu Arg Pro Gly Val Pro Gly Pro Pro Ser Pro Pro Thr 245 250 255 Pro Gln Arg Ser His Gly Pro Pro Ala Asp Glu Val Ala Pro Ala Arg 260 265 270 Val Ala Arg Pro Glu Asn Val Trp Val Pro Val Val Thr Phe Leu Gly 275 280 285 Ala Gly Ala Leu Ala Val Lys Thr Val Arg Glu His Ala Arg Gly Thr 290 295 300 Pro Gly Pro Gly Leu Pro Leu Trp Pro Gln Val Phe Leu Gly Gly His 305 310 315 320 Val Ala Val Ala Leu Thr Glu Leu Cys Gln Ala Leu Pro Pro Trp Asp 325 330 335 Leu Thr Asp Pro Leu Leu Phe Val His Ala Gly Leu Gln Val Ile Asn 340 345 350 Leu Gly Leu Val Phe Arg Phe Ser Glu Val Val Val Tyr Ala Ala Leu 355 360 365 Gly Gly Ala Val Trp Ile Ser Leu Ala Gln Val Leu Gly Leu Arg Arg 370 375 380 Arg Leu His Arg Lys Asp Pro Gly Asp Gly Ala Arg Leu Ala Ala Thr 385 390 395 400 Leu Arg Gly Leu Phe Phe Ser Val Tyr Ala Leu Gly Phe Gly Val Gly 405 410 415 Val Leu Leu 85 1305 DNA Herpes Virus 85 atgtggggcg tgacggaacc accccgcgtg ccatcacggc caaggcgcgg gatgctccgc 60 aacgacagcc accgggccgt gtccccggag gacggccagg gacgggtcga cgacggacgg 120 ccacacctcg cgtgcgtggg ggccctggcg cgggggttca tgcatatctg gcttcaggcc 180 gccacgctgg gttttgcggg atcggtcgtt atgtcgcgcg ggccgtacgc gaatgccgcg 240 tctggggcgt tcgccgtcgg gtgcgccgtg ctgggcttta tgcgcgcacc ccctcccctc 300 gcgcggccca ccgcgcggat atacgcctgg ctcaaactgg cggccggtgg agcggccctt 360 gttctgtgga gtctcgggga gcccggcacg cagccggggg ccccggcccc gggcccggcc 420 acccagtgcc tggcactggg cgccgcctat gcggcgctcc tggtgctcgc cgatgacgtc 480 tatccgctct ttctcctcgc cccggggccc ctgttcgtcg gcaccctggg gatggtcgtc 540 ggcgggctga cgatcggagg cagcgcgcgc tactggtgga tcggtgggcc cgccgcggcc 600 gccctggccg cggcggtgtt ggcgggcccg ggggcgacca ccgccaggga ctgcttttcc 660 agggcttgcc ccgaccaccg ccgcgtctgt gtcatcaccg caggcgagtc tctttcccgc 720 cgccccccgg aggacccaga gcgacccggg gttcccgggc ccccgtcccc cccgaccccc 780 caacgatccc acgggccgcc ggccgatgag gtcgcaccgg ccagggtcgc gcggcccgaa 840 aacgtctggg tgcccgtggt cacctttctg ggggcgggcg cgcttgccgt caagacggtg 900 cgagaacatg cccggggaac gccgggcccg ggcctgccgc tgtggcccca ggtgtttctc 960 ggaggccatg tggcggtggc cctgacggag ctgtgtcagg cgcttccgcc ctgggacctt 1020 acggacccgc tgctgtttgt tcacgccgga ctgcaggtca tcaacctcgg gttggtgttt 1080 cggttttccg aggttgtcgt gtatgcggcg ctagggggtg ccgtgtggat ttcgttggcg 1140 caggtgctgg ggctccggcg tcgcctgcac aggaaggacc ccggggacgg ggcccggttg 1200 gcggcgacgc ttcggggcct cttcttctcc gtgtacgcgc tggggtttgg ggtgggggtg 1260 ctgctgtgcc ctccggggtc aacgggcggg cggtcgggcg attga 1305 86 434 PRT Herpes Virus 86 Met Trp Gly Val Thr Glu Pro Pro Arg Val Pro Ser Arg Pro Arg Arg 1 5 10 15 Gly Met Leu Arg Asn Asp Ser His Arg Ala Val Ser Pro Glu Asp Gly 20 25 30 Gln Gly Arg Val Asp Asp Gly Arg Pro His Leu Ala Cys Val Gly Ala 35 40 45 Leu Ala Arg Gly Phe Met His Ile Trp Leu Gln Ala Ala Thr Leu Gly 50 55 60 Phe Ala Gly Ser Val Val Met Ser Arg Gly Pro Tyr Ala Asn Ala Ala 65 70 75 80 Ser Gly Ala Phe Ala Val Gly Cys Ala Val Leu Gly Phe Met Arg Ala 85 90 95 Pro Pro Pro Leu Ala Arg Pro Thr Ala Arg Ile Tyr Ala Trp Leu Lys 100 105 110 Leu Ala Ala Gly Gly Ala Ala Leu Val Leu Trp Ser Leu Gly Glu Pro 115 120 125 Gly Thr Gln Pro Gly Ala Pro Ala Pro Gly Pro Ala Thr Gln Cys Leu 130 135 140 Ala Leu Gly Ala Ala Tyr Ala Ala Leu Leu Val Leu Ala Asp Asp Val 145 150 155 160 Tyr Pro Leu Phe Leu Leu Ala Pro Gly Pro Leu Phe Val Gly Thr Leu 165 170 175 Gly Met Val Val Gly Gly Leu Thr Ile Gly Gly Ser Ala Arg Tyr Trp 180 185 190 Trp Ile Gly Gly Pro Ala Ala Ala Ala Leu Ala Ala Ala Val Leu Ala 195 200 205 Gly Pro Gly Ala Thr Thr Ala Arg Asp Cys Phe Ser Arg Ala Cys Pro 210 215 220 Asp His Arg Arg Val Cys Val Ile Thr Ala Gly Glu Ser Leu Ser Arg 225 230 235 240 Arg Pro Pro Glu Asp Pro Glu Arg Pro Gly Val Pro Gly Pro Pro Ser 245 250 255 Pro Pro Thr Pro Gln Arg Ser His Gly Pro Pro Ala Asp Glu Val Ala 260 265 270 Pro Ala Arg Val Ala Arg Pro Glu Asn Val Trp Val Pro Val Val Thr 275 280 285 Phe Leu Gly Ala Gly Ala Leu Ala Val Lys Thr Val Arg Glu His Ala 290 295 300 Arg Gly Thr Pro Gly Pro Gly Leu Pro Leu Trp Pro Gln Val Phe Leu 305 310 315 320 Gly Gly His Val Ala Val Ala Leu Thr Glu Leu Cys Gln Ala Leu Pro 325 330 335 Pro Trp Asp Leu Thr Asp Pro Leu Leu Phe Val His Ala Gly Leu Gln 340 345 350 Val Ile Asn Leu Gly Leu Val Phe Arg Phe Ser Glu Val Val Val Tyr 355 360 365 Ala Ala Leu Gly Gly Ala Val Trp Ile Ser Leu Ala Gln Val Leu Gly 370 375 380 Leu Arg Arg Arg Leu His Arg Lys Asp Pro Gly Asp Gly Ala Arg Leu 385 390 395 400 Ala Ala Thr Leu Arg Gly Leu Phe Phe Ser Val Tyr Ala Leu Gly Phe 405 410 415 Gly Val Gly Val Leu Leu Cys Pro Pro Gly Ser Thr Gly Gly Arg Ser 420 425 430 Gly Asp 87 711 DNA Herpes Virus 87 gtggtcctgt ggagcctgtt gtggctcggg gcgggggtgt ccgggggctc ggaaactgcc 60 tccaccgggc ccacgatcac cgcgggagcg gtgacgaacg cgagcgaggc ccccacatcg 120 gggtcccccg ggtcagccgc cagcccggag gtcaccccca catcgacccc aaaccccaac 180 aatgtcacac aaaacaaaac cacccccacc gagccggcca gccccccaac aacccccaag 240 cccacctcca cgcccaaaag cccccccacg tccacccccg accccaaacc caagaacaac 300 accacccccg ccaagtcggg ccgccccact aaaccccccg ggcccgtgtg gtgcgaccgc 360 cgcgacccat tggcccggta cggctcgcgg gtgcagatcc gatgccggtt tcggaattcc 420 acccgcatgg agttccgcct ccagatatgg cgttactcca tgggtccgtc ccccccaatc 480 gctccggctc ccgacctaga ggaggtcctg acgaacatca ccgccccacc cgggggactc 540 ctggtgtacg acagcgcccc caacctaacg gacccccacg tgctctgggc ggagggggcc 600 ggcccgggcg ccgaccctcc gttgtattct gtcaccgggc cgctgccgac ccagcggctg 660 attatcggcg aggtgacgcc cgcgacccag ggaatgtatt acttggcctg g 711 88 237 PRT Herpes Virus 88 Val Val Leu Trp Ser Leu Leu Trp Leu Gly Ala Gly Val Ser Gly Gly 1 5 10 15 Ser Glu Thr Ala Ser Thr Gly Pro Thr Ile Thr Ala Gly Ala Val Thr 20 25 30 Asn Ala Ser Glu Ala Pro Thr Ser Gly Ser Pro Gly Ser Ala Ala Ser 35 40 45 Pro Glu Val Thr Pro Thr Ser Thr Pro Asn Pro Asn Asn Val Thr Gln 50 55 60 Asn Lys Thr Thr Pro Thr Glu Pro Ala Ser Pro Pro Thr Thr Pro Lys 65 70 75 80 Pro Thr Ser Thr Pro Lys Ser Pro Pro Thr Ser Thr Pro Asp Pro Lys 85 90 95 Pro Lys Asn Asn Thr Thr Pro Ala Lys Ser Gly Arg Pro Thr Lys Pro 100 105 110 Pro Gly Pro Val Trp Cys Asp Arg Arg Asp Pro Leu Ala Arg Tyr Gly 115 120 125 Ser Arg Val Gln Ile Arg Cys Arg Phe Arg Asn Ser Thr Arg Met Glu 130 135 140 Phe Arg Leu Gln Ile Trp Arg Tyr Ser Met Gly Pro Ser Pro Pro Ile 145 150 155 160 Ala Pro Ala Pro Asp Leu Glu Glu Val Leu Thr Asn Ile Thr Ala Pro 165 170 175 Pro Gly Gly Leu Leu Val Tyr Asp Ser Ala Pro Asn Leu Thr Asp Pro 180 185 190 His Val Leu Trp Ala Glu Gly Ala Gly Pro Gly Ala Asp Pro Pro Leu 195 200 205 Tyr Ser Val Thr Gly Pro Leu Pro Thr Gln Arg Leu Ile Ile Gly Glu 210 215 220 Val Thr Pro Ala Thr Gln Gly Met Tyr Tyr Leu Ala Trp 225 230 235 89 1536 DNA Herpes Virus 89 atggccccgg ggcgggtggg ccttgccgtg gtcctgtgga gcctgttgtg gctcggggcg 60 ggggtgtccg ggggctcgga aactgcctcc accgggccca cgatcaccgc gggagcggtg 120 acgaacgcga gcgaggcccc cacatcgggg tcccccgggt cagccgccag cccggaggtc 180 acccccacat cgaccccaaa ccccaacaat gtcacacaaa acaaaaccac ccccaccgag 240 ccggccagcc ccccaacaac ccccaagccc acctccacgc ccaaaagccc ccccacgtcc 300 acccccgacc ccaaacccaa gaacaacacc acccccgcca agtcgggccg ccccactaaa 360 ccccccgggc ccgtgtggtg cgaccgccgc gacccattgg cccggtacgg ctcgcgggtg 420 cagatccgat gccggtttcg gaattccacc cgcatggagt tccgcctcca gatatggcgt 480 tactccatgg gtccgtcccc cccaatcgct ccggctcccg acctagagga ggtcctgacg 540 aacatcaccg ccccacccgg gggactcctg gtgtacgaca gcgcccccaa cctaacggac 600 ccccacgtgc tctgggcgga gggggccggc ccgggcgccg accctccgtt gtattctgtc 660 accgggccgc tgccgaccca gcggctgatt atcggcgagg tgacgcccgc gacccaggga 720 atgtattact tggcctgggg ccggatggac agcccgcacg agtacgggac gtgggtgcgc 780 gtccgcatgt tccgcccccc gtctctgacc ctccagcccc acgcggtgat ggagggtcag 840 ccgttcaagg cgacgtgcac ggccgccgcc tactacccgc gtaaccccgt ggagtttgtc 900 tggttcgagg acgaccacca ggtgtttaac ccgggccaga tcgacacgca gacgcacgag 960 caccccgacg ggttcaccac agtctctacc gtgacctccg aggctgtcgg cggccaggtc 1020 cccccgcgga ccttcacctg ccagatgacg tggcatcgcg actccgtgac gttctcgcga 1080 cgcaatgcca ccgggctggc cctggtgctg ccgcggccaa ccatcaccat ggaatttggg 1140 gtccgcattg tggtctgcac ggccggctgc gtccccgagg gcgtgacgtt tgcctggttc 1200 ctgggggacg acccctcacc ggcggctaag tcggccgtta cggcccagga gtcgtgcgac 1260 caccccgggc tggctacggt ccggtccacc ctgcccattt cgtacgacta cagcgagtac 1320 atctgtcggt tgaccggata tccggccggg attcccgttc tagaacacca cggcagtcac 1380 cagcccccac ccagggaccc caccgagcgg caggtgatcg aggcgatcga gtgggtgggg 1440 attggaatcg gggttctcgc ggcgggggtc ctggtcgtaa cggcaatcgt gtacgtcgtc 1500 cgcacatcac agtcgcggca gcgtcatcgg cggtaa 1536 90 511 PRT Herpes Virus 90 Met Ala Pro Gly Arg Val Gly Leu Ala Val Val Leu Trp Ser Leu Leu 1 5 10 15 Trp Leu Gly Ala Gly Val Ser Gly Gly Ser Glu Thr Ala Ser Thr Gly 20 25 30 Pro Thr Ile Thr Ala Gly Ala Val Thr Asn Ala Ser Glu Ala Pro Thr 35 40 45 Ser Gly Ser Pro Gly Ser Ala Ala Ser Pro Glu Val Thr Pro Thr Ser 50 55 60 Thr Pro Asn Pro Asn Asn Val Thr Gln Asn Lys Thr Thr Pro Thr Glu 65 70 75 80 Pro Ala Ser Pro Pro Thr Thr Pro Lys Pro Thr Ser Thr Pro Lys Ser 85 90 95 Pro Pro Thr Ser Thr Pro Asp Pro Lys Pro Lys Asn Asn Thr Thr Pro 100 105 110 Ala Lys Ser Gly Arg Pro Thr Lys Pro Pro Gly Pro Val Trp Cys Asp 115 120 125 Arg Arg Asp Pro Leu Ala Arg Tyr Gly Ser Arg Val Gln Ile Arg Cys 130 135 140 Arg Phe Arg Asn Ser Thr Arg Met Glu Phe Arg Leu Gln Ile Trp Arg 145 150 155 160 Tyr Ser Met Gly Pro Ser Pro Pro Ile Ala Pro Ala Pro Asp Leu Glu 165 170 175 Glu Val Leu Thr Asn Ile Thr Ala Pro Pro Gly Gly Leu Leu Val Tyr 180 185 190 Asp Ser Ala Pro Asn Leu Thr Asp Pro His Val Leu Trp Ala Glu Gly 195 200 205 Ala Gly Pro Gly Ala Asp Pro Pro Leu Tyr Ser Val Thr Gly Pro Leu 210 215 220 Pro Thr Gln Arg Leu Ile Ile Gly Glu Val Thr Pro Ala Thr Gln Gly 225 230 235 240 Met Tyr Tyr Leu Ala Trp Gly Arg Met Asp Ser Pro His Glu Tyr Gly 245 250 255 Thr Trp Val Arg Val Arg Met Phe Arg Pro Pro Ser Leu Thr Leu Gln 260 265 270 Pro His Ala Val Met Glu Gly Gln Pro Phe Lys Ala Thr Cys Thr Ala 275 280 285 Ala Ala Tyr Tyr Pro Arg Asn Pro Val Glu Phe Val Trp Phe Glu Asp 290 295 300 Asp His Gln Val Phe Asn Pro Gly Gln Ile Asp Thr Gln Thr His Glu 305 310 315 320 His Pro Asp Gly Phe Thr Thr Val Ser Thr Val Thr Ser Glu Ala Val 325 330 335 Gly Gly Gln Val Pro Pro Arg Thr Phe Thr Cys Gln Met Thr Trp His 340 345 350 Arg Asp Ser Val Thr Phe Ser Arg Arg Asn Ala Thr Gly Leu Ala Leu 355 360 365 Val Leu Pro Arg Pro Thr Ile Thr Met Glu Phe Gly Val Arg Ile Val 370 375 380 Val Cys Thr Ala Gly Cys Val Pro Glu Gly Val Thr Phe Ala Trp Phe 385 390 395 400 Leu Gly Asp Asp Pro Ser Pro Ala Ala Lys Ser Ala Val Thr Ala Gln 405 410 415 Glu Ser Cys Asp His Pro Gly Leu Ala Thr Val Arg Ser Thr Leu Pro 420 425 430 Ile Ser Tyr Asp Tyr Ser Glu Tyr Ile Cys Arg Leu Thr Gly Tyr Pro 435 440 445 Ala Gly Ile Pro Val Leu Glu His His Gly Ser His Gln Pro Pro Pro 450 455 460 Arg Asp Pro Thr Glu Arg Gln Val Ile Glu Ala Ile Glu Trp Val Gly 465 470 475 480 Ile Gly Ile Gly Val Leu Ala Ala Gly Val Leu Val Val Thr Ala Ile 485 490 495 Val Tyr Val Val Arg Thr Ser Gln Ser Arg Gln Arg His Arg Arg 500 505 510 91 843 DNA Herpes Virus 91 gatgagtacg aggatctgta ctacaccccg tcttcaggta tggcgagtcc cgatagtccg 60 cctgacacct cccgccgtgg cgccctacag acacgctcgc gccagagggg cgaggtccgt 120 ttcgtccagt acgacgagtc ggattatgcc ctctacgggg gctcgtcatc cgaagacgac 180 gaacacccgg aggtcccccg gacgcggcgt cccgtttccg gggcggtttt gtccggcccg 240 gggcctgcgc gggcgcctcc gccacccgct gggtccggag gggccggacg cacacccacc 300 accgcccccc gggccccccg aacccagcgg gtggcgacta aggcccccgc ggccccggcg 360 gcggagacca cccgcggcag gaaatcggcc cagccagaat ccgccgcact cccagacgcc 420 cccgcgtcga cggcgccaac ccgatccaag acacccgcgc aggggctggc cagaaagctg 480 cactttagca ccgccccccc aaaccccgac gcgccatgga ccccccgggt ggccggcttt 540 aacaagcgcg tcttctgcgc cgcggtcggg cgcctggcgg ccatgcatgc ccggatggcg 600 gcggtccagc tctgggacat gtcgcgtccg cgcacagacg aagacctcaa cgaactcctt 660 ggcatcacca ccatccgcgt gacggtctgc gagggcaaaa acctgcttca gcgcgccaac 720 gagttggtga atccagacgt ggtgcaggac gtcgacgcgg ccacggcgac tcgagggcgt 780 tctgcggcgt cgcgccccac cgagcgacct cgagccccag cccgctccgc ttctcgcccc 840 aga 843 92 281 PRT Herpes Virus 92 Asp Glu Tyr Glu Asp Leu Tyr Tyr Thr Pro Ser Ser Gly Met Ala Ser 1 5 10 15 Pro Asp Ser Pro Pro Asp Thr Ser Arg Arg Gly Ala Leu Gln Thr Arg 20 25 30 Ser Arg Gln Arg Gly Glu Val Arg Phe Val Gln Tyr Asp Glu Ser Asp 35 40 45 Tyr Ala Leu Tyr Gly Gly Ser Ser Ser Glu Asp Asp Glu His Pro Glu 50 55 60 Val Pro Arg Thr Arg Arg Pro Val Ser Gly Ala Val Leu Ser Gly Pro 65 70 75 80 Gly Pro Ala Arg Ala Pro Pro Pro Pro Ala Gly Ser Gly Gly Ala Gly 85 90 95 Arg Thr Pro Thr Thr Ala Pro Arg Ala Pro Arg Thr Gln Arg Val Ala 100 105 110 Thr Lys Ala Pro Ala Ala Pro Ala Ala Glu Thr Thr Arg Gly Arg Lys 115 120 125 Ser Ala Gln Pro Glu Ser Ala Ala Leu Pro Asp Ala Pro Ala Ser Thr 130 135 140 Ala Pro Thr Arg Ser Lys Thr Pro Ala Gln Gly Leu Ala Arg Lys Leu 145 150 155 160 His Phe Ser Thr Ala Pro Pro Asn Pro Asp Ala Pro Trp Thr Pro Arg 165 170 175 Val Ala Gly Phe Asn Lys Arg Val Phe Cys Ala Ala Val Gly Arg Leu 180 185 190 Ala Ala Met His Ala Arg Met Ala Ala Val Gln Leu Trp Asp Met Ser 195 200 205 Arg Pro Arg Thr Asp Glu Asp Leu Asn Glu Leu Leu Gly Ile Thr Thr 210 215 220 Ile Arg Val Thr Val Cys Glu Gly Lys Asn Leu Leu Gln Arg Ala Asn 225 230 235 240 Glu Leu Val Asn Pro Asp Val Val Gln Asp Val Asp Ala Ala Thr Ala 245 250 255 Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr Glu Arg Pro Arg Ala 260 265 270 Pro Ala Arg Ser Ala Ser Arg Pro Arg 275 280 93 906 DNA Herpes Virus 93 atgacctctc gccgctccgt gaagtcgggt ccgcgggagg ttccgcgcga tgagtacgag 60 gatctgtact acaccccgtc ttcaggtatg gcgagtcccg atagtccgcc tgacacctcc 120 cgccgtggcg ccctacagac acgctcgcgc cagaggggcg aggtccgttt cgtccagtac 180 gacgagtcgg attatgccct ctacgggggc tcgtcatccg aagacgacga acacccggag 240 gtcccccgga cgcggcgtcc cgtttccggg gcggttttgt ccggcccggg gcctgcgcgg 300 gcgcctccgc cacccgctgg gtccggaggg gccggacgca cacccaccac cgccccccgg 360 gccccccgaa cccagcgggt ggcgactaag gcccccgcgg ccccggcggc ggagaccacc 420 cgcggcagga aatcggccca gccagaatcc gccgcactcc cagacgcccc cgcgtcgacg 480 gcgccaaccc gatccaagac acccgcgcag gggctggcca gaaagctgca ctttagcacc 540 gcccccccaa accccgacgc gccatggacc ccccgggtgg ccggctttaa caagcgcgtc 600 ttctgcgccg cggtcgggcg cctggcggcc atgcatgccc ggatggcggc ggtccagctc 660 tgggacatgt cgcgtccgcg cacagacgaa gacctcaacg aactccttgg catcaccacc 720 atccgcgtga cggtctgcga gggcaaaaac ctgcttcagc gcgccaacga gttggtgaat 780 ccagacgtgg tgcaggacgt cgacgcggcc acggcgactc gagggcgttc tgcggcgtcg 840 cgccccaccg agcgacctcg agccccagcc cgctccgctt ctcgccccag acggcccgtc 900 gagtga 906 94 301 PRT Herpes Virus 94 Met Thr Ser Arg Arg Ser Val Lys Ser Gly Pro Arg Glu Val Pro Arg 1 5 10 15 Asp Glu Tyr Glu Asp Leu Tyr Tyr Thr Pro Ser Ser Gly Met Ala Ser 20 25 30 Pro Asp Ser Pro Pro Asp Thr Ser Arg Arg Gly Ala Leu Gln Thr Arg 35 40 45 Ser Arg Gln Arg Gly Glu Val Arg Phe Val Gln Tyr Asp Glu Ser Asp 50 55 60 Tyr Ala Leu Tyr Gly Gly Ser Ser Ser Glu Asp Asp Glu His Pro Glu 65 70 75 80 Val Pro Arg Thr Arg Arg Pro Val Ser Gly Ala Val Leu Ser Gly Pro 85 90 95 Gly Pro Ala Arg Ala Pro Pro Pro Pro Ala Gly Ser Gly Gly Ala Gly 100 105 110 Arg Thr Pro Thr Thr Ala Pro Arg Ala Pro Arg Thr Gln Arg Val Ala 115 120 125 Thr Lys Ala Pro Ala Ala Pro Ala Ala Glu Thr Thr Arg Gly Arg Lys 130 135 140 Ser Ala Gln Pro Glu Ser Ala Ala Leu Pro Asp Ala Pro Ala Ser Thr 145 150 155 160 Ala Pro Thr Arg Ser Lys Thr Pro Ala Gln Gly Leu Ala Arg Lys Leu 165 170 175 His Phe Ser Thr Ala Pro Pro Asn Pro Asp Ala Pro Trp Thr Pro Arg 180 185 190 Val Ala Gly Phe Asn Lys Arg Val Phe Cys Ala Ala Val Gly Arg Leu 195 200 205 Ala Ala Met His Ala Arg Met Ala Ala Val Gln Leu Trp Asp Met Ser 210 215 220 Arg Pro Arg Thr Asp Glu Asp Leu Asn Glu Leu Leu Gly Ile Thr Thr 225 230 235 240 Ile Arg Val Thr Val Cys Glu Gly Lys Asn Leu Leu Gln Arg Ala Asn 245 250 255 Glu Leu Val Asn Pro Asp Val Val Gln Asp Val Asp Ala Ala Thr Ala 260 265 270 Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr Glu Arg Pro Arg Ala 275 280 285 Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro Val Glu 290 295 300 95 1023 DNA Herpes Virus 95 gactggtttc cctgctacga cgacgccggt gatgaggagt gggcggagga cccgggcgcc 60 atggacacat cccacgatcc cccggacgac gaggttgcct actttgacct gtgccacgaa 120 gtcggcccca cggcggaacc tcgcgaaacg gattcgcccg tgtgttcctg caccgacaag 180 atcggactgc gggtgtgcat gcccgtcccc gccccgtacg tcgtccacgg ttctctaacg 240 atgcgggggg tggcacgggt catccagcag gcggtgctgt tggaccgaga ttttgtggag 300 gccatcggga gctacgtaaa aaacttcctg ttgatcgata cgggggtgta cgcccacggc 360 cacagcctgc gcttgccgta ttttgccaaa atcgcccccg acgggcctgc gtgcggaagg 420 ctgctgccag tgtttgtgat cccccccgcc tgcaaagacg ttccggcgtt tgtcgccgcg 480 cacgccgacc cgcggcgctt ccattttcac gccccgccca cctatctcgc ttccccccgg 540 gagatccgtg tcctgcacag cctgggtggg gactatgtga gcttctttga aaggaaggcg 600 tcccgcaacg cgctggaaca ctttgggcga cgcgagaccc tgacggaggt cctgggtcgg 660 tacaacgtac agccggatgc gggggggacc gtcgaggggt tcgcatcgga actgctgggg 720 cggatagtcg cgtgcatcga aacccacttt cccgaacacg ccggcgaata tcaggccgta 780 tccgtccggc gggccgtcag taaggacgac tgggtcctcc tacagctagt ccccgttcgc 840 ggtaccctgc agcaaagcct gtcgtgtctg cgctttaagc acggccgggc gagtcgcgcc 900 acggcgcgga cattcgtcgc gctgagcgtc ggggccaaca accgcctgtg cgtgtccttg 960 tgtcagcagt gctttgccgc caaatgcgac agcaaccgcc tgcacacgct gtttaccatt 1020 gac 1023 96 341 PRT Herpes Virus 96 Asp Trp Phe Pro Cys Tyr Asp Asp Ala Gly Asp Glu Glu Trp Ala Glu 1 5 10 15 Asp Pro Gly Ala Met Asp Thr Ser His Asp Pro Pro Asp Asp Glu Val 20 25 30 Ala Tyr Phe Asp Leu Cys His Glu Val Gly Pro Thr Ala Glu Pro Arg 35 40 45 Glu Thr Asp Ser Pro Val Cys Ser Cys Thr Asp Lys Ile Gly Leu Arg 50 55 60 Val Cys Met Pro Val Pro Ala Pro Tyr Val Val His Gly Ser Leu Thr 65 70 75 80 Met Arg Gly Val Ala Arg Val Ile Gln Gln Ala Val Leu Leu Asp Arg 85 90 95 Asp Phe Val Glu Ala Ile Gly Ser Tyr Val Lys Asn Phe Leu Leu Ile 100 105 110 Asp Thr Gly Val Tyr Ala His Gly His Ser Leu Arg Leu Pro Tyr Phe 115 120 125 Ala Lys Ile Ala Pro Asp Gly Pro Ala Cys Gly Arg Leu Leu Pro Val 130 135 140 Phe Val Ile Pro Pro Ala Cys Lys Asp Val Pro Ala Phe Val Ala Ala 145 150 155 160 His Ala Asp Pro Arg Arg Phe His Phe His Ala Pro Pro Thr Tyr Leu 165 170 175 Ala Ser Pro Arg Glu Ile Arg Val Leu His Ser Leu Gly Gly Asp Tyr 180 185 190 Val Ser Phe Phe Glu Arg Lys Ala Ser Arg Asn Ala Leu Glu His Phe 195 200 205 Gly Arg Arg Glu Thr Leu Thr Glu Val Leu Gly Arg Tyr Asn Val Gln 210 215 220 Pro Asp Ala Gly Gly Thr Val Glu Gly Phe Ala Ser Glu Leu Leu Gly 225 230 235 240 Arg Ile Val Ala Cys Ile Glu Thr His Phe Pro Glu His Ala Gly Glu 245 250 255 Tyr Gln Ala Val Ser Val Arg Arg Ala Val Ser Lys Asp Asp Trp Val 260 265 270 Leu Leu Gln Leu Val Pro Val Arg Gly Thr Leu Gln Gln Ser Leu Ser 275 280 285 Cys Leu Arg Phe Lys His Gly Arg Ala Ser Arg Ala Thr Ala Arg Thr 290 295 300 Phe Val Ala Leu Ser Val Gly Ala Asn Asn Arg Leu Cys Val Ser Leu 305 310 315 320 Cys Gln Gln Cys Phe Ala Ala Lys Cys Asp Ser Asn Arg Leu His Thr 325 330 335 Leu Phe Thr Ile Asp 340 97 3177 DNA Herpes Virus 97 atggggcagg aagacgggaa ccgcggggag aggcgggcgg ccgggactcc cgtggaggtg 60 accgcgcttt atgcgaccga cgggtgcgtt attacctctt cgatcgccct cctcacaaac 120 tctctactgg gggccgagcc ggtttatata ttcagctacg acgcatacac gcacgatggc 180 cgtgccgacg ggcccacgga gcaagacagg ttcgaagaga gtcgggcgct ctaccaagcg 240 tcgggcgggc taaatggcga ctccttccga gtaacctttt gtttattggg gacggaagtg 300 ggtgggaccc accaggcccg cgggcgaacc cgacccatgt tcgtctgtcg cttcgagcga 360 gcggacgacg tcgccgcgct acaggacgcc ctggcgcacg ggaccccgct acaaccggac 420 cacatcgccg ccaccctgga cgcggaggcc acgttcgcgc tgcatgcgaa catgatcctg 480 gctctcaccg tggccatcaa caacgccagc ccccgcaccg gacgcgacgc cgccgcggcg 540 cagtatgatc agggcgcgtc cctacgctcg ctcgtggggc gcacgtccct gggacaacgc 600 ggccttacca cgctatacgt ccaccacgag gtgcgcgtgc ttgccgcgta ccgcagggcg 660 tattatggaa gcgcgcagag tcccttctgg tttcttagca aattcgggcc ggacgaaaaa 720 agcctggtgc tcaccactcg gtactacctg cttcaggccc agcgtctggg gggcgcgggg 780 gccacgtacg acctgcaggc catcaaggac atctgcgcca cctacgcgat tccccacgcc 840 ccccgccccg acaccgtcag cgctgcgtcc ctgacctcgt ttgccgccat cacgcggttc 900 tgttgcacga gccagtacgc ccgcggggcc gcggcggccg ggtttccgct ttacgtggag 960 cgccgtattg cggccgacgt ccgcgagacc agtgcgctgg agaagttcat aacccacgat 1020 cgcagttgcc tgcgcgtgtc cgaccgtgaa ttcattacgt acatctacct ggcccatttt 1080 gagtgtttca gccccccgcg cctagccacg catcttcggg ccgtgacgac ccacgacccc 1140 aaccccgcgg ccagcacgga gcagccctcg cccctgggca gggaggccgt ggaacaattt 1200 ttttgtcacg tgcgcgccca actgaatatc ggggagtacg tcaaacacaa cgtgaccccc 1260 cgggagaccg tcctggatgg cgatacggcc aaggcctacc tgcgcgctcg cacgtacgcg 1320 cccggggccc tgacgcccgc ccccgcgtat tgcggggccg tggactccgc caccaaaatg 1380 atggggcgtt tggcggacgc cgaaaagctc ctggtccccc gcgggtggcc cgcgtttgcg 1440 cccgccagtc ccggggagga cacggcgggc ggcacgccgc ccccacagac ctgcggaatt 1500 gtcaagcgcc tcctgagact ggccgccacg gaacagcagg gccccacacc cccggcgatc 1560 gcggcgctta tccgtaatgc ggcggtgcag actcccctgc ccgtctaccg gatatccatg 1620 gtccccacgg gacaggcatt tgccgcgctg gcctgggacg actgggcccg cataacgcgg 1680 gacgctcgcc tggccgaagc ggtcgtgtcc gccgaagcgg cggcgcaccc cgaccacggc 1740 gcgctgggca ggcggctcac ggatcgcatc cgcgcccagg gccccgtgat gccccctggc 1800 ggcctggatg ccggggggca gatgtacgtg aatcgcaacg agatattcaa cggcgcgctg 1860 gcaatcacaa acatcatcct ggatctcgac atcgccctga aggagcccgt cccctttcgc 1920 cggctccacg aggccctggg ccactttagg cgcggggctc tggctgcggt tcagctcctg 1980 tttcccgcgg cccgcgtgga ccccgacgca tatccctgtt attttttcaa aagcgcatgt 2040 cggcccggcc cggcgtccgt gggttccggc agcggactcg gcaacgacga cgacggggac 2100 tggtttccct gctacgacga cgccggtgat gaggagtggg cggaggaccc gggcgccatg 2160 gacacatccc acgatccccc ggacgacgag gttgcctact ttgacctgtg ccacgaagtc 2220 ggccccacgg cggaacctcg cgaaacggat tcgcccgtgt gttcctgcac cgacaagatc 2280 ggactgcggg tgtgcatgcc cgtccccgcc ccgtacgtcg tccacggttc tctaacgatg 2340 cggggggtgg cacgggtcat ccagcaggcg gtgctgttgg accgagattt tgtggaggcc 2400 atcgggagct acgtaaaaaa cttcctgttg atcgatacgg gggtgtacgc ccacggccac 2460 agcctgcgct tgccgtattt tgccaaaatc gcccccgacg ggcctgcgtg cggaaggctg 2520 ctgccagtgt ttgtgatccc ccccgcctgc aaagacgttc cggcgtttgt cgccgcgcac 2580 gccgacccgc ggcgcttcca ttttcacgcc ccgcccacct atctcgcttc cccccgggag 2640 atccgtgtcc tgcacagcct gggtggggac tatgtgagct tctttgaaag gaaggcgtcc 2700 cgcaacgcgc tggaacactt tgggcgacgc gagaccctga cggaggtcct gggtcggtac 2760 aacgtacagc cggatgcggg ggggaccgtc gaggggttcg catcggaact gctggggcgg 2820 atagtcgcgt gcatcgaaac ccactttccc gaacacgccg gcgaatatca ggccgtatcc 2880 gtccggcggg ccgtcagtaa ggacgactgg gtcctcctac agctagtccc cgttcgcggt 2940 accctgcagc aaagcctgtc gtgtctgcgc tttaagcacg gccgggcgag tcgcgccacg 3000 gcgcggacat tcgtcgcgct gagcgtcggg gccaacaacc gcctgtgcgt gtccttgtgt 3060 cagcagtgct ttgccgccaa atgcgacagc aaccgcctgc acacgctgtt taccattgac 3120 gccggcacgc catgctcgcc gtccgttccc tgcagcacct ctcaaccgtc gtcttga 3177 98 1058 PRT Herpes Virus 98 Met Gly Gln Glu Asp Gly Asn Arg Gly Glu Arg Arg Ala Ala Gly Thr 1 5 10 15 Pro Val Glu Val Thr Ala Leu Tyr Ala Thr Asp Gly Cys Val Ile Thr 20 25 30 Ser Ser Ile Ala Leu Leu Thr Asn Ser Leu Leu Gly Ala Glu Pro Val 35 40 45 Tyr Ile Phe Ser Tyr Asp Ala Tyr Thr His Asp Gly Arg Ala Asp Gly 50 55 60 Pro Thr Glu Gln Asp Arg Phe Glu Glu Ser Arg Ala Leu Tyr Gln Ala 65 70 75 80 Ser Gly Gly Leu Asn Gly Asp Ser Phe Arg Val Thr Phe Cys Leu Leu 85 90 95 Gly Thr Glu Val Gly Gly Thr His Gln Ala Arg Gly Arg Thr Arg Pro 100 105 110 Met Phe Val Cys Arg Phe Glu Arg Ala Asp Asp Val Ala Ala Leu Gln 115 120 125 Asp Ala Leu Ala His Gly Thr Pro Leu Gln Pro Asp His Ile Ala Ala 130 135 140 Thr Leu Asp Ala Glu Ala Thr Phe Ala Leu His Ala Asn Met Ile Leu 145 150 155 160 Ala Leu Thr Val Ala Ile Asn Asn Ala Ser Pro Arg Thr Gly Arg Asp 165 170 175 Ala Ala Ala Ala Gln Tyr Asp Gln Gly Ala Ser Leu Arg Ser Leu Val 180 185 190 Gly Arg Thr Ser Leu Gly Gln Arg Gly Leu Thr Thr Leu Tyr Val His 195 200 205 His Glu Val Arg Val Leu Ala Ala Tyr Arg Arg Ala Tyr Tyr Gly Ser 210 215 220 Ala Gln Ser Pro Phe Trp Phe Leu Ser Lys Phe Gly Pro Asp Glu Lys 225 230 235 240 Ser Leu Val Leu Thr Thr Arg Tyr Tyr Leu Leu Gln Ala Gln Arg Leu 245 250 255 Gly Gly Ala Gly Ala Thr Tyr Asp Leu Gln Ala Ile Lys Asp Ile Cys 260 265 270 Ala Thr Tyr Ala Ile Pro His Ala Pro Arg Pro Asp Thr Val Ser Ala 275 280 285 Ala Ser Leu Thr Ser Phe Ala Ala Ile Thr Arg Phe Cys Cys Thr Ser 290 295 300 Gln Tyr Ala Arg Gly Ala Ala Ala Ala Gly Phe Pro Leu Tyr Val Glu 305 310 315 320 Arg Arg Ile Ala Ala Asp Val Arg Glu Thr Ser Ala Leu Glu Lys Phe 325 330 335 Ile Thr His Asp Arg Ser Cys Leu Arg Val Ser Asp Arg Glu Phe Ile 340 345 350 Thr Tyr Ile Tyr Leu Ala His Phe Glu Cys Phe Ser Pro Pro Arg Leu 355 360 365 Ala Thr His Leu Arg Ala Val Thr Thr His Asp Pro Asn Pro Ala Ala 370 375 380 Ser Thr Glu Gln Pro Ser Pro Leu Gly Arg Glu Ala Val Glu Gln Phe 385 390 395 400 Phe Cys His Val Arg Ala Gln Leu Asn Ile Gly Glu Tyr Val Lys His 405 410 415 Asn Val Thr Pro Arg Glu Thr Val Leu Asp Gly Asp Thr Ala Lys Ala 420 425 430 Tyr Leu Arg Ala Arg Thr Tyr Ala Pro Gly Ala Leu Thr Pro Ala Pro 435 440 445 Ala Tyr Cys Gly Ala Val Asp Ser Ala Thr Lys Met Met Gly Arg Leu 450 455 460 Ala Asp Ala Glu Lys Leu Leu Val Pro Arg Gly Trp Pro Ala Phe Ala 465 470 475 480 Pro Ala Ser Pro Gly Glu Asp Thr Ala Gly Gly Thr Pro Pro Pro Gln 485 490 495 Thr Cys Gly Ile Val Lys Arg Leu Leu Arg Leu Ala Ala Thr Glu Gln 500 505 510 Gln Gly Pro Thr Pro Pro Ala Ile Ala Ala Leu Ile Arg Asn Ala Ala 515 520 525 Val Gln Thr Pro Leu Pro Val Tyr Arg Ile Ser Met Val Pro Thr Gly 530 535 540 Gln Ala Phe Ala Ala Leu Ala Trp Asp Asp Trp Ala Arg Ile Thr Arg 545 550 555 560 Asp Ala Arg Leu Ala Glu Ala Val Val Ser Ala Glu Ala Ala Ala His 565 570 575 Pro Asp His Gly Ala Leu Gly Arg Arg Leu Thr Asp Arg Ile Arg Ala 580 585 590 Gln Gly Pro Val Met Pro Pro Gly Gly Leu Asp Ala Gly Gly Gln Met 595 600 605 Tyr Val Asn Arg Asn Glu Ile Phe Asn Gly Ala Leu Ala Ile Thr Asn 610 615 620 Ile Ile Leu Asp Leu Asp Ile Ala Leu Lys Glu Pro Val Pro Phe Arg 625 630 635 640 Arg Leu His Glu Ala Leu Gly His Phe Arg Arg Gly Ala Leu Ala Ala 645 650 655 Val Gln Leu Leu Phe Pro Ala Ala Arg Val Asp Pro Asp Ala Tyr Pro 660 665 670 Cys Tyr Phe Phe Lys Ser Ala Cys Arg Pro Gly Pro Ala Ser Val Gly 675 680 685 Ser Gly Ser Gly Leu Gly Asn Asp Asp Asp Gly Asp Trp Phe Pro Cys 690 695 700 Tyr Asp Asp Ala Gly Asp Glu Glu Trp Ala Glu Asp Pro Gly Ala Met 705 710 715 720 Asp Thr Ser His Asp Pro Pro Asp Asp Glu Val Ala Tyr Phe Asp Leu 725 730 735 Cys His Glu Val Gly Pro Thr Ala Glu Pro Arg Glu Thr Asp Ser Pro 740 745 750 Val Cys Ser Cys Thr Asp Lys Ile Gly Leu Arg Val Cys Met Pro Val 755 760 765 Pro Ala Pro Tyr Val Val His Gly Ser Leu Thr Met Arg Gly Val Ala 770 775 780 Arg Val Ile Gln Gln Ala Val Leu Leu Asp Arg Asp Phe Val Glu Ala 785 790 795 800 Ile Gly Ser Tyr Val Lys Asn Phe Leu Leu Ile Asp Thr Gly Val Tyr 805 810 815 Ala His Gly His Ser Leu Arg Leu Pro Tyr Phe Ala Lys Ile Ala Pro 820 825 830 Asp Gly Pro Ala Cys Gly Arg Leu Leu Pro Val Phe Val Ile Pro Pro 835 840 845 Ala Cys Lys Asp Val Pro Ala Phe Val Ala Ala His Ala Asp Pro Arg 850 855 860 Arg Phe His Phe His Ala Pro Pro Thr Tyr Leu Ala Ser Pro Arg Glu 865 870 875 880 Ile Arg Val Leu His Ser Leu Gly Gly Asp Tyr Val Ser Phe Phe Glu 885 890 895 Arg Lys Ala Ser Arg Asn Ala Leu Glu His Phe Gly Arg Arg Glu Thr 900 905 910 Leu Thr Glu Val Leu Gly Arg Tyr Asn Val Gln Pro Asp Ala Gly Gly 915 920 925 Thr Val Glu Gly Phe Ala Ser Glu Leu Leu Gly Arg Ile Val Ala Cys 930 935 940 Ile Glu Thr His Phe Pro Glu His Ala Gly Glu Tyr Gln Ala Val Ser 945 950 955 960 Val Arg Arg Ala Val Ser Lys Asp Asp Trp Val Leu Leu Gln Leu Val 965 970 975 Pro Val Arg Gly Thr Leu Gln Gln Ser Leu Ser Cys Leu Arg Phe Lys 980 985 990 His Gly Arg Ala Ser Arg Ala Thr Ala Arg Thr Phe Val Ala Leu Ser 995 1000 1005 Val Gly Ala Asn Asn Arg Leu Cys Val Ser Leu Cys Gln Gln Cys Phe 1010 1015 1020 Ala Ala Lys Cys Asp Ser Asn Arg Leu His Thr Leu Phe Thr Ile Asp 1025 1030 1035 1040 Ala Gly Thr Pro Cys Ser Pro Ser Val Pro Cys Ser Thr Ser Gln Pro 1045 1050 1055 Ser Ser 99 701 DNA Herpes Virus 99 ttggtcctgc gctccatctc cgagcgcgcg gcggtcgacc gcatcagcga gagctttggc 60 cgcagcgcac aggtcatgca cgaccccttt ggggggcagc cgtttcccgc cgcgaatagc 120 ccctgggccc cggtgctggc gggccaagga gggccctttg acgccgagac cagacgggtc 180 tcctgggaaa ccttggtcgc ccacggcccg agcctctatc gcacttttgc cggcaatcct 240 cgggccgcat cgaccgccaa ggccatgcgc gactgcgtgc tgcgccaaga aaatttcatc 300 gaggcgctgg cctccgccga cgagacgctg gcgtggtgca agatgtgcat ccaccacaac 360 ctgccgctgc gcccccagga ccccattatc gggacgaccg cggctgtgct ggataacctc 420 gccacgcgcc tgcggccctt tctccagtgc tacctgaagg cgcgaggcct gtgcggcctg 480 gacgaactgt gttcgcggcg gcgtctggcg gacattaagg acattgcatc cttcgtgttt 540 gtcattctgg ccaggctcgc caaccgcgtc gagcgtggcg tcgcggagat cgactacgcg 600 acccttggtg tcggggtcgg agagaagatg catttctacc tccccggggc ctgcatggcg 660 ggcctgatcg aaatcctaga cacgcaccgc caggagtgtt c 701 100 233 PRT Herpes Virus 100 Leu Val Leu Arg Ser Ile Ser Glu Arg Ala Ala Val Asp Arg Ile Ser 1 5 10 15 Glu Ser Phe Gly Arg Ser Ala Gln Val Met His Asp Pro Phe Gly Gly 20 25 30 Gln Pro Phe Pro Ala Ala Asn Ser Pro Trp Ala Pro Val Leu Ala Gly 35 40 45 Gln Gly Gly Pro Phe Asp Ala Glu Thr Arg Arg Val Ser Trp Glu Thr 50 55 60 Leu Val Ala His Gly Pro Ser Leu Tyr Arg Thr Phe Ala Gly Asn Pro 65 70 75 80 Arg Ala Ala Ser Thr Ala Lys Ala Met Arg Asp Cys Val Leu Arg Gln 85 90 95 Glu Asn Phe Ile Glu Ala Leu Ala Ser Ala Asp Glu Thr Leu Ala Trp 100 105 110 Cys Lys Met Cys Ile His His Asn Leu Pro Leu Arg Pro Gln Asp Pro 115 120 125 Ile Ile Gly Thr Thr Ala Ala Val Leu Asp Asn Leu Ala Thr Arg Leu 130 135 140 Arg Pro Phe Leu Gln Cys Tyr Leu Lys Ala Arg Gly Leu Cys Gly Leu 145 150 155 160 Asp Glu Leu Cys Ser Arg Arg Arg Leu Ala Asp Ile Lys Asp Ile Ala 165 170 175 Ser Phe Val Phe Val Ile Leu Ala Arg Leu Ala Asn Arg Val Glu Arg 180 185 190 Gly Val Ala Glu Ile Asp Tyr Ala Thr Leu Gly Val Gly Val Gly Glu 195 200 205 Lys Met His Phe Tyr Leu Pro Gly Ala Cys Met Ala Gly Leu Ile Glu 210 215 220 Ile Leu Asp Thr His Arg Gln Glu Cys 225 230 101 1539 DNA Herpes Virus 101 atggcgactg acattgatat gctaattgac ctcggcctgg acctctccga cagcgatctg 60 gacgaggacc cccccgagcc ggcggagagc cgccgcgacg acctggaatc ggacagcagc 120 ggggagtgtt cctcgtcgga cgaggacatg gaagaccccc acggagagga cggaccggag 180 ccgatactcg acgccgctcg cccggcggtc cgcccgtctc gtccagaaga ccccggcgta 240 cccagcaccc agacgcctcg tccgacggag cggcagggcc ccaacgatcc tcaaccagcg 300 ccccacagtg tgtggtcgcg cctcggggcc cggcgaccgt cttgctcccc cgagcagcac 360 gggggcaagg tggcccgcct ccaaccccca ccgaccaaag cccagcctgc ccgcggcgga 420 cgccgtgggc gtcgcagggg tcggggtcgc ggtggtcccg gggctgccga tggtttgtcg 480 gacccccgcc ggcgtgcccc cagaaccaat cgcaaccctg ggggaccccg ccccggggcg 540 gggtggacgg acggccccgg cgccccccat ggcgaggcgt ggcgcggcag tgagcagccc 600 gacccacccg gaggccagcg gacacggggc gtgcgccaag cacccccccc gctaatgacg 660 ctggcgattg cccccccgcc cgcggacccc cgcgccccgg ccccggagcg aaaggcgccc 720 gccgccgaca ccatcgacgc caccacgcgg ttggtcctgc gctccatctc cgagcgcgcg 780 gcggtcgacc gcatcagcga gagctttggc cgcagcgcac aggtcatgca cgaccccttt 840 ggggggcagc cgtttcccgc cgcgaatagc ccctgggccc cggtgctggc gggccaagga 900 gggccctttg acgccgagac cagacgggtc tcctgggaaa ccttggtcgc ccacggcccg 960 agcctctatc gcacttttgc cggcaatcct cgggccgcat cgaccgccaa ggccatgcgc 1020 gactgcgtgc tgcgccaaga aaatttcatc gaggcgctgg cctccgccga cgagacgctg 1080 gcgtggtgca agatgtgcat ccaccacaac ctgccgctgc gcccccagga ccccattatc 1140 gggacgaccg cggctgtgct ggataacctc gccacgcgcc tgcggccctt tctccagtgc 1200 tacctgaagg cgcgaggcct gtgcggcctg gacgaactgt gttcgcggcg gcgtctggcg 1260 gacattaagg acattgcatc cttcgtgttt gtcattctgg ccaggctcgc caaccgcgtc 1320 gagcgtggcg tcgcggagat cgactacgcg acccttggtg tcggggtcgg agagaagatg 1380 catttctacc tccccggggc ctgcatggcg ggcctgatcg aaatcctaga cacgcaccgc 1440 caggagtgtt cgagtcgtgt ctgcgagttg acggccagtc acatcgtcgc ccccccgtac 1500 gtgcacggca aatattttta ttgcaactcc ctgttttag 1539 102 512 PRT Herpes Virus 102 Met Ala Thr Asp Ile Asp Met Leu Ile Asp Leu Gly Leu Asp Leu Ser 1 5 10 15 Asp Ser Asp Leu Asp Glu Asp Pro Pro Glu Pro Ala Glu Ser Arg Arg 20 25 30 Asp Asp Leu Glu Ser Asp Ser Ser Gly Glu Cys Ser Ser Ser Asp Glu 35 40 45 Asp Met Glu Asp Pro His Gly Glu Asp Gly Pro Glu Pro Ile Leu Asp 50 55 60 Ala Ala Arg Pro Ala Val Arg Pro Ser Arg Pro Glu Asp Pro Gly Val 65 70 75 80 Pro Ser Thr Gln Thr Pro Arg Pro Thr Glu Arg Gln Gly Pro Asn Asp 85 90 95 Pro Gln Pro Ala Pro His Ser Val Trp Ser Arg Leu Gly Ala Arg Arg 100 105 110 Pro Ser Cys Ser Pro Glu Gln His Gly Gly Lys Val Ala Arg Leu Gln 115 120 125 Pro Pro Pro Thr Lys Ala Gln Pro Ala Arg Gly Gly Arg Arg Gly Arg 130 135 140 Arg Arg Gly Arg Gly Arg Gly Gly Pro Gly Ala Ala Asp Gly Leu Ser 145 150 155 160 Asp Pro Arg Arg Arg Ala Pro Arg Thr Asn Arg Asn Pro Gly Gly Pro 165 170 175 Arg Pro Gly Ala Gly Trp Thr Asp Gly Pro Gly Ala Pro His Gly Glu 180 185 190 Ala Trp Arg Gly Ser Glu Gln Pro Asp Pro Pro Gly Gly Gln Arg Thr 195 200 205 Arg Gly Val Arg Gln Ala Pro Pro Pro Leu Met Thr Leu Ala Ile Ala 210 215 220 Pro Pro Pro Ala Asp Pro Arg Ala Pro Ala Pro Glu Arg Lys Ala Pro 225 230 235 240 Ala Ala Asp Thr Ile Asp Ala Thr Thr Arg Leu Val Leu Arg Ser Ile 245 250 255 Ser Glu Arg Ala Ala Val Asp Arg Ile Ser Glu Ser Phe Gly Arg Ser 260 265 270 Ala Gln Val Met His Asp Pro Phe Gly Gly Gln Pro Phe Pro Ala Ala 275 280 285 Asn Ser Pro Trp Ala Pro Val Leu Ala Gly Gln Gly Gly Pro Phe Asp 290 295 300 Ala Glu Thr Arg Arg Val Ser Trp Glu Thr Leu Val Ala His Gly Pro 305 310 315 320 Ser Leu Tyr Arg Thr Phe Ala Gly Asn Pro Arg Ala Ala Ser Thr Ala 325 330 335 Lys Ala Met Arg Asp Cys Val Leu Arg Gln Glu Asn Phe Ile Glu Ala 340 345 350 Leu Ala Ser Ala Asp Glu Thr Leu Ala Trp Cys Lys Met Cys Ile His 355 360 365 His Asn Leu Pro Leu Arg Pro Gln Asp Pro Ile Ile Gly Thr Thr Ala 370 375 380 Ala Val Leu Asp Asn Leu Ala Thr Arg Leu Arg Pro Phe Leu Gln Cys 385 390 395 400 Tyr Leu Lys Ala Arg Gly Leu Cys Gly Leu Asp Glu Leu Cys Ser Arg 405 410 415 Arg Arg Leu Ala Asp Ile Lys Asp Ile Ala Ser Phe Val Phe Val Ile 420 425 430 Leu Ala Arg Leu Ala Asn Arg Val Glu Arg Gly Val Ala Glu Ile Asp 435 440 445 Tyr Ala Thr Leu Gly Val Gly Val Gly Glu Lys Met His Phe Tyr Leu 450 455 460 Pro Gly Ala Cys Met Ala Gly Leu Ile Glu Ile Leu Asp Thr His Arg 465 470 475 480 Gln Glu Cys Ser Ser Arg Val Cys Glu Leu Thr Ala Ser His Ile Val 485 490 495 Ala Pro Pro Tyr Val His Gly Lys Tyr Phe Tyr Cys Asn Ser Leu Phe 500 505 510 103 974 DNA Herpes Virus 103 cggcgaatgg cctgtcgtaa gttttgtcgc gtttacgggg gacagggcag gaggaaggag 60 gaggccgtcc cgccggagac aaagccgtcc cgggtgtttc ctcatggccc cttttatacc 120 ccagccgagg acgcgtgcct ggactccccg cccccggaga cccccaaacc ttcccacacc 180 acaccaccca gcgaggccga gcgcctgtgt catctgcagg agatccttgc ccagatgtac 240 ggaaaccagg actaccccat agaggacgac cccagcgcgg atgccgcgga cgatgtcgac 300 gaggacgccc cggacgacgt ggcctatccg gaggaatacg cagaggagct ttttctgccc 360 ggggacgcga ccggtcccct tatcggggcc aacgaccaca tccctccccc gtgtggcgca 420 tctccccccg gtatacgacg acgcagccgg gatgagattg gggccacggg atttaccgcg 480 gaagagctgg acgccatgga cagggaggcg gctcgagcca tcagccgcgg cggcaagccc 540 ccctcgacca tggccaagct ggtgactggc atgggcttta cgatccacgg agcgctcacc 600 ccaggatcgg aggggtgtgt ctttgacagc agccatccag attaccccca acgggtaatc 660 gtgaaggcgg ggtggtacac gagcacgagc cacgaggcgc gactgctgag gcgactggac 720 cacccggcga tcctgcccct cctggacctg catgtcgtct ccggggtcac gtgtctggtc 780 ctccccaaat accaggccga cctgtatacc tatctgagta ggcgcctgaa cccactggga 840 cgcccgcaga tcgcagcggt ctcccggcag ctcctaagcg ccgttgacta cattcaccgc 900 cagggcatta tccaccgcga cattaagacc gaaaatattt ttattaacac ccccgaggac 960 atttgcctgg ggga 974 104 324 PRT Herpes Virus 104 Arg Arg Met Ala Cys Arg Lys Phe Cys Arg Val Tyr Gly Gly Gln Gly 1 5 10 15 Arg Arg Lys Glu Glu Ala Val Pro Pro Glu Thr Lys Pro Ser Arg Val 20 25 30 Phe Pro His Gly Pro Phe Tyr Thr Pro Ala Glu Asp Ala Cys Leu Asp 35 40 45 Ser Pro Pro Pro Glu Thr Pro Lys Pro Ser His Thr Thr Pro Pro Ser 50 55 60 Glu Ala Glu Arg Leu Cys His Leu Gln Glu Ile Leu Ala Gln Met Tyr 65 70 75 80 Gly Asn Gln Asp Tyr Pro Ile Glu Asp Asp Pro Ser Ala Asp Ala Ala 85 90 95 Asp Asp Val Asp Glu Asp Ala Pro Asp Asp Val Ala Tyr Pro Glu Glu 100 105 110 Tyr Ala Glu Glu Leu Phe Leu Pro Gly Asp Ala Thr Gly Pro Leu Ile 115 120 125 Gly Ala Asn Asp His Ile Pro Pro Pro Cys Gly Ala Ser Pro Pro Gly 130 135 140 Ile Arg Arg Arg Ser Arg Asp Glu Ile Gly Ala Thr Gly Phe Thr Ala 145 150 155 160 Glu Glu Leu Asp Ala Met Asp Arg Glu Ala Ala Arg Ala Ile Ser Arg 165 170 175 Gly Gly Lys Pro Pro Ser Thr Met Ala Lys Leu Val Thr Gly Met Gly 180 185 190 Phe Thr Ile His Gly Ala Leu Thr Pro Gly Ser Glu Gly Cys Val Phe 195 200 205 Asp Ser Ser His Pro Asp Tyr Pro Gln Arg Val Ile Val Lys Ala Gly 210 215 220 Trp Tyr Thr Ser Thr Ser His Glu Ala Arg Leu Leu Arg Arg Leu Asp 225 230 235 240 His Pro Ala Ile Leu Pro Leu Leu Asp Leu His Val Val Ser Gly Val 245 250 255 Thr Cys Leu Val Leu Pro Lys Tyr Gln Ala Asp Leu Tyr Thr Tyr Leu 260 265 270 Ser Arg Arg Leu Asn Pro Leu Gly Arg Pro Gln Ile Ala Ala Val Ser 275 280 285 Arg Gln Leu Leu Ser Ala Val Asp Tyr Ile His Arg Gln Gly Ile Ile 290 295 300 His Arg Asp Ile Lys Thr Glu Asn Ile Phe Ile Asn Thr Pro Glu Asp 305 310 315 320 Ile Cys Leu Gly 105 1446 DNA Herpes Virus 105 atggcctgtc gtaagttttg tcgcgtttac gggggacagg gcaggaggaa ggaggaggcc 60 gtcccgccgg agacaaagcc gtcccgggtg tttcctcatg gcccctttta taccccagcc 120 gaggacgcgt gcctggactc cccgcccccg gagaccccca aaccttccca caccacacca 180 cccagcgagg ccgagcgcct gtgtcatctg caggagatcc ttgcccagat gtacggaaac 240 caggactacc ccatagagga cgaccccagc gcggatgccg cggacgatgt cgacgaggac 300 gccccggacg acgtggccta tccggaggaa tacgcagagg agctttttct gcccggggac 360 gcgaccggtc cccttatcgg ggccaacgac cacatccctc ccccgtgtgg cgcatctccc 420 cccggtatac gacgacgcag ccgggatgag attggggcca cgggatttac cgcggaagag 480 ctggacgcca tggacaggga ggcggctcga gccatcagcc gcggcggcaa gcccccctcg 540 accatggcca agctggtgac tggcatgggc tttacgatcc acggagcgct caccccagga 600 tcggaggggt gtgtctttga cagcagccat ccagattacc cccaacgggt aatcgtgaag 660 gcggggtggt acacgagcac gagccacgag gcgcgactgc tgaggcgact ggaccacccg 720 gcgatcctgc ccctcctgga cctgcatgtc gtctccgggg tcacgtgtct ggtcctcccc 780 aagtaccagg ccgacctgta tacctatctg agtaggcgcc tgaacccact gggacgcccg 840 cagatcgcag cggtctcccg gcagctccta agcgccgttg actacattca ccgccagggc 900 attatccacc gcgacattaa gaccgaaaat atttttatta acacccccga ggacatttgc 960 ctgggggact ttggcgccgc gtgcttcgtg cagggttccc gatcaagccc cttcccctac 1020 ggaatcgccg gaaccatcga caccaacgcc cccgaggtcc tggccgggga tccgtatacc 1080 acgaccgtcg acatttggag cgccggtctg gtgatcttcg agactgccgt ccacaacgcg 1140 tccttgttct cggccccccg cggccccaaa aggggcccgt gcgacagtca gatcacccgc 1200 atcatccgac aggcccaggt ccacgttgac gagttttccc cgcatccaga atcgcgcctc 1260 acctcgcgct accgctcccg cgcggccggg aacaatcgcc cgccgtacac ccgaccggcc 1320 tggacccgct actacaagat ggacatagac gtcgaatatc tggtttgcaa agccctcacc 1380 ttcgacggcg cgcttcgccc cagcgccgca gagctgcttt gtttgccgct gtttcaacag 1440 aaatga 1446 106 481 PRT Herpes Virus 106 Met Ala Cys Arg Lys Phe Cys Arg Val Tyr Gly Gly Gln Gly Arg Arg 1 5 10 15 Lys Glu Glu Ala Val Pro Pro Glu Thr Lys Pro Ser Arg Val Phe Pro 20 25 30 His Gly Pro Phe Tyr Thr Pro Ala Glu Asp Ala Cys Leu Asp Ser Pro 35 40 45 Pro Pro Glu Thr Pro Lys Pro Ser His Thr Thr Pro Pro Ser Glu Ala 50 55 60 Glu Arg Leu Cys His Leu Gln Glu Ile Leu Ala Gln Met Tyr Gly Asn 65 70 75 80 Gln Asp Tyr Pro Ile Glu Asp Asp Pro Ser Ala Asp Ala Ala Asp Asp 85 90 95 Val Asp Glu Asp Ala Pro Asp Asp Val Ala Tyr Pro Glu Glu Tyr Ala 100 105 110 Glu Glu Leu Phe Leu Pro Gly Asp Ala Thr Gly Pro Leu Ile Gly Ala 115 120 125 Asn Asp His Ile Pro Pro Pro Cys Gly Ala Ser Pro Pro Gly Ile Arg 130 135 140 Arg Arg Ser Arg Asp Glu Ile Gly Ala Thr Gly Phe Thr Ala Glu Glu 145 150 155 160 Leu Asp Ala Met Asp Arg Glu Ala Ala Arg Ala Ile Ser Arg Gly Gly 165 170 175 Lys Pro Pro Ser Thr Met Ala Lys Leu Val Thr Gly Met Gly Phe Thr 180 185 190 Ile His Gly Ala Leu Thr Pro Gly Ser Glu Gly Cys Val Phe Asp Ser 195 200 205 Ser His Pro Asp Tyr Pro Gln Arg Val Ile Val Lys Ala Gly Trp Tyr 210 215 220 Thr Ser Thr Ser His Glu Ala Arg Leu Leu Arg Arg Leu Asp His Pro 225 230 235 240 Ala Ile Leu Pro Leu Leu Asp Leu His Val Val Ser Gly Val Thr Cys 245 250 255 Leu Val Leu Pro Lys Tyr Gln Ala Asp Leu Tyr Thr Tyr Leu Ser Arg 260 265 270 Arg Leu Asn Pro Leu Gly Arg Pro Gln Ile Ala Ala Val Ser Arg Gln 275 280 285 Leu Leu Ser Ala Val Asp Tyr Ile His Arg Gln Gly Ile Ile His Arg 290 295 300 Asp Ile Lys Thr Glu Asn Ile Phe Ile Asn Thr Pro Glu Asp Ile Cys 305 310 315 320 Leu Gly Asp Phe Gly Ala Ala Cys Phe Val Gln Gly Ser Arg Ser Ser 325 330 335 Pro Phe Pro Tyr Gly Ile Ala Gly Thr Ile Asp Thr Asn Ala Pro Glu 340 345 350 Val Leu Ala Gly Asp Pro Tyr Thr Thr Thr Val Asp Ile Trp Ser Ala 355 360 365 Gly Leu Val Ile Phe Glu Thr Ala Val His Asn Ala Ser Leu Phe Ser 370 375 380 Ala Pro Arg Gly Pro Lys Arg Gly Pro Cys Asp Ser Gln Ile Thr Arg 385 390 395 400 Ile Ile Arg Gln Ala Gln Val His Val Asp Glu Phe Ser Pro His Pro 405 410 415 Glu Ser Arg Leu Thr Ser Arg Tyr Arg Ser Arg Ala Ala Gly Asn Asn 420 425 430 Arg Pro Pro Tyr Thr Arg Pro Ala Trp Thr Arg Tyr Tyr Lys Met Asp 435 440 445 Ile Asp Val Glu Tyr Leu Val Cys Lys Ala Leu Thr Phe Asp Gly Ala 450 455 460 Leu Arg Pro Ser Ala Ala Glu Leu Leu Cys Leu Pro Leu Phe Gln Gln 465 470 475 480 Lys 107 261 DNA Herpes Virus 107 gtctggcatc tggggctttt gggaagcctc gtgggggctg ttcttgccgc cacccatcgg 60 ggacctgcgg ccaacacaac ggacccctta acgcacgccc cagtgtcccc tcaccccagc 120 cccctggggg gctttgccgt ccccctcgta gtcggtgggc tgtgcgccgt agtcctgggg 180 gcggcatgtc tgcttgagct cctgcgtcgt acgtgccgcg ggtgggggcg ttaccatccc 240 tacatggacc cagttgtcgt a 261 108 87 PRT Herpes Virus 108 Val Trp His Leu Gly Leu Leu Gly Ser Leu Val Gly Ala Val Leu Ala 1 5 10 15 Ala Thr His Arg Gly Pro Ala Ala Asn Thr Thr Asp Pro Leu Thr His 20 25 30 Ala Pro Val Ser Pro His Pro Ser Pro Leu Gly Gly Phe Ala Val Pro 35 40 45 Leu Val Val Gly Gly Leu Cys Ala Val Val Leu Gly Ala Ala Cys Leu 50 55 60 Leu Glu Leu Leu Arg Arg Thr Cys Arg Gly Trp Gly Arg Tyr His Pro 65 70 75 80 Tyr Met Asp Pro Val Val Val 85 109 279 DNA Herpes Virus 109 atgtctctgc gcgcagtctg gcatctgggg cttttgggaa gcctcgtggg ggctgttctt 60 gccgccaccc atcggggacc tgcggccaac acaacggacc ccttaacgca cgccccagtg 120 tcccctcacc ccagccccct ggggggcttt gccgtccccc tcgtagtcgg tgggctgtgc 180 gccgtagtcc tgggggcggc atgtctgctt gagctcctgc gtcgtacgtg ccgcgggtgg 240 gggcgttacc atccctacat ggacccagtt gtcgtataa 279 110 92 PRT Herpes Virus 110 Met Ser Leu Arg Ala Val Trp His Leu Gly Leu Leu Gly Ser Leu Val 1 5 10 15 Gly Ala Val Leu Ala Ala Thr His Arg Gly Pro Ala Ala Asn Thr Thr 20 25 30 Asp Pro Leu Thr His Ala Pro Val Ser Pro His Pro Ser Pro Leu Gly 35 40 45 Gly Phe Ala Val Pro Leu Val Val Gly Gly Leu Cys Ala Val Val Leu 50 55 60 Gly Ala Ala Cys Leu Leu Glu Leu Leu Arg Arg Thr Cys Arg Gly Trp 65 70 75 80 Gly Arg Tyr His Pro Tyr Met Asp Pro Val Val Val 85 90 111 1381 DNA Herpes Virus 111 caccgacgaa tcccctaagg gggaggggcc attttacgag gaggaggggt ataacaaagt 60 ctgtctttaa aaagcagggg ttagggagtt gttcggtcat aagcttcagc gcgaacgacc 120 aactaccccg atcatcagtt atccttaagg tctcttttgt gtggtgcgtt ccggtatggg 180 gggggctgcc gccaggttgg gggccgtgat tttgtttgtc gtcatagtgg gcctccatgg 240 ggtccgcagc aaatatgcct tggtggatgc ctctctcaag atggccgacc ccaatcgctt 300 tcgcggcaaa gaccttccgg tcctggacca gctgaccgac cctccggggg tccggcgcgt 360 gtaccacatc caggcgggcc taccggaccc gttccagccc cccagcctcc cgatcacggt 420 ttactacgcc gtgttggagc gcgcctgccg cagcgtgctc ctaaacgcac cgtcggaggc 480 cccccagatt gtccgcgggg cctccgaaga cgtccggaaa caaccctaca acctgaccat 540 cgcttggttt cggatgggag gcaactgtgc tatccccatc acggtcatgg agtacaccga 600 atgctcctac aacaagtctc tgggggcctg tcccatccga acgcagcccc gctggaacta 660 ctatgacagc ttcagcgccg tcagcgagga taacctgggg ttcctgatgc acgcccccgc 720 gtttgagacc gccggcacgt acctgcggct cgtgaagata aacgactgga cggagattac 780 acagtttatc ctggagcacc gagccaaggg ctcctgtaag tacgccctcc cgctgcgcat 840 ccccccgtca gcctgcctct ccccccaggc ctaccagcag ggggtgacgg tggacagcat 900 cgggatgctg ccccgcttca tccccgagaa ccagcgcacc gtcgccgtat acagcttgaa 960 gatcgccggg tggcacgggc ccaaggcccc atacacgagc accctgctgc ccccggagct 1020 gtccgagacc cccaacgcca cgcagccaga actcgccccg gaagaccccg aggattcggc 1080 cctcttggag gaccccgtgg ggacggtggc gccgcaaatc ccaccaaact ggcacatacc 1140 gtcgatccag gacgccgcga cgccttacca tcccccggcc accccgaaca acatgggcct 1200 gatcgccggc gcggtgggcg gcagtctcct ggcagccctg gtcatttgcg gaattgtgta 1260 ctggatgcgc cgccacactc aaaaagcccc aaagcgcata cgcctccccc acatccggga 1320 agacgaccag ccgtcctcgc accagccctt gttttactag ataccccccc ttaatgggtg 1380 c 1381 112 394 PRT Herpes Virus 112 Met Gly Gly Ala Ala Ala Arg Leu Gly Ala Val Ile Leu Phe Val Val 1 5 10 15 Ile Val Gly Leu His Gly Val Arg Ser Lys Tyr Ala Leu Val Asp Ala 20 25 30 Ser Leu Lys Met Ala Asp Pro Asn Arg Phe Arg Gly Lys Asp Leu Pro 35 40 45 Val Leu Asp Gln Leu Thr Asp Pro Pro Gly Val Arg Arg Val Tyr His 50 55 60 Ile Gln Ala Gly Leu Pro Asp Pro Phe Gln Pro Pro Ser Leu Pro Ile 65 70 75 80 Thr Val Tyr Tyr Ala Val Leu Glu Arg Ala Cys Arg Ser Val Leu Leu 85 90 95 Asn Ala Pro Ser Glu Ala Pro Gln Ile Val Arg Gly Ala Ser Glu Asp 100 105 110 Val Arg Lys Gln Pro Tyr Asn Leu Thr Ile Ala Trp Phe Arg Met Gly 115 120 125 Gly Asn Cys Ala Ile Pro Ile Thr Val Met Glu Tyr Thr Glu Cys Ser 130 135 140 Tyr Asn Lys Ser Leu Gly Ala Cys Pro Ile Arg Thr Gln Pro Arg Trp 145 150 155 160 Asn Tyr Tyr Asp Ser Phe Ser Ala Val Ser Glu Asp Asn Leu Gly Phe 165 170 175 Leu Met His Ala Pro Ala Phe Glu Thr Ala Gly Thr Tyr Leu Arg Leu 180 185 190 Val Lys Ile Asn Asp Trp Thr Glu Ile Thr Gln Phe Ile Leu Glu His 195 200 205 Arg Ala Lys Gly Ser Cys Lys Tyr Ala Leu Pro Leu Arg Ile Pro Pro 210 215 220 Ser Ala Cys Leu Ser Pro Gln Ala Tyr Gln Gln Gly Val Thr Val Asp 225 230 235 240 Ser Ile Gly Met Leu Pro Arg Phe Ile Pro Glu Asn Gln Arg Thr Val 245 250 255 Ala Val Tyr Ser Leu Lys Ile Ala Gly Trp His Gly Pro Lys Ala Pro 260 265 270 Tyr Thr Ser Thr Leu Leu Pro Pro Glu Leu Ser Glu Thr Pro Asn Ala 275 280 285 Thr Gln Pro Glu Leu Ala Pro Glu Asp Pro Glu Asp Ser Ala Leu Leu 290 295 300 Glu Asp Pro Val Gly Thr Val Ala Pro Gln Ile Pro Pro Asn Trp His 305 310 315 320 Ile Pro Ser Ile Gln Asp Ala Ala Thr Pro Tyr His Pro Pro Ala Thr 325 330 335 Pro Asn Asn Met Gly Leu Ile Ala Gly Ala Val Gly Gly Ser Leu Leu 340 345 350 Ala Ala Leu Val Ile Cys Gly Ile Val Tyr Trp Met Arg Arg His Thr 355 360 365 Gln Lys Ala Pro Lys Arg Ile Arg Leu Pro His Ile Arg Glu Asp Asp 370 375 380 Gln Pro Ser Ser His Gln Pro Leu Phe Tyr 385 390 113 1092 DNA Herpes Virus 113 attttgtttg tcgtcatagt gggcctccat ggggtccgca gcaaatatgc cttggtggat 60 gcctctctca agatggccga ccccaatcgc tttcgcggca aagaccttcc ggtcctggac 120 cagctgaccg accctccggg ggtccggcgc gtgtaccaca tccaggcggg cctaccggac 180 ccgttccagc cccccagcct cccgatcacg gtttactacg ccgtgttgga gcgcgcctgc 240 cgcagcgtgc tcctaaacgc accgtcggag gccccccaga ttgtccgcgg ggcctccgaa 300 gacgtccgga aacaacccta caacctgacc atcgcttggt ttcggatggg aggcaactgt 360 gctatcccca tcacggtcat ggagtacacc gaatgctcct acaacaagtc tctgggggcc 420 tgtcccatcc gaacgcagcc ccgctggaac tactatgaca gcttcagcgc cgtcagcgag 480 gataacctgg ggttcctgat gcacgccccc gcgtttgaga ccgccggcac gtacctgcgg 540 ctcgtgaaga taaacgactg gacggagatt acacagttta tcctggagca ccgagccaag 600 ggctcctgta agtacgccct cccgctgcgc atccccccgt cagcctgcct ctccccccag 660 gcctaccagc agggggtgac ggtggacagc atcgggatgc tgccccgctt catccccgag 720 aaccagcgca ccgtcgccgt atacagcttg aagatcgccg ggtggcacgg gcccaaggcc 780 ccatacacga gcaccctgct gcccccggag ctgtccgaga cccccaacgc cacgcagcca 840 gaactcgccc cggaagaccc cgaggattcg gccctcttgg aggaccccgt ggggacggtg 900 gcgccgcaaa tcccaccaaa ctggcacata ccgtcgatcc aggacgccgc gacgccttac 960 catcccccgg ccaccccgaa caacatgggc ctgatcgccg gcgcggtggg cggcagtctc 1020 ctggcagccc tggtcatttg cggaattgtg tactggatgc gccgccacac tcaaaaagcc 1080 ccaaagcgca ta 1092 114 364 PRT Herpes Virus 114 Ile Leu Phe Val Val Ile Val Gly Leu His Gly Val Arg Ser Lys Tyr 1 5 10 15 Ala Leu Val Asp Ala Ser Leu Lys Met Ala Asp Pro Asn Arg Phe Arg 20 25 30 Gly Lys Asp Leu Pro Val Leu Asp Gln Leu Thr Asp Pro Pro Gly Val 35 40 45 Arg Arg Val Tyr His Ile Gln Ala Gly Leu Pro Asp Pro Phe Gln Pro 50 55 60 Pro Ser Leu Pro Ile Thr Val Tyr Tyr Ala Val Leu Glu Arg Ala Cys 65 70 75 80 Arg Ser Val Leu Leu Asn Ala Pro Ser Glu Ala Pro Gln Ile Val Arg 85 90 95 Gly Ala Ser Glu Asp Val Arg Lys Gln Pro Tyr Asn Leu Thr Ile Ala 100 105 110 Trp Phe Arg Met Gly Gly Asn Cys Ala Ile Pro Ile Thr Val Met Glu 115 120 125 Tyr Thr Glu Cys Ser Tyr Asn Lys Ser Leu Gly Ala Cys Pro Ile Arg 130 135 140 Thr Gln Pro Arg Trp Asn Tyr Tyr Asp Ser Phe Ser Ala Val Ser Glu 145 150 155 160 Asp Asn Leu Gly Phe Leu Met His Ala Pro Ala Phe Glu Thr Ala Gly 165 170 175 Thr Tyr Leu Arg Leu Val Lys Ile Asn Asp Trp Thr Glu Ile Thr Gln 180 185 190 Phe Ile Leu Glu His Arg Ala Lys Gly Ser Cys Lys Tyr Ala Leu Pro 195 200 205 Leu Arg Ile Pro Pro Ser Ala Cys Leu Ser Pro Gln Ala Tyr Gln Gln 210 215 220 Gly Val Thr Val Asp Ser Ile Gly Met Leu Pro Arg Phe Ile Pro Glu 225 230 235 240 Asn Gln Arg Thr Val Ala Val Tyr Ser Leu Lys Ile Ala Gly Trp His 245 250 255 Gly Pro Lys Ala Pro Tyr Thr Ser Thr Leu Leu Pro Pro Glu Leu Ser 260 265 270 Glu Thr Pro Asn Ala Thr Gln Pro Glu Leu Ala Pro Glu Asp Pro Glu 275 280 285 Asp Ser Ala Leu Leu Glu Asp Pro Val Gly Thr Val Ala Pro Gln Ile 290 295 300 Pro Pro Asn Trp His Ile Pro Ser Ile Gln Asp Ala Ala Thr Pro Tyr 305 310 315 320 His Pro Pro Ala Thr Pro Asn Asn Met Gly Leu Ile Ala Gly Ala Val 325 330 335 Gly Gly Ser Leu Leu Ala Ala Leu Val Ile Cys Gly Ile Val Tyr Trp 340 345 350 Met Arg Arg His Thr Gln Lys Ala Pro Lys Arg Ile 355 360 115 1185 DNA Herpes Virus 115 atgggggggg ctgccgccag gttgggggcc gtgattttgt ttgtcgtcat agtgggcctc 60 catggggtcc gcagcaaata tgccttggtg gatgcctctc tcaagatggc cgaccccaat 120 cgctttcgcg gcaaagacct tccggtcctg gaccagctga ccgaccctcc gggggtccgg 180 cgcgtgtacc acatccaggc gggcctaccg gacccgttcc agccccccag cctcccgatc 240 acggtttact acgccgtgtt ggagcgcgcc tgccgcagcg tgctcctaaa cgcaccgtcg 300 gaggcccccc agattgtccg cggggcctcc gaagacgtcc ggaaacaacc ctacaacctg 360 accatcgctt ggtttcggat gggaggcaac tgtgctatcc ccatcacggt catggagtac 420 accgaatgct cctacaacaa gtctctgggg gcctgtccca tccgaacgca gccccgctgg 480 aactactatg acagcttcag cgccgtcagc gaggataacc tggggttcct gatgcacgcc 540 cccgcgtttg agaccgccgg cacgtacctg cggctcgtga agataaacga ctggacggag 600 attacacagt ttatcctgga gcaccgagcc aagggctcct gtaagtacgc cctcccgctg 660 cgcatccccc cgtcagcctg cctctccccc caggcctacc agcagggggt gacggtggac 720 agcatcggga tgctgccccg cttcatcccc gagaaccagc gcaccgtcgc cgtatacagc 780 ttgaagatcg ccgggtggca cgggcccaag gccccataca cgagcaccct gctgcccccg 840 gagctgtccg agacccccaa cgccacgcag ccagaactcg ccccggaaga ccccgaggat 900 tcggccctct tggaggaccc cgtggggacg gtggcgccgc aaatcccacc aaactggcac 960 ataccgtcga tccaggacgc cgcgacgcct taccatcccc cggccacccc gaacaacatg 1020 ggcctgatcg ccggcgcggt gggcggcagt ctcctggcag ccctggtcat ttgcggaatt 1080 gtgtactgga tgcgccgcca cactcaaaaa gccccaaagc gcatacgcct cccccacatc 1140 cgggaagacg accagccgtc ctcgcaccag cccttgtttt actag 1185 116 394 PRT Herpes Virus 116 Met Gly Gly Ala Ala Ala Arg Leu Gly Ala Val Ile Leu Phe Val Val 1 5 10 15 Ile Val Gly Leu His Gly Val Arg Ser Lys Tyr Ala Leu Val Asp Ala 20 25 30 Ser Leu Lys Met Ala Asp Pro Asn Arg Phe Arg Gly Lys Asp Leu Pro 35 40 45 Val Leu Asp Gln Leu Thr Asp Pro Pro Gly Val Arg Arg Val Tyr His 50 55 60 Ile Gln Ala Gly Leu Pro Asp Pro Phe Gln Pro Pro Ser Leu Pro Ile 65 70 75 80 Thr Val Tyr Tyr Ala Val Leu Glu Arg Ala Cys Arg Ser Val Leu Leu 85 90 95 Asn Ala Pro Ser Glu Ala Pro Gln Ile Val Arg Gly Ala Ser Glu Asp 100 105 110 Val Arg Lys Gln Pro Tyr Asn Leu Thr Ile Ala Trp Phe Arg Met Gly 115 120 125 Gly Asn Cys Ala Ile Pro Ile Thr Val Met Glu Tyr Thr Glu Cys Ser 130 135 140 Tyr Asn Lys Ser Leu Gly Ala Cys Pro Ile Arg Thr Gln Pro Arg Trp 145 150 155 160 Asn Tyr Tyr Asp Ser Phe Ser Ala Val Ser Glu Asp Asn Leu Gly Phe 165 170 175 Leu Met His Ala Pro Ala Phe Glu Thr Ala Gly Thr Tyr Leu Arg Leu 180 185 190 Val Lys Ile Asn Asp Trp Thr Glu Ile Thr Gln Phe Ile Leu Glu His 195 200 205 Arg Ala Lys Gly Ser Cys Lys Tyr Ala Leu Pro Leu Arg Ile Pro Pro 210 215 220 Ser Ala Cys Leu Ser Pro Gln Ala Tyr Gln Gln Gly Val Thr Val Asp 225 230 235 240 Ser Ile Gly Met Leu Pro Arg Phe Ile Pro Glu Asn Gln Arg Thr Val 245 250 255 Ala Val Tyr Ser Leu Lys Ile Ala Gly Trp His Gly Pro Lys Ala Pro 260 265 270 Tyr Thr Ser Thr Leu Leu Pro Pro Glu Leu Ser Glu Thr Pro Asn Ala 275 280 285 Thr Gln Pro Glu Leu Ala Pro Glu Asp Pro Glu Asp Ser Ala Leu Leu 290 295 300 Glu Asp Pro Val Gly Thr Val Ala Pro Gln Ile Pro Pro Asn Trp His 305 310 315 320 Ile Pro Ser Ile Gln Asp Ala Ala Thr Pro Tyr His Pro Pro Ala Thr 325 330 335 Pro Asn Asn Met Gly Leu Ile Ala Gly Ala Val Gly Gly Ser Leu Leu 340 345 350 Ala Ala Leu Val Ile Cys Gly Ile Val Tyr Trp Met Arg Arg His Thr 355 360 365 Gln Lys Ala Pro Lys Arg Ile Arg Leu Pro His Ile Arg Glu Asp Asp 370 375 380 Gln Pro Ser Ser His Gln Pro Leu Phe Tyr 385 390 

What is claimed is:
 1. A method of immunizing a subject comprising providing to the subject a pharmaceutical composition in an amount effective to induce an immune response, the pharmaceutical composition comprising at least one herpesvirus antigen or fragment thereof.
 2. The method of claim 1, wherein the herpesvirus antigen or fragment thereof is further defined as a HSV-1 antigen or fragment thereof.
 3. The method of claim 1, wherein the at least one herpesvirus antigen has an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, or a fragment thereof.
 4. The method of claim 1, wherein the subject is immunized against an animal herpesvirus.
 5. The method of claim 4, wherein the subject is immunized against a human herpesvirus.
 6. The method of claim 5, wherein the subject is immunized against HSV-1, HSV-2, or Varicella Zoster Virus.
 7. The method of claim 5, wherein the subject is immunized against HSV-1.
 8. The method of claim 5, wherein the subject is immunized against HSV-2.
 9. The method of claim 4, wherein the subject is immunized against a cercopithecine, bovine or canine herpesvirus.
 10. The method of claim 1, wherein the method of providing at least one herpesvirus antigen(s) comprises: (a) preparing a pharmaceutical composition comprising at least one polynucleotide encoding a polypeptide having an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, or a fragment thereof; (b) administering one or more polynucleotides in a pharmaceutically acceptable carrier into the subject; and (c) expressing one or more herpesvirus antigens in the subject.
 11. The method of claim 10, wherein the polynucleotide is an expression vector.
 12. The method of claim 11, wherein the expression vector is a genetic immunization vector.
 13. The method of claim 11, wherein the expression vector is a linear expression element or circular expression element expression system.
 14. The method of claim 10, wherein the polynucleotide sequence is set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 or SEQ ID NO:115, or a fragment thereof.
 15. The method of claim 14, wherein the polynucleotide is administered by a intramuscular injection, epidermal injection or particle bombardment.
 16. The method of claim 14, wherein the polynucleotide is administered by intravenous, subcutaneous, intralesional, intraperitoneal, intradermal, oral, or other mucosal or inhaled routes of administration.
 17. The method of claim 16, wherein a second administration is given at least about three weeks after the first administration.
 18. The method of claim 10, wherein at least two polynucleotides encoding different herpesvirus antigens or fragments thereof are administered to a subject.
 19. The method of claim 1, wherein at least two different herpesvirus antigens, or fragments thereof, are provided in an amount effective to induce an immune response.
 20. An isolated polynucleotide comprising a sequence having at least 17 contiguous nucleotides in common with at least one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ BD NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 or SEQ ID NO:115, or its complement.
 21. The polynucleotide of claim 20, further defined as comprising a sequence having least 50 contiguous nucleotides in common with at least one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ BD NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 or SEQ ID NO:115, or its complement.
 22. The polynucleotide of claim 21, further defined as comprising a sequence having all nucleotides in common with at least one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 or SEQ ID NO:115, or its complement.
 23. The polynucleotide of claim 20, further defined as being comprised in a vector.
 24. The polynucleotide of claim 20, further defined as being comprised in a pharmaceutical composition.
 25. The polynucleotide of claim 20, further defined as being comprised in a vaccine.
 26. An isolated polypeptide having at least 5 consecutive amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116.
 27. The polypeptide of claim 26, wherein the polypeptide comprises at least 20 consecutive amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116.
 28. The polypeptide of claim 27, further defined as having an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116.
 29. The polypeptide of claim 26, further defined as being comprised in a pharmaceutical composition.
 30. The polypeptide of claim 26, further defined as being comprised in a vaccine.
 31. The polypeptide of claim 28, further defined as a recombinant polypeptide.
 32. A vaccine composition comprising at least one herpesvirus antigen or fragment thereof or at least one polynucleotide encoding a herpesvirus antigen or a fragment thereof.
 33. The vaccine composition of claim 32, further defined as a genetic vaccine, a polypeptide vaccine, a cell-mediated vaccine, an attenuated pathogen vaccine, a live-vector vaccine, an edible vaccine, a killed pathogen vaccine, a purified sub-unit vaccine, a conjugate vaccine, a virus-like particle vaccine, or a humanized antibody vaccines.
 34. The vaccine composition of claim 33, further defined as comprising a polynucleotide encoding at least one herpesvirus antigen or fragment thereof.
 35. The vaccine composition of claim 33, further defined as comprising at least one herpesvirus antigen or a fragment thereof.
 36. The vaccine composition of claim 32, further defined as comprising at least one polynucleotide encoding a herpesvirus antigen or fragment thereof.
 37. The vaccine composition of claim 36, further defined as comprising at least two polynucleotides encoding different herpesvirus antigens or fragments thereof.
 38. The vaccine composition of claim 36, wherein the polynucleotide encoding the herpesvirus antigen or fragment thereof encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, or a fragment thereof.
 39. The vaccine composition of claim 36, wherein the polynucleotide encoding a herpesvirus antigen or fragment thereof comprises the polynucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 or SEQ ID NO:115, or a fragment thereof.
 40. The vaccine composition of claim 32, further defined as comprising at least one herpesvirus antigen or fragment thereof in a pharmaceutically acceptable carrier.
 41. The vaccine composition of claim 40, further defined as comprising at least two different herpesvirus antigens or fragments thereof in a pharmaceutically acceptable carrier.
 42. The vaccine composition of claim 40, wherein the herpesvirus antigen or fragments thereof has an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, or fragments thereof.
 43. A method of screening for at least one test polypeptide or test polynucleotide encoding a polypeptide for an ability to produce an immune response comprising: (i) obtaining at least one test polypeptide or test polynucleotide by (a) modifying the amino acid sequence of a known antigenic polypeptide or polynucleotide sequence of a polynucleotide encoding a known antigenic polypeptide; (b) obtaining a homolog of a known antigenic sequence of a polynucleotide encoding such a homolog, or (c) obtaining a homolog of a known antigenic sequence or a polynucleotide encoding such a homolog and modifying the amino acid sequence of the homolog or the polynucleotide sequence of the polynucleotide encoding such a homolog; and (ii) testing the test polypeptide or test polynucleotide under appropriate conditions to determine whether the test polypeptide is antigenic or the test polynucleotide encodes an antigenic polypeptide.
 44. The method of claim 43, further defined as comprising obtaining a test polypeptide.
 45. The method of claim 44, wherein obtaining the test polypeptide comprises modifying the amino acid sequence or obtaining a homolog of a least one polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116 or fragment thereof.
 46. The method of claim 43, further defined as comprising obtaining a test polynucleotide.
 47. The method of claim 46, wherein obtaining the test polynucleotide comprises modifying the polynucleotide sequence of at least one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 or SEQ ID NO:115, or fragment thereof.
 48. The method of claim 43, further comprising identifying at least one test polypeptide as being antigenic or at least one test polynucleotide as encoding an antigenic polypeptide.
 49. The method of claim 48, further comprising placing the identified antigenic polypeptide or the polynucleotide encoding an antigenic polypeptide in a pharmaceutical composition.
 50. The method of claim 48, further comprising using the identified antigenic polypeptide or polynucleotide encoding an antigenic polypeptide to vaccinate a subject.
 51. The method of claim 50, wherein the subject is vaccinated against a herpesvirus.
 52. The method of claim 51, wherein the herpesvirus is HSV-1.
 53. The method of claim 50, wherein the subject is vaccinated against a non-herpesvirus disease.
 54. A method of preparing a vaccine comprising obtaining an antigenic polypeptide or a polynucleotide encoding an antigenic polypeptide as determined to be antigenic by the method of claim 43, and placing the polypeptide or polynucleotide in a vaccine composition.
 55. A method of vaccinating a subject comprising preparing a vaccine of claim 54 and vaccinating a subject with the vaccine.
 56. A method of treating a subject infected with a pathogen comprising administering a vaccine composition comprising at least one herpesvirus antigen or fragment thereof, or at least one polynucleotide encoding a herpesvirus antigen or a fragment thereof.
 57. The method of claim 56, wherein the vaccine composition is a genetic vaccine, a polypeptide vaccine, a cell-mediated vaccine, an attenuated pathogen vaccine, a live-vector vaccine, an edible vaccine, a killed pathogen vaccine, a purified sub-unit vaccine, a conjugate vaccine, a virus-like particle vaccine, or a humanized antibody vaccine.
 58. The method of claim 57, wherein the vaccine composition comprises a polynucleotide encoding at least one herpesvirus antigen or fragment thereof.
 59. The method of claim 57, wherein the vaccine composition comprises at least one herpesvirus antigen or fragment thereof.
 60. The method of claim 58, wherein the polynucleotide encoding the herpesvirus antigen or fragment thereof encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, or a fragment thereof.
 61. The method of claim 58, wherein the polynucleotide encoding a herpesvirus antigen or fragment thereof comprises the polynucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71; SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113 or SEQ ID NO:115, or a fragment thereof.
 62. A method of raising a therapeutic immune response against reactivation disease comprising administering a vaccine composition comprising at least one herpesvirus antigen or fragment thereof, or at least one polynucleotide encoding a herpesvirus antigen or a fragment thereof.
 63. The method of claim 62, wherein the herpesvirus antigen comprises an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, or a fragment thereof.
 64. A method of passive immunization comprising administering at least one antigen binding agent reactive to one or more herpesvirus antigen to a subject.
 65. The method of claim 64, wherein the herpesvirus antigen comprises an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, and/or SEQ ID NO:116, or a fragment thereof.
 66. A method for vaccination comprising administering a priming dose of a herpesvirus vaccine composition.
 67. The method of claim 66, wherein the priming dose is followed by a boost dose.
 68. The method of claim 66, wherein the vaccine composition is administered at least once.
 69. The method of claim 68, wherein the vaccine is administered at least twice.
 70. The method of claim 69, wherein the method comprises (a) administering at least one nucleic acid vaccine composition and then (b) administering at least one polypeptide vaccine composition.
 71. The method of claim 69, wherein the method comprises the steps of (a) administering at least one polypeptide vaccine composition and then (b) administering at least one nucleic acid vaccine composition.
 72. The method of claim 67, wherein the method comprises (a) administering at least one nucleic acid vaccine composition and then (b) administering at least one polypeptide vaccine composition.
 73. The method of claim 67, wherein the method comprises the steps of (a) administering at least one polypeptide vaccine composition and then (b) administering at least one nucleic acid vaccine composition. 